Any feedback?
Information on EC 2.7.1.137 - phosphatidylinositol 3-kinase
for references in articles please use BRENDA:EC2.7.1.137Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.7.1.137 phosphatidylinositol 3-kinaseIUBMB Comments
One mammalian isoform is known.
Specify your search results
Word Map
- 2.7.1.137
- wortmannin
- mapks
- mtor
- rapamycin
- erk
- endothelial
- pten
-
signal-regulated
- pkc
- metastasis
- bcl-2
- sirna
- caspase-3
- agonist
- glycogen
- leukemia
- actin
- pik3ca
- phospholipase
-
insulin-like
-
mitogen
- cyclins
- integrins
- tumorigenesis
- irs-1
-
tensin
- tnf
-
neuroprotective
- c-jun
- pi3-kinase
-
dominant-negative
- adipocytes
- nf-kappab
-
anti-apoptotic
-
insulin-stimulated
- gtpases
-
insulin-induced
- akt1
-
transwell
-
platelet-derived
- rac1
- kinase-3
- igf-i
- sh2
- substrate-1
-
pleckstrin
- grb2
-
egf-induced
-
everolimus
-
tyrosine-phosphorylated
- drug development
- medicine
- pharmacology
The enzyme appears in viruses and cellular organisms
Reaction Schemes
Synonyms
pi3k, phosphatidylinositol 3-kinase, pi3 kinase, vps34, phosphoinositide-3-kinase, phosphatidylinositol 3 kinase, ptdins 3-kinase, pik3c3, phosphatidylinositide 3-kinase, hvps34, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
kinase (phosphorylating), phosphatidylinositol 3-
-
-
-
-
kinase, phosphatidylinositol 3- (phosphorylating)
-
-
-
-
p85/p110 phosphoinositide 3-kinase
-
-
-
-
phosphatidylinositol 3'-kinase
-
-
-
-
phosphatidylinositol 3-kinase
-
-
-
-
phosphoinositide 3'-kinase
-
-
-
-
phosphoinositide 3-kinase
-
-
-
-
PI 3-kinase
-
-
-
-
PI3K
-
-
-
-
PtdIns 3'-kinase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
phospho group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
ATP:1-phosphatidyl-1D-myo-inositol 3-phosphotransferase
One mammalian isoform is known.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
115926-52-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
ATP + 1-phosphatidylinositol
ADP + phosphatidylinositol 3-phosphate
-
-
?
additional information
?
-
-
phosphatidylinositol 3-kinase-mediated signaling in the immune system
-
-
?
additional information
?
-
phosphatidylinositol 3-kinase-mediated signaling in the immune system
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
additional information
?
-
-
phosphatidylinositol 3-kinase-mediated signaling in the immune system
-
-
?
additional information
?
-
phosphatidylinositol 3-kinase-mediated signaling in the immune system
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
Lnc-HZ08 regulates BPDE-induced trophoblast cell dysfunctions by promoting PI3K ubiquitin degradation and is associated with miscarriage.
Acidosis
Acidosis impairs insulin receptor substrate-1-associated phosphoinositide 3-kinase signaling in muscle cells: consequences on proteolysis.
Acidosis
Acidosis-induced protein tyrosine phosphorylation depends on Ca2+ influx via voltage-dependent Ca2+ channels in SHR aorta.
Acidosis
Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Acidosis
Extracellular acidosis induces neutrophil activation by a mechanism dependent on activation of phosphatidylinositol 3-kinase/Akt and ERK pathways.
Acidosis
Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Acidosis
Mild acidosis delays neutrophil apoptosis via multiple signaling pathways and acts in concert with inflammatory mediators.
Acne Vulgaris
Insulin and insulin-like growth factor-1 can modulate the phosphoinositide-3-kinase/Akt/FoxO1 pathway in SZ95 sebocytes in vitro.
Acromegaly
The possible role of mRNA expression changes of GH/IGF-1/insulin axis components in subcutaneous adipose tissue in metabolic disturbances of patients with acromegaly.
Acute Kidney Injury
Mangiferin Ameliorates Cisplatin Induced Acute Kidney Injury by Upregulating Nrf-2 via the Activation of PI3K and Exhibits Synergistic Anticancer Activity With Cisplatin.
Acute Lung Injury
Dexamethasone ameliorates H2S-induced acute lung injury by increasing claudin-5 expression via the PI3K pathway.
Acute Lung Injury
Effective attenuation of acute lung injury in vivo and the formyl peptide-induced neutrophil activation in vitro by CYL-26z through the phosphoinositide 3-kinase gamma pathway.
Acute Lung Injury
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.
Adenocarcinoma
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Adenocarcinoma
Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase.
Adenocarcinoma
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Adenocarcinoma
Apoptosis initiation of ?-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway.
Adenocarcinoma
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.
Adenocarcinoma
Dehydroglyasperin D Inhibits the Proliferation of HT-29 Human Colorectal Cancer Cells Through Direct Interaction With Phosphatidylinositol 3-kinase.
Adenocarcinoma
Distinctive Patterns of CTNNB1 (?-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Adenocarcinoma
Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K.
Adenocarcinoma
Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.
Adenocarcinoma
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Adenocarcinoma
Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.
Adenocarcinoma
Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology.
Adenocarcinoma
Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.
Adenocarcinoma
FKBP10 functioned as a cancer-promoting factor mediates cell proliferation, invasion, and migration via regulating PI3K signaling pathway in stomach adenocarcinoma.
Adenocarcinoma
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Adenocarcinoma
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
Adenocarcinoma
Impairement of HT29 Cancer Cells Cohesion by the Soluble Form of Neurotensin Receptor-3.
Adenocarcinoma
Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma.
Adenocarcinoma
Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.
Adenocarcinoma
MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro.
Adenocarcinoma
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Adenocarcinoma
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Adenocarcinoma
Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.
Adenocarcinoma
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
Adenocarcinoma
Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells.
Adenocarcinoma
PI3K inhibition as a novel therapeutic strategy for neoadjuvant chemoradiotherapy resistant oesophageal adenocarcinoma.
Adenocarcinoma
PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells.
Adenocarcinoma
PlGF knockdown inhibited tumor survival and migration in gastric cancer cell via PI3K/Akt and p38MAPK pathways.
Adenocarcinoma
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Adenocarcinoma
RSK activation via ERK modulates human colon cancer cells response to PTHrP.
Adenocarcinoma
Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
Adenocarcinoma
Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin.
Adenocarcinoma
Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
Adenocarcinoma
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Adenocarcinoma
Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth.
Adenocarcinoma
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.
Adenocarcinoma
Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia.
Adenocarcinoma
ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine.
Adenocarcinoma of Lung
Analysis of genomic variation in lung adenocarcinoma patients revealed the critical role of PI3K complex.
Adenocarcinoma of Lung
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Adenocarcinoma of Lung
Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.
Adenocarcinoma of Lung
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Adenocarcinoma of Lung
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
Adenocarcinoma of Lung
Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.
Adenocarcinoma of Lung
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Adenocarcinoma of Lung
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas.
Adenocarcinoma of Lung
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Adenocarcinoma of Lung
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.
Adenocarcinoma of Lung
Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer.
Adenocarcinoma of Lung
Interleukin-1?-induced interleukin-6 production in A549 cells is mediated by both phosphatidylinositol 3-kinase and interleukin-1 receptor-associated kinase-4.
Adenocarcinoma of Lung
LncRNA MALAT1 regulates trophoblast cells migration and invasion via miR-206/IGF-1 axis.
Adenocarcinoma of Lung
mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Adenocarcinoma of Lung
Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells.
Adenocarcinoma of Lung
Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells).
Adenocarcinoma of Lung
Oncogenic activation of the PI3-kinase p110? isoform via the tumor-derived PIK3C?(D1067V) kinase domain mutation.
Adenocarcinoma of Lung
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
Adenocarcinoma of Lung
Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.
Adenocarcinoma of Lung
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Adenocarcinoma of Lung
Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
Adenocarcinoma of Lung
Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Adenocarcinoma of Lung
Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
Adenocarcinoma of Lung
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
Adenocarcinoma of Lung
[Effect of Buzhong Yiqi decoction on PI3K and AKT in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor].
Adenocarcinoma, Follicular
Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
Adenocarcinoma, Mucinous
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Adenoma
Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells.
Adenoma
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.
Adenoma
Distinctive Patterns of CTNNB1 (?-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Adenoma
Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway.
Adenoma
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
Adenoma
Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma.
Adenoma
Sclerosing Polycystic "Adenosis" of Salivary Glands: A Neoplasm Characterized by PI3K Pathway Alterations More Correctly Named Sclerosing Polycystic Adenoma.
Adenoma
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.
Adenoma
Senescence-associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15.
Adenoma
The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2?×?2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
Adenomatous Polyposis Coli
Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase.
Adenomatous Polyposis Coli
Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Adenomatous Polyposis Coli
Genomic instability and colon carcinogenesis: from the perspective of genes.
Adenomatous Polyposis Coli
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Adenomyosis
Loss of PP2A and PTEN immunoexpression coexists with survivin overexpression in adenomyosis.
Adenoviridae Infections
Adenovirus E4-ORF1 Dysregulates Epidermal Growth Factor and Insulin/Insulin-Like Growth Factor Receptors To Mediate Constitutive Myc Expression.
Adrenal Cortex Neoplasms
Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Adrenocortical Carcinoma
AngII induces transient phospholipase D activity in the H295R glomerulosa cell model.
Adrenocortical Carcinoma
Insulin-Like Growth Factor-Phosphatidylinositol 3 Kinase Signaling in Canine Cortisol-Secreting Adrenocortical Tumors.
Agammaglobulinemia
Agammaglobulinemia and absent B lineage cells in a patient lacking the p85? subunit of PI3K.
aldehyde dehydrogenase (nad+) deficiency
Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice.
Alveolar Bone Loss
A circRNA-miRNA-mRNA network plays a role in the protective effect of diosgenin on alveolar bone loss in ovariectomized rats.
Alzheimer Disease
"Olfactory three-needle" acupuncture enhances synaptic function in A?1-42-induced Alzheimer's disease via activating PI3K/AKT/GSK-3? signaling pathway.
Alzheimer Disease
Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade.
Alzheimer Disease
AMPK activation does not enhance autophagy in neurons in contrast to MTORC1 inhibition: different impact on ?-amyloid clearance.
Alzheimer Disease
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Alzheimer Disease
Bilobalide regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway.
Alzheimer Disease
Crocin protects against beta-amyloid peptide-induced apoptosis in PC12 cells via PI3 K pathway.
Alzheimer Disease
Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease.
Alzheimer Disease
Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
Alzheimer Disease
Neuroprotective effect of Annona muricata-derived polysaccharides in neuronal HT22 cell damage induced by hydrogen peroxide.
Alzheimer Disease
PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila.
Alzheimer Disease
PI3K inhibition causes the accumulation of ubiquitinated presenilin 1 without affecting the proteasome activity.
Alzheimer Disease
Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling.
Alzheimer Disease
Prolonged Alzheimer-like tau hyperphosphorylation induced by simultaneous inhibition of phosphoinositol-3 kinase and protein kinase C in N2a cells.
Alzheimer Disease
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
Alzheimer Disease
[Effects of curcumin on expression of PI3K and p-pI3K in hippocampus of AD mice].
Ameloblastoma
Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
Ameloblastoma
TNFalpha played a role in induction of Akt and MAPK signals in ameloblastoma.
Amnesia
Clionosterol and Ethyl Cholestan-22-enol Isolated from the Rhizome of Polygala tenuifolia Inhibit Phosphatidylinositol 3-Kinase/Akt Pathway.
Amyloidosis
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.
Amyotrophic Lateral Sclerosis
Phosphatidylinositol 3-kinase: increased activity and protein level in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Targeting autophagy in disease: established and new strategies.
Anaphylaxis
Loss of IL-4R?-mediated PI3K signaling accelerates the progression of IgE/mast cell-mediated reactions.
Anaphylaxis
Protein kinase CK2/PTEN pathway plays a key role in platelet-activating factor-mediated murine anaphylactic shock.
Anaphylaxis
Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Anemia
Equine lentivirus counteracts SAMHD1 restriction by Rev-mediated degradation of SAMHD1 via the BECN1-dependent lysosomal pathway.
Aneurysm
Abnormal mechanosensing and cofilin activation promote the progression of ascending aortic aneurysms in mice.
Antiphospholipid Syndrome
Inhibition of the mTORC pathway in the antiphospholipid syndrome.
Anus Neoplasms
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Aortic Aneurysm, Abdominal
Astragaloside IV Attenuated 3,4-Benzopyrene-Induced Abdominal Aortic Aneurysm by Ameliorating Macrophage-Mediated Inflammation.
Aortic Aneurysm, Abdominal
Inhibition of Phosphatidylinositol 3-Kinase ? by IPI-549 Attenuates Abdominal Aortic Aneurysm Formation in Mice.
Aortic Aneurysm, Abdominal
Inhibition of Phosphatidylinositol 3-kinease suppresses formation and progression of experimental abdominal aortic aneurysms.
Arrhythmias, Cardiac
Cardioprotection by PI3K-mediated signaling is required for anti-arrhythmia and myocardial repair in response to ischemic preconditioning in infarcted pig hearts.
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Arteriovenous Malformations
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.
Arthritis
Adiponectin Induces Oncostatin M Expression in Osteoblasts through the PI3K/Akt Signaling Pathway.
Arthritis
BAFF/BAFF-R involved in antibodies production of rats with collagen-induced arthritis via PI3K-Akt-mTOR signaling and the regulation of paeoniflorin.
Arthritis
CCN1 induces oncostatin M production in osteoblasts via integrin-dependent signal pathways.
Arthritis
Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats.
Arthritis
Interleukin-1?-induced interleukin-6 production in A549 cells is mediated by both phosphatidylinositol 3-kinase and interleukin-1 receptor-associated kinase-4.
Arthritis
Loss of phosphoinositide 3-kinase gamma decreases migration and activation of phagocytes but not T cell activation in antigen-induced arthritis.
Arthritis
MiR-let-7a regulates anti-citrullinated protein antibody-induced macrophage activation and correlates with the development of experimental rheumatoid arthritis.
Arthritis
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.
Arthritis
The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Arthritis
Thrombin promotes matrix metalloproteinase-13 expression through the PKC? c-Src/EGFR/PI3K/Akt/AP-1 signaling pathway in human chondrocytes.
Arthritis
[Relations of synovial angiogenesis and PTEN/PI3K/AKT signaling pathway in rats with adjuvant arthritis].
Arthritis
[Therapeutic potential of phosphoinositide 3-kinase inhibitors in rheumatoid arthritis]
Arthritis, Experimental
Relationship between PI3K pathway and angiogenesis in CIA rat synovium.
Arthritis, Experimental
The PI-3-Kinase P110? Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis.
Arthritis, Experimental
[Effect of Xinfeng Capsule on Beclin1/PI3K-AKT-mTOR of Adjuvant Arthritis Rats].
Arthritis, Psoriatic
The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Arthritis, Rheumatoid
Amelioration of collagen-induced arthritis in rats by adenovirus-mediated PTEN gene transfer.
Arthritis, Rheumatoid
Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts.
Arthritis, Rheumatoid
Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis.
Arthritis, Rheumatoid
Downregulated microRNA-135a ameliorates rheumatoid arthritis by inactivation of the phosphatidylinositol 3-kinase/AKT signaling pathway via phosphatidylinositol 3-kinase regulatory subunit 2.
Arthritis, Rheumatoid
Effect of CD95 on inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis.
Arthritis, Rheumatoid
META060 inhibits osteoclastogenesis and MMPs in vitro, and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
Arthritis, Rheumatoid
Necessary role of phosphatidylinositol 3-kinase in transforming growth factor beta-mediated activation of Akt in normal and rheumatoid arthritis synovial fibroblasts.
Arthritis, Rheumatoid
PI3 kinase ? is a key regulator of synoviocyte function in rheumatoid arthritis.
Arthritis, Rheumatoid
PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
Arthritis, Rheumatoid
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Arthritis, Rheumatoid
Relationship between PI3K pathway and angiogenesis in CIA rat synovium.
Arthritis, Rheumatoid
Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
Arthritis, Rheumatoid
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.
Arthritis, Rheumatoid
The PI-3-Kinase P110? Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis.
Arthritis, Rheumatoid
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
Arthritis, Rheumatoid
[Abnormal signaling activity of phosphatidylinositol 3-kinase pathway in peripheral blood T cells from patients with systemic lupus erythematosus]
Arthritis, Rheumatoid
[Therapeutic potential of phosphoinositide 3-kinase inhibitors in rheumatoid arthritis]
Asthenozoospermia
Phosphatidylinositol 3-kinase inhibition enhances human sperm motility and sperm-zona pellucida binding.
Asthenozoospermia
[Influence of LY294002 on sperm motility in asthenozoospermia patients in vitro]
Asthma
Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice.
Asthma
An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model.
Asthma
Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling by the PI3K inhibitor LY294002.
Asthma
Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management.
Asthma
DEK-targeting aptamer DTA-64 attenuates bronchial EMT-mediated airway remodelling by suppressing TGF-?1/Smad, MAPK and PI3K signalling pathway in asthma.
Asthma
Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K).
Asthma
Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma.
Asthma
Dual ERK and phosphatidylinositol 3-kinase pathways control airway smooth muscle proliferation: differences in asthma.
Asthma
Inflammatory cellular phenotypes and molecular mechanisms of glucocorticoid resistance in patients with bronchial asthma.
Asthma
Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis.
Asthma
Inhibiting AKT phosphorylation employing non-cytotoxic anthraquinones ameliorates TH2 mediated allergic airways disease and rhinovirus exacerbation.
Asthma
Investigation into the Role of PI3K and JAK3 Kinase Inhibitors in Murine Models of Asthma.
Asthma
Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma.
Asthma
p110?/? Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway Inflammation.
Asthma
Phenotypic characterization of lung macrophages in asthmatic patients: Overexpression of CCL17.
Asthma
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation.
Asthma
Phosphatidylinositol 3-kinase inhibitor suppresses inducible nitric oxide synthase expression in bronchiole epithelial cells in asthmatic rats.
Asthma
Phosphatidylinositol 3-Kinase Mediates ?-Catenin Dysfunction of Airway Epithelium in a Toluene Diisocyanate-Induced Murine Asthma Model.
Asthma
Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell proliferation.
Asthma
Phosphatidylinositol 3-kinase-? controls endoplasmic reticulum membrane fluidity and permeability in fungus-induced allergic inflammation in mice.
Asthma
Phosphatidylinositol 3-kinases pathway mediates lung caspase-1 activation and high mobility group box 1 production in a toluene-diisocyanate induced murine asthma model.
Asthma
Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.
Asthma
PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model.
Asthma
PI3K and Notch signal pathways coordinately regulate the activation and proliferation of T lymphocytes in asthma.
Asthma
PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma.
Asthma
PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge.
Asthma
PI3K/AKT/mTOR and TLR4/MyD88/NF-?B Signaling Inhibitors Attenuate Pathological Mechanisms of Allergic Asthma.
Asthma
PI3K? contributes to ER stress-associated asthma through ER-redox disturbances: the involvement of the RIDD-RIG-I-NF-?B axis.
Asthma
Secretory Inositol Polyphosphate 4-Phosphatase Protects Against Airway Inflammation and Remodeling.
Asthma
The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity.
Asthma
The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
Asthma
The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma.
Asthma
The phosphoinositide 3'-kinase p110? modulates contractile protein production and IL-6 release in human airway smooth muscle.
Asthma
[Coordinated regulation of PI3K and Notch signal pathways in the activation and proliferation of CD4(+)T lymphocytes in asthma mice].
Asthma
[Expression profiles of PI3K, NF-?B, and STAT1 in peripheral blood mononuclear cells in children with bronchial asthma].
Asthma
[Intervention mechanism of moxa-cone moxibustion at Shu- and Mu-acupoints on the expression of ROR?t/Foxp3 in asthma mice: an analysis based on PI3K signaling pathway].
Asthma
[The effect of phosphoinositide-3-kinase and signal transducer and activator of transcription-6 on the proliferation of T lymphocytes in bronchial asthma]
Astrocytoma
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
Astrocytoma
Activation of phosphatidylinositol 3 kinase by muscarinic receptors in astrocytoma cells.
Astrocytoma
Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.
Astrocytoma
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.
Astrocytoma
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Astrocytoma
Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells.
Astrocytoma
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Astrocytoma
Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes.
Astrocytoma
The Prognostic Significance of RB and PI3K Pathway Alterations in IDH-Mutant Grade II/III Astrocytomas.
Ataxia
An Unusual Case of Metastatic Basal Cell Carcinoma of the Prostate: A Case Report and Literature Review.
Ataxia
Benzo[a]pyrene induces complex H2AX phosphorylation patterns by multiple kinases including ATM, ATR, and DNA-PK.
Ataxia
Effect of ovarian hormones on survival genes in laser captured serotonin neurons from macaques.
Ataxia
Evolving possible link between PI3K and NO pathways in neuroprotective mechanism of ischemic postconditioning in mice.
Ataxia
Induction of H2AX phosphorylation in tumor cells by gossypol acetic acid is mediated by phosphatidylinositol 3-kinase (PI3K) family.
Ataxia
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Ataxia Telangiectasia
A novel mutation in ATM gene in a Saudi female with ataxia telangiectasia.
Ataxia Telangiectasia
Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase.
Ataxia Telangiectasia
ATM, a paradigm for a stress-responsive signal transducer in higher vertebrate cells.
Ataxia Telangiectasia
DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product.
Ataxia Telangiectasia
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Ataxia Telangiectasia
ERK kinases modulate the activation of PI3 kinase related kinases (PIKKs) in DNA damage response.
Ataxia Telangiectasia
Human SMG-1 is Involved in Gemcitabine-Induced Primary microRNA-155/BIC Up-Regulation in Human Pancreatic Cancer PANC-1 Cells.
Ataxia Telangiectasia
Inside-Out Signaling Pathways from Nuclear Reactive Oxygen Species Control Pulmonary Innate Immunity.
Ataxia Telangiectasia
Nitric oxide-induced apoptosis in lymphoblastoid and fibroblast cells dependent on the phosphorylation and activation of p53.
Ataxia Telangiectasia
Orphan nuclear receptor SHP negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of STAT5 transactivation.
Ataxia Telangiectasia
PP2A Regulates Phosphorylation-Dependent Isomerization of Cytoplasmic and Mitochondrial-Associated ATR by Pin1 in DNA Damage Responses.
Ataxia Telangiectasia
Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM.
Ataxia Telangiectasia
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Ataxia Telangiectasia
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1.
Ataxia Telangiectasia
Six Novel ATM Gene Variants in Sri Lankan Patients with Ataxia Telangiectasia.
Ataxia Telangiectasia
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Ataxia Telangiectasia
Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, induces accumulation of DNA double-strand breaks.
Atherosclerosis
1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase.
Atherosclerosis
7?-Hydroxycholesterol induces inflammation by enhancing production of chemokine (C-C motif) ligand 2.
Atherosclerosis
Calcium channel blockers suppress cytokine-induced activation of human neutrophils.
Atherosclerosis
Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells.
Atherosclerosis
Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-gamma-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis.
Atherosclerosis
Heat-killed Staphylococcus aureus reduces atherosclerosis by inducing anti-inflammatory macrophages.
Atherosclerosis
Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway.
Atherosclerosis
LncRNA ENST00113 promotes proliferation, survival, and migration by activating PI3K/Akt/mTOR signaling pathway in atherosclerosis.
Atherosclerosis
LRP1 regulates architecture of the vascular wall by controlling PDGFRbeta-dependent phosphatidylinositol 3-kinase activation.
Atherosclerosis
Macrophage SR-BI modulates autophagy via VPS34 complex and PPAR? transcription of Tfeb in atherosclerosis.
Atherosclerosis
Network pharmacology-based exploration of therapeutic mechanism of Liu-Yu-Tang in atypical antipsychotic drug-induced metabolic syndrome.
Atherosclerosis
OxLDL induces mitogen-activated protein kinase activation mediated via PI3-kinase/Akt in vascular smooth muscle cells.
Atherosclerosis
Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
Atherosclerosis
PI3K p110? Deletion Attenuates Murine Atherosclerosis by Reducing Macrophage Proliferation but Not Polarization or Apoptosis in Lesions.
Atherosclerosis
PI3K regulates the activation of NLRP3 inflammasome in atherosclerosis through part-dependent AKT signaling pathway.
Atherosclerosis
Potent inhibition of serum-stimulated responses in vascular smooth muscle cell proliferation by 2-chloro-3-(4-hexylphenyl)-amino-1,4-naphthoquinone, a newly synthesized 1,4-naphthoquinone derivative.
Atherosclerosis
Systemic application of 3-methyladenine markedly inhibited atherosclerotic lesion in ApoE(-/-) mice by modulating autophagy, foam cell formation and immune-negative molecules.
Atherosclerosis
The Phosphoinositide 3-Kinase Signaling Pathway is Involved in the Control of Modified Low-Density Lipoprotein Uptake by Human Macrophages.
Atherosclerosis
Transplant atherosclerosis: role of phenotypic modulation of vascular smooth muscle by nitric oxide.
Atherosclerosis
[Hyperinsulinemia induced immune maturation of human monocyte derived dendritic cells: bridging between diabetes and atherosclerosis]
Atrial Fibrillation
Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence.
Atrial Fibrillation
Laminar shear stress alters endothelial KCa2.3 expression in H9c2 cells partially via regulating the PI3K/Akt/p300 axis.
Autoimmune Diseases
8e Protects against Acute Cerebral Ischemia by Inhibition of PI3K?-Mediated Superoxide Generation in Microglia.
Autoimmune Diseases
A combined risk score enhances prediction of type 1 diabetes among susceptible children.
Autoimmune Diseases
An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Autoimmune Diseases
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.
Autoimmune Diseases
Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.
Autoimmune Diseases
Immunomodulatory effects of Nigella sativa seed polysaccharides by gut microbial and proteomic technologies.
Autoimmune Diseases
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Autoimmune Diseases
Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.
Autoimmune Diseases
Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors for the Treatment of Inflammation and Autoimmune Disease.
Autoimmune Diseases
Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
Autoimmune Diseases
Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
Autoimmune Diseases
PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation.
Autoimmune Diseases
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1? production.
Autoimmune Diseases
PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt.
Autoimmune Diseases
Platelet PI3K? Contributes to Carotid Intima-Media Thickening under Severely Reduced Flow Conditions.
Autoimmune Diseases
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
Autoimmune Diseases
The PI-3-Kinase P110? Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis.
Autoimmune Diseases
The Selective Phosphoinoside-3-Kinase p110? Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.
Autoimmune Diseases
WITHDRAWN: Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors for the Treatment of Inflammation and Autoimmune Disease.
Autoimmune Lymphoproliferative Syndrome
Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature.
Bacterial Infections
Invasion of HeLa cells by group B streptococcus requires the phosphoinositide-3-kinase signalling pathway and modulates phosphorylation of host-cell Akt and glycogen synthase kinase-3.
Bacterial Infections
Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia.
Bacterial Infections
Phosphatidylinositol 3-Kinase p110? Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections.
Bacterial Infections
Phosphoinositide 3-kinase in nitric oxide synthesis in macrophage: critical dimerization of inducible nitric-oxide synthase.
Bacterial Infections
Role of EGFR transactivation in preventing apoptosis in Pseudomonas aeruginosa-infected human corneal epithelial cells.
Bacterial Infections
Role of epidermal growth factor receptor transactivation in PPAR gamma-dependent suppression of Helicobacter pylori interference with gastric mucin synthesis.
Bacterial Infections
Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells.
Biliary Tract Neoplasms
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Biliary Tract Neoplasms
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Blister
ADP Ribosylation Factor 6 (Arf6) Acts through FilGAP Protein to Down-regulate Rac Protein and Regulates Plasma Membrane Blebbing.
Blister
Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex.
Bone Diseases
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Bone Diseases
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Bone Diseases, Metabolic
Identification of Differential Genes Expression Profiles and Pathways of Bone Marrow Mesenchymal Stem Cells of Adolescent Idiopathic Scoliosis Patients by Microarray and Integrated Gene Network Analysis.
Bone Marrow Failure Disorders
Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish.
Bone Neoplasms
Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ-opioid receptor.
Bone Neoplasms
Electroacupuncture Attenuates Morphine Tolerance in Rats with Bone Cancer Pain by Inhibiting PI3K/Akt/JNK1/2 Signaling Pathway in the Spinal Dorsal Horn.
Bone Neoplasms
Formaldehyde up-regulates TRPV1 through MAPK and PI3K signaling pathways in a rat model of bone cancer pain.
Bone Neoplasms
Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain.
Bone Neoplasms
[Effects of intrathecal injection PI3K antagonist on inflammatory cytokines in spinal cord of bone cancer pain model in rats].
Bone Resorption
Cepharanthine Prevents Estrogen Deficiency-Induced Bone Loss by Inhibiting Bone Resorption.
Bone Resorption
Phosphatidylinositol 3,4,5-trisphosphate directs association of Src homology 2-containing signaling proteins with gelsolin.
Bone Resorption
Prostate transmembrane protein androgen induced 1 is induced by activation of osteoclasts and regulates bone resorption.
Bone Resorption
Rho-A is critical for osteoclast podosome organization, motility, and bone resorption.
Bone Resorption
Role of Cbl-PI3K Interaction during Skeletal Remodeling in a Murine Model of Bone Repair.
Bone Resorption
The phosphoinositide-3-kinase isoform PI3K? regulates osteoclast-mediated bone resorption.
Bone Resorption
Wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, inhibits osteoclastic bone resorption in vitro.
Bradycardia
Vagal stimulation suppresses ischemia-induced myocardial interstitial myoglobin release.
Brain Death
Altered Phosphatidylinositol 3-Kinase and Calcium Signaling in Cardiac Dysfunction After Brain Death in Rats.
Brain Diseases
Impact of ambient temperature on inflammation-induced encephalopathy in endotoxemic mice-role of phosphoinositide 3-kinase gamma.
Brain Diseases
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Brain Edema
Activation of the Melanocortin-1 Receptor by NDP-MSH Attenuates Oxidative Stress and Neuronal Apoptosis through PI3K/Akt/Nrf2 Pathway after Intracerebral Hemorrhage in Mice.
Brain Edema
Fibroblast growth factors preserve blood-brain barrier integrity through RhoA inhibition after intracerebral hemorrhage in mice.
Brain Edema
Pre-ischemic treadmill training alleviates brain damage via GLT-1-mediated signal pathway after ischemic stroke in rats.
Brain Edema
[Therapeutic hypothermia reduced brain damage on rats after cardiopulmonary resuscitation by activating III-type PI3K pathway to increase autophagy].
Brain Infarction
Pre-ischemic treadmill training alleviates brain damage via GLT-1-mediated signal pathway after ischemic stroke in rats.
Brain Injuries
Astragaloside IV alleviates the brain damage induced by subarachnoid hemorrhage via PI3K/Akt signaling pathway.
Brain Injuries
Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain.
Brain Injuries
Phosphoinositide 3-Kinase Gamma Contributes to Neuroinflammation in a Rat Model of Surgical Brain Injury.
Brain Injuries
The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction.
Brain Injuries
[Gly14]-Humanin Offers Neuroprotection through Glycogen Synthase Kinase-3? Inhibition in a Mouse Model of Intracerebral Hemorrhage.
Brain Injuries, Traumatic
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Brain Ischemia
Activation of the Akt/GSK3beta signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats.
Brain Ischemia
Early Activation of Phosphatidylinositol 3-Kinase after Ischemic Stroke Reduces Infarct Volume and Improves Long-Term Behavior.
Brain Ischemia
Emulsified Isoflurane Protects Against Transient Focal Cerebral Ischemia Injury in Rats via the PI3K/Akt Signaling Pathway.
Brain Ischemia
Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice.
Brain Ischemia
Icariin and mesenchymal stem cells synergistically promote angiogenesis and neurogenesis after cerebral ischemia via PI3K and ERK1/2 pathways.
Brain Ischemia
Inhibition of MLK3-MKK4/7-JNK1/2 pathway by Akt1 in exogenous estrogen-induced neuroprotection against transient global cerebral ischemia by a non-genomic mechanism in male rats.
Brain Ischemia
Neuroprotection of selenite against ischemic brain injury through negatively regulating early activation of ASK1/JNK cascade via activation of PI3K/AKT pathway.
Brain Ischemia
Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition.
Brain Ischemia
Oxidative stress affects the integrin-linked kinase signaling pathway after transient focal cerebral ischemia.
Brain Ischemia
PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats.
Brain Ischemia
PI3K/Akt Pathway Contributes to Neurovascular Unit Protection of Xiao-Xu-Ming Decoction against Focal Cerebral Ischemia and Reperfusion Injury in Rats.
Brain Ischemia
Possible Involvement of PI3-K/Akt-Dependent GSK-3? Signaling in Proliferation of Neural Progenitor Cells After Hypoxic Exposure.
Brain Ischemia
[Protective effects and mechanisms of Xingnaojing Injection on early global brain ischemic-induced deep coma in rats].
Brain Neoplasms
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
Brain Neoplasms
A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.
Brain Neoplasms
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Brain Neoplasms
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Brain Neoplasms
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Brain Neoplasms
Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Brain Neoplasms
Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
Brain Neoplasms
Mechanisms of Disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors.
Brain Neoplasms
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.
Brain Neoplasms
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.
Brain Neoplasms
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.
Brain Neoplasms
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Brain Neoplasms
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
Brain Neoplasms
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.
Brain Neoplasms
Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation.
Brain Neoplasms
Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.
Brain Neoplasms
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
Brain Neoplasms
PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
Brain Neoplasms
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer.
Brain Neoplasms
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Brain Neoplasms
Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy.
Brain Neoplasms
Quantitating cell-cell interaction functions with applications to glioblastoma multiforme cancer cells.
Brain Neoplasms
Sorafenib/Regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Brain Neoplasms
Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer Cells.
Brain Neoplasms
Striking the balance between PTEN and PDK1: it all depends on the cell context.
Brain Neoplasms
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Brain Neoplasms
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Brain Neoplasms
The catalytic phosphoinositol 3-kinase isoform p110? is required for glioma cell migration and invasion.
Brain Neoplasms
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Brain Neoplasms
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
Brain Neoplasms
Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer.
Brain Neoplasms
Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer.
Breast Neoplasms
"PIKing" the Winner for Phosphatidylinositol 3-Kinase Inhibitors in ErbB2-Positive Breast Cancer: Let's Not "PTENed" It's Easy!
Breast Neoplasms
(-)-Liriopein B Suppresses Breast Cancer Progression via Inhibition of Multiple Kinases.
Breast Neoplasms
11C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging.
Breast Neoplasms
17?-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells.
Breast Neoplasms
3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but akt-independent manner.
Breast Neoplasms
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Breast Neoplasms
3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers.
Breast Neoplasms
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
Breast Neoplasms
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Breast Neoplasms
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Breast Neoplasms
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Breast Neoplasms
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Breast Neoplasms
A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
Breast Neoplasms
A novel carcinogenic PI3K? mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.
Breast Neoplasms
A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer.
Breast Neoplasms
A novel Phosphatidylinositol 3-Kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes.
Breast Neoplasms
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
Breast Neoplasms
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.
Breast Neoplasms
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
Breast Neoplasms
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
Breast Neoplasms
A PI3K p110?-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
Breast Neoplasms
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
Breast Neoplasms
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Breast Neoplasms
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Breast Neoplasms
A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo.
Breast Neoplasms
A systematic review and meta-analysis of selected toxicity endpoints of alpelisib.
Breast Neoplasms
Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion.
Breast Neoplasms
Abrogating endocrine resistance by targeting ER? and PI3K in breast cancer.
Breast Neoplasms
Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells.
Breast Neoplasms
Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells.
Breast Neoplasms
Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors.
Breast Neoplasms
Adiponectin induces breast cancer cell migration and growth factor expression.
Breast Neoplasms
ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells.
Breast Neoplasms
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.
Breast Neoplasms
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Breast Neoplasms
AKT Regulation of Estrogen Receptor {beta} Transcriptional Activity in Breast Cancer.
Breast Neoplasms
Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer.
Breast Neoplasms
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.
Breast Neoplasms
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data.
Breast Neoplasms
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.
Breast Neoplasms
Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Breast Neoplasms
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer.
Breast Neoplasms
Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Breast Neoplasms
Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
Breast Neoplasms
An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells.
Breast Neoplasms
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
Breast Neoplasms
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Breast Neoplasms
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Breast Neoplasms
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Breast Neoplasms
Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Breast Neoplasms
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Breast Neoplasms
Analysis of the ways and methods of signaling pathways in regulating cell cycle of NIH3T3 at transcriptional level.
Breast Neoplasms
AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner.
Breast Neoplasms
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Breast Neoplasms
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Breast Neoplasms
Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.
Breast Neoplasms
Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Breast Neoplasms
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Breast Neoplasms
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Breast Neoplasms
Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.
Breast Neoplasms
Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
Breast Neoplasms
Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk.
Breast Neoplasms
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
Breast Neoplasms
Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study.
Breast Neoplasms
Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and in-silico expression analysis of CXCL12-CXCR4 associated biological regulatory network.
Breast Neoplasms
Author Correction: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-?B signaling.
Breast Neoplasms
Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.
Breast Neoplasms
Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.
Breast Neoplasms
AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats.
Breast Neoplasms
BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.
Breast Neoplasms
Benchmarking to the Gold Standard: Hyaluronan-Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture.
Breast Neoplasms
BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
Breast Neoplasms
Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4).
Breast Neoplasms
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.
Breast Neoplasms
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
Breast Neoplasms
Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.
Breast Neoplasms
Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.
Breast Neoplasms
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Breast Neoplasms
Breast Cancer Special Feature: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Breast Neoplasms
Breast cancer tissue slices as a model for evaluation of response to rapamycin.
Breast Neoplasms
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
Breast Neoplasms
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.
Breast Neoplasms
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Breast Neoplasms
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Breast Neoplasms
Calycosin Suppresses Breast Cancer Cell Growth via ER?-Dependent Regulation of IGF-1R, p38 MAPK and PI3K/Akt Pathways.
Breast Neoplasms
Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
Breast Neoplasms
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Breast Neoplasms
Capsaicin suppresses breast cancer cell viability by regulating the CDK8/PI3K/Akt/Wnt/??catenin signaling pathway.
Breast Neoplasms
Casticin inhibits breast cancer cell migration and invasion by down-regulation of PI3K/Akt signaling pathway.
Breast Neoplasms
Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
Breast Neoplasms
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Breast Neoplasms
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Breast Neoplasms
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.
Breast Neoplasms
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Breast Neoplasms
Characterization of the Components and Pharmacological Effects of Mountain-Cultivated Ginseng and Garden Ginseng Based on the Integrative Pharmacology Strategy.
Breast Neoplasms
Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer.
Breast Neoplasms
Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification.
Breast Neoplasms
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Breast Neoplasms
Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.
Breast Neoplasms
Clinical implications of Girdin and PI3K protein expression in breast cancer.
Breast Neoplasms
Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
Breast Neoplasms
Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Breast Neoplasms
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Breast Neoplasms
Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors.
Breast Neoplasms
CNK1 is a novel Akt interaction partner that promotes cell proliferation through the Akt-FoxO signalling axis.
Breast Neoplasms
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
Breast Neoplasms
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Breast Neoplasms
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Breast Neoplasms
Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Breast Neoplasms
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Breast Neoplasms
Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Breast Neoplasms
Combined Inhibition of Both p110? and p110? Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER(+) Breast Cancer.
Breast Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Breast Neoplasms
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Breast Neoplasms
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Breast Neoplasms
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Breast Neoplasms
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer.
Breast Neoplasms
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Breast Neoplasms
Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2- Breast cancer: A network meta-analysis of 19 RCTs.
Breast Neoplasms
Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Breast Neoplasms
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Breast Neoplasms
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
Breast Neoplasms
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Breast Neoplasms
Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation.
Breast Neoplasms
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.
Breast Neoplasms
Cooperative oncogenic effect and cell signaling crosstalk of co?occurring HER2 and mutant PIK3CA in mammary epithelial cells.
Breast Neoplasms
Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer.
Breast Neoplasms
Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Breast Neoplasms
Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.
Breast Neoplasms
Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer.
Breast Neoplasms
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
Breast Neoplasms
CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
Breast Neoplasms
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer.
Breast Neoplasms
Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer.
Breast Neoplasms
CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways.
Breast Neoplasms
Cytokines secreted by bone-metastatic breast cancer cells alter the expression pattern of f-actin and reduce focal adhesion plaques in osteoblasts through PI3K.
Breast Neoplasms
Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
Breast Neoplasms
Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer.
Breast Neoplasms
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Breast Neoplasms
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Breast Neoplasms
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Breast Neoplasms
Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Breast Neoplasms
Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Breast Neoplasms
Development of PI3K inhibitors: advances in clinical trials and new strategies (Review).
Breast Neoplasms
Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Breast Neoplasms
Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Breast Neoplasms
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Breast Neoplasms
Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds.
Breast Neoplasms
Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.
Breast Neoplasms
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Breast Neoplasms
Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Breast Neoplasms
Discovery, synthesis and molecular corroborations of medicinally important novel pyrazoles; drug efficacy determinations through in silico, in vitro and cytotoxicity validations.
Breast Neoplasms
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Neoplasms
Disulfiram Treatment Facilitates Phosphoinositide 3-Kinase Inhibition in Human Breast Cancer Cells In vitro and In vivo.
Breast Neoplasms
DNA damage uncouples the mitogenic response to IGF-I in MCF-7 malignant breast cancer cells by switching the roles of PI3 kinase and p21WAF1/Cip1.
Breast Neoplasms
Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF-? pathways in MCF-7 Cancer cells with PX-866 and Raloxifene.
Breast Neoplasms
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Breast Neoplasms
Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy.
Breast Neoplasms
Dual inhibition of PI3K and mTOR mitigates feedback-loop pAkt activation to improve tamoxifen response in breast cancer cells.
Breast Neoplasms
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Breast Neoplasms
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.
Breast Neoplasms
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer.
Breast Neoplasms
Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer.
Breast Neoplasms
Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway.
Breast Neoplasms
Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Breast Neoplasms
Effect of Taraxacum officinale extract on PI3K/Akt pathway in DMBA induced breast cancer in albino rats.
Breast Neoplasms
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression.
Breast Neoplasms
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Breast Neoplasms
EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling.
Breast Neoplasms
Electrochemical assay of the relationship between the inhibition of phosphatidylinositol 3-kinase pathway and estrogen receptor expression in breast cancer.
Breast Neoplasms
Elevated V-ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer.
Breast Neoplasms
Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells.
Breast Neoplasms
EMT transition alters interstitial fluid flow-induced signaling in ERBB2-positive breast cancer cells.
Breast Neoplasms
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Breast Neoplasms
Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status.
Breast Neoplasms
Enhanced PI3K p110? signaling confers acquired lapatinib resistance that can be effectively reversed by a p110?-selective PI3K inhibitor.
Breast Neoplasms
Enhanced sensitivity to rapamycin following long-term oestrogen deprivation in MCF-7, T-47-D and ZR-75-1 human breast cancer cells.
Breast Neoplasms
Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme.
Breast Neoplasms
ER and PI3K independently modulate endocrine resistance in ER positive breast cancer.
Breast Neoplasms
ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.
Breast Neoplasms
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Breast Neoplasms
Erratum for the Research Article: "The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation" by D. P. Kodack, V. Askoxylakis, G. B. Ferraro, Q. Sheng, M. Badeaux, S. Goel, X. Qi, R. Shankaraiah, Z. A. Cao, R. R. Ramjiawan, D. Bezwada, B. Patel, Y. Song, C. Costa, K. Naxerova, C. S. F. Wong, J. Kloepper, R. Das, A. Tam, J. Tanboon, D. G. Duda, C. R. Miller, M. B. Siegel, C. K. Anders, M. Sanders, M. V. Estrada, R. Schlegel, C. L. Arteaga, E. Brachtel, A. Huang, D. Fukumura, J. A. Engelman, R. K. Jain.
Breast Neoplasms
Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins.
Breast Neoplasms
Estradiol regulates the insulin-like growth factor-I (IGF-I) signalling pathway: a crucial role of phosphatidylinositol 3-kinase (PI 3-kinase) in estrogens requirement for growth of MCF-7 human breast carcinoma cells.
Breast Neoplasms
Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells.
Breast Neoplasms
Estrogen receptor ? induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells.
Breast Neoplasms
Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Breast Neoplasms
Ethanol Extracts of Dietary Herb, Alpinia nantoensis, Exhibit Anticancer Potential in Human Breast Cancer Cells.
Breast Neoplasms
Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells.
Breast Neoplasms
Evaluation of the Expression Level and Hormone Receptor Association of miR-126 in Breast Cancer.
Breast Neoplasms
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.
Breast Neoplasms
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Breast Neoplasms
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Breast Neoplasms
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
Breast Neoplasms
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
Breast Neoplasms
Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.
Breast Neoplasms
Fenhexamid induces cancer growth and survival via estrogen receptor-dependent and PI3K-dependent pathways in breast cancer models.
Breast Neoplasms
Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.
Breast Neoplasms
FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer.
Breast Neoplasms
Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.
Breast Neoplasms
FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells.
Breast Neoplasms
Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.
Breast Neoplasms
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Breast Neoplasms
Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.
Breast Neoplasms
Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration.
Breast Neoplasms
Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells.
Breast Neoplasms
GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer.
Breast Neoplasms
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Breast Neoplasms
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
Breast Neoplasms
Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer.
Breast Neoplasms
Genetics of breast cancer bone metastasis: a sequential multistep pattern.
Breast Neoplasms
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Breast Neoplasms
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Breast Neoplasms
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Breast Neoplasms
GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation.
Breast Neoplasms
Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals.
Breast Neoplasms
Growth factors change nuclear distribution of estrogen receptor-alpha via mitogen-activated protein kinase or phosphatidylinositol 3-kinase cascade in a human breast cancer cell line.
Breast Neoplasms
Guizhi Fuling Decoction inhibiting the PI3K and MAPK pathways in breast cancer cells revealed by HTS2 technology and systems pharmacology.
Breast Neoplasms
Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness.
Breast Neoplasms
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.
Breast Neoplasms
Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.
Breast Neoplasms
Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Breast Neoplasms
Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Breast Neoplasms
Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
Breast Neoplasms
Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes.
Breast Neoplasms
High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1?) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells.
Breast Neoplasms
Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer.
Breast Neoplasms
Highly sensitive profiling of CD44(+)/CD24(-) breast cancer stem cells by combining global mRNA amplification and next generation sequencing: Evidence for a hyperactive PI3K pathway.
Breast Neoplasms
hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Breast Neoplasms
Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.
Breast Neoplasms
Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance.
Breast Neoplasms
How Protein Kinase A Activates Canonical Tyrosine Kinase Signaling Pathways To Promote Granulosa Cell Differentiation.
Breast Neoplasms
HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Breast Neoplasms
Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
Breast Neoplasms
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Breast Neoplasms
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
Breast Neoplasms
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
Breast Neoplasms
Identification of mTORC2 as a Necessary Component of HRG/ErbB2-dependent Cellular Transformation.
Breast Neoplasms
IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors.
Breast Neoplasms
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Breast Neoplasms
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.
Breast Neoplasms
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Breast Neoplasms
ING5 inhibits epithelial-mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway.
Breast Neoplasms
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Breast Neoplasms
Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
Breast Neoplasms
Inhibition of ?-enolase affects the biological activity of breast cancer cells by attenuating PI3K/Akt signaling pathway.
Breast Neoplasms
Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K? inhibition through the transcriptional regulation of ER?.
Breast Neoplasms
Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells.
Breast Neoplasms
Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
Breast Neoplasms
Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
Breast Neoplasms
Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Breast Neoplasms
Inhibition of PI3K signaling triggered apoptotic potential of curcumin which is hindered by Bcl-2 through activation of autophagy in MCF-7 cells.
Breast Neoplasms
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.
Breast Neoplasms
Inhibition of the PI3K-AKT-mTOR pathway suppresses the adipocyte-mediated proliferation and migration of breast cancer cells.
Breast Neoplasms
Inhibitors of PI3K/ERK 1/2/p38 MAPK Show Preferential Activity Against Endocrine Resistant Breast Cancer Cells.
Breast Neoplasms
Inhibitors of STAT3, ?-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Breast Neoplasms
INPP4B promotes PI3K?-dependent late endosome formation and Wnt/?-catenin signaling in breast cancer.
Breast Neoplasms
Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells.
Breast Neoplasms
Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells.
Breast Neoplasms
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Breast Neoplasms
Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer.
Breast Neoplasms
Integrative genomic approaches identify IKBKE as a breast cancer oncogene.
Breast Neoplasms
Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
Breast Neoplasms
Jolkinolide B inhibits proliferation or migration and promotes apoptosis of MCF-7 or BT-474 breast cancer cells by downregulating the PI3K-Akt pathway.
Breast Neoplasms
KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.
Breast Neoplasms
Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Breast Neoplasms
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Breast Neoplasms
Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway.
Breast Neoplasms
L-plastin Ser5 phosphorylation is modulated by the PI3K/SGK pathway and promotes breast cancer cell invasiveness.
Breast Neoplasms
Lapatinib inhibits the activation of NF-?B through reducing phosphorylation of I?B-? in breast cancer cells.
Breast Neoplasms
LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
Breast Neoplasms
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Breast Neoplasms
Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling.
Breast Neoplasms
Lipoxygenase catalyzed metabolites derived from docosahexaenoic acid are promising antitumor agents against breast cancer.
Breast Neoplasms
LKB1 when associated with methylatedERa is a marker of bad prognosis in breast cancer.
Breast Neoplasms
LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.
Breast Neoplasms
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.
Breast Neoplasms
Low Dose of Acacetin Promotes Breast Cancer MCF-7 Cells Proliferation Through the Activation of ERK/ PI3K /AKT and Cyclin Signaling Pathway.
Breast Neoplasms
Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Breast Neoplasms
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Breast Neoplasms
Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-?B signaling.
Breast Neoplasms
Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
Breast Neoplasms
Manganese-12 acetate suppresses the migration, invasion, and epithelial-mesenchymal transition by inhibiting Wnt/?-catenin and PI3K/AKT signaling pathways in breast cancer cells.
Breast Neoplasms
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
Breast Neoplasms
Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro-tumorigenic secretome.
Breast Neoplasms
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
Breast Neoplasms
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Breast Neoplasms
Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.
Breast Neoplasms
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
Breast Neoplasms
miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.
Breast Neoplasms
Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
Breast Neoplasms
Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.
Breast Neoplasms
Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase.
Breast Neoplasms
MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Breast Neoplasms
Model-based in silico analysis of the PI3K/Akt pathway: the elucidation of cross-talk between diabetes and breast cancer.
Breast Neoplasms
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Breast Neoplasms
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer.
Breast Neoplasms
Molecular classification of estrogen receptor-positive/luminal breast cancers.
Breast Neoplasms
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Breast Neoplasms
Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents.
Breast Neoplasms
Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Breast Neoplasms
Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer.
Breast Neoplasms
More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
Breast Neoplasms
mTORC1 inhibition is required for sensitivity to PI3K p110? inhibitors in PIK3CA-mutant breast cancer.
Breast Neoplasms
Multiorgan metastasis of human HER-2? breast cancer in Rag2?/?;Il2rg?/? mice and treatment with PI3K inhibitor.
Breast Neoplasms
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Breast Neoplasms
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
Breast Neoplasms
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Breast Neoplasms
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
Breast Neoplasms
Natural product toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor.
Breast Neoplasms
NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
Breast Neoplasms
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Breast Neoplasms
New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen.
Breast Neoplasms
Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Breast Neoplasms
Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling.
Breast Neoplasms
Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling.
Breast Neoplasms
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.
Breast Neoplasms
Novel strategy in breast cancer therapy: Revealing the bright side of ginsenosides.
Breast Neoplasms
Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors.
Breast Neoplasms
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Breast Neoplasms
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Breast Neoplasms
Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Breast Neoplasms
Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.
Breast Neoplasms
Olaparib and ?-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Breast Neoplasms
Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects.
Breast Neoplasms
Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40.
Breast Neoplasms
Oncogene PRR14 promotes breast cancer through activation of PI3K signal pathway and inhibition of CHEK2 pathway.
Breast Neoplasms
Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.
Breast Neoplasms
Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
Breast Neoplasms
Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer.
Breast Neoplasms
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.
Breast Neoplasms
Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Breast Neoplasms
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Breast Neoplasms
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
Breast Neoplasms
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Breast Neoplasms
Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
Breast Neoplasms
Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis.
Breast Neoplasms
Overexpression of seven in absentia homolog 2 protein in human breast cancer tissues is associated with the promotion of tumor cell malignant behavior in in vitro.
Breast Neoplasms
Overview of the relevance of PI3K pathway in HR-positive breast cancer.
Breast Neoplasms
Oxymatrine Inhibits the Proliferation and Invasion of Breast Cancer Cells via the PI3K Pathway.
Breast Neoplasms
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
Breast Neoplasms
P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils.
Breast Neoplasms
p-TSA.H2O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer.
Breast Neoplasms
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Breast Neoplasms
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K? Inhibition.
Breast Neoplasms
PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.
Breast Neoplasms
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-? degrader activity in antitumor efficacy.
Breast Neoplasms
Pharmacological explorations of eco-friendly amide substituted (Z)-?-enaminones as anti-breast cancer drugs.
Breast Neoplasms
Pharmacological inactivation of the PI3K p110? prevents breast tumour progression by targeting cancer cells and macrophages.
Breast Neoplasms
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Breast Neoplasms
Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors.
Breast Neoplasms
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Breast Neoplasms
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.
Breast Neoplasms
Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.
Breast Neoplasms
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Breast Neoplasms
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Breast Neoplasms
Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.
Breast Neoplasms
Phosphatidylinositol 3-kinase (PI3K?)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.
Breast Neoplasms
Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.
Breast Neoplasms
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
Breast Neoplasms
Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
Breast Neoplasms
Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells.
Breast Neoplasms
Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes.
Breast Neoplasms
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.
Breast Neoplasms
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Breast Neoplasms
Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer.
Breast Neoplasms
Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations.
Breast Neoplasms
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Breast Neoplasms
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Breast Neoplasms
Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
Breast Neoplasms
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Breast Neoplasms
Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.
Breast Neoplasms
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth.
Breast Neoplasms
Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
Breast Neoplasms
Phosphoinositide 3-kinase signaling pathway mediated by p110? regulates invadopodia formation.
Breast Neoplasms
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Breast Neoplasms
Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Breast Neoplasms
Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44.
Breast Neoplasms
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
Breast Neoplasms
Phosphorylation and mRNA Splicing of Collapsin Response Mediator Protein-2 Determine Inhibition of Rho-Associated Protein Kinase (ROCK)-II Function in Carcinoma Cell Migration and Invasion.
Breast Neoplasms
Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential.
Breast Neoplasms
Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
Breast Neoplasms
PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis.
Breast Neoplasms
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer.
Breast Neoplasms
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Breast Neoplasms
PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1? expression in MCF-7 breast cancer cells.
Breast Neoplasms
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
Breast Neoplasms
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Breast Neoplasms
PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.
Breast Neoplasms
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Breast Neoplasms
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Breast Neoplasms
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.
Breast Neoplasms
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Breast Neoplasms
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Breast Neoplasms
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
Breast Neoplasms
PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
Breast Neoplasms
PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation.
Breast Neoplasms
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Breast Neoplasms
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
Breast Neoplasms
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
Breast Neoplasms
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer.
Breast Neoplasms
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
Breast Neoplasms
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.
Breast Neoplasms
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
Breast Neoplasms
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
Breast Neoplasms
PI3K Regulates YAP/TAZ in Mammary Tumorigenesis through Multiple Signaling Pathways.
Breast Neoplasms
PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer.
Breast Neoplasms
PI3K-p110? mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Breast Neoplasms
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Breast Neoplasms
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Breast Neoplasms
PI3K? inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism.
Breast Neoplasms
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Breast Neoplasms
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Breast Neoplasms
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Breast Neoplasms
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
Breast Neoplasms
PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
Breast Neoplasms
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
Breast Neoplasms
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Breast Neoplasms
PIK3CA gene amplification and PI3K p110? protein expression in breast carcinoma.
Breast Neoplasms
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Breast Neoplasms
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Breast Neoplasms
PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
Breast Neoplasms
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Breast Neoplasms
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Breast Neoplasms
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
Breast Neoplasms
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.
Breast Neoplasms
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Breast Neoplasms
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.
Breast Neoplasms
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Breast Neoplasms
PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
Breast Neoplasms
PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Breast Neoplasms
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Breast Neoplasms
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
Breast Neoplasms
Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking PDK1-AKT interaction.
Breast Neoplasms
Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition.
Breast Neoplasms
Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
Breast Neoplasms
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Breast Neoplasms
pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation.
Breast Neoplasms
Pre-clinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts.
Breast Neoplasms
Pre-existing Cell States Control Heterogeneity of Both EGFR and CXCR4 Signaling.
Breast Neoplasms
Preclinical Evaluation of a Fluorine-18 (18F)-Labeled Phosphatidylinositol 3-Kinase Inhibitor for Breast Cancer Imaging.
Breast Neoplasms
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.
Breast Neoplasms
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Breast Neoplasms
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Breast Neoplasms
Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
Breast Neoplasms
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Breast Neoplasms
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Breast Neoplasms
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Breast Neoplasms
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.
Breast Neoplasms
Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.
Breast Neoplasms
Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.
Breast Neoplasms
Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells.
Breast Neoplasms
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
Breast Neoplasms
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.
Breast Neoplasms
Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.
Breast Neoplasms
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Breast Neoplasms
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.
Breast Neoplasms
PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the ?-catenin signaling pathway.
Breast Neoplasms
PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Breast Neoplasms
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Breast Neoplasms
PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Breast Neoplasms
Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells.
Breast Neoplasms
Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Breast Neoplasms
Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Breast Neoplasms
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Breast Neoplasms
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Breast Neoplasms
Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.
Breast Neoplasms
Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.
Breast Neoplasms
RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling.
Breast Neoplasms
RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells.
Breast Neoplasms
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Breast Neoplasms
Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Breast Neoplasms
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
Breast Neoplasms
RTK-dependent inducible degradation of mutant PI3K? drives GDC-0077 (Inavolisib) efficacy.
Breast Neoplasms
Science Signaling Podcast for 21 February 2017: Pentraxin-3 in basal-like breast cancer.
Breast Neoplasms
Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy.
Breast Neoplasms
Serglycin promotes breast cancer cell aggressiveness: Induction of epithelial to mesenchymal transition, proteolytic activity and IL-8 signaling.
Breast Neoplasms
Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase.
Breast Neoplasms
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Breast Neoplasms
SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.
Breast Neoplasms
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
Breast Neoplasms
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Breast Neoplasms
Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells.
Breast Neoplasms
Signaling pathways responsible for cancer cell invasion as targets for cancer therapy.
Breast Neoplasms
Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer.
Breast Neoplasms
Signalling mechanisms regulating phenotypic changes in breast cancer cells.
Breast Neoplasms
Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.
Breast Neoplasms
Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Breast Neoplasms
Simultaneous Inhibition of EGFR and PI3K Enhances Radiosensitivity In Human Breast Cancer.
Breast Neoplasms
SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.
Breast Neoplasms
Specific requirement for the p85-p110alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells.
Breast Neoplasms
Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target.
Breast Neoplasms
Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.
Breast Neoplasms
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
Breast Neoplasms
Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways.
Breast Neoplasms
Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells.
Breast Neoplasms
Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins.
Breast Neoplasms
Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.
Breast Neoplasms
Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K.
Breast Neoplasms
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
Breast Neoplasms
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.
Breast Neoplasms
Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer.
Breast Neoplasms
Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.
Breast Neoplasms
Suppressing the molecular signaling pathways involved in inflammation and cancer in breast cancer cell lines MDA-MB-231 and MCF-7 by miR-590.
Breast Neoplasms
Suppression of epidermal growth factor receptor-mediated ?-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Breast Neoplasms
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Breast Neoplasms
Surfactin suppresses TPA-induced breast cancer cell invasion through the inhibition of MMP-9 expression.
Breast Neoplasms
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Breast Neoplasms
Synthesis and Anticancer Activity of the (R,S)-Benzofused 1,5-Oxathiepine Moiety Tethered to Purines through Alkylidenoxy Linkers.
Breast Neoplasms
Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Breast Neoplasms
Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells.
Breast Neoplasms
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Breast Neoplasms
Tanshinone IIA Induces Mitochondria Dependent Apoptosis in Prostate Cancer Cells in Association with an Inhibition of Phosphoinositide 3-Kinase/AKT Pathway.
Breast Neoplasms
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Breast Neoplasms
Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.
Breast Neoplasms
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Breast Neoplasms
Targeting PI3K and AMPK? Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer.
Breast Neoplasms
Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: which combination makes the whole greater than the sum of its parts?
Breast Neoplasms
Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Breast Neoplasms
Targeting the Phosphatidyl Inositol 3-Kinase Signaling Pathway in Breast Cancer.
Breast Neoplasms
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Breast Neoplasms
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Breast Neoplasms
Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Breast Neoplasms
TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer.
Breast Neoplasms
Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Breast Neoplasms
Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Breast Neoplasms
TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways.
Breast Neoplasms
The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.
Breast Neoplasms
The anticancer activities of Vernonia amygdalina Delile. Leaves on 4T1 breast cancer cells through phosphoinositide 3-kinase (PI3K) pathway.
Breast Neoplasms
The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
Breast Neoplasms
The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
Breast Neoplasms
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Breast Neoplasms
The catalytic class I(A) PI3K isoforms play divergent roles in breast cancer cell migration.
Breast Neoplasms
The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
Breast Neoplasms
The Comparison of RhoC and PI3K Gene Expression on the Breast Cancer Tissue and Benign Tumour Tissue.
Breast Neoplasms
The Effect of Chrysin Loaded PLGA-PEG on Metalloproteinase Gene Expression in Mouse 4T1 Tumor Model.
Breast Neoplasms
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.
Breast Neoplasms
The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K/Akt pathway and cell proliferation.
Breast Neoplasms
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
Breast Neoplasms
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
Breast Neoplasms
The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells.
Breast Neoplasms
The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
Breast Neoplasms
The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.
Breast Neoplasms
The inhibition of PI3K and NF?B promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells.
Breast Neoplasms
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Breast Neoplasms
The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway.
Breast Neoplasms
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to the Cytotoxic Effect of Carboplatin in Breast Cancer In Vitro.
Breast Neoplasms
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
Breast Neoplasms
The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts.
Breast Neoplasms
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer.
Breast Neoplasms
The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Breast Neoplasms
The PI3K and AIB1 interaction is involved in estrogen treated breast cancer cells.
Breast Neoplasms
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.
Breast Neoplasms
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Breast Neoplasms
The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings.
Breast Neoplasms
The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
Breast Neoplasms
The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis.
Breast Neoplasms
The Preparation of Ginsenoside Rg5, Its Antitumor Activity against Breast Cancer Cells and Its Targeting of PI3K.
Breast Neoplasms
The PREX1/Rac signaling axis: Potential as a biomarker and therapeutic target in breast cancer.
Breast Neoplasms
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.
Breast Neoplasms
The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells.
Breast Neoplasms
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
Breast Neoplasms
The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors.
Breast Neoplasms
Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.
Breast Neoplasms
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.
Breast Neoplasms
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.
Breast Neoplasms
Three-dimensional extracellular matrix culture models of EGFR signalling and drug response.
Breast Neoplasms
Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.
Breast Neoplasms
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Breast Neoplasms
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Breast Neoplasms
Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.
Breast Neoplasms
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
Breast Neoplasms
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
Breast Neoplasms
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Breast Neoplasms
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Breast Neoplasms
Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.
Breast Neoplasms
Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes.
Breast Neoplasms
Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Breast Neoplasms
Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
Breast Neoplasms
Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion.
Breast Neoplasms
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.
Breast Neoplasms
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
Breast Neoplasms
USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor ?.
Breast Neoplasms
Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
Breast Neoplasms
WAVE3 phosphorylation regulates the interplay between PI3K, TGF-?, and EGF signaling pathways in breast cancer.
Breast Neoplasms
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Breast Neoplasms
Wortmannin Reduces Metastasis and Angiogenesis of Human Breast Cancer Cells via Nuclear Factor- B-dependent Matrix Metalloproteinase-9 and Interleukin-8 Pathways.
Breast Neoplasms
ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells.
Breast Neoplasms
[Overexpression of HER2/neu downregulates wild p53 protein expression via PI3K and Ras/Raf/MEK/ERK pathways in human breast cancer cells]
Breast Neoplasms
[PI3K/AKT pathway activation and therapeutic consequences in breast cancer].
Breast Neoplasms
[The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7]
Bronchitis, Chronic
Phosphatidylinositol 3-kinase mediates mitogen-induced human airway smooth muscle cell proliferation.
Burkitt Lymphoma
BET Inhibition-Induced GSK3? Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
Burkitt Lymphoma
Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70.
Burkitt Lymphoma
Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
Burkitt Lymphoma
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
Burkitt Lymphoma
Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
Burkitt Lymphoma
Immunocytochemical detection of phosphatidylinositol 3 kinase in Burkitt lymphoma cells.
Burkitt Lymphoma
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Burkitt Lymphoma
Inhibition of the PI3K/AKT-NF-?B pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt's lymphoma.
Burkitt Lymphoma
Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Burkitt Lymphoma
Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells.
Burkitt Lymphoma
Simultaneous inhibition of Vps34 kinase would enhance PI3K? inhibitor cytotoxicity in the B-cell malignancies.
Capsule Opacification
Erufosine, a phosphoinositide-3-kinase inhibitor, to mitigate posterior capsule opacification in the human capsular bag model.
Carcinogenesis
(+)-2-(1-Hydroxyl-4-oxocyclohexyl) ethyl caffeate suppresses solar UV-induced skin carcinogenesis by targeting PI3K, ERK1/2, and p38.
Carcinogenesis
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
Carcinogenesis
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.
Carcinogenesis
A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer.
Carcinogenesis
A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma.
Carcinogenesis
A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.
Carcinogenesis
A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis.
Carcinogenesis
A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.
Carcinogenesis
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms.
Carcinogenesis
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Carcinogenesis
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Carcinogenesis
Activation of PDK-1 maintains mouse embryonic stem cell self-renewal in a PKB-dependent manner.
Carcinogenesis
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
Carcinogenesis
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
Carcinogenesis
Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Carcinogenesis
Airway PI3K pathway activation is an early and reversible event in lung cancer development.
Carcinogenesis
Altered Composition of Fatty Acids Exacerbates Hepatotumorigenesis during Activation of the Phosphatidylinositol 3-kinase Pathway.
Carcinogenesis
Arsenite-induced stress signaling: Modulation of the phosphoinositide 3'-kinase/Akt/FoxO signaling cascade.
Carcinogenesis
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Carcinogenesis
Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis.
Carcinogenesis
Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc.
Carcinogenesis
Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Carcinogenesis
BARgaining membranes for autophagosome formation: Regulation of autophagy and tumorigenesis by Bif-1/Endophilin B1.
Carcinogenesis
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Carcinogenesis
Biochemical and biological characterization of tumor-associated mutations of p110alpha.
Carcinogenesis
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Carcinogenesis
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
Carcinogenesis
BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737.
Carcinogenesis
Caffeine promotes ultraviolet B-induced apoptosis in human keratinocytes without complete DNA repair.
Carcinogenesis
Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.
Carcinogenesis
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Carcinogenesis
Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice.
Carcinogenesis
Class 1A PI3K regulates vessel integrity during development and tumorigenesis.
Carcinogenesis
CLDN4 silencing promotes proliferation and reduces chemotherapy sensitivity of gastric cancer cells through activation of the PI3K/Akt signalling pathway.
Carcinogenesis
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Carcinogenesis
Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Carcinogenesis
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Carcinogenesis
Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy.
Carcinogenesis
Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression.
Carcinogenesis
Correction: Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism.
Carcinogenesis
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Carcinogenesis
Crosstalking between Androgen and PI3K/AKT Signaling Pathways in Prostate Cancer Cells.
Carcinogenesis
Dally Proteoglycan Mediates the Autonomous and Nonautonomous Effects on Tissue Growth Caused by Activation of the PI3K and TOR Pathways.
Carcinogenesis
Depletion of PI3K p85alpha induces cell cycle arrest and apoptosis in colorectal cancer cells.
Carcinogenesis
Development and validation of a novel survival model for head and neck squamous cell carcinoma based on autophagy-related genes.
Carcinogenesis
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3K? inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Carcinogenesis
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Carcinogenesis
Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides.
Carcinogenesis
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
Carcinogenesis
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Carcinogenesis
Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma.
Carcinogenesis
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Carcinogenesis
Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist.
Carcinogenesis
Enhanced Urinary Bladder, Liver and Colon Carcinogenesis in Zucker Diabetic Fatty Rats in a Multiorgan Carcinogenesis Bioassay: Evidence for Mechanisms Involving Activation of PI3K Signaling and Impairment of p53 on Urinary Bladder Carcinogenesis.
Carcinogenesis
EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Carcinogenesis
Epigenetically silenced LINC02381 functions as a tumor suppressor by regulating PI3K-Akt signaling pathway.
Carcinogenesis
Expression cloning of protein targets for 3-phosphorylated phosphoinositides.
Carcinogenesis
Expression of factors and key components associated with the PI3K signaling pathway in colon cancer.
Carcinogenesis
Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer.
Carcinogenesis
Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget's disease.
Carcinogenesis
Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma.
Carcinogenesis
Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Carcinogenesis
Fangchinoline suppresses the proliferation, invasion and tumorigenesis of human osteosarcoma cells through the inhibition of PI3K and downstream signaling pathways.
Carcinogenesis
Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Carcinogenesis
FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway.
Carcinogenesis
FOXO3 Is Inhibited by Oncogenic PI3K/Akt Signaling but Can Be Reactivated by the NSAID Sulindac Sulfide.
Carcinogenesis
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Carcinogenesis
Functional inhibition of PI3K by the betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation.
Carcinogenesis
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Carcinogenesis
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Carcinogenesis
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Carcinogenesis
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Carcinogenesis
Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Carcinogenesis
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Carcinogenesis
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Carcinogenesis
Genomic instability and colon carcinogenesis: from the perspective of genes.
Carcinogenesis
Giant obscurins regulate the PI3K cascade in breast epithelial cells via direct binding to the PI3K/p85 regulatory subunit.
Carcinogenesis
Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors.
Carcinogenesis
High-throughput screening campaigns against a PI3K? isoform bearing the H1047R mutation identified potential inhibitors with novel scaffolds.
Carcinogenesis
HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3? signaling pathway.
Carcinogenesis
Homeobox gene Cdx1 regulates Ras, Rho and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells.
Carcinogenesis
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Carcinogenesis
Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
Carcinogenesis
Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer.
Carcinogenesis
Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
Carcinogenesis
Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus.
Carcinogenesis
Immunohistochemical characterisation of molecular subtypes in endometrial cancer.
Carcinogenesis
Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
Carcinogenesis
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Carcinogenesis
Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway.
Carcinogenesis
Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma.
Carcinogenesis
Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.
Carcinogenesis
Kaposi¿s sarcoma-associated herpesvirus G-protein coupled receptor activates the canonical Wnt/ß-catenin signaling pathway.
Carcinogenesis
Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth.
Carcinogenesis
Krebs medal review. How a lipid mediates tumour suppression: Delivered on 29 June 2010 at the 35th FEBS Congress in Gothenburg, Sweden.
Carcinogenesis
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin.
Carcinogenesis
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
Carcinogenesis
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
Carcinogenesis
Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population.
Carcinogenesis
Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism.
Carcinogenesis
Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro-tumorigenic secretome.
Carcinogenesis
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
Carcinogenesis
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy.
Carcinogenesis
MiR-7-5p inhibits thyroid cell proliferation by targeting the EGFR/MAPK and IRS2/PI3K signaling pathways.
Carcinogenesis
Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis.
Carcinogenesis
Modulation of integrin-linked kinase (ILK) expression in human oesophageal squamous cell carcinoma cell lines by the EGF and TGFbeta1 growth factors.
Carcinogenesis
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Carcinogenesis
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Carcinogenesis
Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy.
Carcinogenesis
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Carcinogenesis
Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth.
Carcinogenesis
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Carcinogenesis
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.
Carcinogenesis
NF-kappaB regulates androgen receptor expression and prostate cancer growth.
Carcinogenesis
Novel mutations of the HRAS gene and absence of hotspot mutations of the BRAF genes in oral squamous cell carcinoma in a Greek population.
Carcinogenesis
Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis.
Carcinogenesis
Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
Carcinogenesis
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Carcinogenesis
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Carcinogenesis
P55PIK Regulates P53-Dependent Apoptosis in Cancer Cells by Interacting with P53 DNA-Specific Domain.
Carcinogenesis
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Carcinogenesis
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Carcinogenesis
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Carcinogenesis
Phosphatidylinositol 3-Kinase Inhibitor LY294002 Suppresses Proliferation and Sensitizes Doxorubicin Chemotherapy in Bladder Cancer Cells.
Carcinogenesis
Phosphatidylinositol 3-kinase, a novel target molecule for the inhibitory effects of kaempferol on neoplastic cell transformation.
Carcinogenesis
Phosphoinositol 3-kinase, a novel target molecule for the inhibitory effects of juglone on TPA-induced cell transformation.
Carcinogenesis
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
Carcinogenesis
Phosphorylation of middle T by pp60c-src: a switch for binding of phosphatidylinositol 3-kinase and optimal tumorigenesis.
Carcinogenesis
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
Carcinogenesis
PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine.
Carcinogenesis
PI3K is required for the physical interaction and functional inhibition of NF-?B by ?-catenin in colorectal cancer cells.
Carcinogenesis
PI3K Regulates YAP/TAZ in Mammary Tumorigenesis through Multiple Signaling Pathways.
Carcinogenesis
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
Carcinogenesis
PI3K/Akt Pathway and miR-21 are Involved in N-Ethyl-N-Nitrosourea-Induced F1 Mouse Lung Tumorigenesis: Effect of Inositol Hexaphosphate.
Carcinogenesis
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Carcinogenesis
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Carcinogenesis
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
Carcinogenesis
PIK3CA Is Regulated by CUX1, Promotes Cell Growth and Metastasis in Bladder Cancer via Activating Epithelial-Mesenchymal Transition.
Carcinogenesis
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
Carcinogenesis
PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival.
Carcinogenesis
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
Carcinogenesis
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
Carcinogenesis
PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.
Carcinogenesis
PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance.
Carcinogenesis
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
Carcinogenesis
Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
Carcinogenesis
PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo.
Carcinogenesis
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Carcinogenesis
Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer.
Carcinogenesis
Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis.
Carcinogenesis
Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas.
Carcinogenesis
PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis.
Carcinogenesis
Quantitative redox imaging biomarkers for studying tissue metabolic state and its heterogeneity.
Carcinogenesis
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.
Carcinogenesis
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.
Carcinogenesis
Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis.
Carcinogenesis
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
Carcinogenesis
Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains.
Carcinogenesis
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Carcinogenesis
Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Carcinogenesis
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.
Carcinogenesis
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Carcinogenesis
Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression.
Carcinogenesis
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.
Carcinogenesis
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Carcinogenesis
Romidepsin (FK228) and its analogs directly inhibit PI3K activity and potently induce apoptosis as HDAC/PI3K dual inhibitors.
Carcinogenesis
Sh3glb1/Bif-1 and mitophagy: Acquisition of apoptosis resistance during Myc-driven lymphomagenesis.
Carcinogenesis
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
Carcinogenesis
Simultaneous inhibition of PI3K? and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.
Carcinogenesis
Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses.
Carcinogenesis
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Carcinogenesis
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Carcinogenesis
Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue.
Carcinogenesis
SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation.
Carcinogenesis
Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3K?) and Its Involvement in Oncogenesis: An in Silico Insight.
Carcinogenesis
Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K?-specific inhibitors for the treatment of hematologic malignancies.
Carcinogenesis
Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression.
Carcinogenesis
Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells.
Carcinogenesis
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Carcinogenesis
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Carcinogenesis
Taxifolin Suppresses UV-Induced Skin Carcinogenesis by Targeting EGFR and PI3K.
Carcinogenesis
TGF-beta inhibits Akt-induced transformation in intestinal epithelial cells.
Carcinogenesis
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.
Carcinogenesis
The botanical component p-hydroxycinnamic acid suppresses the growth and bone metastatic activity of human prostate cancer PC-3 cells in vitro.
Carcinogenesis
The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
Carcinogenesis
The Frequencies and Clinical Implications of Mutations in 33 Kinase-Related Genes in Locally Advanced Rectal Cancer: A Pilot Study.
Carcinogenesis
The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways.
Carcinogenesis
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
Carcinogenesis
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.
Carcinogenesis
The p110? and p110? isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.
Carcinogenesis
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Carcinogenesis
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
Carcinogenesis
The phytochemical p-hydroxycinnamic acid suppresses the growth and stimulates the death in human liver cancer HepG2 cells.
Carcinogenesis
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Carcinogenesis
The Rho guanine nucleotide exchange factor ARHGEF5 promotes tumor malignancy via epithelial-mesenchymal transition.
Carcinogenesis
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
Carcinogenesis
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Carcinogenesis
The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses.
Carcinogenesis
Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice.
Carcinogenesis
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Carcinogenesis
Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Carcinogenesis
Upregulation of FLJ10540, a PI3K-association protein, in rostral ventrolateral medulla impairs brain stem cardiovascular regulation during mevinphos intoxication.
Carcinogenesis
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
Carcinogenesis
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.
Carcinogenesis
[Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients].
Carcinogenesis
[Clinicopathological Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-small Cell Lung Cancer.]
Carcinogenesis
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
Carcinoid Tumor
Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling.
Carcinoid Tumor
Secretin Receptor Promotes the Proliferation of Endocrine Tumor Cells Via the PI3K/AKT Pathway.
Carcinoma
A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer.
Carcinoma
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Carcinoma
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Carcinoma
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Carcinoma
A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.
Carcinoma
A novel mitogenic signaling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of a Gq/11 protein, phosphatidylinositol 3-kinase beta, and protein kinase Cepsilon.
Carcinoma
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
Carcinoma
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Carcinoma
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Carcinoma
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Carcinoma
Abnormal expression of PI3K isoforms in patients with tobacco-related oral squamous cell carcinoma.
Carcinoma
Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas.
Carcinoma
Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
Carcinoma
Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion.
Carcinoma
Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Carcinoma
Adaptive resistance to PI3K?-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells.
Carcinoma
Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas.
Carcinoma
Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy.
Carcinoma
AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.
Carcinoma
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Carcinoma
Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.
Carcinoma
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Carcinoma
Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy.
Carcinoma
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Carcinoma
Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.
Carcinoma
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Carcinoma
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Carcinoma
Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.
Carcinoma
Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells.
Carcinoma
Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
Carcinoma
Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3-kinase Inhibition in the Human Cervical Cancer Cell-line.
Carcinoma
Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells.
Carcinoma
AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Carcinoma
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.
Carcinoma
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Carcinoma
Biallelic ERBB3 loss-of-function variants are associated with a novel multisystem syndrome without congenital contracture.
Carcinoma
Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Carcinoma
Brassinin enhances the anticancer actions of paclitaxel by targeting multiple signaling pathways in colorectal cancer cells.
Carcinoma
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Carcinoma
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Carcinoma
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Carcinoma
C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways.
Carcinoma
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Carcinoma
Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells.
Carcinoma
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Carcinoma
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma
Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia.
Carcinoma
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Carcinoma
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.
Carcinoma
Contribution of the PI3K/MMPs/Ln-5?2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas.
Carcinoma
Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity.
Carcinoma
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Carcinoma
Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
Carcinoma
Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Carcinoma
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Carcinoma
Differential DNA methylation status between breast carcinomatous and normal tissues.
Carcinoma
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Carcinoma
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.
Carcinoma
Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Carcinoma
Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.
Carcinoma
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Carcinoma
Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Carcinoma
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Carcinoma
E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells.
Carcinoma
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Carcinoma
Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.
Carcinoma
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Carcinoma
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Carcinoma
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Carcinoma
Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.
Carcinoma
Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors.
Carcinoma
Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
Carcinoma
Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor.
Carcinoma
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Carcinoma
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Carcinoma
Erratum to: Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Carcinoma
Esophageal squamous cell carcinoma transcriptome reveals the effect of FOXM1 on patient outcome through novel PIK3R3 mediated activation of PI3K signaling pathway.
Carcinoma
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Carcinoma
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
Carcinoma
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Carcinoma
Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.
Carcinoma
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.
Carcinoma
Expression of Phosphoinositide 3-Kinase p110? and p110? Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma.
Carcinoma
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Carcinoma
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Carcinoma
Ferulic Acid Induces Apoptosis of HeLa and Caski Cervical Carcinoma Cells by Down-Regulating the Phosphatidylinositol 3-Kinase (PI3K)/Akt Signaling Pathway.
Carcinoma
Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells.
Carcinoma
Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter-1 and hypoxia-inducible-factor-1? and the phosphoinositide 3-kinase/protein kinase B pathway.
Carcinoma
Formal model of the interplay between TGF?1 and MMP-9 and their dynamics in hepatocellular carcinoma.
Carcinoma
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Carcinoma
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Carcinoma
Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.
Carcinoma
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.
Carcinoma
Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin ?1 Signaling Pathways in Bladder Carcinoma.
Carcinoma
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Carcinoma
GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
Carcinoma
GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.
Carcinoma
Hepatocyte growth factor inhibits anoikis of pancreatic carcinoma cells through phosphatidylinositol 3-kinase pathway.
Carcinoma
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Carcinoma
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Carcinoma
High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations.
Carcinoma
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Carcinoma
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Carcinoma
Identification of a developmental gene expression signature, including HOX genes, for the normal human colonic crypt stem cell niche - Overexpression of the signature parallels stem cell overpopulation during colon tumorigenesis.
Carcinoma
Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses.
Carcinoma
Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
Carcinoma
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Carcinoma
In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
Carcinoma
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Carcinoma
Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
Carcinoma
Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells.
Carcinoma
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Carcinoma
Inhibition of PI3K Isoform p110? Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
Carcinoma
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Carcinoma
Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45.
Carcinoma
Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17.
Carcinoma
Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine.
Carcinoma
JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Carcinoma
Knockdown of ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.
Carcinoma
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
Carcinoma
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Carcinoma
Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/?-catenin signaling pathway.
Carcinoma
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.
Carcinoma
Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor.
Carcinoma
LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
Carcinoma
MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck.
Carcinoma
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.
Carcinoma
Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma.
Carcinoma
MicroRNA?98/PTEN/AKT pathway inhibits cell proliferation and malignant progression of hypopharyngeal carcinoma by MTDH.
Carcinoma
Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma.
Carcinoma
Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Carcinoma
Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.
Carcinoma
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Carcinoma
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.
Carcinoma
Mutational status of PIK3ca oncogene in oral cancer-In the new age of PI3K inhibitors.
Carcinoma
Network Analysis of the Focal Adhesion to Invadopodia Transition Identifies a PI3K-PKC? Invasive Signaling Axis.
Carcinoma
NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells.
Carcinoma
Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.
Carcinoma
Omega-3 polyunsaturated fatty acids selectively inhibit growth in neoplastic oral keratinocytes by differentially activating ERK1/2.
Carcinoma
Oncogenic activation of the PI3-kinase p110? isoform via the tumor-derived PIK3C?(D1067V) kinase domain mutation.
Carcinoma
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Carcinoma
Oral squamous cell carcinoma (OSCC)-derived exosomal MiR-221 targets and regulates phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) to promote human umbilical vein endothelial cells migration and tube formation.
Carcinoma
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.
Carcinoma
Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells.
Carcinoma
p120-catenin suppresses proliferation and tumor growth of oral squamous cell carcinoma via inhibiting nuclear phospholipase C-?1 signaling.
Carcinoma
p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors.
Carcinoma
Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.
Carcinoma
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
Carcinoma
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Carcinoma
Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells.
Carcinoma
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Carcinoma
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Carcinoma
Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.
Carcinoma
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer.
Carcinoma
PI3k and Stat3: Oncogenes that are Required for Gap Junctional, Intercellular Communication.
Carcinoma
PI3K Catalytic Subunits ? and ? Modulate Cell Death and IL-6 Secretion Induced by Talc Particles in Human Lung Carcinoma Cells.
Carcinoma
PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.
Carcinoma
PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
Carcinoma
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
Carcinoma
PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma.
Carcinoma
PI3K is required for both basal and LPA-induced DNA synthesis in oral carcinoma cells.
Carcinoma
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Carcinoma
PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation.
Carcinoma
PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation.
Carcinoma
PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
Carcinoma
PIK3C3 Acts as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and Was Regulated by MiR-340-5p.
Carcinoma
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
Carcinoma
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Carcinoma
PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals.
Carcinoma
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Carcinoma
Progranulin expression induced by follicle-stimulating hormone in ovarian cancer cell lines depends on the histological subtype.
Carcinoma
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.
Carcinoma
PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
Carcinoma
PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Carcinoma
PTHrP increases xenograft growth and promotes integrin alpha6beta4 expression and Akt activation in colon cancer.
Carcinoma
RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Carcinoma
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Carcinoma
Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: Clinicopathological features and biomarkers of adenoid cystic carcinoma.
Carcinoma
Reduced expression of E-cadherin and p120-catenin and elevated expression of PLC-?1 and PIKE are associated with aggressiveness of oral squamous cell carcinoma.
Carcinoma
Retraction. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells.
Carcinoma
Salivary Duct Carcinoma: Targeting the Phosphatidylinositol 3-Kinase Pathway by Blocking Mammalian Target of Rapamycin With Temsirolimus.
Carcinoma
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Carcinoma
Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-?B Pathway Activity: A Novel Approach to a Long-Standing Enigma.
Carcinoma
Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.
Carcinoma
Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Carcinoma
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Carcinoma
Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
Carcinoma
SLC39A6 Promotes Aggressiveness of Esophageal Carcinoma Cells by Increasing Intracellular Levels of Zinc, Activating Phosphatidylinositol 3-kinase Signaling, and Upregulating Genes That Regulate Metastasis.
Carcinoma
SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis.
Carcinoma
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.
Carcinoma
STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
Carcinoma
Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002.
Carcinoma
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K? inhibition in head and neck squamous cell carcinoma.
Carcinoma
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Carcinoma
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
Carcinoma
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Carcinoma
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Carcinoma
Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer.
Carcinoma
TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN.
Carcinoma
The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function.
Carcinoma
The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro.
Carcinoma
The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1? and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
Carcinoma
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
Carcinoma
The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
Carcinoma
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Carcinoma
The p110? and p110? isoforms of class I phosphatidylinositol 3-kinase are involved in toll-like receptor 5 signaling in epithelial cells.
Carcinoma
The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
Carcinoma
The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.
Carcinoma
The phosphoinositide-3-kinase/Akt pathway mediates the transient increase in Nanog expression during differentiation of F9 cells.
Carcinoma
The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.
Carcinoma
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Carcinoma
Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.
Carcinoma
Transmembrane Collagen XVII Modulates Integrin Dependent Keratinocyte Migration via PI3K/Rac1 Signaling.
Carcinoma
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Carcinoma
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
Carcinoma
[Corrigendum] STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
Carcinoma
[Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells].
Carcinoma
[Effect of licochalcone A on autophagy in renal cell carcinoma via PI3K/Akt/mTOR signaling pathway].
Carcinoma
[Effects of class I( phosphatidylinositol-3-kinases inhibitor on gastric cancer cell xenografts in nude mice].
Carcinoma
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]
Carcinoma
[Expression and clinical significance of PI3K in esophageal squamous cell carcinoma].
Carcinoma
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Carcinoma
[Expression and significance of Ki-67, PI3K and Beclin1 in oral squamous cell carcinoma].
Carcinoma
[Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer]
Carcinoma
[Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells]
Carcinoma
[Research of Feiliuping Gao and its combination with different types of drugs intervention on expression of PI3K/AKT/NF-?B in lung metastatic microenvironment].
Carcinoma, Adenoid Cystic
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
Carcinoma, Adenoid Cystic
JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Carcinoma, Adenoid Cystic
Problematic breast tumors reassessed in light of novel molecular data.
Carcinoma, Adenoid Cystic
Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: Clinicopathological features and biomarkers of adenoid cystic carcinoma.
Carcinoma, Basal Cell
PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation.
Carcinoma, Ductal
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Carcinoma, Ductal
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
Carcinoma, Ductal
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Carcinoma, Ductal
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
Carcinoma, Endometrioid
Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.
Carcinoma, Endometrioid
Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/?-catenin and PTEN.
Carcinoma, Endometrioid
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
Carcinoma, Endometrioid
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Carcinoma, Endometrioid
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
Carcinoma, Hepatocellular
A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion.
Carcinoma, Hepatocellular
A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulationof hepatic VLDL triglyceride secretion.
Carcinoma, Hepatocellular
Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation.
Carcinoma, Hepatocellular
Alpha-fetoprotein: A new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines.
Carcinoma, Hepatocellular
Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line.
Carcinoma, Hepatocellular
Arctigenin, a Natural Lignan Compound, Induces Apoptotic Death of Hepatocellular Carcinoma Cells via Suppression of PI3-K/Akt Signaling.
Carcinoma, Hepatocellular
Asparagus Polysaccharide inhibits the Hypoxia-induced migration, invasion and angiogenesis of Hepatocellular Carcinoma Cells partly through regulating HIF1?/VEGF expression via MAPK and PI3K signaling pathway.
Carcinoma, Hepatocellular
Author Correction: Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Basic fibroblast growth factor upregulates survivin expression in hepatocellular carcinoma cells via a protein kinase B-dependent pathway.
Carcinoma, Hepatocellular
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Carcinoma, Hepatocellular
BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K.
Carcinoma, Hepatocellular
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma, Hepatocellular
CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways.
Carcinoma, Hepatocellular
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Carcinoma, Hepatocellular
Correction to: Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Detection of a 60 kDa tyrosine-phosphorylated protein in insulin-stimulated hepatoma cells that associates with the SH2 domain of phosphatidylinositol 3-kinase.
Carcinoma, Hepatocellular
Direct association of heat shock protein 20 (HSPB6) with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma: regulation of the PI3K activity.
Carcinoma, Hepatocellular
Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Carcinoma, Hepatocellular
Effects of PI3K and p42/p44 MAPK on overexpression of vascular endothelial growth factor in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Carcinoma, Hepatocellular
GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
Carcinoma, Hepatocellular
Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.
Carcinoma, Hepatocellular
Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase.
Carcinoma, Hepatocellular
Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma.
Carcinoma, Hepatocellular
Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis.
Carcinoma, Hepatocellular
Heterogeneous kinetics of AKT signaling in individual cells are accounted for by variable protein concentration.
Carcinoma, Hepatocellular
HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Carcinoma, Hepatocellular
Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis.
Carcinoma, Hepatocellular
Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
Carcinoma, Hepatocellular
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Carcinoma, Hepatocellular
Improved synergistic anticancer efficacy of quercetin in combination with PI-103, rottlerin, and G0 6983 against MCF-7 and RAW 264.7 cells.
Carcinoma, Hepatocellular
Increased activity and nuclear localisation of inositol lipid signal transduction enzymes in rat hepatoma cells.
Carcinoma, Hepatocellular
Induction of apoptosis and suppression of angiogenesis of hepatocellular carcinoma by HS-159, a novel phosphatidylinositol 3-kinase inhibitor.
Carcinoma, Hepatocellular
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling.
Carcinoma, Hepatocellular
Inhibition of B7-H4 promotes hepatocellular carcinoma cell apoptosis and autophagy through the PI3K signaling pathway.
Carcinoma, Hepatocellular
Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells.
Carcinoma, Hepatocellular
Insulin downregulates C3 gene expression in human HepG2 cells through activation of PPAR?.
Carcinoma, Hepatocellular
Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways.
Carcinoma, Hepatocellular
Involvement of c-Met- and phosphatidylinositol 3-kinase dependent pathways in arsenite-induced downregulation of catalase in hepatoma cells.
Carcinoma, Hepatocellular
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.
Carcinoma, Hepatocellular
IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Carcinoma, Hepatocellular
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin.
Carcinoma, Hepatocellular
Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway.
Carcinoma, Hepatocellular
Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Melatonin and (-)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer.
Carcinoma, Hepatocellular
Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing Survivin.
Carcinoma, Hepatocellular
Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade.
Carcinoma, Hepatocellular
Morin fosters apoptosis in experimental hepatocellular carcinogenesis model.
Carcinoma, Hepatocellular
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.
Carcinoma, Hepatocellular
Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Nickel and copper ion-induced stress signaling in human hepatoma cells: analysis of phosphoinositide 3'-kinase/Akt signaling.
Carcinoma, Hepatocellular
Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway.
Carcinoma, Hepatocellular
Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Overexpression of integrin beta1 inhibits proliferation of hepatocellular carcinoma cell SMMC-7721 through preventing Skp2-dependent degradation of p27 via PI3K pathway.
Carcinoma, Hepatocellular
Overexpression of PEMT2 downregulates the PI3K/Akt signaling pathway in rat hepatoma cells.
Carcinoma, Hepatocellular
Overexpression of PIK3R1 promotes hepatocellular carcinoma progression.
Carcinoma, Hepatocellular
PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
Carcinoma, Hepatocellular
Phosphorylated p27(Kip1) on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro.
Carcinoma, Hepatocellular
PI3K class 1B controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation.
Carcinoma, Hepatocellular
PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.
Carcinoma, Hepatocellular
POSSIBLE REGULATION OF LDL-RECEPTOR BY NARINGENIN IN HEPG2 HEPATOMA CELL LINE.
Carcinoma, Hepatocellular
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Carcinoma, Hepatocellular
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Hepatocellular
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Carcinoma, Hepatocellular
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway.
Carcinoma, Hepatocellular
Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
Carcinoma, Hepatocellular
Role of hesperetin in LDL-receptor expression in hepatoma HepG2 cells.
Carcinoma, Hepatocellular
Selective Targeting of ?v?5 Integrin in HepG2 Cell Line by RGDechi15D Peptide.
Carcinoma, Hepatocellular
Staurosporine suppresses survival of HepG2 cancer cells through Omi/HtrA2-mediated inhibition of PI3K/Akt signaling pathway.
Carcinoma, Hepatocellular
Stimulation of glycogen synthesis by insulin requires S6 kinase and phosphatidylinositol-3-kinase in HTC-IR cells.
Carcinoma, Hepatocellular
STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway.
Carcinoma, Hepatocellular
Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Carcinoma, Hepatocellular
Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.
Carcinoma, Hepatocellular
The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family.
Carcinoma, Hepatocellular
The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade.
Carcinoma, Hepatocellular
The essential role of phosphatidylinositol 3-kinase and of p38 mitogen-activated protein kinase activation in the antioxidant response element-mediated rGSTA2 induction by decreased glutathione in H4IIE hepatoma cells.
Carcinoma, Hepatocellular
The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade.
Carcinoma, Hepatocellular
The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway.
Carcinoma, Hepatocellular
The ménage à trois of autophagy, lipid droplets and liver disease.
Carcinoma, Hepatocellular
The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
Carcinoma, Hepatocellular
The phosphoinositide 3-kinase pathway and glycogen synthase kinase-3 positively regulate the activity of metal-responsive transcription factor-1 in response to zinc ions.
Carcinoma, Hepatocellular
The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases.
Carcinoma, Hepatocellular
Therapeutic dose of HIV-1 protease inhibitor saquinavir does not permanently influence early insulin signaling.
Carcinoma, Hepatocellular
Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1.
Carcinoma, Hepatocellular
Two specific inhibitors of the phosphatidylinositol 3-kinase LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and thus sensitize SMMC-7721 human hepatocarcinoma cells to cycloheximide-induced apoptosis.
Carcinoma, Hepatocellular
Ubiquitination of UVRAG by SMURF1 promotes autophagosome maturation and inhibits hepatocellular carcinoma growth.
Carcinoma, Hepatocellular
Velvet antler polypeptide prevents the disruption of hepatic tight junctions via inhibiting oxidative stress in cholestatic mice and liver cell lines.
Carcinoma, Hepatocellular
Vps34 Inhibits Hepatocellular Carcinoma Invasion by Regulating Endosome-Lysosome Trafficking via Rab7-RILP and Rab11.
Carcinoma, Hepatocellular
Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.
Carcinoma, Hepatocellular
[Insulin/PI3K signalling pathway regulates the expression of survivin in liver cancer HepG2 cells]
Carcinoma, Hepatocellular
[Roles of PIK3R1 gene in development of hepatocellular carcinoma].
Carcinoma, Intraductal, Noninfiltrating
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Carcinoma, Intraductal, Noninfiltrating
Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
Carcinoma, Intraductal, Noninfiltrating
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ--Implications for Progression to Invasive Breast Carcinoma.
Carcinoma, Lewis Lung
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Carcinoma, Lewis Lung
[Research of Feiliuping Gao and its combination with different types of drugs intervention on expression of PI3K/AKT/NF-?B in lung metastatic microenvironment].
Carcinoma, Lobular
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.
Carcinoma, Merkel Cell
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Carcinoma, Merkel Cell
Phosphatidylinositol 3-kinase p110? expression in Merkel cell carcinoma.
Carcinoma, Mucoepidermoid
Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Carcinoma, Non-Small-Cell Lung
A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
Carcinoma, Non-Small-Cell Lung
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Carcinoma, Non-Small-Cell Lung
Andrographolide down-regulates hypoxia-inducible factor-1? in human non-small cell lung cancer A549 cells.
Carcinoma, Non-Small-Cell Lung
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Carcinoma, Non-Small-Cell Lung
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Carcinoma, Non-Small-Cell Lung
BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating ?-catenin/ZEB1 regulatory loop.
Carcinoma, Non-Small-Cell Lung
Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
Carcinoma, Non-Small-Cell Lung
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Carcinoma, Non-Small-Cell Lung
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
DEPENDENCE ON THE MUC1-C ONCOPROTEIN IN NON-SMALL CELL LUNG CANCER CELLS WITH EGFR AND K-RAS MUTATIONS.
Carcinoma, Non-Small-Cell Lung
Diprophylline inhibits non-small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway.
Carcinoma, Non-Small-Cell Lung
Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Carcinoma, Non-Small-Cell Lung
Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Carcinoma, Non-Small-Cell Lung
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers.
Carcinoma, Non-Small-Cell Lung
Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines.
Carcinoma, Non-Small-Cell Lung
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
Carcinoma, Non-Small-Cell Lung
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Carcinoma, Non-Small-Cell Lung
Identification of a subset of human non-small cell lung cancer patients with high PI3K? and low PTEN expression, more prevalent in squamous cell carcinoma.
Carcinoma, Non-Small-Cell Lung
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Carcinoma, Non-Small-Cell Lung
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways.
Carcinoma, Non-Small-Cell Lung
MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway.
Carcinoma, Non-Small-Cell Lung
MiR-503 targets PI3K p85 and IKK-? and suppresses progression of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
Carcinoma, Non-Small-Cell Lung
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Notch signaling: a hero or villain in the war against cancer?
Carcinoma, Non-Small-Cell Lung
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Carcinoma, Non-Small-Cell Lung
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
PI3K expression predicts overall survival in lung adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy.
Carcinoma, Non-Small-Cell Lung
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Carcinoma, Non-Small-Cell Lung
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Non-Small-Cell Lung
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Carcinoma, Non-Small-Cell Lung
Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Carcinoma, Non-Small-Cell Lung
Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell.
Carcinoma, Non-Small-Cell Lung
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Carcinoma, Non-Small-Cell Lung
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The influence of circular RNAs on autophagy and disease progression.
Carcinoma, Non-Small-Cell Lung
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Carcinoma, Non-Small-Cell Lung
The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.
Carcinoma, Non-Small-Cell Lung
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Carcinoma, Non-Small-Cell Lung
TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1.
Carcinoma, Non-Small-Cell Lung
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
Carcinoma, Non-Small-Cell Lung
VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy.
Carcinoma, Non-Small-Cell Lung
W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors.
Carcinoma, Non-Small-Cell Lung
[Clinical Significance and Mechanism of PI3K p110? Overexpression? in Non-small Cell Lung Cancer].
Carcinoma, Non-Small-Cell Lung
[Clinicopathological Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-small Cell Lung Cancer.]
Carcinoma, Non-Small-Cell Lung
[Enhanced growth inhibition by combined two pathway inhibitors on K-ras mutated non-small cell lung cancer cells].
Carcinoma, Non-Small-Cell Lung
[Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer]
Carcinoma, Non-Small-Cell Lung
[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
Carcinoma, Non-Small-Cell Lung
[The Relationship between the PI3K/Akt/mTOR Signal Transduction Pathway and Non-small Cell Lung Cancer.]
Carcinoma, Ovarian Epithelial
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Carcinoma, Ovarian Epithelial
Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
Carcinoma, Ovarian Epithelial
Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
Carcinoma, Ovarian Epithelial
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Carcinoma, Ovarian Epithelial
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway.
Carcinoma, Ovarian Epithelial
Olaparib and ?-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Carcinoma, Ovarian Epithelial
The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
Carcinoma, Ovarian Epithelial
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
Carcinoma, Ovarian Epithelial
[Effects of PI3K/Akt/NF-?B signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
Carcinoma, Ovarian Epithelial
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Carcinoma, Ovarian Epithelial
[Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma]
Carcinoma, Pancreatic Ductal
Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines.
Carcinoma, Renal Cell
A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.
Carcinoma, Renal Cell
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
Carcinoma, Renal Cell
Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Carcinoma, Renal Cell
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Carcinoma, Renal Cell
C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways.
Carcinoma, Renal Cell
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Carcinoma, Renal Cell
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Carcinoma, Renal Cell
Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Carcinoma, Renal Cell
Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Carcinoma, Renal Cell
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.
Carcinoma, Renal Cell
Insulin induces heme oxygenase-1 through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in renal cells.
Carcinoma, Renal Cell
Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.
Carcinoma, Renal Cell
Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.
Carcinoma, Renal Cell
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells.
Carcinoma, Renal Cell
PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation.
Carcinoma, Renal Cell
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.
Carcinoma, Renal Cell
RLIP76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
Carcinoma, Renal Cell
Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.
Carcinoma, Renal Cell
Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Carcinoma, Renal Cell
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
Carcinoma, Renal Cell
The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.
Carcinoma, Renal Cell
[Effect of licochalcone A on autophagy in renal cell carcinoma via PI3K/Akt/mTOR signaling pathway].
Carcinoma, Squamous Cell
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Carcinoma, Squamous Cell
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Carcinoma, Squamous Cell
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Carcinoma, Squamous Cell
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Carcinoma, Squamous Cell
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Carcinoma, Squamous Cell
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Carcinoma, Squamous Cell
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Carcinoma, Squamous Cell
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Carcinoma, Squamous Cell
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.
Carcinoma, Squamous Cell
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Carcinoma, Squamous Cell
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Carcinoma, Squamous Cell
Enforced C-Src Activation Causes Compartmental Dysregulation of PI3K and PTEN Molecules in Lipid Rafts of Tongue Squamous Carcinoma Cells by Attenuating Rac1-Akt-GLUT-1-Mediated Sphingolipid Synthesis.
Carcinoma, Squamous Cell
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Erratum to: Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Carcinoma, Squamous Cell
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Carcinoma, Squamous Cell
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.
Carcinoma, Squamous Cell
Expression of PI3K and ERK in Uygur and Han patients with cervical squamous cancer.
Carcinoma, Squamous Cell
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Carcinoma, Squamous Cell
FHOD1, a Formin Upregulated in Epithelial-Mesenchymal Transition, Participates in Cancer Cell Migration and Invasion.
Carcinoma, Squamous Cell
Further evidence for the involvement of insulin receptor substrates in epidermal growth factor-induced activation of phosphatidylinositol 3-kinase.
Carcinoma, Squamous Cell
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Carcinoma, Squamous Cell
GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.
Carcinoma, Squamous Cell
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Carcinoma, Squamous Cell
In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
Carcinoma, Squamous Cell
Inhibition of PI3K Isoform p110? Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
Carcinoma, Squamous Cell
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Carcinoma, Squamous Cell
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
Carcinoma, Squamous Cell
MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Carcinoma, Squamous Cell
Mutational status of PIK3ca oncogene in oral cancer-In the new age of PI3K inhibitors.
Carcinoma, Squamous Cell
p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors.
Carcinoma, Squamous Cell
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells.
Carcinoma, Squamous Cell
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
Carcinoma, Squamous Cell
PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Carcinoma, Squamous Cell
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Squamous Cell
RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Reduced expression of E-cadherin and p120-catenin and elevated expression of PLC-?1 and PIKE are associated with aggressiveness of oral squamous cell carcinoma.
Carcinoma, Squamous Cell
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Carcinoma, Squamous Cell
Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
Carcinoma, Squamous Cell
SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis.
Carcinoma, Squamous Cell
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K? inhibition in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Carcinoma, Squamous Cell
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Carcinoma, Squamous Cell
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
Carcinoma, Squamous Cell
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Carcinoma, Squamous Cell
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.
Carcinoma, Squamous Cell
Transmembrane Collagen XVII Modulates Integrin Dependent Keratinocyte Migration via PI3K/Rac1 Signaling.
Carcinoma, Squamous Cell
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Carcinosarcoma
Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Carcinosarcoma
The Rho/Rho-kinase and the phosphatidylinositol 3-kinase pathways are essential for spontaneous locomotion of Walker 256 carcinosarcoma cells.
Cardiomegaly
?-Adrenergic receptor-PI3K signaling crosstalk in mouse heart: elucidation of immediate downstream signaling cascades.
Cardiomegaly
A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy.
Cardiomegaly
Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice.
Cardiomegaly
Allicin attenuates pathological cardiac hypertrophy by inhibiting autophagy via activation of PI3K/Akt/mTOR and MAPK/ERK/mTOR signaling pathways.
Cardiomegaly
Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes.
Cardiomegaly
Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy.
Cardiomegaly
Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function.
Cardiomegaly
Class III PI3K-mediated prolonged activation of autophagy plays a critical role in the transition of cardiac hypertrophy to heart failure.
Cardiomegaly
CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3K?-Akt signaling.
Cardiomegaly
Decreased p110alpha catalytic activity accompanies increased myocyte apoptosis and cardiac hypertrophy in leptin deficient ob/ob mice.
Cardiomegaly
Differential PI3K signal transduction in obesity-associated cardiac hypertrophy and response to ischemia.
Cardiomegaly
Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
Cardiomegaly
FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
Cardiomegaly
Identification of Potentially Relevant Genes for Excessive Exercise-Induced Pathological Cardiac Hypertrophy in Zebrafish.
Cardiomegaly
Impaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive rats.
Cardiomegaly
Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.
Cardiomegaly
MicroRNA-200a-3p Is a Positive Regulator in Cardiac Hypertrophy Through Directly Targeting WDR1 as Well as Modulating PTEN/PI3K/AKT/CREB/WDR1 Signaling.
Cardiomegaly
Phosphoinositide dependent protein kinase 1 is required for exercise-induced cardiac hypertrophy but not the associated mitochondrial adaptations.
Cardiomegaly
Regulation of L-type inward calcium channel activity by captopril and angiotensin II via the phosphatidyl inositol 3-kinase pathway in cardiomyocytes from volume-overload hypertrophied rat hearts.
Cardiomegaly
Regulation of PI3K and Hand2 gene on physiological hypertrophy of heart following high-intensity interval, and endurance training.
Cardiomegaly
Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.
Cardiomyopathies
Manipulation of cardiac phosphatidylinositol 3-kinase (PI3K)/Akt signaling by apoptosis regulator through modulating IAP expression (ARIA) regulates cardiomyocyte death during doxorubicin-induced cardiomyopathy.
Cardiomyopathies
Resveratrol Protects the Myocardium in Sepsis by Activating the Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway and Inhibiting the Nuclear Factor-?B (NF-?B) Signaling Pathway.
Cardiomyopathies
Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110?) signaling.
Cardiomyopathy, Dilated
Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies.
Cardiomyopathy, Dilated
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
Cardiomyopathy, Hypertrophic
Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy.
Cardiotoxicity
IGF1-PI3K-induced physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity.
Cardiotoxicity
Insulin Signaling in Bupivacaine-induced Cardiac Toxicity: Sensitization during Recovery and Potentiation by Lipid Emulsion.
Cardiotoxicity
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth.
Cardiotoxicity
PI3K? is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart.
Cardiotoxicity
Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo.
Cardiovascular Diseases
Association with Longevity of Phosphatidylinositol 3-Kinase Regulatory Subunit 1 Gene Variants Stems from Protection against Mortality Risk in Men with Cardiovascular Disease.
Cardiovascular Diseases
Effect of the Interplay Between Genetic and Behavioral Risks on Survival After Age 75.
Cardiovascular Diseases
IGF1-PI3K-induced physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity.
Cardiovascular Diseases
Inflammation and apoptosis in aortic tissues of aged type II diabetes: Amelioration with alpha-lipoic acid through phosphatidylinositol 3-kinase/Akt- dependent mechanism.
Cardiovascular Diseases
Phosphoinositide 3-kinase in disease: timing, location, and scaffolding.
Cardiovascular Diseases
The Role of RP105 in Cardiovascular Disease through Regulating TLR4 and PI3K Signaling Pathways.
Cardiovascular Diseases
Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
Cardiovascular Diseases
Tissue-specific impairment of insulin signaling in vasculature and skeletal muscle of fructose-fed rats.
Castleman Disease
Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature.
Cataract
Alterations in lens protein tyrosine phosphorylation and phosphatidylinositol 3-kinase signaling during selenite cataract formation.
Cataract
Deletion of autophagy-related 5 (Atg5) and Pik3c3 in the lens causes cataract independent of programmed organelle degradation.
Cataract
Rapamycin relieves the cataract caused by ablation of Gja8b through stimulating autophagy in zebrafish.
Celiac Disease
Interferon-? Activates Transglutaminase 2 via a Phosphatidylinositol-3-Kinase-Dependent Pathway: Implications for Celiac Sprue Therapy.
Cell Transformation, Neoplastic
Cyanidin suppresses neoplastic cell transformation by directly targeting phosphatidylinositol 3-kinase
Cell Transformation, Neoplastic
Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K.
Cell Transformation, Neoplastic
Phosphatidylinositol 3-kinase, a novel target molecule for the inhibitory effects of kaempferol on neoplastic cell transformation.
Cell Transformation, Neoplastic
Species- and cell type-specific requirements for cellular transformation.
Central Nervous System Neoplasms
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
Cerebellar Neoplasms
Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors.
Cerebral Infarction
Activation of the phosphatidylinositol 3-kinase pathway plays important roles in reduction of cerebral infarction by cilnidipine.
Cerebral Infarction
Atorvastatin Rejuvenates Neural Stem Cells Injured by Oxygen-Glucose Deprivation and Induces Neuronal Differentiation Through Activating the PI3K/Akt and ERK Pathways.
Cerebral Infarction
LncRNA SNHG1 inhibits neuronal apoptosis in cerebral infarction rats through PI3K/Akt signaling pathway.
Cerebral Infarction
MicroRNA?634 alters nerve apoptosis via the PI3K/Akt pathway in cerebral infarction.
Cerebral Infarction
The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction.
Cervical Intraepithelial Neoplasia
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]
Chagas Disease
Chagas' disease parasite-derived neurotrophic factor activates cholinergic gene expression in neuronal PC12 cells.
Chancre
Recombinant Treponema pallidum protein Tp0136 promotes fibroblast migration by modulating MCP-1/CCR2 through TLR4.
Chemical and Drug Induced Liver Injury
Polygenic architecture informs potential vulnerability to drug-induced liver injury.
Cholangiocarcinoma
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Cholangiocarcinoma
Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth.
Cholangiocarcinoma
Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Cholangiocarcinoma
Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells.
Cholangiocarcinoma
Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.
Cholangiocarcinoma
Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.
Cholangiocarcinoma
Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.
Cholera
Role of cAMP-PKA-PLC signaling cascade on dopamine-induced PKC-mediated inhibition of renal Na(+)-K(+)-ATPase activity.
Cholestasis
Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats.
Cholestasis
ERK1/2 and p38 MAPKs are complementarily involved in estradiol 17ß-D-glucuronide-induced cholestasis: crosstalk with cPKC and PI3K.
Cholestasis
Paeonia lactiflora Pall. protects against ANIT-induced cholestasis by activating Nrf2 via PI3K/Akt signaling pathway.
Cholestasis
Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17?-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C.
Cholestasis
Rifampicin induces clathrin-dependent endocytosis and ubiquitin-proteasome degradation of MRP2 via oxidative stress-activated PKC-ERK/JNK/p38 and PI3K signaling pathways in HepG2 cells.
Cholestasis
Sequential activation of classic PKC and estrogen receptor ? is involved in estradiol 17ß-D-glucuronide-induced cholestasis.
Cholestasis
Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets.
Chondrosarcoma
?5 integrin up-regulation in brain-derived neurotrophic factor promotes cell motility in human chondrosarcoma.
Chondrosarcoma
Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-? pathway.
Chondrosarcoma
Amphiregulin promotes cisplatin chemoresistance by upregulating ABCB1 expression in human chondrosarcoma.
Chondrosarcoma
Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13.
Chondrosarcoma
CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells.
Chondrosarcoma
CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin dependent pathway.
Chondrosarcoma
CCN6-mediated MMP-9 activation enhances metastatic potential of human chondrosarcoma.
Chondrosarcoma
High hydrostatic pressure induces ERK and PI3 kinase phosphorylation in human HCS-2/8 chondrosarcoma cells.
Chondrosarcoma
Interleukin-11 increases cell motility and up-regulates intercellular adhesion molecule-1 expression in human chondrosarcoma cells.
Chondrosarcoma
TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells.
Chordoma
Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Chordoma
Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.
Choriocarcinoma
Angiotensin II augmented migration and invasion of choriocarcinoma cells involves PI3K activation through the AT1 receptor.
Choriocarcinoma
Inhibition of the PI3K-Akt pathway suppresses sFlt1 expression in human placental hypoxia models in vitro.
Choriocarcinoma
Inhibitory Effects of Quercetin on Progression of Human Choriocarcinoma Cells Are Mediated Through PI3K/AKT and MAPK Signal Transduction Cascades.
Choriocarcinoma
Low molecular weight hyaluronan induces migration of human choriocarcinoma JEG-3 cells mediated by RHAMM as well as by PI3K and MAPK pathways.
Choriocarcinoma
MAPK and PI3K activities are required for leptin stimulation of protein synthesis in human trophoblastic cells.
Choriocarcinoma
Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma.
Choriocarcinoma
Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.
Clonorchiasis
Characterization and identification of differentially expressed microRNAs during the process of the peribiliary fibrosis induced by Clonorchis sinensis.
Coinfection
The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes.
Colitis
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110?.
Colitis
Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.
Colitis
Arctigenin ameliorates inflammation in vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing M1 macrophages to M2-like macrophages.
Colitis
Arginase activity in alternatively activated macrophages protects PI3Kp110? deficient mice from dextran sodium sulfate induced intestinal inflammation.
Colitis
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
Colitis
COX-1/PGE2/EP4 alleviates mucosal injury by upregulating ?-arr1-mediated Akt signaling in colitis.
Colitis
In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.
Colitis
Interaction between sphingosine kinase/sphingosine 1 phosphate and transforming growth factor-?/Smads pathways in experimental intestinal fibrosis. An in vivo immunohistochemical study.
Colitis
Loss of Phosphoinositide 3-Kinase p110? is Protective in the Acute Phase but Detrimental in the Resolution Phase of Hapten-Induced Colitis.
Colitis
PI3K p85? Subunit-deficient Macrophages Protect Mice from Acute Colitis due to the Enhancement of IL-10 Production.
Colitis
PI3K/AKT signaling is essential for communication between tissue infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
Colitis
Protective effects of panax notoginseng saponin on dextran sulfate sodium-induced colitis in rats through phosphoinositide-3-kinase protein kinase B signaling pathway inhibition.
Colitis
Regulation of transient receptor potential cation channel subfamily V1 protein synthesis by the phosphoinositide 3-kinase/Akt pathway in colonic hypersensitivity.
Colitis
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Colitis
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.
Colitis, Ulcerative
A study on regulatory mechanism of miR-223 in ulcerative colitis through PI3K/Akt-mTOR signaling pathway.
Colitis, Ulcerative
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Colitis, Ulcerative
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Colitis, Ulcerative
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Colitis, Ulcerative
Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer.
Colitis, Ulcerative
[Effects of PI3K signaling pathway on pathogenesis of ulcerative colitis]
Colitis, Ulcerative
[Expression of phophatidylinositol 3-kinase and effects of wortmannin on the expression of tumor necrosis factor-alpha in ulcerative colitis]
Colonic Neoplasms
?-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
Colonic Neoplasms
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Colonic Neoplasms
Activation of NF-kappaB binding in HT-29 colon cancer cells by inhibition of phosphatidylinositol 3-kinase.
Colonic Neoplasms
Activation of the PI3K/Akt Pathway Mediates Bone Morphogenetic Protein 2-Induced Invasion of Pancreatic Cancer Cells Panc-1.
Colonic Neoplasms
Activin and TGF? use diverging mitogenic signaling in advanced colon cancer.
Colonic Neoplasms
An I?B? phosphorylation inhibitor induces heme oxygenase-1(HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3K/Akt signaling in an NF-?B-independent mechanism.
Colonic Neoplasms
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
Colonic Neoplasms
Antitumor activity of ?-2-himachalen-6-ol in colon cancer is mediated through its inhibition of the PI3K and MAPK pathways.
Colonic Neoplasms
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Colonic Neoplasms
AP-2? Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.
Colonic Neoplasms
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.
Colonic Neoplasms
Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.
Colonic Neoplasms
Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29.
Colonic Neoplasms
Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells.
Colonic Neoplasms
circCDYL/microRNA-105-5p participates in modulating growth and migration of colon cancer cells.
Colonic Neoplasms
Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway.
Colonic Neoplasms
Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3?/cyclin D1 pathway.
Colonic Neoplasms
CXCL12 gene silencing down-regulates metastatic potential via blockage of MAPK/PI3K/AP-1 signaling pathway in colon cancer.
Colonic Neoplasms
CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K/Akt/NF-?B signaling pathway.
Colonic Neoplasms
Daucus carota Pentane-Based Fractions Suppress Proliferation and Induce Apoptosis in Human Colon Adenocarcinoma HT-29 Cells by Inhibiting the MAPK and PI3K Pathways.
Colonic Neoplasms
Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling.
Colonic Neoplasms
Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities.
Colonic Neoplasms
DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis.
Colonic Neoplasms
DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation.
Colonic Neoplasms
Down regulation of the expression of the p110, p85 and p55 subunits of phosphatidylinositol 3-kinase during colon cancer cell anchorage-independent growth.
Colonic Neoplasms
Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma.
Colonic Neoplasms
Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer.
Colonic Neoplasms
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Colonic Neoplasms
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.
Colonic Neoplasms
Effect of bevacizumab on expression level of GLI1 and ING4 in colon cancer animal model.
Colonic Neoplasms
Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway.
Colonic Neoplasms
Epidermal growth factor stimulates nuclear factor-?B activation and heme oxygenase-1 expression via c-Src, NADPH oxidase, PI3K, and Akt in human colon cancer cells.
Colonic Neoplasms
Epigallocatechin-3-gallate inhibits proliferation and triggers apoptosis in colon cancer via the hedgehog/phosphoinositide 3-kinase pathways.
Colonic Neoplasms
Expression of factors and key components associated with the PI3K signaling pathway in colon cancer.
Colonic Neoplasms
F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway.
Colonic Neoplasms
Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k/Akt signaling.
Colonic Neoplasms
Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor.
Colonic Neoplasms
Ghrelin induces colon cancer cell proliferation through the GHS-R, Ras, PI3K, Akt, and mTOR signaling pathways.
Colonic Neoplasms
Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement.
Colonic Neoplasms
Heregulin-Induced VEGF Expression via the ErbB3 Signaling Pathway in Colon Cancer.
Colonic Neoplasms
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
Colonic Neoplasms
Human ?-defensin 5 suppressed colon cancer growth by targeting PI3K pathway.
Colonic Neoplasms
Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc.
Colonic Neoplasms
IGF-1 induces expression of zinc-finger protein 143 in colon cancer cells through phosphatidylinositide 3-kinase and reactive oxygen species.
Colonic Neoplasms
IL13 Receptor ?2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis.
Colonic Neoplasms
In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells.
Colonic Neoplasms
Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to G?i and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells.
Colonic Neoplasms
Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers.
Colonic Neoplasms
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Colonic Neoplasms
Inhibition of phosphatidylinositide 3-kinase ameliorates antiproliferation by benzyl isothiocyanate in human colon cancer cells.
Colonic Neoplasms
Inhibition of phosphatidylinositide 3-kinase impairs the benzyl isothiocyanate-induced accumulation of autophagic molecules and Nrf2 in human colon cancer cells.
Colonic Neoplasms
Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation.
Colonic Neoplasms
Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.
Colonic Neoplasms
Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17.
Colonic Neoplasms
Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.
Colonic Neoplasms
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the ?GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo.
Colonic Neoplasms
Knockdown of ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.
Colonic Neoplasms
Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells.
Colonic Neoplasms
Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.
Colonic Neoplasms
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins.
Colonic Neoplasms
LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells.
Colonic Neoplasms
Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1.
Colonic Neoplasms
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
Colonic Neoplasms
Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
Colonic Neoplasms
mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.
Colonic Neoplasms
Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs-Targeting Immunotherapy of Colon Cancer.
Colonic Neoplasms
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.
Colonic Neoplasms
NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway.
Colonic Neoplasms
Nuclear accumulation of ?-catenin and forkhead box O3a in colon cancer: Dangerous liaison.
Colonic Neoplasms
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
Colonic Neoplasms
Phosphatidylinositol 3-kinase (PI3K) signaling does not activate the Wnt cascade.
Colonic Neoplasms
Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948.
Colonic Neoplasms
PI3K/Akt and GSK-3beta prevents in a differential fashion the malignant phenotype of colorectal cancer cells.
Colonic Neoplasms
PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells.
Colonic Neoplasms
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Colonic Neoplasms
Proteomic analysis of colonic myofibroblasts and effect on colon cancer cell proliferation.
Colonic Neoplasms
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.
Colonic Neoplasms
Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis.
Colonic Neoplasms
Regulation of YAP through an Akt-dependent process by 3, 3'-diindolylmethane in human colon cancer cells.
Colonic Neoplasms
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Colonic Neoplasms
Retinol decreases phosphatidylinositol 3-kinase activity in colon cancer cells.
Colonic Neoplasms
Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells.
Colonic Neoplasms
Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
Colonic Neoplasms
Survival advantages conferred to colon cancer cells by E-selectin-induced activation of the PI3K-NFkappaB survival axis downstream of Death Receptor-3.
Colonic Neoplasms
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Colonic Neoplasms
Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002.
Colonic Neoplasms
Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer.
Colonic Neoplasms
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Colonic Neoplasms
Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL).
Colonic Neoplasms
The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer.
Colonic Neoplasms
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.
Colonic Neoplasms
The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter.
Colonic Neoplasms
Thioredoxin-Like Protein 2 Is Overexpressed in Colon Cancer and Promotes Cancer Cell Metastasis by Interaction with Ran.
Colonic Neoplasms
TIMP-3 and Phosphatidylinositol 3-kinase genes were found to be related to the progression of colon cancer in a comparison of pneumoperitoneum and laparotomy in a murine model.
Colonic Neoplasms
TLR-4 signalling accelerates colon cancer cell adhesion via NF-?B mediated transcriptional up-regulation of Nox-1.
Colonic Neoplasms
Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer.
Colonic Neoplasms
Upregulation of miR-542-3p inhibits the growth and invasion of human colon cancer cells through PI3K/AKT/survivin signaling.
Colonic Neoplasms
Ursodeoxycholic acid protects colon cancer HCT116 cells from deoxycholic acid-induced apoptosis by inhibiting apoptosome formation.
Colonic Neoplasms
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear ?-Catenin depend on active PI3K signaling.
Colonic Neoplasms
[Corrigendum] Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells.
Colonic Neoplasms
[Effects and mechanisms of phosphatidylinositol 3 kinase B signal pathway on colon cancer cell SW480].
Colorectal Neoplasms
"Squirrel" Primer-Based PCR Assay for Direct and Targeted Sanger Sequencing of Short Genomic Segments.
Colorectal Neoplasms
18 ?-glycyrrhetinic acid exhibits potent antitumor effects against colorectal cancer via inhibition of cell proliferation and migration.
Colorectal Neoplasms
19PPreclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
Colorectal Neoplasms
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
Colorectal Neoplasms
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Colorectal Neoplasms
A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab.
Colorectal Neoplasms
A Deregulated PI3K-AKT Signaling Pathway in Patients with Colorectal Cancer.
Colorectal Neoplasms
A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer.
Colorectal Neoplasms
A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis.
Colorectal Neoplasms
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Colorectal Neoplasms
A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.
Colorectal Neoplasms
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Colorectal Neoplasms
ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells.
Colorectal Neoplasms
Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer.
Colorectal Neoplasms
Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Colorectal Neoplasms
Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Colorectal Neoplasms
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Colorectal Neoplasms
Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.
Colorectal Neoplasms
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
Colorectal Neoplasms
BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737.
Colorectal Neoplasms
Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
Colorectal Neoplasms
Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Colorectal Neoplasms
Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer.
Colorectal Neoplasms
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Colorectal Neoplasms
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Colorectal Neoplasms
Combining Trail with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
Colorectal Neoplasms
Correction: Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
Colorectal Neoplasms
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
Colorectal Neoplasms
Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer: evidence for a second phosphotyrosine substrate recognition pocket.
Colorectal Neoplasms
Current Advances and Trends in KRAS Targeted Therapies for Colorectal Cancer.
Colorectal Neoplasms
Dehydroglyasperin D Inhibits the Proliferation of HT-29 Human Colorectal Cancer Cells Through Direct Interaction With Phosphatidylinositol 3-kinase.
Colorectal Neoplasms
Depletion of PI3K p85alpha induces cell cycle arrest and apoptosis in colorectal cancer cells.
Colorectal Neoplasms
Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.
Colorectal Neoplasms
Differential modulation of zinc-stimulated p21(Cip/WAF1) and cyclin D1 induction by inhibition of PI3 kinase in HT-29 colorectal cancer cells.
Colorectal Neoplasms
Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor.
Colorectal Neoplasms
Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways.
Colorectal Neoplasms
Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
Colorectal Neoplasms
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Colorectal Neoplasms
Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
Colorectal Neoplasms
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Colorectal Neoplasms
Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Colorectal Neoplasms
Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer.
Colorectal Neoplasms
Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
Colorectal Neoplasms
Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2.
Colorectal Neoplasms
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.
Colorectal Neoplasms
Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells.
Colorectal Neoplasms
Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.
Colorectal Neoplasms
Epigenetically silenced LINC02381 functions as a tumor suppressor by regulating PI3K-Akt signaling pathway.
Colorectal Neoplasms
ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.
Colorectal Neoplasms
Expression profile and biological function of miR-455-5p in colorectal carcinoma.
Colorectal Neoplasms
EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer.
Colorectal Neoplasms
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Colorectal Neoplasms
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Colorectal Neoplasms
Heregulin-Induced VEGF Expression via the ErbB3 Signaling Pathway in Colon Cancer.
Colorectal Neoplasms
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Colorectal Neoplasms
Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway.
Colorectal Neoplasms
IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells.
Colorectal Neoplasms
Inactivating Frameshift Mutation of INPP4B Encoding a PI3K Pathway Phosphatase in Gastric and Colorectal Cancers.
Colorectal Neoplasms
Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors.
Colorectal Neoplasms
Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways.
Colorectal Neoplasms
Induction of apoptosis in colorectal cancer cells by peroxisome proliferators-activated receptor gamma activation up-regulating PTEN and inhibiting PI3K activity.
Colorectal Neoplasms
Inhibition of phosphatidylinositide 3-kinase ameliorates antiproliferation by benzyl isothiocyanate in human colon cancer cells.
Colorectal Neoplasms
Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development.
Colorectal Neoplasms
Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors.
Colorectal Neoplasms
Intestinal epithelial-specific PTEN inactivation results in tumor formation.
Colorectal Neoplasms
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Colorectal Neoplasms
Justicidin A-induced autophagy flux enhances apoptosis of human colorectal cancer cells via class III PI3K and Atg5 pathway.
Colorectal Neoplasms
Linc02381 Exacerbates Rheumatoid Arthritis Through Adsorbing miR-590-5p and Activating the Mitogen-Activated Protein Kinase Signaling Pathway in Rheumatoid arthritis-fibroblast-like synoviocytes.
Colorectal Neoplasms
Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells.
Colorectal Neoplasms
Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in PIK3CA-Mutant Colorectal Cancer.
Colorectal Neoplasms
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
Colorectal Neoplasms
MicroRNA-21 promotes phosphatase gene and protein kinase B/phosphatidylinositol 3-kinase expression in colorectal cancer.
Colorectal Neoplasms
miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells.
Colorectal Neoplasms
MiR-27b targets PI3K p110? to inhibit proliferation and migration in colorectal cancer stem cell.
Colorectal Neoplasms
MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.
Colorectal Neoplasms
MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway.
Colorectal Neoplasms
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Colorectal Neoplasms
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.
Colorectal Neoplasms
Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
Colorectal Neoplasms
mTORC1 and mTORC2 regulate EMT, motility and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.
Colorectal Neoplasms
Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
Colorectal Neoplasms
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers.
Colorectal Neoplasms
Phosphatidylinositol 3-kinase mediates the ability of retinol to decrease colorectal cancer cell invasion.
Colorectal Neoplasms
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Colorectal Neoplasms
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Colorectal Neoplasms
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Colorectal Neoplasms
Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma.
Colorectal Neoplasms
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
Colorectal Neoplasms
PI3K is required for the physical interaction and functional inhibition of NF-?B by ?-catenin in colorectal cancer cells.
Colorectal Neoplasms
PI3K p110? Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells.
Colorectal Neoplasms
PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.
Colorectal Neoplasms
PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer.
Colorectal Neoplasms
PIK3R3 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease.
Colorectal Neoplasms
Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.
Colorectal Neoplasms
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Colorectal Neoplasms
Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC).
Colorectal Neoplasms
Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer.
Colorectal Neoplasms
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review.
Colorectal Neoplasms
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Colorectal Neoplasms
Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Colorectal Neoplasms
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Colorectal Neoplasms
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Colorectal Neoplasms
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Colorectal Neoplasms
Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Colorectal Neoplasms
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Colorectal Neoplasms
Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf.
Colorectal Neoplasms
Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation.
Colorectal Neoplasms
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Colorectal Neoplasms
Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Colorectal Neoplasms
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Colorectal Neoplasms
Specific inhibition of p110? subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
Colorectal Neoplasms
Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis.
Colorectal Neoplasms
Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor.
Colorectal Neoplasms
Tankyrase Inhibition Blocks Wnt/?-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Colorectal Neoplasms
TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting ?-CATENIN and AKT Signaling in Colorectal Cancer.
Colorectal Neoplasms
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Colorectal Neoplasms
Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Colorectal Neoplasms
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer.
Colorectal Neoplasms
The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population.
Colorectal Neoplasms
The effects of silencing of PI3K p85? on 5-FU-induced colorectal cancer cells apoptosis.
Colorectal Neoplasms
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Colorectal Neoplasms
The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.
Colorectal Neoplasms
The role of ppar? and autophagy in ros production, lipid droplets biogenesis and its involvement with colorectal cancer cells modulation.
Colorectal Neoplasms
The roles of microbial products in the development of colorectal cancer: a review.
Colorectal Neoplasms
The Safe Soluble Compound Dehydroascorbic Acid Inhibits Various Upstream and Downstream Effectors of PI3K and KRAS Signaling Pathways in Undruggable PIK3CA/KRAS-Mutant Colorectal Cancer Stem-Like Cells.
Colorectal Neoplasms
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Colorectal Neoplasms
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.
Colorectal Neoplasms
Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells.
Colorectal Neoplasms
[Influence of phosphatidylinositol-3-kinases P85? silence by RNA interference on cell cycle and apoptosis of colorectal cancer cells in vitro.]
Colorectal Neoplasms
[PI3K p85alpha expression and its role in the progression of colorectal cancer.]
Colorectal Neoplasms
[PI3K p85alpha gene silencing by RNA interference promotes 5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells]
Communicable Diseases
A Case for Phosphoinositide 3-Kinase-Targeted Therapy for Infectious Disease.
Communicable Diseases
Transcriptomic and Network Analysis Highlight the Association of Diabetes at Different Stages of Alzheimer's Disease.
Confusion
Opposite effects of wortmannin and 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride on toll-like receptor-mediated nitric oxide production: negative regulation of nuclear factor-{kappa}B by phosphoinositide 3-kinase.
Coronary Artery Disease
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Coronary Occlusion
Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning.
Coronary Occlusion
Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits.
Coronary Occlusion
Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits.
Costello Syndrome
Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.
Cough
Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis.
COVID-19
Suppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase.
Coxsackievirus Infections
Coxsackievirus infection induces a non-canonical autophagy independent of the ULK and PI3K complexes.
Crohn Disease
Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets.
Crohn Disease
Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion.
Crohn Disease
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Crohn Disease
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Crohn Disease
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Cryptococcosis
Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.
Cystadenoma
Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.
Cystic Fibrosis
Expression of miR?542?3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.
Cystic Fibrosis
Involvement of phosphatidylinositol 3-kinase in cAMP- and cGMP-induced duodenal epithelial CFTR activation in mice.
Cystic Fibrosis
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.
Cystitis
Suppression of the PI3K pathway in vivo reduces cystitis-induced bladder hypertrophy and restores bladder capacity examined by magnetic resonance imaging.
Cysts
HGF-induced serine 897 phosphorylation of EphA2 regulates epithelial morphogenesis of MDCK cells in 3D culture.
Cysts
High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease.
Cysts
PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts.
Cysts
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation.
Cysts
The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium.
Decompression Sickness
Structural pathway for allosteric activation of the autophagic PI 3-kinase complex I.
Dehydration
Importance of inositols and their derivatives in cowpea under root dehydration: An omics perspective.
Dementia
Clionosterol and Ethyl Cholestan-22-enol Isolated from the Rhizome of Polygala tenuifolia Inhibit Phosphatidylinositol 3-Kinase/Akt Pathway.
Dementia
Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.
Dementia, Vascular
Naomaitai Ameliorated Brain Damage in Rats with Vascular Dementia by PI3K/PDK1/AKT Signaling Pathway.
Dengue
Dengue virus enhances thrombomodulin and ICAM-1 expression through the macrophage migration inhibitory factor induction of the MAPK and PI3K signaling pathways.
Dermatitis
Blockade of phosphatidylinositol 3-kinase PI3K? or PI3K? reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis.
Dermatitis
Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice.
Dermatitis, Exfoliative
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Diabetes Complications
Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control.
Diabetes Complications
Network pharmacology-based exploration of therapeutic mechanism of Liu-Yu-Tang in atypical antipsychotic drug-induced metabolic syndrome.
Diabetes Complications
Reappraisal of metallothionein: Clinical implications for patients with diabetes mellitus.
Diabetes Complications
[Role of protein kinase C isozymes in cellular functions and pathological conditions]
Diabetes Mellitus
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Diabetes Mellitus
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus
Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.
Diabetes Mellitus
Curcumin anti-diabetic effect mainly correlates with its anti-apoptotic actions and PI3K/Akt signal pathway regulation in the liver.
Diabetes Mellitus
Human umbilical cord mesenchymal stem cells reduce oxidative damage and apoptosis in diabetic nephropathy by activating Nrf2.
Diabetes Mellitus
Liver paraoxonase 3 expression and the effect of liraglutide treatment in a rat model of diabetes.
Diabetes Mellitus
Regulation of gene expression during severe caloric restriction: lack of induction of p85 alpha phosphatidylinositol 3-kinase mRNA in skeletal muscle of patients with type II (non-insulin-dependent) diabetes mellitus.
Diabetes Mellitus
Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus.
Diabetes Mellitus
Tacrolimus inhibits insulin release and promotes apoptosis of Min6 cells through the inhibition of the PI3K/Akt/mTOR pathway.
Diabetes Mellitus
TGF-{beta}1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus.
Diabetes Mellitus
The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
Diabetes Mellitus
The impact of exposure of diabetic rats to 900 MHz electromagnetic radiation emitted from mobile phone antenna on hepatic oxidative stress.
Diabetes Mellitus
Type 1 diabetes mellitus associated with activated phosphatidylinositol 3-kinase delta syndrome, type 2.
Diabetes Mellitus
[Effect of Shenqi compound on PTEN/PI3K signal transduction in GK rats with diabetes mellitus macroangiopathy]
Diabetes Mellitus
[Effects of Qizhi Jiangtang capsule on protein expressions of InsR, PI3K, GLUT2 and p-JNK in hepatic tissues of rats with type 2 diabetes].
Diabetes Mellitus
[Mechanism of advanced glycation end products inhibiting the proliferation of peripheral blood mononuclear cells and osteoblasts in rats].
Diabetes Mellitus
[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus]
Diabetes Mellitus, Type 1
A combined risk score enhances prediction of type 1 diabetes among susceptible children.
Diabetes Mellitus, Type 1
Regulation of the inducible nitric oxide synthase and sodium pump in type 1 diabetes.
Diabetes Mellitus, Type 1
Type 1 diabetes mellitus associated with activated phosphatidylinositol 3-kinase delta syndrome, type 2.
Diabetes Mellitus, Type 1
[Role of phosphatidylinositol 3-kinase in platelet aggregation in type 1 diabetes mellitus]
Diabetes Mellitus, Type 2
A new layer of phosphoinositide-mediated allosteric regulation uncovered for SHIP2.
Diabetes Mellitus, Type 2
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Diabetes Mellitus, Type 2
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Diabetes Mellitus, Type 2
Class IA phosphatidylinositol 3-kinase in pancreatic ? cells controls insulin secretion by multiple mechanisms.
Diabetes Mellitus, Type 2
Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study.
Diabetes Mellitus, Type 2
Curcumin anti-diabetic effect mainly correlates with its anti-apoptotic actions and PI3K/Akt signal pathway regulation in the liver.
Diabetes Mellitus, Type 2
Effect of Aerobic and Resistance Training on Endothelial Progenitor Cells in Mice with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Effects of exercise on AMPK signaling and downstream components to PI3K in rat with type 2 diabetes.
Diabetes Mellitus, Type 2
Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie2 receptor.
Diabetes Mellitus, Type 2
Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin.
Diabetes Mellitus, Type 2
Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM.
Diabetes Mellitus, Type 2
Gene encoding the catalytic subunit p110beta of human phosphatidylinositol 3-kinase: cloning, genomic structure, and screening for variants in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase.
Diabetes Mellitus, Type 2
Human umbilical cord mesenchymal stem cells reduce oxidative damage and apoptosis in diabetic nephropathy by activating Nrf2.
Diabetes Mellitus, Type 2
Impact of rs361072 in the phosphoinositide 3-kinase p110beta gene on whole-body glucose metabolism and subunit protein expression in skeletal muscle.
Diabetes Mellitus, Type 2
Impaired muscle glycogen synthase in type 2 diabetes is associated with diminished phosphatidylinositol 3-kinase activation.
Diabetes Mellitus, Type 2
In vitro and in vivo studies of a naturally occurring variant of the human p85alpha regulatory subunit of the phosphoinositide 3-kinase: inhibition of protein kinase B and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity.
Diabetes Mellitus, Type 2
Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart.
Diabetes Mellitus, Type 2
Inhibition of the PI 3-kinase pathway disrupts the unfolded protein response and reduces sensitivity to ER stress-dependent apoptosis.
Diabetes Mellitus, Type 2
Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation.
Diabetes Mellitus, Type 2
Insulin-like growth factor 1 regulates growth of endometrial carcinoma through PI3k signaling pathway in insulin-resistant type 2 diabetes.
Diabetes Mellitus, Type 2
Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.
Diabetes Mellitus, Type 2
Macrophage Rewiring by Nutrient Associated PI3K Dependent Pathways.
Diabetes Mellitus, Type 2
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Diabetes Mellitus, Type 2
Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
Diabetes Mellitus, Type 2
Prevalence of a polymorphism of the phosphatidylinositol 3-kinase p85 alpha regulatory subunit (codon 326 Met-->Ile) in Japanese NIDDM patients.
Diabetes Mellitus, Type 2
Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance.
Diabetes Mellitus, Type 2
Role of p110a subunit of PI3-kinase in skeletal muscle mitochondrial homeostasis and metabolism.
Diabetes Mellitus, Type 2
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice.
Diabetes Mellitus, Type 2
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
Diabetes Mellitus, Type 2
The Combined Deletion of S6K1 and Akt2 Deteriorates Glycemic Control in a High-Fat Diet.
Diabetes Mellitus, Type 2
The impact of exposure of diabetic rats to 900 MHz electromagnetic radiation emitted from mobile phone antenna on hepatic oxidative stress.
Diabetes Mellitus, Type 2
Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3.
Diabetes Mellitus, Type 2
Variant in the regulatory subunit of phosphatidylinositol 3-kinase (p85alpha): preliminary evidence indicates a potential role of this variant in the acute insulin response and type 2 diabetes in Pima women.
Diabetes Mellitus, Type 2
[Effect of "Spleen-Stomach Harmonizing" Needling on Insulin Resistance and Expression of Insulin Receptor Substrate-1, -2, and Glucose Transporter-4 in Insulin Resistance Type 2 Diabetes Rats].
Diabetes Mellitus, Type 2
[Effects of Astragalus membranaceus and Potentilla discolor mixture on insulin resistance and its related mRNA expressions in KKAy mice with type 2 diabetes].
Diabetes Mellitus, Type 2
[Effects of Qizhi Jiangtang capsule on protein expressions of InsR, PI3K, GLUT2 and p-JNK in hepatic tissues of rats with type 2 diabetes].
Diabetes, Gestational
Analysis of phosphatidylinositol 3-kinase activation in the adipose tissue of gestational diabetes mellitus patients and insulin resistance.
Diabetes, Gestational
Effect of miR-29b on rats with gestational diabetes mellitus by targeting PI3K/Akt signal.
Diabetes, Gestational
Expression of PI3-K, PKB and GSK-3 ? in the skeletal muscle tissue of gestational diabetes mellitus.
Diabetes, Gestational
Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus.
Diabetes, Gestational
Relationships of SLC2A4, RBP4, PCK1, and PI3K Gene Polymorphisms with Gestational Diabetes Mellitus in a Chinese Population.
Diabetes, Gestational
The association of leukocyte phosphatidylinositol 3-kinase delta overexpression with gestational diabetes mellitus (GDM).
Diabetic Angiopathies
[High D-glucose alters PI3K and Akt signaling and leads to endothelial cell migration, proliferation and angiogenesis dysfunction]
Diabetic Cardiomyopathies
Baicalein Protects Rats with Diabetic Cardiomyopathy Against Oxidative Stress and Inflammation Injury via Phosphatidylinositol 3-Kinase (PI3K)/AKT Pathway.
Diabetic Cardiomyopathies
Phosphoinositide 3-kinase (p110?) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.
Diabetic Cardiomyopathies
The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats.
Diabetic Cardiomyopathies
Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110?) signaling.
Diabetic Ketoacidosis
Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Diabetic Nephropathies
Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway.
Diabetic Nephropathies
KCa3.1 mediates dysfunction of tubular autophagy in diabetic kidneys via PI3k/Akt/mTOR signaling pathways.
Diabetic Nephropathies
Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
Diabetic Nephropathies
Sitagliptin improves renal function in diabetic nephropathy in male Sprague Dawley rats through upregulating heme oxygenase-1 expression.
Diabetic Nephropathies
The effects of microRNA-126 reduced inflammation and apoptosis of diabetic nephropathy through PI3K/AKT signalling pathway by VEGF.
Diabetic Nephropathies
[Down-regulation of PTEN expression in kidney and its role in development of diabetic nephropathy in rats].
Diabetic Retinopathy
Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control.
Diabetic Retinopathy
[Role of protein kinase C isozymes in cellular functions and pathological conditions]
Diffuse Intrinsic Pontine Glioma
Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
Digestive System Neoplasms
Novel role of microRNA-126 in digestive system cancers: From bench to bedside.
Disorders of Sex Development
Sex differences in autophagy-mediated diseases: toward precision medicine.
Distemper
Autophagy induction by the pathogen receptor NECTIN4 and sustained autophagy contribute to peste des petits ruminants virus infectivity.
DNA Repair-Deficiency Disorders
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
Drug Resistant Epilepsy
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
Drug Resistant Epilepsy
[Expression of PI3K pathway proteins in refractory epilepsy associated with cortical malformation development].
Dyslipidemias
Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities.
Dyslipidemias
Cyclocarya paliurus Leaves Tea Improves Dyslipidemia in Diabetic Mice: A Lipidomics-Based Network Pharmacology Study.
Dyslipidemias
Forced internal desynchrony induces cardiometabolic alterations in adult rats.
Dysplastic Nevus Syndrome
Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Dysplastic Nevus Syndrome
Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
Antigen-induced pten gene deletion in T cells exacerbates neuropathology in experimental autoimmune encephalomyelitis.
Encephalomyelitis
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Encephalomyelitis
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Encephalomyelitis
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.
Encephalomyelitis
Loss of Phosphatase and Tensin Homolog in APCs Impedes Th17-Mediated Autoimmune Encephalomyelitis.
Encephalomyelitis
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1? production.
Encephalomyelitis
WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism.
Encephalomyelitis
ZSTK474, a novel PI3K inhibitor, modulates human CD14(+) monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Antigen-induced pten gene deletion in T cells exacerbates neuropathology in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Encephalomyelitis, Autoimmune, Experimental
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Encephalomyelitis, Autoimmune, Experimental
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.
Encephalomyelitis, Autoimmune, Experimental
Loss of Phosphatase and Tensin Homolog in APCs Impedes Th17-Mediated Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1? production.
Encephalomyelitis, Autoimmune, Experimental
WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism.
Encephalomyelitis, Autoimmune, Experimental
ZSTK474, a novel PI3K inhibitor, modulates human CD14(+) monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.
Endometrial Hyperplasia
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Endometrial Neoplasms
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Endometrial Neoplasms
Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Endometrial Neoplasms
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Endometrial Neoplasms
Class I Phosphoinositide 3-Kinase PIK3CA/p110? and PIK3CB/p110? Isoforms in Endometrial Cancer.
Endometrial Neoplasms
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Endometrial Neoplasms
Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
Endometrial Neoplasms
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.
Endometrial Neoplasms
Ellagic acid exerts antitumor effects via the PI3K signaling pathway in endometrial cancer.
Endometrial Neoplasms
Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
Endometrial Neoplasms
Endometrial cancer cells exhibit high expression of p110? and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Endometrial Neoplasms
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
Endometrial Neoplasms
Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Endometrial Neoplasms
G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.
Endometrial Neoplasms
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Endometrial Neoplasms
Geraniol Inhibits Endometrial Carcinoma via Downregulating Oncogenes and Upregulating Tumour Suppressor Genes.
Endometrial Neoplasms
Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells.
Endometrial Neoplasms
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Endometrial Neoplasms
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
Endometrial Neoplasms
High Phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3Kinase inhibition.
Endometrial Neoplasms
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Endometrial Neoplasms
Insulin-like growth factor 1 regulates growth of endometrial carcinoma through PI3k signaling pathway in insulin-resistant type 2 diabetes.
Endometrial Neoplasms
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Endometrial Neoplasms
Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
Endometrial Neoplasms
Key factors mediated by PI3K signaling pathway and related genes in endometrial carcinoma.
Endometrial Neoplasms
Lack of Estrogen Receptor-? Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma.
Endometrial Neoplasms
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
Endometrial Neoplasms
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
Endometrial Neoplasms
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
Endometrial Neoplasms
LncRNA TDRG1 enhances tumorigenicity in endometrial carcinoma by binding and targeting VEGF-A protein.
Endometrial Neoplasms
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Endometrial Neoplasms
Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Endometrial Neoplasms
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Endometrial Neoplasms
Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice.
Endometrial Neoplasms
New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes.
Endometrial Neoplasms
New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway--The Devil Is in the Details.
Endometrial Neoplasms
Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
Endometrial Neoplasms
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Endometrial Neoplasms
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Endometrial Neoplasms
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Endometrial Neoplasms
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Endometrial Neoplasms
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Endometrial Neoplasms
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
Endometrial Neoplasms
PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-?/VEGF pathway in endometrial cancer.
Endometrial Neoplasms
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Endometrial Neoplasms
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Endometrial Neoplasms
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
Endometrial Neoplasms
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Endometrial Neoplasms
PIK3R1 (p85-alpha/p85{alpha}) is Somatically Mutated at High Frequency in Primary Endometrial Cancer.
Endometrial Neoplasms
PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
Endometrial Neoplasms
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.
Endometrial Neoplasms
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Endometrial Neoplasms
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Endometrial Neoplasms
Regulation of epithelial-mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs.
Endometrial Neoplasms
Relevance of lipogenesis and AMPK/Akt/mTOR signaling pathway in endometrial cancer.
Endometrial Neoplasms
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
Endometrial Neoplasms
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Endometrial Neoplasms
Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.
Endometrial Neoplasms
Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells.
Endometrial Neoplasms
Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway.
Endometrial Neoplasms
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.
Endometrial Neoplasms
YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
Endometrial Neoplasms
[Activation of phosphatidylinositol 3-kinase-protein kinase B (PI3K-PKB) induced by 17beta-estradiol in endometrial carcinoma cell (Ishikawa)]
Endometrial Neoplasms
[Effect of GPER on the activation of PI3K/Akt induced by 17?-estradiol in endometrial carcinoma cells].
Endometrial Neoplasms
[Influence of pertussis toxin on GPER-mediated activation of phosphatidylinositol 3-kinase/protein kinase B signaling induced by 17?-estradiol in endometrial carcinoma cells].
Endometrial Neoplasms
[Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
Endometriosis
Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis.
Endometriosis
Differences in autophagy-associated mRNAs in peritoneal fluid of patients with endometriosis and gynecologic cancers.
Endometriosis
DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection.
Endometriosis
Effects of inhibiting the PI3K/Akt/mTOR signaling pathway on the pain of sciatic endometriosis in a rat model.
Endometriosis
Osteopontin Regulates Endometrial Stromal Cell Migration in Endometriosis through the PI3K Pathway : Osteopontin Regulates Endometrial Cell Migration in Endometriosis.
Endometriosis
PI3K/AKT pathway is altered in the endometriosis patient's endometrium and presents differences according to severity stage.
Endometriosis
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.
Endometriosis
Transcriptome meta-analysis reveals differences of immune profile between eutopic endometrium from stage I-II and III-IV endometriosis independently of hormonal milieu.
Endotoxemia
Cardiac Specific Expression of Heat Shock Protein 27 Attenuated Endotoxin-Induced Cardiac Dysfunction and Mortality in Mice through a PI3K/Akt Dependent Mechanism.
Endotoxemia
Insulin hypersensitivity induced by hepatic PTEN gene ablation protects from murine endotoxemia.
Endotoxemia
Myeloid cell-specific inositol polyphosphate-4-phosphatase type I knockout mice impair bacteria clearance in a murine peritonitis model.
Endotoxemia
PI3K p110? subunit in leptin receptor expressing cells is required for the acute hypophagia induced by endotoxemia.
Endotoxemia
Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Endotoxemia
Sustained endotoxemia leads to marked down-regulation of early steps in the insulin-signaling cascade.
Enteritis
Role of Host Type IA Phosphoinositide 3-Kinase Pathway Components in Invasin-Mediated Internalization of Yersinia enterocolitica.
Enterocolitis, Necrotizing
Effects of oxidative stress on intestinal type I insulin-like growth factor receptor expression.
Enterocolitis, Necrotizing
Phosphatidylinositol 3-kinase pathway regulates hypoxia-inducible factor-1 to protect from intestinal injury during necrotizing enterocolitis.
Eosinophilia
Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K).
Eosinophilia
The p110? subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice.
Ependymoma
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression free survival.
Ephemeral Fever
Inhibitors of phosphatidylinositol 3-kinase and mTOR but not Akt enhance replication of bovine ephemeral fever virus.
Epidermolysis Bullosa Dystrophica
Finding patients using similarity measures in a rare diseases-oriented clinical data warehouse: Dr. Warehouse and the needle in the needle stack.
Epilepsy
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Epilepsy
Gene Expression Profiling of a Hypoxic Seizure Model of Epilepsy Suggests a Role for mTOR and Wnt Signaling in Epileptogenesis.
Epilepsy
Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3? signaling pathway.
Epilepsy
MicroRNA?155 contributes to the occurrence of epilepsy through the PI3K/Akt/mTOR signaling pathway.
Epilepsy
Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy.
Epilepsy
Multi-scale top-down approach for modelling epileptic protein-protein interaction network analysis to identify driver nodes and pathways.
Epilepsy
Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.
Epilepsy
Phosphoinositide 3-Kinases Upregulate System xc(-) via Eukaryotic Initiation Factor 2? and Activating Transcription Factor 4?-?A Pathway Active in Glioblastomas and Epilepsy.
Epilepsy
PI3K, mTOR and GSK3 modulate cytokines' production in peripheral leukocyte in temporal lobe epilepsy.
Epilepsy
Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy.
Epilepsy
Target identification, screening and in vivo evaluation of pyrrolone-fused benzosuberene compounds against human epilepsy using Zebrafish model of pentylenetetrazol-induced seizures.
Epilepsy
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
Epilepsy
[Roles and mechanisms of traditional Chinese medicine and its active ingredients in treating epilepsy].
Epilepsy, Temporal Lobe
PI3K, mTOR and GSK3 modulate cytokines' production in peripheral leukocyte in temporal lobe epilepsy.
Epiretinal Membrane
Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes.
Epstein-Barr Virus Infections
Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets.
Epstein-Barr Virus Infections
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.
Epstein-Barr Virus Infections
Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling.
Epstein-Barr Virus Infections
LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required.
Epstein-Barr Virus Infections
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
Equine Infectious Anemia
Equine lentivirus counteracts SAMHD1 restriction by Rev-mediated degradation of SAMHD1 via the BECN1-dependent lysosomal pathway.
Esophageal Neoplasms
Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells.
Esophageal Neoplasms
Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway.
Esophageal Neoplasms
Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway.
Esophageal Neoplasms
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Esophageal Neoplasms
MicroRNA-124 inhibits proliferation and metastasis of esophageal cancer via negatively regulating NRP1.
Esophageal Neoplasms
MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.
Esophageal Neoplasms
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Esophageal Neoplasms
PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Adaptive resistance to PI3K?-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells.
Esophageal Squamous Cell Carcinoma
Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma transcriptome reveals the effect of FOXM1 on patient outcome through novel PIK3R3 mediated activation of PI3K signaling pathway.
Esophageal Squamous Cell Carcinoma
High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations.
Esophageal Squamous Cell Carcinoma
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
Esophageal Squamous Cell Carcinoma
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Esophageal Squamous Cell Carcinoma
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
PIK3C3 Acts as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and Was Regulated by MiR-340-5p.
Esophageal Squamous Cell Carcinoma
Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma.
Esophageal Squamous Cell Carcinoma
STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
Esophageal Squamous Cell Carcinoma
[Corrigendum] STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway.
Esophageal Squamous Cell Carcinoma
[Expression and clinical significance of PI3K in esophageal squamous cell carcinoma].
Exanthema
PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
Extranodal Extension
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma.
Fanconi Anemia
Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes.
Fatty Liver
Data on Lipocalin 2 and phosphatidylinositol 3-kinase signaling in a methionine- and choline-deficient model of non-alcoholic steatohepatitis.
Fatty Liver
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD.
Fatty Liver
Loss of PI3K p110? in the Adipose Tissue Results in Infertility and Delayed Puberty Onset in Male Mice.
Fatty Liver
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
Fatty Liver
PIK3R3 regulates PPAR? expression to stimulate fatty acid ?-oxidation and decrease hepatosteatosis.
Fetal Growth Retardation
MiR-199a-5p regulates sirtuin1 and PI3K in the rat hippocampus with intrauterine growth restriction.
Fibrosarcoma
Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells.
Fibrosarcoma
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Fibrosarcoma
Microgravity-Induced Transcriptome Adaptation in Mouse Paraspinal longissimus dorsi Muscle Highlights Insulin Resistance-Linked Genes.
Fibrosarcoma
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines.
Fibrosarcoma
Requirement of phosphoinositide 3-kinase and Akt for interferon-beta-mediated induction of the beta-R1 (SCYB11) gene.
Foot-and-Mouth Disease
Autophagic degradation of SQSTM1 inhibits ovarian cancer motility by decreasing DICER1 and AGO2 to induce MIRLET7A-3P.
Foot-and-Mouth Disease
Poliovirus induces autophagic signaling independent of the ULK1 complex.
Foot-and-Mouth Disease
Productive Entry of Foot-and-Mouth Disease Virus via Macropinocytosis Independent of Phosphatidylinositol 3-Kinase.
Fragile X Syndrome
Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome.
Fragile X Syndrome
Selective role of the catalytic PI3K subunit p110? in impaired higher order cognition in fragile X syndrome.
Gallbladder Neoplasms
Regional Differences in Gallbladder Cancer Pathogenesis: Insights from a Comparison of Cell Cycle-Regulatory, PI3K, and Pro-Angiogenic Protein Expression.
Gallbladder Neoplasms
Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Further Options for an Orphan Cancer.
Gastritis
A novel gastroprotective effect of zeaxanthin against stress-induced gastritis in male rats targeting the expression of HIF-1?, TFF-1 and MMP-9 through PI3K/Akt/JNK signaling pathway.
Gastritis
Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1? expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.
Gastritis, Atrophic
Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.
Gastrointestinal Neoplasms
Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.
Gastrointestinal Neoplasms
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Gastrointestinal Neoplasms
Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer.
Gastrointestinal Stromal Tumors
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
Gastrointestinal Stromal Tumors
Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.
Gastrointestinal Stromal Tumors
Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1.
Gastrointestinal Stromal Tumors
Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
Gastrointestinal Stromal Tumors
Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets.
Gastrointestinal Stromal Tumors
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Gastrointestinal Stromal Tumors
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
Gastroparesis
Significance of dynamic changes in gastric smooth muscle cell apoptosis, PI3K-AKT-mTOR and AMPK-mTOR signaling in a rat model of diabetic gastroparesis.
Genetic Diseases, Inborn
Neuropsychological Attention Skills and Related Behaviours in Adults with Tuberous Sclerosis Complex.
Genetic Diseases, Inborn
Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
Genetic Diseases, Inborn
The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.
Genetic Diseases, Inborn
Two Monogenetic Disorders, Activated PI3-Kinase-? Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Germinoma
Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma.
Gestational Trophoblastic Disease
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
Glaucoma
Integrative transcriptomic and proteomic analysis reveals CD9/ITGA4/PI3K-Akt axis mediates trabecular meshwork cell apoptosis in human glaucoma.
Glaucoma
Intra-Cellular Calcium Signaling Pathways (PKC, RAS/RAF/MAPK, PI3K) in Lamina Cribrosa Cells in Glaucoma.
Glioblastoma
5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.
Glioblastoma
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.
Glioblastoma
A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma.
Glioblastoma
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Glioblastoma
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
Glioblastoma
A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration.
Glioblastoma
Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
Glioblastoma
Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme.
Glioblastoma
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Glioblastoma
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Glioblastoma
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Glioblastoma
BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.
Glioblastoma
BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-?B/MGMT signaling pathway.
Glioblastoma
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Glioblastoma
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Glioblastoma
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
Glioblastoma
Cadmium induces CCL2 production in glioblastoma cells via activation of MAPK, PI3K, and PKC pathways.
Glioblastoma
Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
Glioblastoma
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Glioblastoma
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
Glioblastoma
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
Glioblastoma
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Glioblastoma
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
Glioblastoma
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Glioblastoma
Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.
Glioblastoma
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Glioblastoma
Cordyceps militaris and mycelial fermentation induced apoptosis and autophagy of human glioblastoma cells.
Glioblastoma
Correction to: Synergism between the phosphatidylinositol 3-kinase p110? isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
Glioblastoma
Correction: A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Glioblastoma
DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy.
Glioblastoma
Deoxypodophyllotoxin inhibits cell viability and invasion by blocking the PI3K/Akt signaling pathway in human glioblastoma cells.
Glioblastoma
Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
Glioblastoma
Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma.
Glioblastoma
Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions.
Glioblastoma
Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.
Glioblastoma
Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
Glioblastoma
Dual functional nanoparticles efficiently across the blood-brain barrier to combat glioblastoma via simultaneously inhibit the PI3K pathway and NKG2A axis.
Glioblastoma
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Glioblastoma
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
Glioblastoma
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
Glioblastoma
Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
Glioblastoma
ERK and PI3K signaling cascades induce Nrf2 activation and regulate cell viability partly through Nrf2 in human glioblastoma cells.
Glioblastoma
GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death.
Glioblastoma
Gene silencing reveals a specific function of hVps34 phosphatidylinositol 3-kinase in late versus early endosomes.
Glioblastoma
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.
Glioblastoma
Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.
Glioblastoma
Growth factor receptors signaling in glioblastoma cells: therapeutic implications.
Glioblastoma
HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.
Glioblastoma
Hypoxia and EGF Stimulation Regulate VEGF Expression in Human Glioblastoma Multiforme (GBM) Cells by Differential Regulation of the PI3K/Rho-GTPase and MAPK Pathways.
Glioblastoma
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma.
Glioblastoma
Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.
Glioblastoma
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Glioblastoma
Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of ?-catenin-mediated transcription.
Glioblastoma
Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
Glioblastoma
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma.
Glioblastoma
Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Glioblastoma
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Glioblastoma
Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells.
Glioblastoma
Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
Glioblastoma
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.
Glioblastoma
Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets.
Glioblastoma
Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures.
Glioblastoma
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Glioblastoma
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
Glioblastoma
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Glioblastoma
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Glioblastoma
LY294002 induces differentiation and inhibits invasion of glioblastoma cells by targeting GSK-3beta and MMP.
Glioblastoma
Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells.
Glioblastoma
MDM2 regulates hypoxic hypoxia-inducible factor 1? stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
Glioblastoma
MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.
Glioblastoma
Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma.
Glioblastoma
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Glioblastoma
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.
Glioblastoma
Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Glioblastoma
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Glioblastoma
Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking.
Glioblastoma
Opposing effects of PI3K/Akt and Smad-dependent signaling pathways in NAG-1-induced glioblastoma cell apoptosis.
Glioblastoma
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Glioblastoma
Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019.
Glioblastoma
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Glioblastoma
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Glioblastoma
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Glioblastoma
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
Glioblastoma
Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
Glioblastoma
PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
Glioblastoma
PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD.
Glioblastoma
PI3K p110? isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
Glioblastoma
PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.
Glioblastoma
PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.
Glioblastoma
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Glioblastoma
PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter.
Glioblastoma
Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule.
Glioblastoma
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Glioblastoma
Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma.
Glioblastoma
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling.
Glioblastoma
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.
Glioblastoma
Review: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Glioblastoma
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511.
Glioblastoma
Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis.
Glioblastoma
Synergism between the phosphatidylinositol 3-kinase p110? isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation.
Glioblastoma
Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Glioblastoma
Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma.
Glioblastoma
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Glioblastoma
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Glioblastoma
Thalidomide attenuates development of morphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling pathways.
Glioblastoma
The catalytic phosphoinositol 3-kinase isoform p110? is required for glioma cell migration and invasion.
Glioblastoma
The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase ?
Glioblastoma
The Oncogene Addiction Switch from NOTCH to PI3K Requires Simultaneous Targeting of NOTCH and PI3K Pathway Inhibition in Glioblastoma.
Glioblastoma
The PI3K pathway impacts stem gene expression in a set of glioblastoma cell lines.
Glioblastoma
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.
Glioblastoma
The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
Glioblastoma
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair.
Glioblastoma
The RNA helicase DHX33 is required for cancer cell proliferation in human glioblastoma and confers resistance to PI3K/mTOR inhibition.
Glioblastoma
The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
Glioblastoma
Three-dimensional Invasion of Human Glioblastoma Cells Remains Unchanged by X-ray and Carbon Ion Irradiation In Vitro.
Glioblastoma
Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.
Glioblastoma
Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling.
Glioblastoma
Transcriptomics predicts compound synergy in drug and natural product treated glioblastoma cells.
Glioblastoma
Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer.
Glioblastoma
Wortmannin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation.
Glioma
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Glioma
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
Glioma
A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways.
Glioma
A novel function of Goalpha: mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells.
Glioma
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Glioma
ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Glioma
Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
Glioma
ARID1A is a tumour suppressor and inhibits glioma cell proliferation via the PI3K pathwa.
Glioma
Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas.
Glioma
beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury.
Glioma
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Glioma
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Glioma
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
Glioma
Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote ?-irradiation-induced cell death in primary stem-like glioma cells.
Glioma
Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27(kip1).
Glioma
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Glioma
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Glioma
Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Glioma
Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound.
Glioma
Delayed growth of glioma by Scutellaria flavonoids involve inhibition of Akt, GSK-3 and NF-kappaB signaling.
Glioma
Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells.
Glioma
Differentiation antagonizing non-protein coding RNA modulates the proliferation, migration, and angiogenesis of glioma cells by targeting the miR-216a/LGR5 axis and the PI3K/AKT signaling pathway.
Glioma
Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo.
Glioma
Drak/STK17A drives neoplastic glial proliferation through modulation of MRLC signaling.
Glioma
Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
Glioma
Effect of Tenuifoliside A isolated from Polygala tenuifolia on the ERK and PI3K pathways in C6 glioma cells.
Glioma
Effects of nonselective cation channels and PI3K on endothelin-1-induced PYK2 tyrosine phosphorylation in C6 glioma cells.
Glioma
Epigenetic induction of melatonin MT1 receptors by valproate: Neurotherapeutic implications.
Glioma
Eriodictyol Inhibits Proliferation, Metastasis and Induces Apoptosis of Glioma Cells via PI3K/Akt/NF-?B Signaling Pathway.
Glioma
Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism.
Glioma
Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells.
Glioma
Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients.
Glioma
Glioblastoma multiforme cells: Expression of erythropoietin receptor and response to erythropoietin.
Glioma
Glioma cells promote the expression of vascular cell adhesion molecule-1 on bone marrow-derived mesenchymal stem cells: a possible mechanism for their tropism toward gliomas.
Glioma
Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis.
Glioma
High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas.
Glioma
Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
Glioma
IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K/Akt1/NF-?B-p65.
Glioma
Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation.
Glioma
Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas.
Glioma
Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Glioma
Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells.
Glioma
Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
Glioma
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.
Glioma
Inhibitory effect of penta-acetyl geniposide on C6 glioma cells metastasis by inhibiting matrix metalloproteinase-2 expression involved in both the PI3K and ERK signaling pathways.
Glioma
Integrin ?4 is involved in the regulation of glioma-induced motility of bone marrow mesenchymal stem cells.
Glioma
Knockdown of Serine Threonine Tyrosine Kinase 1 (STYK1) Inhibits the Migration and Tumorigenesis in Glioma Cells.
Glioma
Knockdown of TRIM37 suppresses the proliferation, migration and invasion of glioma cells through the inactivation of PI3K/Akt signaling pathway.
Glioma
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Glioma
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Glioma
MCL1 Gene Silencing Promotes Senescence and Apoptosis of Glioma Cells via Inhibition of the PI3K/Akt Signaling Pathway.
Glioma
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Glioma
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
Glioma
MicroRNA-126 acts as a tumor suppressor in glioma cells by targeting insulin receptor substrate 1 (IRS-1).
Glioma
MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway.
Glioma
MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3.
Glioma
miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma.
Glioma
miR-3175 and miR-134 affect proliferation, invasion and apoptosis of glioma cells through PI3K/AKT signaling pathway.
Glioma
miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways.
Glioma
NS1619 regulates the expression of caveolin-1 protein in a time-dependent manner via ROS/PI3K/PKB/FoxO1 signaling pathway in brain tumor microvascular endothelial cells.
Glioma
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Glioma
NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Glioma
Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival.
Glioma
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Glioma
PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway.
Glioma
Phosphatidylinositol 3-kinase activity is required for the expression of glial fibrillary acidic protein upon cAMP-dependent induction of differentiation in rat C6 glioma.
Glioma
Phosphatidylinositol 3-kinase activity is required for the induction of differentiation in C6 glioma cells by panaxydol.
Glioma
Phosphoinositide-3-kinase inhibition elevates ferritin level resulting depletion of labile iron pool and blocking of glioma cell proliferation.
Glioma
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Glioma
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
Glioma
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
Glioma
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.
Glioma
Plexin-B1 indirectly affects glioma invasiveness and angiogenesis by regulating the RhoA/?v?3 signaling pathway and SRPK1.
Glioma
Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.
Glioma
Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models.
Glioma
Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Glioma
Protein tyrosine kinase-dependent regulation of adenylate cyclase and phosphatidylinositol 3-kinase activates the expression of glial fibrillary acidic protein upon induction of differentiation in rat c6 glioma.
Glioma
Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines.
Glioma
Reactive blue 2 inhibition of cyclic AMP-dependent differentiation of rat C6 glioma cells by purinergic receptor-independent inactivation of phosphatidylinositol 3-kinase.
Glioma
Review: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Glioma
Roundabout4 suppresses glioma-induced endothelial cell proliferation, migration and tube formation in vitro by inhibiting VEGR2-mediated PI3K/AKT and FAK signaling pathways.
Glioma
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511.
Glioma
Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation.
Glioma
Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3?/?-catenin signaling pathway.
Glioma
Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression.
Glioma
Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta.
Glioma
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Glioma
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Glioma
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Glioma
Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
Glioma
T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model.
Glioma
Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway.
Glioma
The catalytic phosphoinositol 3-kinase isoform p110? is required for glioma cell migration and invasion.
Glioma
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Glioma
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.
Glioma
Thrombin-induced Migration and Matrix Metalloproteinase-9 Expression Are Regulated by MAPK and PI3K Pathways in C6 Glioma Cells.
Glioma
Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.
Glioma
Twisted gastrulation signaling modulator 1 promotes the ability of glioma cell through activating Akt pathway.
Glioma
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.
Glioma
V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
Glioma
Valproic Acid Promotes Human Glioma U87 Cells Apoptosis and Inhibits Glycogen Synthase Kinase-3? Through ERK/Akt Signaling.
Glioma
[Effect of Brucea Javanica Oil Emulsion on the Invasiveness of Glioma Cells and Its Possible Mechanism].
Glioma
[Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses proliferation and promotes apoptosis of U251 glioblastoma cells].
Glucose Intolerance
3-Deoxyglucosone Induced Acute Glucose Intolerance in Sprague-Dawley Rats: Involvement of Insulin Resistance and Impaired ?-cell Function.
Glucose Intolerance
Deletion of Protein Kinase C ? in POMC Neurons Predisposes to Diet-Induced Obesity.
Glucose Intolerance
Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity.
Glucose Intolerance
Loss of PI3K p110? in the Adipose Tissue Results in Infertility and Delayed Puberty Onset in Male Mice.
Glucose Intolerance
Maternal Inulin Supplementation Alters Hepatic DNA Methylation Profile and Improves Glucose Metabolism in Offspring Mice.
Graft vs Host Disease
Azole antifungals and new targeted therapies for hematological malignancy.
Graft vs Host Disease
Gene Expression Profiling-Based Identification of CD28 and PI3K as New Biomarkers for Chronic Graft-Versus-Host Disease.
Granulosa Cell Tumor
Constitutive Activation of PI3K in Oocyte Induces Ovarian Granulosa Cell Tumors.
Granulosa Cell Tumor
Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.
Granulosa Cell Tumor
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Graves Ophthalmopathy
Ganglioside GT1b increases hyaluronic acid synthase 2 via PI3K activation with TLR2 dependence in orbital fibroblasts from thyroid eye disease patients.
Hamartoma
Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
Hamartoma
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Hamartoma Syndrome, Multiple
PI3K Isoforms Have Spatially Distinct Roles in PTEN Hamartoma Tumor Syndrome.
Hamartoma Syndrome, Multiple
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.
Hamartoma Syndrome, Multiple
Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
Hamartoma Syndrome, Multiple
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Hamartoma Syndrome, Multiple
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.
Head and Neck Neoplasms
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Head and Neck Neoplasms
Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.
Head and Neck Neoplasms
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Head and Neck Neoplasms
Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer.
Head and Neck Neoplasms
Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
Head and Neck Neoplasms
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Head and Neck Neoplasms
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Head and Neck Neoplasms
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
Head and Neck Neoplasms
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Head and Neck Neoplasms
Paracrine Interaction of Cancer Stem Cell Populations Is Regulated by the Senescence-Associated Secretory Phenotype (SASP).
Head and Neck Neoplasms
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Head and Neck Neoplasms
Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.
Head and Neck Neoplasms
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
Head and Neck Neoplasms
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.
Head and Neck Neoplasms
The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells.
Hearing Loss
Activation of PI3K signaling prevents aminoglycoside-induced hair cell death in the murine cochlea.
Hearing Loss
Characterization of EGR-1 Expression in the Auditory Cortex Following Kanamycin-Induced Hearing Loss in Mice.
Hearing Loss
SOD2 Alleviates Hearing Loss Induced by Noise and Kanamycin in Mitochondrial DNA4834-deficient Rats by Regulating PI3K/MAPK Signaling.
Heart Diseases
Jujuboside A Protects H9C2 Cells from Isoproterenol-Induced Injury via Activating PI3K/Akt/mTOR Signaling Pathway.
Heart Diseases
LY294002 prevents lipopolysaccharide?induced hepatitis in a murine model by suppressing I?B phosphorylation.
Heart Diseases
Murine Polyomavirus Cell Surface Receptors Activate Distinct Signaling Pathways Required for Infection.
Heart Diseases
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Heart Diseases
Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure.
Heart Diseases
Role of PI3 kinase gamma in excitation-contraction coupling and heart disease.
Heart Diseases
Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
Heart Diseases
Specific PI3K Isoform Modulation in Heart Failure: Lessons from Transgenic Mice.
Heart Failure
Class III PI3K-mediated prolonged activation of autophagy plays a critical role in the transition of cardiac hypertrophy to heart failure.
Heart Failure
CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3K?-Akt signaling.
Heart Failure
Differential PI3K signal transduction in obesity-associated cardiac hypertrophy and response to ischemia.
Heart Failure
Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure.
Heart Failure
Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling.
Heart Failure
Pharmacological Inhibition of Phosphoinositide 3-Kinase Gamma (PI3K?) Promotes Infarct Resorption and Prevents Adverse Cardiac Remodeling after Myocardial Infarction in Mice.
Heart Failure
Specific PI3K Isoform Modulation in Heart Failure: Lessons from Transgenic Mice.
Heart Failure
Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression.
Heart Failure
Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure.
Heart Failure
Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).
Heart Failure
[Novel concepts in beta-adrenergic receptor signaling: therapeutic options for heart failure]
Heart Valve Diseases
[PTEN/PI3K pathways are involved in the signal transduction of myocardial remodeling in patients with congestive heart failure]
Hemangioma
Propranolol inhibits the activity of PI3K, AKT, and HIF-1? in infantile hemangiomas.
Hemangioma
ShcA and Grb2 mediate polyoma middle T antigen-induced endothelial transformation and Gab1 tyrosine phosphorylation.
Hemangiosarcoma
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Hemangiosarcoma
Active TGF-? signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Hemangiosarcoma
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Hematologic Neoplasms
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K ?/? Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.
Hematologic Neoplasms
Azole antifungals and new targeted therapies for hematological malignancy.
Hematologic Neoplasms
Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Hematologic Neoplasms
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Hematologic Neoplasms
Combined inhibition of PI3K-related DNA-damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.
Hematologic Neoplasms
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Hematologic Neoplasms
Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Hematologic Neoplasms
Duvelisib, an oral dual PI3K-?, ? inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Hematologic Neoplasms
Duvelisib, an oral dual PI3K-?,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
Hematologic Neoplasms
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Hematologic Neoplasms
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Hematologic Neoplasms
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Hematologic Neoplasms
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
Hematologic Neoplasms
Mammalian target of rapamycin as a target in hematological malignancies.
Hematologic Neoplasms
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Hematologic Neoplasms
Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish.
Hematologic Neoplasms
Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis.
Hematologic Neoplasms
Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3K? isoform.
Hematologic Neoplasms
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Hematologic Neoplasms
Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
Hematologic Neoplasms
Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K?-specific inhibitors for the treatment of hematologic malignancies.
Hematologic Neoplasms
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
Hematologic Neoplasms
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
Hematologic Neoplasms
The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.
Hematologic Neoplasms
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
Hematologic Neoplasms
Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies.
Hematoma, Subdural, Chronic
Activation of PI3 kinase / Akt signaling in chronic subdural hematoma outer membranes.
Hemorrhagic Stroke
Circulating lncRNAs HIF1A-AS2 and LINLK-A: Role and Relation to Hypoxia-Inducible Factor-1? in Cerebral Stroke Patients.
Hepatic Veno-Occlusive Disease
Chlorogenic acid suppresses monocrotaline-induced sinusoidal obstruction syndrome: The potential contribution of NF?B, Egr1, Nrf2, MAPKs and PI3K signals.
Hepatitis
Hepatitis B virus X protein activates a survival signaling by linking SRC to phosphatidylinositol 3-kinase.
Hepatitis
LY294002 prevents lipopolysaccharide?induced hepatitis in a murine model by suppressing I?B phosphorylation.
Hepatitis
Marmoset Viral Hepatic Inflammation Induced by Hepatitis C Virus Core Protein via IL-32.
Hepatitis B
Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas.
Hepatitis B
Hepatitis B virus X protein activates a survival signaling by linking SRC to phosphatidylinositol 3-kinase.
Hepatitis B
Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway.
Hepatitis B
Phosphatidylinositol 3-kinase is required for the regulation of hepatitis B surface antigen production and mitogen-activated protein kinase activation by insulin but not by TPA.
Hepatitis C
Hepatitis C virus regulates the production of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells through PI3K pathway and autocrine signaling.
Hepatitis C
Rab5 and Class III PI-3-Kinase Vps34 Are Involved in Hepatitis C Virus NS4B-Induced Autophagy.
Hepatitis C
Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.
Hepatitis, Alcoholic
Phosphoinositide-3-kinase inhibition with theophylline reverses steroid insensitivity in acute alcoholic hepatitis.
Hepatoblastoma
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Hepatoblastoma
Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma.
Herpes Simplex
Brain-derived neurotrophic factor induces excitotoxic sensitivity in cultured embryonic rat spinal motor neurons through activation of the phosphatidylinositol 3-kinase pathway.
Herpes Simplex
Herpes simplex virus protein kinases US3 and UL13 modulate VP11/12 phosphorylation, virion packaging, and phosphatidylinositol 3-kinase/Akt signaling activity.
Herpes Simplex
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Herpes Simplex
Phosphatidylinositol 3-kinase confers resistance to encephalomyocarditis and herpes simplex virus-induced cell death through the activation of distinct downstream effectors.
Herpes Simplex
PI3K/Akt signaling mediated apoptosis blockage and viral gene expression in oral epithelial cells during herpes simplex virus infection.
Herpes Simplex
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Herpes Simplex
Schizophrenia Susceptibility Genes Directly Implicated in the Life Cycles of Pathogens: Cytomegalovirus, Influenza, Herpes simplex, Rubella, and Toxoplasma gondii.
Herpes Zoster
Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation.
Herpesviridae Infections
Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome (APDS): Case Report and Review.
Herpesviridae Infections
Regulation of PI3K/Akt dependent apoptotic markers during b virus infection of human and macaque fibroblasts.
Herpesviridae Infections
The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.
Histiocytic Sarcoma
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Histiocytic Sarcoma
Multi-omics approach identifies germline regulatory variants associated with hematopoietic malignancies in retriever dog breeds.
Histiocytosis
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Histiocytosis, Langerhans-Cell
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
HIV Infections
Constitutive activation of phosphatidylinositol 3-kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-alpha release in alveolar macrophages from asymptomatic HIV-positive persons in vitro.
Hodgkin Disease
HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3.
Hodgkin Disease
PI3K? inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Huntington Disease
Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease.
Huntington Disease
ULK1-mediated phosphorylation of ATG14 promotes autophagy and is impaired in Huntington's disease models.
Hyperalgesia
Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation.
Hyperalgesia
Activation of protein kinase B/Akt in the periphery contributes to pain behavior induced by capsaicin in rats.
Hyperalgesia
Beneficial Effects of Electroacupuncture on Neuropathic Pain Evoked by Spinal Cord Injury and Involvement of PI3K-mTOR Mechanisms.
Hyperalgesia
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury.
Hyperalgesia
Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ-opioid receptor.
Hyperalgesia
Electroacupuncture inhibits phosphorylation of spinal phosphatidylinositol 3-kinase/Akt in a carrageenan-induced inflammatory rat model.
Hyperalgesia
GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican.
Hyperalgesia
Involvement of pro-inflammatory cytokines in diabetic neuropathic pain via central PI3K/Akt/mTOR signal pathway.
Hyperalgesia
Mechanical allodynia and enhanced responses to capsaicin are mediated by PI3K in a paclitaxel model of peripheral neuropathy.
Hyperalgesia
Microglial BDNF, PI3K, and p-ERK in the Spinal Cord Are Suppressed by Pulsed Radiofrequency on Dorsal Root Ganglion to Ease SNI-Induced Neuropathic Pain in Rats.
Hyperalgesia
Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain.
Hyperalgesia
Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization.
Hyperalgesia
Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane.
Hyperalgesia
Post-surgical inhibition of phosphatidylinositol 3-kinase attenuates the plantar incision-induced postoperative pain behavior via spinal Akt activation in male mice.
Hyperalgesia
Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia.
Hyperalgesia
SDF1-CXCR4 Signaling Contributes to the Transition from Acute to Chronic Pain State.
Hyperalgesia
Spinal phosphinositide 3-kinase-Akt-mammalian target of rapamycin signaling cascades in inflammation-induced hyperalgesia.
Hyperalgesia
The Inhibitory Effects of Slow-Releasing Hydrogen Sulfide Donors in the Mechanical Allodynia, Grip Strength Deficits, and Depressive-Like Behaviors Associated with Chronic Osteoarthritis Pain.
Hyperandrogenism
Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway.
Hypercalcemia
Calcium-sensing receptor induces proliferation through p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase but not extracellularly regulated kinase in a model of humoral hypercalcemia of malignancy.
Hyperglycemia
Acute exercise reduces hepatic glucose production through the inhibition of Foxo1/HNF-4alpha pathway in insulin resistant mice.
Hyperglycemia
Alpha lipoic acid protects against dexamethasone-induced metabolic abnormalities via APPL1 and PGC-1 ? up regulation.
Hyperglycemia
Anti-Apoptotic Effect of IGF1 on Schwann Exposed to Hyperglycemia is Mediated by Neuritin, a Novel Neurotrophic Factor.
Hyperglycemia
Chronic treatment with LY294002, an inhibitor of phosphatidylinositol 3-kinase, attenuates ischemia/reperfusion-induced cardiac dysfunction in normotensive and hypertensive diabetic animals.
Hyperglycemia
Comparison of pancreatic beta cells and alpha cells under hyperglycemia: Inverse coupling in pAkt-FoxO1.
Hyperglycemia
Gamma-glutamyl-carboxylated Gas6 mediates positive role of vitamin K on lowering hyperglycemia in type 2 diabetes.
Hyperglycemia
Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction.
Hyperglycemia
Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.
Hyperglycemia
Hyperglycemia inhibits insulin activation of Akt/protein kinase B but not phosphatidylinositol 3-kinase in rat skeletal muscle.
Hyperglycemia
Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation.
Hyperglycemia
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Hyperglycemia
Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells.
Hyperglycemia
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Hyperglycemia
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
Hyperglycemia
Minocycline Effectively Protects the Rabbit's Spinal Cord From Aortic Occlusion-Related Ischemia.
Hyperglycemia
Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII.
Hyperglycemia
Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors.
Hyperglycemia
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Hyperglycemia
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Hyperglycemia
PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
Hyperglycemia
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Hyperglycemia
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
Hyperglycemia
Supplementation with Vitis vinifera L. skin extract improves insulin resistance and prevents hepatic lipid accumulation and steatosis in high-fat diet-fed mice.
Hyperglycemia
Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition.
Hyperglycemia
The effect of PPAR? agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia.
Hyperglycemia
Thyroid Hormone Ameliorates Diabetic Nephropathy in a Mouse Model of Type II Diabetes.
Hyperglycemia
Tributyltin in male mice disrupts glucose homeostasis as well as recovery after exposure: mechanism analysis.
Hyperinsulinism
A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats.
Hyperinsulinism
ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia.
Hyperinsulinism
Critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappa B in obesity.
Hyperinsulinism
Effects of endurance exercise training on insulin signaling in human skeletal muscle: interactions at the level of phosphatidylinositol 3-kinase, Akt, and AS160.
Hyperinsulinism
Hepatic deletion of p110α and p85α results in insulin resistance despite sustained IRS1-associated phosphatidylinositol kinase activity.
Hyperinsulinism
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Hyperinsulinism
Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus.
Hyperinsulinism
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Hyperinsulinism
Insulin signaling and insulin sensitivity after exercise in human skeletal muscle.
Hyperinsulinism
IRS-1 Serine Phosphorylation and Insulin Resistance in Skeletal Muscle From Pancreas Transplant Recipients.
Hyperinsulinism
Is daytime insulin more physiologic and less atherogenic than bedtime insulin?
Hyperinsulinism
Supplementation with Vitis vinifera L. skin extract improves insulin resistance and prevents hepatic lipid accumulation and steatosis in high-fat diet-fed mice.
Hyperinsulinism
Tributyltin in male mice disrupts glucose homeostasis as well as recovery after exposure: mechanism analysis.
Hyperinsulinism
[Hyperinsulinemia induced immune maturation of human monocyte derived dendritic cells: bridging between diabetes and atherosclerosis]
Hyperlipidemias
Alpha lipoic acid protects against dexamethasone-induced metabolic abnormalities via APPL1 and PGC-1 ? up regulation.
Hyperlipidemias
Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.
Hyperpigmentation
A novel synthetic Piper amide derivative NED-180 inhibits hyperpigmentation by activating the PI3K and ERK pathways and by regulating Ca2+ influx via TRPM1 channels.
Hyperpigmentation
Diosgenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signaling.
Hypersensitivity
Activation of phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root ganglia and spinal cord contributes to the neuropathic pain induced by spinal nerve ligation in rats.
Hypersensitivity
Activation of protein kinase B/Akt signaling pathway contributes to mechanical hypersensitivity induced by capsaicin.
Hypersensitivity
Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.
Hypersensitivity
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.
Hypersensitivity
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Hypersensitivity
Dectin-1-Mediated Pathway Contributes to Fusarium proliferatum-Induced CXCL-8 Release from Human Respiratory Epithelial Cells.
Hypersensitivity
Effect and mechanisms of sacral nerve stimulation on visceral hypersensitivity mediated by nerve growth factor.
Hypersensitivity
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Hypersensitivity
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Hypersensitivity
Inhibition of lymphocyte kinase Lck and phosphatidylinositol 3-kinase by a novel immunosuppressant, lymphostin.
Hypersensitivity
Insulin hypersensitivity induced by hepatic PTEN gene ablation protects from murine endotoxemia.
Hypersensitivity
Involvement of pro-inflammatory cytokines in diabetic neuropathic pain via central PI3K/Akt/mTOR signal pathway.
Hypersensitivity
Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia.
Hypersensitivity
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.
Hypersensitivity
Pharmacological inhibition of PI5P4K?/? disrupts cell energy metabolism and selectively kills p53-null tumor cells.
Hypersensitivity
Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization.
Hypersensitivity
Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy.
Hypersensitivity
PI3K p110? uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
Hypersensitivity
PI3Kgamma adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells.
Hypersensitivity
Rapamycin alleviates proinflammatory cytokines and nociceptive behavior induced by chemotherapeutic paclitaxel.
Hypersensitivity
Rational Design of Novel Phosphoinositide 3-Kinase Gamma (PI3K?) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.
Hypersensitivity
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Hypersensitivity
Regulation of transient receptor potential cation channel subfamily V1 protein synthesis by the phosphoinositide 3-kinase/Akt pathway in colonic hypersensitivity.
Hypersensitivity
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Hypersensitivity
Spinal SHP2 Contributes to Exaggerated Incisional Pain in Adult Rats Subjected to Neonatal and Adult Incisions via PI3K.
Hypersensitivity
SWAP-70 regulates mast cell FcepsilonRI-mediated signaling and anaphylaxis.
Hypersensitivity
The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity.
Hypersensitivity
[EXPRESS] Involvement of pro-inflammation signal pathway in inhibitory effects of rapamycin on oxaliplatin-induced neuropathic pain.
Hypertension
Activation of the phosphatidylinositol 3-kinase pathway plays important roles in reduction of cerebral infarction by cilnidipine.
Hypertension
Active Rho kinase (ROK-alpha ) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells.
Hypertension
Chronic blockade of phosphatidylinositol 3-kinase in the nucleus tractus solitarii is prohypertensive in the spontaneously hypertensive rat.
Hypertension
Chronic treatment with LY294002, an inhibitor of phosphatidylinositol 3-kinase, attenuates ischemia/reperfusion-induced cardiac dysfunction in normotensive and hypertensive diabetic animals.
Hypertension
Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats.
Hypertension
Long-term treadmill training ameliorates endothelium-dependent vasorelaxation mediated by insulin and insulin-like growth factor-1 in hypertension.
Hypertension
Low [Mg2+]e enhances arterial spontaneous tone via phosphatidylinositol 3-kinase in DOCA-salt hypertension.
Hypertension
Lower cardiovagal tone and baroreflex sensitivity associated with hepatic insulin resistance and promote cardiovascular disorders in Tibetan minipigs induced by a high fat and high cholesterol diet.
Hypertension
Myeloid PTEN deficiency aggravates renal inflammation and fibrosis in angiotensin II-induced hypertension.
Hypertension
Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase in vasoconstriction: effects of rho-kinase and hypertension.
Hypertension
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Hypertension
PI3-kinase-induced hyperreactivity in DOCA-salt hypertension is independent of GSK-3 activity.
Hypertension
PI3K signaling: A key pathway in the control of sympathetic traffic and arterial pressure by leptin.
Hypertension
Receptor-independent activation of GABAergic neurotransmission and receptor-dependent nontranscriptional activation of phosphatidylinositol 3-kinase/protein kinase Akt pathway in short-term cardiovascular actions of dexamethasone at the nucleus tractus solitarii of the rat.
Hypertension
Reversal of the Warburg effect with DCA in PDGF?treated human PASMC is potentiated by pyruvate dehydrogenase kinase?1 inhibition mediated through blocking Akt/GSK?3? signalling.
Hypertension
Soluble form of vascular cell adhesion molecule 1 induces migration and proliferation of vascular smooth muscle cells.
Hypertension
SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension.
Hypertension
Suppression of Phosphatidylinositol 3-Kinase/Akt Signaling Attenuates Hypoxia-Induced Pulmonary Hypertension Through the Downregulation of Lysyl Oxidase.
Hypertension
The Functional Role of PI3K in Maintenance of Blood Pressure and Baroreflex Suppression in (mRen2)27 and mRen2.Lewis Rat.
Hypertension
The phosphoinositide-3 kinase signaling is involved in neuroinflammation in hypertensive rats.
Hypertension
Upregulated function of phosphatidylinositol-3-kinase in genetically hypertensive rats: a moderator of arterial hypercontractility.
Hypertension, Pulmonary
Hypoxic upregulation of preproendothelin-1 gene expression is associated with protein tyrosine kinase-PI3K signaling in cultured lung vascular endothelial cells.
Hypertension, Pulmonary
NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation.
Hypertension, Pulmonary
[Expression of mitogen-actived protein kinase, phosphatidylinositol 3-kinase and hypoxia-inducible factor-1alpha in pulmonary arteries of patients with chronic obstructive pulmonary disease]
Hypertrophy, Right Ventricular
Inhibition of Phosphatidylinositol-3-kinase/Akt Signaling Attenuates Hypoxia-Induced Pulmonary Artery Remodeling and Suppresses CREB Depletion in Arterial Smooth Muscle Cells.
Hypertrophy, Right Ventricular
Ligustrazine Suppresses Platelet-Derived Growth Factor-BB-Induced Pulmonary Artery Smooth Muscle Cell Proliferation and Inflammation by Regulating the PI3K/AKT Signaling Pathway.
Hypoglycemia
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.
Hypoglycemia
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.
Hypoglycemia
Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.
Hypotension
Activation of PI3K/Akt signaling in rostral ventrolateral medulla impairs brain stem cardiovascular regulation that underpins circulatory depression during mevinphos intoxication.
Hypotension
Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
Hypotension
Cyclosporine counteracts endotoxemia-evoked reductions in blood pressure and cardiac autonomic dysfunction via central sGC/MAPKs signaling in rats.
Hypotension
Phosphatidylinositol 3-kinase inhibition induces vasodilator effect of sevoflurane via reduction of Rho kinase activity.
Hypothyroidism
Class III PI3K Vps34 Controls Thyroid Hormone Production by Regulating Thyroglobulin Iodination, Lysosomal Proteolysis, and Tissue Homeostasis.
Hypothyroidism
Neurotoxicity of developmental hypothyroxinemia and hypothyroidism in rats: Impairments of long-term potentiation are mediated by phosphatidylinositol 3-kinase signaling pathway.
Hypoxia-Ischemia, Brain
Neuroprotective effects of electroacupuncture on hypoxic-ischemic encephalopathy in newborn rats are associated with increased expression of GDNF-RET and protein kinase B.
Idiopathic Pulmonary Fibrosis
Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis
Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
PI3K p110? overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition.
Immune System Diseases
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Immune System Diseases
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
Infarction, Middle Cerebral Artery
Both PI3K/Akt and ERK1/2 pathways participate in the protection by dexmedetomidine against transient focal cerebral ischemia/reperfusion injury in rats.
Infarction, Middle Cerebral Artery
Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain.
Infarction, Middle Cerebral Artery
MiR-124 affects the apoptosis of brain vascular endothelial cells and ROS production through regulating PI3K/AKT signaling pathway.
Infections
A calmodulin-like protein suppresses RNA silencing and promotes geminivirus infection by degrading SGS3 via the autophagy pathway in Nicotiana benthamiana.
Infections
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Infections
A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway.
Infections
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
Infections
Acidosis impairs insulin receptor substrate-1-associated phosphoinositide 3-kinase signaling in muscle cells: consequences on proteolysis.
Infections
Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration.
Infections
Activation of PI3K/Akt signaling has a dominant negative effect on IL-12 production by macrophages infected with Leishmania amazonensis promastigotes.
Infections
Activation of the phosphatidylinositol 3-kinase/Akt pathway contributes to survival of primary epithelial cells infected with the periodontal pathogen Porphyromonas gingivalis.
Infections
Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway during porcine circovirus type 2 infection facilitates cell survival and viral replication.
Infections
Adenovirus infection activates akt1 and induces cell proliferation in pancreatic islets1.
Infections
Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta.
Infections
African swine fever virus infects macrophages, the natural host cells, via clathrin- and cholesterol-dependent endocytosis.
Infections
Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway.
Infections
Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions.
Infections
Anti-chlamydial Th17 responses are controlled by the inducible costimulator partially through phosphoinositide 3-kinase signaling.
Infections
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.
Infections
Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome (APDS): Case Report and Review.
Infections
Autophagy induction by the pathogen receptor NECTIN4 and sustained autophagy contribute to peste des petits ruminants virus infectivity.
Infections
B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation.
Infections
Binding of Avibirnavirus VP3 to the PIK3C3-PDPK1 complex inhibits autophagy by activating the AKT-MTOR pathway.
Infections
Biphasic activation of PI3K/Akt and MAPK/Erk1/2 signaling pathways in bovine herpesvirus type 1 infection of MDBK cells.
Infections
Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence.
Infections
BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway.
Infections
Both PI3K- and mTOR-signaling pathways take part in CVB3-induced apoptosis of Hela cells.
Infections
Bovine herpesvirus type 4 infection modulates autophagy in a permissive cell line.
Infections
Bta-miR-223 Targeting CBLB Contributes to Resistance to Staphylococcus aureus Mastitis Through the PI3K/AKT/NF-?B Pathway.
Infections
BX-795 inhibits HSV-1 and HSV-2 replication by blocking the JNK/p38 pathways without interfering with PDK1 activity in host cells.
Infections
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
Infections
Campylobacter jejuni induces an anti-inflammatory response in human intestinal epithelial cells through activation of phosphatidylinositol 3-kinase/Akt pathway.
Infections
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Infections
CCR5-Dependent Activation of mTORC1 Regulates Translation of Inducible NO Synthase and COX-2 during Encephalomyocarditis Virus Infection.
Infections
Cdc42 and the phosphatidylinositol 3-kinase-Akt pathway are essential for PspC-mediated internalization of pneumococci by respiratory epithelial cells.
Infections
Cell Surface THY-1 Contributes to Human Cytomegalovirus Entry via a Macropinocytosis-like Process.
Infections
Cellular Trans-Differentiation and Morphogenesis Toward the Lymphatic Lineage in Regenerative Medicine.
Infections
Centrally acting drug moxonidine decreases reactive oxygen species via inactivation of the phosphoinositide-3 kinase signaling in the rostral ventrolateral medulla in hypertensive rats.
Infections
Characterization of entry and infection of monocytic THP-1 cells by Kaposi's sarcoma associated herpesvirus (KSHV): role of heparan sulfate, DC-SIGN, integrins and signaling.
Infections
Chlamydia pneumoniae infection induces vascular smooth muscle cell migration via Rac1 activation.
Infections
Chlamydia pneumoniae infection promotes vascular smooth muscle cell migration through Toll-like receptor 2-related signaling pathway.
Infections
Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function.
Infections
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Infections
Cross-talk between STAT1 and PI3K/AKT signaling in HIV-1-induced blood-brain barrier dysfunction: Role of CCR5 and implications for viral neuropathogenesis.
Infections
Dengue virus enhances thrombomodulin and ICAM-1 expression through the macrophage migration inhibitory factor induction of the MAPK and PI3K signaling pathways.
Infections
Densovirus infectious pathway requires clathrin-mediated endocytosis followed by trafficking to the nucleus.
Infections
Detergent-resistant microdomains mediate activation of host cell signaling in response to attaching-effacing bacteria.
Infections
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Infections
Distinct signalling mechanisms mediate neutrophil attraction to bacterial infection and tissue injury.
Infections
Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells.
Infections
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Infections
Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation.
Infections
Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.
Infections
Enterococcus faecalis infection activates phosphatidylinositol 3-kinase signaling to block apoptotic cell death in macrophages.
Infections
Entry of human rhinovirus 89 via ICAM-1 into HeLa epithelial cells is inhibited by actin skeleton disruption and by bafilomycin.
Infections
EphrinA2 receptor (EphA2) is an invasion and intracellular signaling receptor for Chlamydia trachomatis.
Infections
Epithelial PI3K signaling is required for {beta}-catenin activation and host defense against Citrobacter rodentium infection.
Infections
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.
Infections
Equine Herpesvirus Type 1 Enhances Viral Replication in CD172a+ Monocytic Cells upon Adhesion to Endothelial Cells.
Infections
Equine lentivirus counteracts SAMHD1 restriction by Rev-mediated degradation of SAMHD1 via the BECN1-dependent lysosomal pathway.
Infections
Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins.
Infections
Escherichia coli K-1 interaction with human brain micro-vascular endothelial cells triggers phospholipase C-gamma1 activation downstream of phosphatidylinositol 3-kinase.
Infections
Expression of PI3K and ERK in Uygur and Han patients with cervical squamous cancer.
Infections
Fatty acid synthase and stearoyl-CoA desaturase-1 are conserved druggable cofactors of Old World Alphavirus genome replication.
Infections
Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection.
Infections
Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection.
Infections
Flavone resistant Leishmania donovani over expresses LdMRP2 transporter in the parasite and activates host MRP2 on macrophages to circumvent the flavone-mediated cell death.
Infections
Four major factors regulate phosphatidylinositol 3-kinase signaling pathway in cancers induced by infection of human papillomaviruses.
Infections
Functional differentiation of three phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) in response to Vibrio anguillarum infection in turbot (Scophthalmus maximus).
Infections
Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
Infections
Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation.
Infections
Helicobacter pylori regulates cellular migration and apoptosis by activation of phosphatidylinositol 3-kinase signaling.
Infections
Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.
Infections
Hepatitis C Virus Upregulates Beclin1 for Induction of Autophagy and Activates mTOR Signaling.
Infections
Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.
Infections
Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
Infections
Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on Phase I clinical Trials.
Infections
Highly pathogenic PRRSV induces IL-17 production via the activation of IRAK1-PI3K-p38MAPK-C/EBP?/CREB pathways.
Infections
HIV infection of primary human T cells is determined by tunable thresholds of T cell activation.
Infections
Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus.
Infections
Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling.
Infections
Human papillomavirus 16 infection predicts poor outcome in patients with esophageal squamous cell carcinoma.
Infections
Hydrogen sulfide-induced GAPDH sulfhydration disrupts the CCAR2-SIRT1 interaction to initiate autophagy.
Infections
Hypoglycaemia induced by Trichinella infection is due to the increase of glucose uptake in infected muscle cells.
Infections
IL-10 knockdown with siRNA enhances the efficacy of Doxorubicin chemotherapy in EBV-positive tumors by inducing lytic cycle via PI3K/p38 MAPK/NF-kB pathway.
Infections
Impaired B cell function during viral infections due to PTEN-mediated inhibition of the PI3K pathway.
Infections
Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages.
Infections
Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad.
Infections
Infection with genotoxin-producing Salmonella enterica synergises with loss of the tumour suppressor APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells.
Infections
Infectious bursal disease virus activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway by interaction of VP5 protein with the p85? subunit of PI3K.
Infections
Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses.
Infections
Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion.
Infections
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Infections
Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice.
Infections
Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.
Infections
Insulin-stimulated phosphorylation of endothelial nitric oxide synthase at serine-615 contributes to nitric oxide synthesis.
Infections
Integrating high-content imaging and chemical genetics to probe host cellular pathways critical for Yersinia pestis infection.
Infections
Integrative Transcriptomic Analysis Reveals the Immune Mechanism for a CyHV-3-Resistant Common Carp Strain.
Infections
Integrin-linked kinase modulates lipopolysaccharide- and Helicobacter pylori-induced nuclear factor ?B-activated tumor necrosis factor-? production via regulation of p65 serine 536 phosphorylation.
Infections
Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages.
Infections
Intracellular Networks of the PI3K/AKT and MAPK Pathways for Regulating Toxoplasma gondii-Induced IL-23 and IL-12 Production in Human THP-1 Cells.
Infections
Invasion of HeLa cells by group B streptococcus requires the phosphoinositide-3-kinase signalling pathway and modulates phosphorylation of host-cell Akt and glycogen synthase kinase-3.
Infections
Involvement of the PI3K and ERK signaling pathways in largemouth bass virus-induced apoptosis and viral replication.
Infections
Isofraxidin ameliorated influenza viral inflammation in rodents via inhibiting platelet aggregation.
Infections
Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.
Infections
Legionella pneumophila infection is enhanced in a RacH-null mutant of Dictyostelium.
Infections
Life After Death: Are Autophagy Genes Involved in Cell Death and Survival during Plant Innate Immune Responses?
Infections
Lipid rafts of primary endothelial cells are essential for Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-induced phosphatidylinositol 3-kinase and RhoA-GTPases critical for microtubule dynamics and nuclear delivery of viral DNA but dispensable for binding and entry.
Infections
LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.
Infections
Lysophosphatidylcholine Promotes Phagosome Maturation and Regulates Inflammatory Mediator Production Through the Protein Kinase A-Phosphatidylinositol 3?Kinase-p38 Mitogen-Activated Protein Kinase Signaling Pathway During Mycobacterium tuberculosis Infection in Mouse Macrophages.
Infections
M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival.
Infections
Macrophage pro-inflammatory response to Francisella novicida infection is regulated by SHIP.
Infections
Macrophage's proinflammatory response to a mycobacterial infection is dependent on sphingosine kinase-mediated activation of phosphatidylinositol phospholipase C, protein kinase C, ERK1/2, and phosphatidylinositol 3-kinase.
Infections
Macrophages target Salmonella by Lc3-associated phagocytosis in a systemic infection model.
Infections
Marek's Disease Virus Activates the PI3K/Akt Pathway Through Interaction of Its Protein Meq With the P85 Subunit of PI3K to Promote Viral Replication.
Infections
Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection.
Infections
Minocycline differentially modulates macrophage mediated peripheral immune response following Japanese encephalitis virus infection.
Infections
miRNA-23a has effects to improve lung injury induced by sepsis in vitro and vivo study.
Infections
mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.
Infections
Murine Polyomavirus Cell Surface Receptors Activate Distinct Signaling Pathways Required for Infection.
Infections
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Infections
Myeloid cell IL-10 production in response to leishmania involves inactivation of glycogen synthase kinase-3? downstream of phosphatidylinositol-3 kinase.
Infections
NFAT AND CREB REGULATE KAPOSI'S SARCOMA ASSOCIATED HERPES VIRUS (KSHV) INDUCED CYCLOOXYGENASE-2 (COX-2).
Infections
Non-opsonic phagocytosis of Legionella pneumophila by macrophages is mediated by phosphatidylinositol 3-kinase.
Infections
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Infections
Participation of the phosphatidylinositol 3-kinase/Akt pathway in JunÃn virus replication in vitro.
Infections
Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells.
Infections
Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain.
Infections
Phosphatidylinositol 3-kinase and frabin mediate Cryptosporidium parvum cellular invasion via activation of Cdc42.
Infections
Phosphatidylinositol 3-kinase at The Very Early Symbiont Perception: A Local Nodulation Control under Stress Conditions?
Infections
Phosphatidylinositol 3-kinase regulates macrophage responses to double-stranded RNA and encephalomyocarditis virus.
Infections
Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).
Infections
Phosphoinositide 3-kinase family in channel catfish and their regulated expression after bacterial infection.
Infections
Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence.
Infections
Phosphoinositide-3 kinase inhibition modulates responses to rhinovirus by mechanisms that are predominantly independent of autophagy.
Infections
Phosphoinositide-3-kinase-dependent, MyD88-independent induction of CC-type chemokines characterizes the macrophage response to Toxoplasma gondii strains with high virulence.
Infections
Phosphoinositides differentially regulate bacterial uptake and Nramp1-induced resistance to Legionella infection in Dictyostelium.
Infections
Phosphorylation of PI3K/Akt and MAPK/ERK in an early entry step of enterovirus 71.
Infections
PI3K signaling delays Sendai virus-induced apoptosis by preventing XIAP degradation.
Infections
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans.
Infections
PI3K signaling regulates rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells.
Infections
PI3K-dependent host cell actin rearrangements are required for Cronobacter sakazakii invasion of human brain microvascular endothelial cells.
Infections
PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes.
Infections
PI3K/Akt signaling mediated apoptosis blockage and viral gene expression in oral epithelial cells during herpes simplex virus infection.
Infections
PI3K/Akt-Beclin1 signaling pathway positively regulates phagocytosis and negatively mediates NF-?B-dependent inflammation in Staphylococcus aureus-infected macrophages.
Infections
PI3K? Is Critical for Dendritic Cell-Mediated CD8+ T Cell Priming and Viral Clearance during Influenza Virus Infection.
Infections
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Infections
PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis.
Infections
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Infections
Platelet-activating factor mediates Porphyromonas gingivalis lipopolysaccharide interference with salivary mucin synthesis via phosphatidylinositol 3-kinase-dependent constitutive nitric-oxide synthase activation.
Infections
Productive Entry of Foot-and-Mouth Disease Virus via Macropinocytosis Independent of Phosphatidylinositol 3-Kinase.
Infections
Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent.
Infections
Protein kinase C isozymes regulate matrix metalloproteinase-1 expression and cell invasion in Helicobacter pylori infection.
Infections
Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes.
Infections
Rab5 activation by Toll-like receptor 2 is required for Trypanosoma cruzi internalization and replication in macrophages.
Infections
Rac1-dependent endocytosis and Rab5-dependent intracellular trafficking are required by Enterovirus A71 and Coxsackievirus A10 to establish infections.
Infections
Restoration of Akt activity by the bisperoxovanadium compound bpV(pic) attenuates hippocampal apoptosis in experimental neonatal pneumococcal meningitis.
Infections
Risk1, a Phosphatidylinositol 3-Kinase Effector, Promotes Rickettsia typhi Intracellular Survival.
Infections
Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.
Infections
Role of EGFR transactivation in preventing apoptosis in Pseudomonas aeruginosa-infected human corneal epithelial cells.
Infections
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Infections
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Infections
Root hair curling and Rhizobium infection in Medicago truncatula are mediated by phosphatidylinositide-regulated endocytosis and reactive oxygen species.
Infections
ROS-mediated PI3K activation drives mitochondrial transfer from stromal cells to hematopoietic stem cells in response to infection.
Infections
RP105 Engages Phosphatidylinositol 3-Kinase p110? To Facilitate the Trafficking and Secretion of Cytokines in Macrophages during Mycobacterial Infection.
Infections
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.
Infections
Shiga toxin type-2 (Stx2) induces glutamate release via phosphoinositide 3-kinase (PI3K) pathway in murine neurons.
Infections
Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells.
Infections
Soluble Egg Antigen Activates M2 Macrophages via the STAT6 and PI3K Pathways, and Schistosoma Japonicum Alternatively Activates Macrophage Polarization to Improve the Survival Rate of Septic Mice.
Infections
Sorting nexin (MoVps17) is required for fungal development and plant infection by regulating endosome dynamics in the rice blast fungus.
Infections
Spring viraemia of carp virus enters grass carp ovary cells via clathrin-mediated endocytosis and macropinocytosis.
Infections
Suppression of host PTEN gene expression for Leishmania donovani survival in Indian visceral leishmaniasis.
Infections
Synergistic Interaction between Leptin and Cholecystokinin in the Rat Nodose Ganglia Is Mediated by PI3K and STAT3 Signaling Pathways: IMPLICATIONS FOR LEPTIN AS A REGULATOR OF SHORT TERM SATIETY.
Infections
Targeting PI3K-p110? Suppresses Influenza Viral Infection in Chronic Obstructive Pulmonary Disease.
Infections
Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.
Infections
The Chinese herbal prescription JZ-1 induces autophagy to protect against herpes simplex Virus-2 in human vaginal epithelial cells by inhibiting the PI3K/Akt/mTOR pathway.
Infections
The Effector TepP Mediates Recruitment and Activation of Phosphoinositide 3-Kinase on Early Chlamydia trachomatis Vacuoles.
Infections
The immunity-related GTPase Irgm3 relieves endoplasmic reticulum stress response during coxsackievirus B3 infection via a PI3K/Akt dependent pathway.
Infections
The Inhibition of PI3K-Akt Pathway Enhances Gamma-2 Herpesvirus Lytic Replication and Facilitates Reactivation from Latency.
Infections
The nuclear protein Sam68 is redistributed to the cytoplasm and is involved in PI3K/Akt activation during EV71 infection.
Infections
The p110? isoforme of phosphatidylinositol 3-kinase plays an important role in host defense against chlamydial lung infection through influencing CD4+ T-cell function.
Infections
The Phosphatidylinositol 3-Kinase p110?/PTEN Signaling Pathway Is Crucial for HIV-1 Entry.
Infections
The PI3K-Akt signaling pathway is important for Staphylococcus aureus internalization by endothelial cells.
Infections
The Role of PI3K/AKT Pathway and NADPH Oxidase 4 in Host ROS Manipulation by Toxoplasma gondii.
Infections
The role of the PI3K-Akt signal transduction pathway in Autographa californica multiple nucleopolyhedrovirus infection of Spodoptera frugiperda cells.
Infections
The study on the role of Hepatitis B virus X protein and apoptosis in HBV intrauterine infection.
Infections
Toxoplasma gondii Proliferation Require Down-Regulation of Host Nox4 Expression via Activation of PI3 Kinase/Akt Signaling Pathway.
Infections
Transcriptome analysis of liver elucidates key immune-related pathways in Nile tilapia Oreochromis niloticus following infection with tilapia lake virus.
Infections
Transcriptome analysis of NF-kappaB- and phosphatidylinositol 3-kinase-regulated genes in human cytomegalovirus-infected monocytes.
Infections
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
Infections
Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry.
Infections
Transient activation of the PI3K/Akt pathway promotes Newcastle disease virus replication and enhances anti-apoptotic signaling responses.
Infections
Trypanosoma cruzi: phosphatidylinositol 3-kinase and protein kinase B activation is associated with parasite invasion.
Infections
Variant PIK3R1 Hypermorphic Mutation and Clinical Phenotypes in a Family with Short Statures, Mild Immunodeficiency and Lymphoma.
Infections
Varicella-zoster virus requires a functional PI3K/Akt/GSK-3alpha/beta signaling cascade for efficient replication.
Infections
VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells.
Infections
Vibrio parahaemolyticus orchestrates a multifaceted host cell infection by induction of autophagy, cell rounding, and then cell lysis.
Infections
[Screening of differentially expressed genes in placentas with hepatitis B virus infection by suppression subtractive hybridization technique]
Infertility
Human sperm anatomy: different expression and localization of phosphatidylinositol 3-kinase in normal and varicocele human spermatozoa.
Infertility
Loss of PI3K p110? in the Adipose Tissue Results in Infertility and Delayed Puberty Onset in Male Mice.
Infertility
New strategy for in vitro activation of primordial follicles with mTOR and PI3K stimulators.
Infertility
[Effect of electroacupuncture on levels of serum sex hormones and expression of ovarian auto-phagy related factors in rats with polycystic ovary syndrome].
Infertility, Male
Human sperm anatomy: different expression and localization of phosphatidylinositol 3-kinase in normal and varicocele human spermatozoa.
Inflammatory Bowel Diseases
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110?.
Inflammatory Bowel Diseases
Emerging views of mitophagy in immunity and autoimmune diseases.
Inflammatory Bowel Diseases
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Inflammatory Bowel Diseases
PI3K/AKT signaling is essential for communication between tissue infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
Inflammatory Bowel Diseases
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Inflammatory Bowel Diseases
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Inflammatory Bowel Diseases
Sprouty2 limits intestinal tuft and goblet cell numbers through GSK3?-mediated restriction of epithelial IL-33.
Inflammatory Bowel Diseases
The PI3K pathway as a therapeutic intervention point in inflammatory bowel disease.
Inflammatory Bowel Diseases
The role of phosphoinositide 3-kinase signaling in intestinal inflammation.
Inflammatory Bowel Diseases
The roles of microbial products in the development of colorectal cancer: a review.
Influenza, Human
A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway.
Influenza, Human
A Peptide Derived from Phosphoinositide 3-kinase Inhibits Endocytosis and Influenza Virus Infection.
Influenza, Human
Activation of phosphatidylinositol 3-kinase signaling by the nonstructural NS1 protein is not conserved among type A and B influenza viruses.
Influenza, Human
An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir.
Influenza, Human
Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation.
Influenza, Human
Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence.
Influenza, Human
Inability of NS1 protein from an H5N1 influenza virus to activate PI3K/Akt signaling pathway correlates to the enhanced virus replication upon PI3K inhibition.
Influenza, Human
Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K.
Influenza, Human
Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses.
Influenza, Human
Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling.
Influenza, Human
Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion.
Influenza, Human
Influenza A viruses and PI3K: Are there time, place and manner restrictions?
Influenza, Human
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Influenza, Human
Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice.
Influenza, Human
Innate Immune Response to Influenza A Virus in Differentiated Human Alveolar Type II cells.
Influenza, Human
Loss of function of the influenza A virus NS1 protein promotes apoptosis but this is not due to a failure to activate phosphatidylinositol 3-kinase (PI3K).
Influenza, Human
Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity.
Influenza, Human
Molecular Basis of the Ternary Interaction between NS1 of the 1918 Influenza A Virus, PI3K, and CRK.
Influenza, Human
Phosphatidylinositol-3-kinase (PI3K) is activated by influenza virus vRNA via the pathogen pattern receptor Rig-I to promote efficient type I interferon production.
Influenza, Human
PI3K? Is Critical for Dendritic Cell-Mediated CD8+ T Cell Priming and Viral Clearance during Influenza Virus Infection.
Influenza, Human
Reorganization of the host cell Crk(L)-PI3 kinase signaling complex by the influenza A virus NS1 protein.
Influenza, Human
Role of G protein and protein kinase signalling in influenza virus budding in MDCK cells.
Influenza, Human
SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation.
Influenza, Human
Strain-specific contribution of NS1-activated PI3K signaling to influenza A virus replication and virulence.
Influenza, Human
The human adenovirus E4-ORF1 protein subverts discs large 1 to mediate membrane recruitment and dysregulation of phosphatidylinositol 3-kinase.
Influenza, Human
Understanding the Binding Transition State After the Conformational Selection Step: The Second Half of the Molecular Recognition Process Between NS1 of the 1918 Influenza Virus and Host p85?.
Insulin Resistance
7-o-methylaromadendrin stimulates glucose uptake and improves insulin resistance in vitro.
Insulin Resistance
A Chinese Herbal Decoction, Dang Gui Bu Xue Tang, Prepared from Radix Astragali and Radix Angelicae sinensis, Ameliorates Insulin Resistance Induced by A High-Fructose Diet in Rats.
Insulin Resistance
A common variation of the PTEN gene is associated with peripheral insulin resistance.
Insulin Resistance
A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats.
Insulin Resistance
A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response.
Insulin Resistance
Abelmoschus esculentus subfractions attenuate beta amyloid-induced neuron apoptosis by regulating DPP-4 with improving insulin resistance signals.
Insulin Resistance
Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction.
Insulin Resistance
Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats.
Insulin Resistance
Acetylation and insulin resistance: a focus on metabolic and mitogenic cascades of insulin signaling.
Insulin Resistance
Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin.
Insulin Resistance
Activation of opioid mu-receptors by loperamide to improve interleukin-6-induced inhibition of insulin signals in myoblast C2C12 cells.
Insulin Resistance
Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production.
Insulin Resistance
Adipocyte-Derived Exosomes Carrying Sonic Hedgehog Mediate M1 Macrophage Polarization-Induced Insulin Resistance via Ptch and PI3K Pathways.
Insulin Resistance
Adipose tissue insulin resistance due to loss of PI3K p110? leads to decreased energy expenditure and obesity.
Insulin Resistance
Adipose tissue insulin sensitivity and macrophage recruitment: Does PI3K pick the pathway?
Insulin Resistance
Alterations in the insulin signaling pathway induced by immortalization and H-ras transformation of brown adipocytes.
Insulin Resistance
Amelioration of Insulin Resistance by Scopoletin in High-Glucose-Induced, Insulin-Resistant HepG2 Cells.
Insulin Resistance
Amino acid availability regulates S6K1 and protein synthesis in avian insulin-insensitive QM7 myoblasts.
Insulin Resistance
An Integrated Approach Based on Network Pharmacology Combined with Experimental Verification Reveals AMPK/PI3K/Akt Signaling is an Important Way for the Anti-Type 2 Diabetic Activity of Silkworm Excrement.
Insulin Resistance
Analysis of phosphatidylinositol 3-kinase activation in the adipose tissue of gestational diabetes mellitus patients and insulin resistance.
Insulin Resistance
Anemarrhena saponins attenuate insulin resistance in rats with high-fat diet-induced obesity via the IRS-1/PI3K/AKT pathway.
Insulin Resistance
Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I.
Insulin Resistance
Association of impaired phosphatidylinositol 3-kinase activity in GLUT1-containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome.
Insulin Resistance
Astragalus polysaccharides attenuates TNF-?-induced insulin resistance via suppression of miR-721 and activation of PPAR-? and PI3K/AKT in 3T3-L1 adipocytes.
Insulin Resistance
Attenuated Pik3r1 Expression Prevents Insulin Resistance and Adipose Tissue Macrophage Accumulation in Diet-Induced Obese Mice.
Insulin Resistance
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Insulin Resistance
Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats.
Insulin Resistance
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
Insulin Resistance
Calorie restriction increases muscle insulin action but not IRS-1-, IRS-2-, or phosphotyrosine-PI 3-kinase.
Insulin Resistance
Calorie restriction prevents the development of insulin resistance and impaired insulin signaling in skeletal muscle of ovariectomized rats.
Insulin Resistance
Calorie Restriction-Induced Increase in Skeletal Muscle Insulin Sensitivity Is Not Prevented by Overexpression of the p55? Subunit of Phosphoinositide 3-Kinase.
Insulin Resistance
Cardiac insulin resistance is associated with an impaired recruitment of phosphatidylinositol 3-kinase to GLUT4 vesicles.
Insulin Resistance
Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation.
Insulin Resistance
Caulerpa lentillifera extract ameliorates insulin resistance and regulates glucose metabolism in C57BL/KsJ-db/db mice via PI3K/AKT signaling pathway in myocytes.
Insulin Resistance
Cellular mechanism of insulin resistance: potential links with inflammation.
Insulin Resistance
Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons.
Insulin Resistance
Central insulin-mediated regulation of hepatic glucose production [Review].
Insulin Resistance
Chromium malate alleviates high-glucose and insulin resistance in L6 skeletal muscle cells by regulating glucose uptake and insulin sensitivity signaling pathways.
Insulin Resistance
Chronic ethanol treatment of human hepatocytes inhibits the activation of the insulin signaling pathway by increasing cytosolic free calcium levels.
Insulin Resistance
Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.
Insulin Resistance
Cinnamon polyphenols regulate multiple metabolic pathways involved in insulin signaling and intestinal lipoprotein metabolism of small intestinal enterocytes.
Insulin Resistance
Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling.
Insulin Resistance
Coordinated balancing of muscle oxidative metabolism through PGC-1? increases metabolic flexibility and preserves insulin sensitivity.
Insulin Resistance
Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction.
Insulin Resistance
Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.
Insulin Resistance
Defect in skeletal muscle phosphatidylinositol-3-kinase in obese insulin-resistant mice.
Insulin Resistance
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.
Insulin Resistance
Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction.
Insulin Resistance
DhHP-6 ameliorates hepatic oxidative stress and insulin resistance in type 2 diabetes mellitus through the PI3K/AKT and AMPK pathway.
Insulin Resistance
Diabetes recurrence after metabolic surgeries correlates with re-impaired insulin sensitivity rather than beta-cell function.
Insulin Resistance
Diacerhein attenuates the inflammatory response and improves survival in a model of severe sepsis.
Insulin Resistance
Dietary Lycium barbarum polysaccharide induces Nrf2/ARE pathway and ameliorates insulin resistance induced by high-fat via activation of PI3K/AKT signaling.
Insulin Resistance
Differential effects of exercise on insulin-signaling gene expression in human skeletal muscle.
Insulin Resistance
Dissecting the mechanism of insulin resistance using a novel heterodimerization strategy to activate Akt.
Insulin Resistance
Down regulation of brain cellular prion protein in an animal model of insulin resistance: possible implication in increased prevalence of stroke in pre-diabetics/diabetics.
Insulin Resistance
Effect of chromium citrate on the mechanism of glucose transport and insulin resistance in Buffalo rat liver cells.
Insulin Resistance
Effect of fetal dexamethasone exposure on the development of adult insulin sensitivity in a rat model.
Insulin Resistance
Effect of phosphotyrosyl-IRS-1 level and insulin receptor tyrosine kinase activity on insulin-stimulated phosphatidylinositol 3, MAP, and S6 kinase activities.
Insulin Resistance
Effect of short-term exercise training on insulin-stimulated PI 3-kinase activity in human skeletal muscle.
Insulin Resistance
Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA?treated HepG2 cells.
Insulin Resistance
Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior.
Insulin Resistance
Effects of sleeve gastrectomy plus trunk vagotomy compared with sleeve gastrectomy on glucose metabolism in diabetic rats.
Insulin Resistance
Electroacupuncture mitigates endothelial dysfunction via effects on the PI3K/Akt signalling pathway in high fat diet-induced insulin-resistant rats.
Insulin Resistance
Emodin Regulates Glucose Utilization by Activating AMP-activated Protein Kinase.
Insulin Resistance
Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation.
Insulin Resistance
Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin.
Insulin Resistance
G-protein coupled receptor 120 is involved in glucose metabolism in fat cells.
Insulin Resistance
Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110? isoform of phosphatidylinositol 3-kinase.
Insulin Resistance
Genetic deletion of the angiotensin-(1-7) receptor Mas leads to alterations in gut villi length modulating TLR4/PI3K/AKT and produces microbiome dysbiosis.
Insulin Resistance
Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes.
Insulin Resistance
High-fat diet alters PP2A, TC10, and CIP4 expression in visceral adipose tissue of rats.
Insulin Resistance
High-Fat Diet Obesity Associated with Insulin Resistance Increases Cell Proliferation, Estrogen Receptor, and PI3K Proteins in Rat Ventral Prostate.
Insulin Resistance
High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats.
Insulin Resistance
Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance via reduction in association of the Glucocorticoid Receptor with phosphatidylinositol-3-kinase.
Insulin Resistance
Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation.
Insulin Resistance
Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle.
Insulin Resistance
Hydrogen Sulfide Treatment Promotes Glucose Uptake by Increasing Insulin Receptor Sensitivity and Ameliorates Kidney Lesions in Type 2 Diabetes.
Insulin Resistance
Hypoglycemic Activity and Antioxidative Stress of Extracts and Corymbiferin from Swertia bimaculata In Vitro and In Vivo.
Insulin Resistance
Hypoglycemic activity of the extracts of Belamcanda chinensis leaves (BCLE) on KK-Ay mice.
Insulin Resistance
Hypoglycemic effects of Grifola frondosa (Maitake) polysaccharides F2 and F3 through improvement of insulin resistance in diabetic rats.
Insulin Resistance
Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.
Insulin Resistance
Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes.
Insulin Resistance
Impact of weight cycling on CTRP3 expression, adipose tissue inflammation and insulin sensitivity in C57BL/6J mice.
Insulin Resistance
Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation.
Insulin Resistance
Inducible nitric oxide synthase deficiency ameliorates skeletal muscle insulin resistance but does not alter unexpected lower blood glucose levels after burn injury in C57BL/6 mice.
Insulin Resistance
Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity.
Insulin Resistance
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Insulin Resistance
Inhibition of 11?-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance.
Insulin Resistance
Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Insulin Resistance
Inhibition of Soluble Epoxide Hydrolase Limits Mitochondrial Damage and Preserves Function Following Ischemic Injury.
Insulin Resistance
Inhibitors of phosphatidylinositol 3-kinase amplify insulin release from islets of lean but not obese mice.
Insulin Resistance
Insulin and insulin signaling play a critical role in fat induction of insulin resistance in mouse.
Insulin Resistance
Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin.
Insulin Resistance
Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression and translocation.
Insulin Resistance
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Insulin Resistance
Insulin signal transduction by a mutant human insulin receptor lacking the NPEY sequence. Evidence for an alternate mitogenic signaling pathway that is independent of Shc phosphorylation.
Insulin Resistance
Insulin-mediated pseudoacromegaly in a patient with severe insulin resistance: association of defective insulin-stimulated glucose transport with impaired phosphatidylinositol 3-kinase activity in fibroblasts.
Insulin Resistance
Knockdown of STEAP4 inhibits insulin-stimulated glucose transport and GLUT4 translocation via attenuated phosphorylation of Akt, independent of the effects of EEA1.
Insulin Resistance
Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons.
Insulin Resistance
Leucine reduces the duration of insulin-induced PI 3-kinase activity in rat skeletal muscle.
Insulin Resistance
Link between the renin-angiotensin system and insulin resistance: Implications for cardiovascular disease.
Insulin Resistance
Long-term denervation impairs insulin receptor substrate-1-mediated insulin signaling in skeletal muscle.
Insulin Resistance
Losartan Reduces Insulin Resistance by Inhibiting Oxidative Stress and Enhancing Insulin Signaling Transduction.
Insulin Resistance
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model.
Insulin Resistance
Maternal nicotine exposure aggravates metabolic associated fatty liver disease via PI3K/Akt signaling in adult offspring mice.
Insulin Resistance
Maternal protein restriction affects postnatal growth and the expression of key proteins involved in lifespan regulation in mice.
Insulin Resistance
Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle.
Insulin Resistance
Mechanisms of hemorrhage-induced hepatic insulin resistance: role of tumor necrosis factor-alpha.
Insulin Resistance
Membrane-targeted phosphatidylinositol 3-kinase mimics insulin actions and induces a state of cellular insulin resistance.
Insulin Resistance
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Insulin Resistance
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
Insulin Resistance
MicroRNA-351 eases insulin resistance and liver gluconeogenesis via the PI3K/AKT pathway by inhibiting FLOT2 in mice of gestational diabetes mellitus.
Insulin Resistance
miR-200s contribute to interleukin-6 (IL-6)-induced insulin resistance in hepatocytes.
Insulin Resistance
MiRNA-21 Reverses High Glucose and High Insulin Induced Insulin Resistance in 3T3-L1 Adipocytes through Targeting Phosphatase and Tensin Homologue.
Insulin Resistance
Mitochondrial dysfunction in insulin resistance: differential contributions of chronic insulin and saturated fatty acid exposure in muscle cells.
Insulin Resistance
Molecular mechanism of insulin resistance in obesity and type 2 diabetes.
Insulin Resistance
Monoclonal antibody to six transmembrane epithelial antigen of prostate-4 influences insulin sensitivity by attenuating phosphorylation of P13K (P85) and Akt: possible mitochondrial mechanism.
Insulin Resistance
Mulberry Bark Alleviates Effect of STZ Inducing Diabetic Mice through Negatively Regulating FoxO1.
Insulin Resistance
Narrow-Leafed Lupin (Lupinus angustifolius L.) Seeds Gamma-Conglutin is an Anti-Inflammatory Protein Promoting Insulin Resistance Improvement and Oxidative Stress Amelioration in PANC-1 Pancreatic Cell-Line.
Insulin Resistance
Network pharmacology-based exploration of therapeutic mechanism of Liu-Yu-Tang in atypical antipsychotic drug-induced metabolic syndrome.
Insulin Resistance
Network Pharmacology-Based Strategy Reveals the Effects of Hedysarum multijugum Maxim.-Radix Salviae Compound on Oxidative Capacity and Cardiomyocyte Apoptosis in Rats with Diabetic Cardiomyopathy.
Insulin Resistance
Neuronal Sirt1 Deficiency Increases Insulin Sensitivity in Both Brain and Peripheral Tissues.
Insulin Resistance
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Insulin Resistance
NF-{kappa}B-Inducing Kinase (NIK) Mediates Skeletal Muscle Insulin Resistance: Blockade by Adiponectin.
Insulin Resistance
Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity.
Insulin Resistance
Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1.
Insulin Resistance
Old biliverdin reductase: links to insulin resistance and may be a novel therapeutic target.
Insulin Resistance
Oleic Acid Protects Against Insulin Resistance by Regulating the Genes Related to the PI3K Signaling Pathway.
Insulin Resistance
Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance.
Insulin Resistance
Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase.
Insulin Resistance
Palmitic Acid Induces MicroRNA-221 Expression to Decrease Glucose Uptake in HepG2 Cells via the PI3K/AKT/GLUT4 Pathway.
Insulin Resistance
Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus.
Insulin Resistance
Persistent activation of phosphatidylinositol 3-kinase causes insulin resistance due to accelerated insulin-induced insulin receptor substrate-1 degradation in 3T3-L1 adipocytes.
Insulin Resistance
Phosphatidyl Inositol 3-Kinase Signaling in Hypothalamic Proopiomelanocortin Neurons Contributes to the Regulation of Glucose Homeostasis.
Insulin Resistance
Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: A distinct branch of PI3K signaling.
Insulin Resistance
Phosphatidylinositol 3-kinase and dynamics of insulin resistance in denervated slow and fast muscles in vivo.
Insulin Resistance
Phosphatidylinositol 3-kinase inhibitors reveal a unique mechanism of enhancing insulin secretion in 832/13 rat insulinoma cells.
Insulin Resistance
Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population.
Insulin Resistance
Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus.
Insulin Resistance
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.
Insulin Resistance
Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.
Insulin Resistance
Physicochemical Characterization of Hizikia fusiforme Polysaccharide and Its Hypoglycemic Activity via Mediating Insulin-Stimulated Blood Glucose Utilization of Skeletal Muscle in Type 2 Diabetic Rats.
Insulin Resistance
Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes.
Insulin Resistance
PI3-kinase mutation linked to insulin and growth factor resistance in vivo.
Insulin Resistance
Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation.
Insulin Resistance
Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism.
Insulin Resistance
Preventive effect of oleate on palmitate-induced insulin resistance in skeletal muscle and its mechanism of action.
Insulin Resistance
Promoter polymorphisms -359T/C and -303A/G of the catalytic subunit p110beta gene of human phosphatidylinositol 3-kinase are not associated with insulin secretion or insulin sensitivity in finnish subjects.
Insulin Resistance
Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes.
Insulin Resistance
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis.
Insulin Resistance
Purple sweet potato color improves hippocampal insulin resistance via down-regulating SOCS3 and galectin-3 in high-fat diet mice.
Insulin Resistance
Randomized clinical trial to compare the effects of preoperative oral carbohydrate versus placebo on insulin resistance after colorectal surgery.
Insulin Resistance
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
Insulin Resistance
Reduction of the PI3K/Akt related signaling activities in skeletal muscle tissues involves insulin resistance in intrauterine growth restriction rats with catch-up growth.
Insulin Resistance
Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes.
Insulin Resistance
Regulation of insulin resistance and glucose metabolism by interaction of PIM kinases and insulin receptor substrates.
Insulin Resistance
Rescuing 3T3-L1 adipocytes from insulin resistance induced by stimulation of Akt-mammalian target of rapamycin/p70 S6 kinase (S6K1) pathway and serine phosphorylation of insulin receptor substrate-1: effect of reduced expression of p85alpha subunit of phosphatidylinositol 3-kinase and S6K1 kinase.
Insulin Resistance
Restored insulin-sensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy.
Insulin Resistance
Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach.
Insulin Resistance
Reversal of insulin resistance postpartum is linked to enhanced skeletal muscle insulin signaling.
Insulin Resistance
Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1.
Insulin Resistance
Role of miRNAs in the pathogenesis of T2DM, insulin secretion, insulin resistance, and ? cell dysfunction: the story so far.
Insulin Resistance
Role of p110a subunit of PI3-kinase in skeletal muscle mitochondrial homeostasis and metabolism.
Insulin Resistance
Role of retinol-binding protein 4 in the pathogenesis of Type 2 diabetes.
Insulin Resistance
Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis.
Insulin Resistance
Scopoletin increases glucose uptake through activation of PI3K and AMPK signaling pathway and improves insulin sensitivity in 3T3-L1 cells.
Insulin Resistance
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
Insulin Resistance
Stimulatory effect of docosahexaenoic acid alone or loaded in zinc oxide or silver nanoparticles on the expression of glucose transport pathway.
Insulin Resistance
Structure and in vitro hypoglycemic activity of a homogenous polysaccharide purified from Sargassum pallidum.
Insulin Resistance
Study on the metabolism toxicity, susceptibility and mechanism of di-(2-ethylhexyl) phthalate on rat liver BRL cells with insulin resistance in vitro.
Insulin Resistance
Supplementation with Vitis vinifera L. skin extract improves insulin resistance and prevents hepatic lipid accumulation and steatosis in high-fat diet-fed mice.
Insulin Resistance
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.
Insulin Resistance
Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle.
Insulin Resistance
Tectorigenin Attenuates Palmitate-Induced Endothelial Insulin Resistance via Targeting ROS-Associated Inflammation and IRS-1 Pathway.
Insulin Resistance
The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome.
Insulin Resistance
The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis.
Insulin Resistance
The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study.
Insulin Resistance
The ER?-PI3K Cascade in Proopiomelanocortin Progenitor Neurons Regulates Feeding and Glucose Balance in Female Mice.
Insulin Resistance
The level of insulin receptor tyrosine kinase activity modulates the activities of phosphatidylinositol 3-kinase, microtubule-associated protein, and S6 kinases.
Insulin Resistance
The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance.
Insulin Resistance
The possible role of mRNA expression changes of GH/IGF-1/insulin axis components in subcutaneous adipose tissue in metabolic disturbances of patients with acromegaly.
Insulin Resistance
Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins.
Insulin Resistance
Transcription factor TIP27 regulates glucose homeostasis and insulin sensitivity in a PI3-kinase/Akt-dependent manner in mice.
Insulin Resistance
Trilobatin ameliorates insulin resistance through IRS-AKT-GLUT4 signaling pathway in C2C12 myotubes and ob/ob mice.
Insulin Resistance
Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner.
Insulin Resistance
Tumor necrosis factor-alpha, sphingomyelinase and ceramides activate tyrosine kinase, p21Ras and phosphatidylinositol 3-kinase: implications for glucose transport and insulin resistance.
Insulin Resistance
Understanding the mode-of-action of Cassia auriculata via in silico and in vivo studies towards validating it as a long term therapy for type II diabetes.
Insulin Resistance
Vascular insulin resistance: a potential link between cardiovascular and metabolic diseases.
Insulin Resistance
Verapamil toxicity dysregulates the phosphatidylinositol 3-kinase pathway.
Insulin Resistance
Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism.
Insulin Resistance
Xiao Ke Qing improves glycometabolism and ameliorates insulin resistance by regulating the PI3K/Akt pathway in KKAy mice.
Insulin Resistance
[Cell biological mechanism involved in the effect of sodium selenite on improving insulin sensitivity]
Insulin Resistance
[Correlation between growth hormone/insulin-like growth factor-1 resistance and insulin resistance in non catch-up growth rats born small for gestational age]
Insulin Resistance
[Detection and significance of phosphatidylinositol 3-kinase in adipose tissue of polycystic ovary syndrome patients with insulin resistance]
Insulin Resistance
[Development of insulin resistance in muscle and adipose tissue during obesity in the mouse. Role of phosphatidylinositol 3-kinase]
Insulin Resistance
[Effect of "Spleen-Stomach Harmonizing" Needling on Insulin Resistance and Expression of Insulin Receptor Substrate-1, -2, and Glucose Transporter-4 in Insulin Resistance Type 2 Diabetes Rats].
Insulin Resistance
[Effects of Astragalus membranaceus and Potentilla discolor mixture on insulin resistance and its related mRNA expressions in KKAy mice with type 2 diabetes].
Insulin Resistance
[Effects of electroacupuncture intervention on expression of hypothalamic PI 3 K and p-PI 3 K Proteins in insulin resistance model rats].
Insulin Resistance
[Effects of L-Arg on expression of PI3K and PKB in liver among low-birth-weight newborn rats].
Insulin Resistance
[Effects of retinol binding protein 4 knockdown on the PI3K/Akt pathways in porcine adipocytes].
Insulin Resistance
[Progress in the role of oxidative stress in the pathogenesis of type 2 diabetes].
Insulin Resistance
[Role of protein kinase C isozymes in cellular functions and pathological conditions]
Insulin Resistance
[Study on the mechanism of insulin resistance in rats born with intrauterine growth retardation]
Insulinoma
Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways.
Insulinoma
Differential Signaling by Regulatory Subunits of Phosphoinositide-3-kinase Influences Cell Survival in INS-1E Insulinoma Cells.
Insulinoma
Expression and function of the calcium-sensing receptor in pancreatic islets and insulinoma cells.
Insulinoma
Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase.
Insulinoma
Insulin/phosphatidylinositol 3-kinase pathway accelerates the glucose-induced first phase insulin secretion through TrpV2 recruitment in pancreatic beta-cells.
Insulinoma
Phosphatidylinositol 3-kinase inhibitors reveal a unique mechanism of enhancing insulin secretion in 832/13 rat insulinoma cells.
Insulinoma
Triiodothyronine (T3) induces proinsulin gene expression by activating PI3K: possible roles for GSK-3? and the transcriptional factor PDX-1.
Intellectual Disability
Deletion of PTEN produces deficits in conditioned fear and increases fragile X mental retardation protein.
Intellectual Disability
Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Intervertebral Disc Degeneration
The mechanism of Bushen Huoxue decoction in treating intervertebral disc degeneration based on network pharmacology.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Iron Overload
Zinc induces iron egress from intestinal Caco-2 cells via induction of Hephaestin: A role for PI3K in intestinal iron absorption.
Irritable Bowel Syndrome
From psychology to physicality: how nerve growth factor transduces early life stress into gastrointestinal motility disorders later in life.
Ischemic Stroke
Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway.
Ischemic Stroke
Early Activation of Phosphatidylinositol 3-Kinase after Ischemic Stroke Reduces Infarct Volume and Improves Long-Term Behavior.
Ischemic Stroke
Electroacupuncture Inhibits Neuronal Autophagy and Apoptosis via the PI3K/AKT Pathway Following Ischemic Stroke.
Ischemic Stroke
Medicarpin Protects Cerebral Microvascular Endothelial Cells Against Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury via the PI3K/Akt/FoxO Pathway: A Study of Network Pharmacology Analysis and Experimental Validation.
Ischemic Stroke
Netrin-1 Ameliorates Blood-Brain Barrier Impairment Secondary to Ischemic Stroke via the Activation of PI3K Pathway.
Ischemic Stroke
Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition.
Ischemic Stroke
Pre-ischemic treadmill training alleviates brain damage via GLT-1-mediated signal pathway after ischemic stroke in rats.
Ischemic Stroke
S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating ?7 nAChR and PI3K / Akt / GSK3? signal pathway in rats.
Joint Diseases
Synergistic collagenase expression and cartilage collagenolysis are phosphatidylinositol 3-kinase/Akt signaling-dependent.
Kashin-Beck Disease
Role of selenoprotein S (SEPS1) -105G>A polymorphisms and PI3K/Akt signaling pathway in Kashin-Beck disease.
Keloid
Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway.
Keloid
Interleukin-18 system plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions.
Keloid
Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor.
Keloid
Madecassoside suppresses migration of fibroblasts from keloids: involvement of p38 kinase and PI3K signaling pathways.
Keloid
Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids.
Keloid
Upregulation of microRNA-205 suppresses vascular endothelial growth factor expression-mediated PI3K/Akt signaling transduction in human keloid fibroblasts.
Keloid
Wubeizi Ointment Suppresses Keloid Formation through Modulation of the mTOR Pathway.
Ketosis
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Kidney Neoplasms
CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway.
Kidney Neoplasms
Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Kidney Neoplasms
Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer.
Kidney Neoplasms
Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent.
Kidney Neoplasms
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Klatskin Tumor
Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells.
Klippel-Trenaunay-Weber Syndrome
Haploinsufficiency of Klippel-Trenaunay syndrome gene Aggf1 inhibits developmental and pathological angiogenesis by inactivating PI3K and AKT and disrupts vascular integrity by activating VE-cadherin.
Klippel-Trenaunay-Weber Syndrome
Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study.
Laryngeal Neoplasms
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.
Latent Infection
Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells.
Latent Infection
Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation.
Learning Disabilities
Role of Class III phosphoinositide 3-kinase in the brain development: possible involvement in specific learning disorders.
Leiomyoma
All-trans-retinoic acid mediates changes in PI3K and retinoic acid signaling proteins of leiomyomas.
Leiomyoma
Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology.
Leiomyoma
Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications.
Leiomyoma
Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of ?-catenin and of signaling interactions.
Leiomyosarcoma
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics.
Leiomyosarcoma
Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways.
Leiomyosarcoma
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Leishmaniasis
Inhibition of CD40-induced N-Ras activation reduces leishmania major infection.
Leishmaniasis
Pharmacological inhibition of p110? subunit of PI3K confers protection against experimental leishmaniasis.
Leishmaniasis, Cutaneous
Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis.
Leishmaniasis, Visceral
Deficiency of p110? isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani.
LEOPARD Syndrome
Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.
Leukemia
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Leukemia
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Leukemia
A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments.
Leukemia
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Leukemia
Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line.
Leukemia
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.
Leukemia
Activation of PDK-1 maintains mouse embryonic stem cell self-renewal in a PKB-dependent manner.
Leukemia
Activation of phosphatidylinositol-3-kinase in Jurkat T cells depends on the presence of the p56lck tyrosine kinase.
Leukemia
Active lipids of Ganoderma lucidum spores-induced apoptosis in human leukemia THP-1 cells via MAPK and PI3K pathways.
Leukemia
Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
Leukemia
Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells.
Leukemia
BAD Dephosphorylation and Decreased Expression of MCL-1 Induce Rapid Apoptosis in Prostate Cancer Cells.
Leukemia
Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
Leukemia
BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth.
Leukemia
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Leukemia
CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide.
Leukemia
Chemical modification of santonin into a diacetoxy acetal form confers the ability to induce differentiation of human promyelocytic leukemia cells via the down-regulation of NF-kappaB DNA binding activity.
Leukemia
CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.
Leukemia
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Leukemia
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Leukemia
Combined Inhibition of PI3K and mTOR Exerts Synergistic Antiproliferative Effect, but Diminishes Differentiative Properties of Rapamycin in Acute Myeloid Leukemia Cells.
Leukemia
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Leukemia
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
Leukemia
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Leukemia
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Leukemia
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias.
Leukemia
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110? subunit of PI3 kinase.
Leukemia
Effect of wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) on N-formyl-methionyl-leucyl-phenylalanine-induced phospholipase D activation in differentiated HL60 cells: possible involvement of phosphatidylinositol 3-kinase in phospholipase D activation.
Leukemia
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Leukemia
Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
Leukemia
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Leukemia
GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation.
Leukemia
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110?.
Leukemia
Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
Leukemia
High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.
Leukemia
Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
Leukemia
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Leukemia
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Leukemia
Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells.
Leukemia
Inhibition of phosphatidylinositol 3-kinase causes apoptosis in retinoic acid differentiated hl-60 leukemia cells.
Leukemia
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.
Leukemia
Inhibition of PI-3-K and AKT Amplifies Kv1.3 Inhibitor-Induced Death of Human T Leukemia Cells.
Leukemia
Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
Leukemia
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
Leukemia
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
Leukemia
Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Leukemia
MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Leukemia
Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway.
Leukemia
NF-?B-dependent Mechanism of Action of c-Myc Inhibitor 10058-F4: Highlighting a Promising Effect of c-Myc Inhibition in Leukemia Cells, Irrespective of p53 Status.
Leukemia
Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
Leukemia
Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
Leukemia
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
Leukemia
Phosphatidylinositol 3-kinase in HL-60 nuclei is bound to the nuclear matrix and increases during granulocytic differentiation.
Leukemia
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
Leukemia
Phosphatidylinositol 3-kinase is required for the induction of ornithine decarboxylase in leukemia cells stimulated to growth.
Leukemia
Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.
Leukemia
PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL.
Leukemia
PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
Leukemia
PI3K p110? uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
Leukemia
PI3K target based novel cyano derivative of betulinic acid induces its signalling inhibition by down-regulation of pGSK3? and cyclin D1 and potentially checks cancer cell proliferation.
Leukemia
Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish.
Leukemia
Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice.
Leukemia
PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
Leukemia
Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells.
Leukemia
Posttranscriptional regulation of the p85? adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells.
Leukemia
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Leukemia
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Leukemia
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Leukemia
Propofol Treatment Inhibits Constitutive Apoptosis in Human Primary Neutrophils and Granulocyte-Differentiated Human HL60 Cells.
Leukemia
Rac and phosphatidylinositol 3-kinase regulate the protein kinase B in Fc epsilon RI signaling in RBL 2H3 mast cells.
Leukemia
Semaphorin 4D is a potential biomarker in pediatric leukemia and promotes leukemogenesis by activating PI3K/AKT and ERK signaling pathways.
Leukemia
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
Leukemia
Silencing c-Myc translation as a therapeutic strategy through targeting PI3K? and CK1? in hematological malignancies.
Leukemia
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
Leukemia
Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status.
Leukemia
Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Leukemia
Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-? Inhibitor CAL-101.
Leukemia
Synthesis and biological evaluation of novel pyrimidine-5-carbonitriles featuring morpholine moiety as antitumor agents.
Leukemia
Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase.
Leukemia
Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
Leukemia
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
Leukemia
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Leukemia
The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of KMT2A-rearranged Leukemia.
Leukemia
The Inhibitory NKR-P1B:Clr-b Recognition Axis Facilitates Detection of Oncogenic Transformation and Cancer Immunosurveillance.
Leukemia
The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase.
Leukemia
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Leukemia
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Leukemia
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
Leukemia
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.
Leukemia
Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia.
Leukemia
[Regulation of All-trans Retinoic Acid and Arsenic Trioxide on CD44v6 Expression in NB4 Cells].
Leukemia, Erythroblastic, Acute
Combined inhibition of PI3K and activation of MAPK p38 signaling pathways trigger erythroid alternative splicing switch of 4.1R pre-mRNA in DMSO-induced erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Phosphatidylinositol 3-kinase activity in murine erythroleukemia cells during DMSO-induced differentiation.
Leukemia, Erythroblastic, Acute
Subtle distinct regulations of late erythroid molecular events by PI3K/AKT-mediated activation of Spi-1/PU.1 oncogene autoregulation loop.
Leukemia, Erythroblastic, Acute
[Involvement of regulating the phosphatidylinositol 3-kinase signaling pathway in the process of herbimycin A-induced erythroid cell differentiation in the K562 erythroleukemia cell line]
Leukemia, Large Granular Lymphocytic
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations.
Leukemia, Lymphocytic, Chronic, B-Cell
A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib.
Leukemia, Lymphocytic, Chronic, B-Cell
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Leukemia, Lymphocytic, Chronic, B-Cell
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment.
Leukemia, Lymphocytic, Chronic, B-Cell
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Leukemia, Lymphocytic, Chronic, B-Cell
Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.
Leukemia, Lymphocytic, Chronic, B-Cell
Development of PI3K inhibitors: advances in clinical trials and new strategies (Review).
Leukemia, Lymphocytic, Chronic, B-Cell
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Duvelisib, an oral dual PI3K-?,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
Leukemia, Lymphocytic, Chronic, B-Cell
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Epilepsia partialis continua revealing idelalisib-associated PML-IRIS: clinical and pathological features.
Leukemia, Lymphocytic, Chronic, B-Cell
Erratum to: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase ? but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Leukemia, Lymphocytic, Chronic, B-Cell
Idelalisib for the treatment of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110?, for relapsed/refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Leukemia, Lymphocytic, Chronic, B-Cell
Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
Leukemia, Lymphocytic, Chronic, B-Cell
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.
Leukemia, Lymphocytic, Chronic, B-Cell
IGF1R as druggable target mediating PI3K-? inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Leukemia, Lymphocytic, Chronic, B-Cell
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL.
Leukemia, Lymphocytic, Chronic, B-Cell
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Phosphatidylinositol 3-kinase-? inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Leukemia, Lymphocytic, Chronic, B-Cell
Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes.
Leukemia, Lymphocytic, Chronic, B-Cell
Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia..
Leukemia, Lymphocytic, Chronic, B-Cell
Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Leukemia, Lymphocytic, Chronic, B-Cell
PI3-kinase inhibitors in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
Leukemia, Lymphocytic, Chronic, B-Cell
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Leukemia, Lymphocytic, Chronic, B-Cell
PI3K p110? inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.
Leukemia, Lymphocytic, Chronic, B-Cell
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
Leukemia, Lymphocytic, Chronic, B-Cell
PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Leukemia, Lymphocytic, Chronic, B-Cell
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Leukemia, Lymphocytic, Chronic, B-Cell
The dual PI3K?/CK1? inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
Leukemia, Lymphocytic, Chronic, B-Cell
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.
Leukemia, Lymphocytic, Chronic, B-Cell
The PI3K p110? Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Leukemia, Lymphocytic, Chronic, B-Cell
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Leukemia, Lymphoid
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Leukemia, Lymphoid
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Leukemia, Lymphoid
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Leukemia, Mast-Cell
Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line.
Leukemia, Mast-Cell
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NF-?B suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The anti-tumoral effect of PI3K inhibitor and MEK inhibitor combined with STI571 on chronic myeloid leukemia cells in a bone marrow stromal cell co-culture system]
Leukemia, Myeloid
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Leukemia, Myeloid
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110?.
Leukemia, Myeloid
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.
Leukemia, Myeloid, Acute
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
ACLY is the novel signaling target of PIP2/PIP3 and Lyn in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Arsenic Trioxide and Thalidomide Combination Induces Autophagy Along with Apoptosis in Acute Myeloid Cell Lines.
Leukemia, Myeloid, Acute
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Leukemia, Myeloid, Acute
Azole antifungals and new targeted therapies for hematological malignancy.
Leukemia, Myeloid, Acute
Camel Whey Protein Disrupts the Cross-Talk Between PI3K and BCL-2 Signals and Mediates Apoptosis in Primary Acute Myeloid Leukemia Cells.
Leukemia, Myeloid, Acute
Combined Inhibition of PI3K and mTOR Exerts Synergistic Antiproliferative Effect, but Diminishes Differentiative Properties of Rapamycin in Acute Myeloid Leukemia Cells.
Leukemia, Myeloid, Acute
Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110d subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors.
Leukemia, Myeloid, Acute
Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation.
Leukemia, Myeloid, Acute
Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Leukemia, Myeloid, Acute
Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy.
Leukemia, Myeloid, Acute
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110? subunit of PI3 kinase.
Leukemia, Myeloid, Acute
Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.
Leukemia, Myeloid, Acute
Gab2 Is Involved in Differential Phosphoinositide 3-Kinase Signaling by Two Splice Forms of c-Kit.
Leukemia, Myeloid, Acute
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Leukemia, Myeloid, Acute
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
Leukemia, Myeloid, Acute
mTOR regulates cell survival after etoposide treatment in primary AML cells.
Leukemia, Myeloid, Acute
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
Leukemia, Myeloid, Acute
PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.
Leukemia, Myeloid, Acute
Posttranscriptional regulation of the p85? adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells.
Leukemia, Myeloid, Acute
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Leukemia, Myeloid, Acute
Puquitinib, a novel orally available PI3K? inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
Leukemia, Myeloid, Acute
Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Leukemia, Myeloid, Acute
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Survival of acute myeloid leukemia cells requires PI3 kinase activation.
Leukemia, Myeloid, Acute
Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
Leukemia, Myeloid, Acute
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Leukemia, Myeloid, Acute
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
Leukemia, Myeloid, Acute
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
Leukemia, Myeloid, Acute
The role of autophagy in targeted therapy for acute myeloid leukemia.
Leukemia, Myeloid, Acute
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.
Leukemia, Myeloid, Acute
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
Leukemia, Myelomonocytic, Juvenile
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Leukemia, Promyelocytic, Acute
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Leukemia, Promyelocytic, Acute
NF-?B-dependent Mechanism of Action of c-Myc Inhibitor 10058-F4: Highlighting a Promising Effect of c-Myc Inhibition in Leukemia Cells, Irrespective of p53 Status.
Leukemia, Promyelocytic, Acute
The role of autophagy in targeted therapy for acute myeloid leukemia.
Leukemia, Promyelocytic, Acute
[Regulation of All-trans Retinoic Acid and Arsenic Trioxide on CD44v6 Expression in NB4 Cells].
Leukemia, T-Cell
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Leukemia, T-Cell
The human adenovirus E4-ORF1 protein subverts discs large 1 to mediate membrane recruitment and dysregulation of phosphatidylinositol 3-kinase.
Leukemia, T-Cell
The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome.
Leukemia, T-Cell
The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
Leukemia-Lymphoma, Adult T-Cell
Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL).
Leukemia-Lymphoma, Adult T-Cell
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Lewy Body Disease
Alteration of Upstream Autophagy-Related Proteins (ULK1, ULK2, Beclin1, VPS34 and AMBRA1) in Lewy Body Disease.
Lipodystrophy
Iris Malformation and Anterior Segment Dysgenesis in Mice and Humans With a Mutation in PI 3-Kinase.
Lipodystrophy
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
Lipodystrophy
SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
Lipodystrophy
Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy.
Lipoma
Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies.
Lipoma
The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells.
Liposarcoma
Novel Dedifferentiated Liposarcoma Xenograft Models Reveal PTEN Down-Regulation as a Malignant Signature and Response to PI3K Pathway Inhibition.
Liposarcoma
Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma.
Liposarcoma, Myxoid
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
Liver Cirrhosis
Active Compounds Derived from Fuzheng Huayu Formula Protect Hepatic Parenchymal Cells from Apoptosis Based on Network Pharmacology and Transcriptomic Analysis.
Liver Cirrhosis
Effect of miR-182 on hepatic fibrosis induced by Schistosomiasis japonica by targeting FOXO1 through PI3K/AKT signaling pathway.
Liver Cirrhosis
Germacrone improves liver fibrosis by regulating the PI3K/AKT/mTOR signalling pathway.
Liver Cirrhosis
HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis.
Liver Cirrhosis
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.
Liver Cirrhosis
NF-?B inhibition alleviates carbon tetrachloride-induced liver fibrosis via suppression of activated hepatic stellate cells.
Liver Cirrhosis
Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells.
Liver Diseases
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Liver Diseases
Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease.
Liver Diseases
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD.
Liver Diseases
Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner.
Liver Diseases
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
Liver Diseases
PIK3R3 regulates PPAR? expression to stimulate fatty acid ?-oxidation and decrease hepatosteatosis.
Liver Diseases
Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway.
Liver Neoplasms
A combination of Citrus reticulata peel and black tea inhibits migration and invasion of liver cancer via PI3K/AKT and MMPs signaling pathway.
Liver Neoplasms
A phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migration.
Liver Neoplasms
Anesthetic effects of isoflurane and the molecular mechanism underlying isoflurane?inhibited aggressiveness of hepatic carcinoma.
Liver Neoplasms
Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways.
Liver Neoplasms
Dynamic interplay of two molecular switches enabled by the MEK1/2-ERK1/2 and IL-6-STAT3 signaling axes controls epithelial cell migration in response to growth factors.
Liver Neoplasms
Gomisin N Exerts Anti-liver Cancer Effects and Regulates PI3K-Akt and mTOR-ULK1 Pathways in Vitro.
Liver Neoplasms
Inhibition of PI3K/Akt and ERK signaling decreases visfatin-induced invasion in liver cancer cells.
Liver Neoplasms
LY?294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF?1? pathway.
Liver Neoplasms
MicroRNA-26b inhibits the tumor growth of human liver cancer through the PI3K/Akt and NF-?B/MMP-9/VEGF pathways.
Liver Neoplasms
Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma.
Liver Neoplasms
PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor.
Liver Neoplasms
PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.
Liver Neoplasms
Sedanolide induces autophagy through the PI3K, p53 and NF-?B signaling pathways in human liver cancer cells.
Liver Neoplasms
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Liver Neoplasms
Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression.
Liver Neoplasms
Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
Liver Neoplasms
The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers.
Liver Neoplasms
Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer.
Liver Neoplasms
[Integrin ?5 silencing inhibits proliferation, invasion and metastasis of human liver cancer Bel-7404 cells in vitro].
Liver Neoplasms, Experimental
Increased activity and nuclear localisation of inositol lipid signal transduction enzymes in rat hepatoma cells.
Lordosis
Participation of growth factor signal transduction pathways in estradiol facilitation of female reproductive behavior.
Lung Diseases
Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis.
Lung Diseases
Genetic Deletion and Pharmacological Inhibition of PI3K ? Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease.
Lung Diseases
MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway.
Lung Injury
?-Opioid receptor signalling via PI3K/Akt pathway ameliorates lipopolysaccharide-induced acute respiratory distress syndrome.
Lung Injury
Anti-malarial drug artesunate protects against cigarette smoke-induced lung injury in mice.
Lung Injury
Dexmedetomidine Ameliorates Post-CPB Lung Injury in Rats by Activating the PI3K/Akt Pathway.
Lung Injury
Effects of phosphoinositide 3-kinase in protease-induced acute and chronic lung inflammation, remodeling and emphysema in rats.
Lung Injury
Expression of phosphatidylinositol-3 kinase and effects of inhibitor Wortmannin on expression of tumor necrosis factor-? in severe acute pancreatitis associated with acute lung injury.
Lung Injury
Regulation of phosphatidylinositol 3-kinase by polyisoprenyl phosphates in neutrophil-mediated tissue injury.
Lung Neoplasms
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Lung Neoplasms
A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
Lung Neoplasms
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
Lung Neoplasms
A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis.
Lung Neoplasms
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Lung Neoplasms
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Lung Neoplasms
AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways.
Lung Neoplasms
Aclidinium Bromide holds promising inhibitory effects in A549 lung cancer cells potentials by regulating PI3K / AKT signaling pathway.
Lung Neoplasms
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
Lung Neoplasms
Airway Microbiota Is Associated with Up-Regulation of the PI3K Pathway in Lung Cancer.
Lung Neoplasms
Airway PI3K pathway activation is an early and reversible event in lung cancer development.
Lung Neoplasms
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
Lung Neoplasms
All-Trans Retinoic Acid Induces Proliferation, Survival, and Migration in A549 Lung Cancer Cells by Activating the ERK Signaling Pathway through a Transcription-Independent Mechanism.
Lung Neoplasms
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Lung Neoplasms
Analysis of the Protein-Protein Interaction Network Identifying c-Met as a Target of Gigantol in the Suppression of Lung Cancer Metastasis.
Lung Neoplasms
Andrographolide down-regulates hypoxia-inducible factor-1? in human non-small cell lung cancer A549 cells.
Lung Neoplasms
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Lung Neoplasms
Assessment of FGFR1 Over-Expression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening.
Lung Neoplasms
BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating ?-catenin/ZEB1 regulatory loop.
Lung Neoplasms
Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
Lung Neoplasms
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Lung Neoplasms
Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.
Lung Neoplasms
Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin.
Lung Neoplasms
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Lung Neoplasms
Characteristics of the PI3K/AKT and MAPK/ERK pathways involved in the maintenance of self-renewal in lung cancer stem-like cells.
Lung Neoplasms
cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer.
Lung Neoplasms
Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.
Lung Neoplasms
Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers.
Lung Neoplasms
Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Lung Neoplasms
Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer.
Lung Neoplasms
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Lung Neoplasms
Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Lung Neoplasms
Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology.
Lung Neoplasms
Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activator Nutlin-3.
Lung Neoplasms
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI 3-kinase in KRAS mutant lung cancer.
Lung Neoplasms
Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A Review.
Lung Neoplasms
Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer.
Lung Neoplasms
DEPENDENCE ON THE MUC1-C ONCOPROTEIN IN NON-SMALL CELL LUNG CANCER CELLS WITH EGFR AND K-RAS MUTATIONS.
Lung Neoplasms
Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.
Lung Neoplasms
Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
Lung Neoplasms
Diprophylline inhibits non-small cell lung cancer A549 cell proliferation and migration, and promotes apoptosis, by downregulating PI3K signaling pathway.
Lung Neoplasms
Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
Lung Neoplasms
DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis.
Lung Neoplasms
Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
Lung Neoplasms
Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells.
Lung Neoplasms
Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Lung Neoplasms
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Lung Neoplasms
Effects of direct current electric fields on lung cancer cell electrotaxis in a PMMA-based microfluidic device.
Lung Neoplasms
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers.
Lung Neoplasms
FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Lung Neoplasms
Fibroblast activation protein-? promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways.
Lung Neoplasms
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
Lung Neoplasms
Five genes may predict metastasis in non-small cell lung cancer using bioinformatics analysis.
Lung Neoplasms
Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines.
Lung Neoplasms
Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer.
Lung Neoplasms
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
Lung Neoplasms
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Lung Neoplasms
Identification of a subset of human non-small cell lung cancer patients with high PI3K? and low PTEN expression, more prevalent in squamous cell carcinoma.
Lung Neoplasms
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
Lung Neoplasms
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.
Lung Neoplasms
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Lung Neoplasms
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways.
Lung Neoplasms
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Lung Neoplasms
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Lung Neoplasms
Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer.
Lung Neoplasms
Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism.
Lung Neoplasms
Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1.
Lung Neoplasms
MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway.
Lung Neoplasms
MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway.
Lung Neoplasms
miR-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells.
Lung Neoplasms
MiR-503 targets PI3K p85 and IKK-? and suppresses progression of non-small cell lung cancer.
Lung Neoplasms
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
Lung Neoplasms
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Lung Neoplasms
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.
Lung Neoplasms
Molybdenum disulfide-based hyaluronic acid-guided multifunctional theranostic nanoplatform for magnetic resonance imaging and synergetic chemo-photothermal therapy.
Lung Neoplasms
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Lung Neoplasms
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.
Lung Neoplasms
Oncogenic KRAS signaling and YAP1/?-catenin: Similar cell cycle control in tumor initiation.
Lung Neoplasms
Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway.
Lung Neoplasms
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Lung Neoplasms
Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation.
Lung Neoplasms
Paclitaxel increases the sensitivity of lung cancer cells to lobaplatin via PI3K/Akt pathway.
Lung Neoplasms
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Lung Neoplasms
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Lung Neoplasms
Phosphatidylinositol 3-kinase could be a promising target in lung cancer therapy.
Lung Neoplasms
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
Lung Neoplasms
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Lung Neoplasms
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer.
Lung Neoplasms
PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[?]indene Derivative in Lung Cancer Cells.
Lung Neoplasms
PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy.
Lung Neoplasms
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Lung Neoplasms
Potential mechanism of interleukin-8 production from lung cancer cells: An involvement of EGF-EGFR-PI3K-Atk-Erk pathway.
Lung Neoplasms
Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway.
Lung Neoplasms
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Lung Neoplasms
Regulation of angiogenic factors by the PI3K/Akt pathway in A549 lung cancer cells under hypoxic conditions.
Lung Neoplasms
Regulatory roles of OASL in lung cancer cell sensitivity to Actinidia chinensis Planch root extract (acRoots).
Lung Neoplasms
Regulatory roles of osteopontin in human lung cancer cell epithelial-to-mesenchymal transitions and responses.
Lung Neoplasms
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lung Neoplasms
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
Lung Neoplasms
Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Lung Neoplasms
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Lung Neoplasms
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Lung Neoplasms
Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase.
Lung Neoplasms
Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.
Lung Neoplasms
SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.
Lung Neoplasms
SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer.
Lung Neoplasms
Study of EGCG induced apoptosis in lung cancer cells by inhibiting PI3K/Akt signaling pathway.
Lung Neoplasms
Sulindac compounds facilitate the cytotoxicity of ?-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
Lung Neoplasms
Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Lung Neoplasms
Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell.
Lung Neoplasms
Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
Lung Neoplasms
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Lung Neoplasms
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Lung Neoplasms
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Lung Neoplasms
Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity.
Lung Neoplasms
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Lung Neoplasms
The anti-tumor effect of taxifolin on lung cancer via suppressing stemness and epithelial-mesenchymal transition in vitro and oncogenesis in nude mice.
Lung Neoplasms
The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
Lung Neoplasms
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells.
Lung Neoplasms
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Lung Neoplasms
The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Lung Neoplasms
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Lung Neoplasms
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Lung Neoplasms
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
Lung Neoplasms
The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.
Lung Neoplasms
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
Lung Neoplasms
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Lung Neoplasms
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Lung Neoplasms
The synergistic antitumour effect of multi-components from Pulsatilla chinensis saponins in NCI-H460 lung cancer cell line through induction of apoptosis.
Lung Neoplasms
Therapeutic efficacy of hydrogen?rich saline alone and in combination with PI3K inhibitor in non?small cell lung cancer.
Lung Neoplasms
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer.
Lung Neoplasms
TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1.
Lung Neoplasms
VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.
Lung Neoplasms
Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils.
Lung Neoplasms
VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy.
Lung Neoplasms
W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors.
Lung Neoplasms
Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo.
Lung Neoplasms
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
Lung Neoplasms
[Clinical Significance and Mechanism of PI3K p110? Overexpression? in Non-small Cell Lung Cancer].
Lung Neoplasms
[Clinicopathological Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-small Cell Lung Cancer.]
Lung Neoplasms
[Effects of combined therapy of Phosphatidylinositol 3p-Kinase and Paclitaxel in human lung cancer nude mice model.]
Lung Neoplasms
[Enhanced growth inhibition by combined two pathway inhibitors on K-ras mutated non-small cell lung cancer cells].
Lung Neoplasms
[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
Lung Neoplasms
[The Relationship between the PI3K/Akt/mTOR Signal Transduction Pathway and Non-small Cell Lung Cancer.]
Lupus Erythematosus, Cutaneous
Upcoming therapeutic targets in cutaneous lupus erythematous.
Lupus Erythematosus, Systemic
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Lupus Erythematosus, Systemic
Emerging views of mitophagy in immunity and autoimmune diseases.
Lupus Erythematosus, Systemic
Neutralizing interferon-? blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients.
Lupus Erythematosus, Systemic
[Abnormal signaling activity of phosphatidylinositol 3-kinase pathway in peripheral blood T cells from patients with systemic lupus erythematosus]
Lymphadenitis
Role of Host Type IA Phosphoinositide 3-Kinase Pathway Components in Invasin-Mediated Internalization of Yersinia enterocolitica.
Lymphadenopathy
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Lymphadenopathy
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Lymphadenopathy
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Lymphadenopathy
Genetic Defects in Phosphoinositide 3-Kinase ? Influence CD8+ T Cell Survival, Differentiation, and Function.
Lymphadenopathy
Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
Lymphadenopathy
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Lymphatic Diseases
Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction.
Lymphatic Metastasis
Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma.
Lymphatic Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Lymphatic Metastasis
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Lymphatic Metastasis
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.
Lymphatic Metastasis
Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1? expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.
Lymphatic Metastasis
MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.
Lymphatic Metastasis
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Lymphatic Metastasis
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Lymphatic Metastasis
The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer.
Lymphatic Metastasis
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
Lymphatic Metastasis
[Expression and significance of Ki-67, PI3K and Beclin1 in oral squamous cell carcinoma].
Lymphohistiocytosis, Hemophagocytic
Hemophagocytic Lymphohistiocytosis in Activated PI3K Delta Syndrome: an Illustrative Case Report.
Lymphoma
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Lymphoma
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Lymphoma
Analyzing synergistic and non-synergistic interactions in signalling pathways using Boolean Nested Effect Models.
Lymphoma
Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase 3? signaling pathway.
Lymphoma
Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia.
Lymphoma
BET Inhibition-Induced GSK3? Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
Lymphoma
BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3K? inhibitors by suppressing PI3K reactivation and c-MYC expression.
Lymphoma
Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells.
Lymphoma
CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line.
Lymphoma
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Lymphoma
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
Lymphoma
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
Lymphoma
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Lymphoma
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Lymphoma
Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.
Lymphoma
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Lymphoma
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Lymphoma
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
Lymphoma
Correction: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma.
Lymphoma
CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis.
Lymphoma
Diosmetin inhibits cell proliferation and induces apoptosis by regulating autophagy via the mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells.
Lymphoma
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Lymphoma
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Lymphoma
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Lymphoma
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Lymphoma
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Lymphoma
Effects of AS2541019, a novel selective PI3K? inhibitor, on antibody production and hamster to rat xenotransplantation.
Lymphoma
Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Lymphoma
Epstein-Barr Virus Latent Membrane Protein 1 Regulates Host B Cell MicroRNA-155 and Its Target FOXO3a via PI3K p110? Activation.
Lymphoma
ER? targets ZAK and attenuates cellular hypertrophy via SUMO-1 modification in H9c2 cells.
Lymphoma
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Lymphoma
Formaldehyde induces the apoptosis of BMCs of BALB/c mice via the PTEN/PI3K/Akt signal transduction pathway.
Lymphoma
Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
Lymphoma
GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.
Lymphoma
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Lymphoma
Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Lymphoma
Improved synergistic anticancer efficacy of quercetin in combination with PI-103, rottlerin, and G0 6983 against MCF-7 and RAW 264.7 cells.
Lymphoma
Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas.
Lymphoma
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Lymphoma
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3K? inhibition through PIK3IP1.
Lymphoma
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Lymphoma
Insights into the structural specificity of the cytotoxicity of 3-deoxyphosphatidylinositols.
Lymphoma
Integrin CD11b attenuates colitis by strengthening Src-Akt pathway to polarize anti-inflammatory IL-10 expression.
Lymphoma
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
Lymphoma
Kinetic modeling of hyperpolarized 13C label exchange between pyruvate and lactate in tumor cells.
Lymphoma
Ligation of CD40 receptor in human B lymphocytes triggers the 5-lipoxygenase pathway to produce reactive oxygen species and activate p38 MAPK.
Lymphoma
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Lymphoma
LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells.
Lymphoma
MCL1 Gene Silencing Promotes Senescence and Apoptosis of Glioma Cells via Inhibition of the PI3K/Akt Signaling Pathway.
Lymphoma
Membrane Ig cross-linking regulates phosphatidylinositol 3-kinase in B lymphocytes.
Lymphoma
Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.
Lymphoma
MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma.
Lymphoma
MicroRNA-17?92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.
Lymphoma
microRNA-212-induced protection of the heart against myocardial infarction occurs via the interplay between AQP9 and PI3K/Akt signaling pathway.
Lymphoma
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.
Lymphoma
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Lymphoma
MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Lymphoma
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Lymphoma
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Lymphoma
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
Lymphoma
P110?-mediated constitutive PI3K signaling limits the efficacy of p110?-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Lymphoma
Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Lymphoma
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase ? Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
Lymphoma
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Lymphoma
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Lymphoma
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Lymphoma
Phosphatidylinositol-3-kinase activity is required for the anti-ig-mediated growth inhibition of a human B-lymphoma cell line.
Lymphoma
PI3K?-selective and PI3K?/?-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lymphoma
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ?/? in relapsed refractory B cell lymphoma.
Lymphoma
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors.
Lymphoma
Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.
Lymphoma
Primary malignant lymphoma of the brain: analysis of MMAC1 (PTEN) tumor suppressor gene.
Lymphoma
Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
Lymphoma
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Lymphoma
Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma.
Lymphoma
Quercetin Regresses Dalton's Lymphoma Growth via Suppression of PI3K/AKT Signaling Leading to Upregulation of p53 and Decrease in Energy Metabolism.
Lymphoma
Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
Lymphoma
Regulation of phosphoinositide 3-kinase signaling by oxidants: hydrogen peroxide selectively enhances immunoreceptor-induced recruitment of phosphatidylinositol (3,4) bisphosphate-binding PH domain proteins.
Lymphoma
Role of dephosphorylation of FOXO1 on apoptosis induced by wortmannin for non-Hodgkin's lymphoma cells.
Lymphoma
Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas.
Lymphoma
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Lymphoma
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Lymphoma
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Lymphoma
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Lymphoma
Silencing c-Myc translation as a therapeutic strategy through targeting PI3K? and CK1? in hematological malignancies.
Lymphoma
Simultaneous pan-PI3K and MEK inhibition as a potential therapeutic strategy in peripheral T cell lymphomas.
Lymphoma
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Lymphoma
Src Kinase and Syk Activation Initiate PI3K Signaling by a Chimeric Latent Membrane Protein 1 in Epstein-Barr Virus (EBV)+ B Cell Lymphomas.
Lymphoma
Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth.
Lymphoma
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Lymphoma
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Lymphoma
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
Lymphoma
The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.
Lymphoma
Tormentic acid inhibits IL-1?-induced chondrocyte apoptosis by activating the PI3K/Akt signaling pathway.
Lymphoma
Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K.
Lymphoma
Uncovering the potential of PI3K inhibitors in cutaneous T cell lymphoma: insights from high throughput in vitro screenings.
Lymphoma
[Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines.]
Lymphoma, B-Cell
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Lymphoma, B-Cell
Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase ? (PI3K?) in Animal and B-Cell Lymphoma Models.
Lymphoma, B-Cell
Alpinia oxyphylla Miq. fruit extract activates IGFR-PI3K/Akt signaling to induce Schwann cell proliferation and sciatic nerve regeneration.
Lymphoma, B-Cell
Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Lymphoma, B-Cell
Anti-proliferative and apoptosis inducing effect of nimbolide by altering molecules involved in apoptosis and IGF signalling via PI3K/Akt in prostate cancer (PC-3) cell line.
Lymphoma, B-Cell
Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway.
Lymphoma, B-Cell
AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway.
Lymphoma, B-Cell
BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Lymphoma, B-Cell
BET Inhibition-Induced GSK3? Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
Lymphoma, B-Cell
Blockade of Emodin on Amyloid-? 25-35-Induced Neurotoxicity in A?PP/PS1 Mice and PC12 Cells through Activation of the Class III Phosphatidylinositol 3-Kinase/Beclin-1/B-Cell Lymphoma 2 Pathway.
Lymphoma, B-Cell
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Lymphoma, B-Cell
Cinobufagin Induces Cell Cycle Arrest at the G2/M Phase and Promotes Apoptosis in Malignant Melanoma Cells.
Lymphoma, B-Cell
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Lymphoma, B-Cell
Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.
Lymphoma, B-Cell
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Lymphoma, B-Cell
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lymphoma, B-Cell
Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Lymphoma, B-Cell
Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
Lymphoma, B-Cell
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Lymphoma, B-Cell
Effect of Huaier on the proliferation and apoptosis of human gastric cancer cells through modulation of the PI3K/AKT signaling pathway.
Lymphoma, B-Cell
Effects of AS2541019, a novel selective PI3K? inhibitor, on antibody production and hamster to rat xenotransplantation.
Lymphoma, B-Cell
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Lymphoma, B-Cell
Epstein-Barr Virus Latent Membrane Protein 1 Regulates Host B Cell MicroRNA-155 and Its Target FOXO3a via PI3K p110? Activation.
Lymphoma, B-Cell
Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-?B in B-cell lymphomas to increase MIP-1? production.
Lymphoma, B-Cell
Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
Lymphoma, B-Cell
Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway.
Lymphoma, B-Cell
Expression of glucose transporter-1, hypoxia-inducible factor-1?, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review.
Lymphoma, B-Cell
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Lymphoma, B-Cell
Fibronectin protected bovine preantral follicles from the deleterious effects of kisspeptin.
Lymphoma, B-Cell
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Lymphoma, B-Cell
Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
Lymphoma, B-Cell
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Lymphoma, B-Cell
Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
Lymphoma, B-Cell
HIF-?/PKM2 and PI3K-AKT pathways involved in the protection by dexmedetomidine against isoflurane or bupivacaine-induced apoptosis in hippocampal neuronal HT22 cells.
Lymphoma, B-Cell
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Lymphoma, B-Cell
Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Lymphoma, B-Cell
Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway.
Lymphoma, B-Cell
Lens differentiation is controlled by the balance between PDGF and FGF signaling.
Lymphoma, B-Cell
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Lymphoma, B-Cell
MCL1 Gene Silencing Promotes Senescence and Apoptosis of Glioma Cells via Inhibition of the PI3K/Akt Signaling Pathway.
Lymphoma, B-Cell
Melatonin mitigates the adverse effect of hypoxia during myocardial differentiation in mouse embryonic stem cells.
Lymphoma, B-Cell
microRNA-212-induced protection of the heart against myocardial infarction occurs via the interplay between AQP9 and PI3K/Akt signaling pathway.
Lymphoma, B-Cell
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Lymphoma, B-Cell
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Lymphoma, B-Cell
PI3K-AKT Signaling Activation and Icariin: The Potential Effects on the Perimenopausal Depression-Like Rat Model.
Lymphoma, B-Cell
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K ?/? in relapsed refractory B cell lymphoma.
Lymphoma, B-Cell
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Lymphoma, B-Cell
Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas.
Lymphoma, B-Cell
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Lymphoma, B-Cell
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.
Lymphoma, B-Cell
Single and combined BTK and PI3K? inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Lymphoma, B-Cell
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Lymphoma, B-Cell
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Lymphoma, B-Cell
Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma.
Lymphoma, B-Cell
Treadmill exercise reduces spinal cord injury-induced apoptosis by activating the PI3K/Akt pathway in rats.
Lymphoma, B-Cell
Upregulated microRNA-132 rescues cardiac fibrosis and restores cardiocyte proliferation in dilated cardiomyopathy through the phosphatase and tensin homolog-mediated PI3K/Akt signal transduction pathway.
Lymphoma, B-Cell
[Effects of 7-difluoromethy-5, 4'-dimethoxygenistein on ?stress urinary incontinence model in rats and its mechanisms].
Lymphoma, B-Cell
[Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines.]
Lymphoma, B-Cell, Marginal Zone
CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis.
Lymphoma, Follicular
An analysis of genetic targets for guiding clinical management of follicular lymphoma.
Lymphoma, Follicular
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Lymphoma, Follicular
Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Lymphoma, Follicular
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Lymphoma, Follicular
Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.
Lymphoma, Follicular
Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Lymphoma, Follicular
Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.
Lymphoma, Follicular
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Lymphoma, Follicular
Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Lymphoma, Follicular
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Lymphoma, Follicular
Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.
Lymphoma, Follicular
Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Lymphoma, Follicular
PI3K? inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.
Lymphoma, Follicular
Refining the management of relapsed or refractory follicular lymphoma.
Lymphoma, Follicular
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Lymphoma, Follicular
The PI3K p110? Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Lymphoma, Large B-Cell, Diffuse
Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Lymphoma, Large B-Cell, Diffuse
BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
BET Inhibition-Induced GSK3? Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.
Lymphoma, Large B-Cell, Diffuse
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Lymphoma, Large B-Cell, Diffuse
Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Lymphoma, Large B-Cell, Diffuse
Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Lymphoma, Large B-Cell, Diffuse
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Lymphoma, Large B-Cell, Diffuse
Expression of glucose transporter-1, hypoxia-inducible factor-1?, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review.
Lymphoma, Large B-Cell, Diffuse
Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Lymphoma, Large B-Cell, Diffuse
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Lymphoma, Large B-Cell, Diffuse
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Lymphoma, Large B-Cell, Diffuse
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Lymphoma, Large B-Cell, Diffuse
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
[Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines.]
Lymphoma, Large-Cell, Anaplastic
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Lymphoma, Mantle-Cell
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas.
Lymphoma, Mantle-Cell
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Correction: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Lymphoma, Mantle-Cell
P110?-mediated constitutive PI3K signaling limits the efficacy of p110?-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Lymphoma, Mantle-Cell
Putative Roles for PI3K ? and ? Isoforms in Refractory Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth.
Lymphoma, Mantle-Cell
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Lymphoma, Mantle-Cell
The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.
Lymphoma, Non-Hodgkin
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Lymphoma, Non-Hodgkin
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lymphoma, Non-Hodgkin
Duvelisib, an oral dual PI3K-?, ? inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Lymphoma, Non-Hodgkin
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Lymphoma, Non-Hodgkin
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.
Lymphoma, Non-Hodgkin
Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
Lymphoma, Non-Hodgkin
Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Lymphoma, Non-Hodgkin
Identification of a potent and selective phosphatidylinositol 3-kinase ? inhibitor for the treatment of non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
IGF1R as druggable target mediating PI3K-? inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Lymphoma, Non-Hodgkin
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Lymphoma, Non-Hodgkin
Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110?, for treating relapsed or refractory non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Lymphoma, Non-Hodgkin
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
Lymphoma, T-Cell
GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.
Lymphoma, T-Cell
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K ?/? Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Lymphoma, T-Cell
Simultaneous pan-PI3K and MEK inhibition as a potential therapeutic strategy in peripheral T cell lymphomas.
Lymphoma, T-Cell, Cutaneous
Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors.
Lymphoma, T-Cell, Cutaneous
Simultaneous pan-PI3K and MEK inhibition as a potential therapeutic strategy in peripheral T cell lymphomas.
Lymphoma, T-Cell, Cutaneous
Uncovering the potential of PI3K inhibitors in cutaneous T cell lymphoma: insights from high throughput in vitro screenings.
Lymphoma, T-Cell, Cutaneous
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.
Lymphopenia
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Lymphopenia
Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency.
Lymphopenia
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Lymphopenia
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Lymphoproliferative Disorders
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Lymphoproliferative Disorders
Involvement of PI3K in HCV-related lymphoproliferative disorders.
Macular Degeneration
Activation of type 5 metabotropic glutamate receptor promotes the proliferation of rat retinal progenitor cell via activation of the PI-3-K and MAPK signaling pathways.
Macular Degeneration
Insensitivity of PI3K/Akt/GSK3 signaling in peripheral blood mononuclear cells of age-related macular degeneration patients.
Malaria, Cerebral
Phosphatidylinositol 3-Kinase ? is required for the development of experimental cerebral malaria.
Malnutrition
Impaired insulin secretion and decreased expression of the nutritionally responsive ribosomal kinase protein S6K-1 in pancreatic islets from malnourished rats.
Malnutrition
Protein calorie restriction has opposite effects on glucose metabolism and insulin gene expression in fetal and adult rat endocrine pancreas.
Malnutrition
Up-regulation of phosphatidylinositol 3-kinase and glucose transporter 4 in muscle of rats subjected to maternal undernutrition.
Malnutrition
[Expression of the hepatic insulin signal transduction proteins in the rats with intrauterine growth retardation during the perinatal period.]
Marek Disease
Marek's Disease Virus Activates the PI3K/Akt Pathway Through Interaction of Its Protein Meq With the P85 Subunit of PI3K to Promote Viral Replication.
Marfan Syndrome
LRP1 regulates architecture of the vascular wall by controlling PDGFRbeta-dependent phosphatidylinositol 3-kinase activation.
Mastocytosis
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
Mastocytosis
PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability.
Mastocytosis, Systemic
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Measles
Autophagy induction by the pathogen receptor NECTIN4 and sustained autophagy contribute to peste des petits ruminants virus infectivity.
Medulloblastoma
A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110{gamma} Isoform in Medulloblastoma Cell Proliferation and Chemoresistance.
Medulloblastoma
Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice.
Medulloblastoma
ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.
Medulloblastoma
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
Medulloblastoma
Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors.
Medulloblastoma
Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells.
Medulloblastoma
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Medulloblastoma
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Medulloblastoma
Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.
Medulloblastoma
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.
Medulloblastoma
PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Medulloblastoma
Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.
Medulloblastoma
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Medulloblastoma
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Medulloblastoma
The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
Medulloblastoma
The Phosphoinositide 3-Kinase p110? Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
Medulloblastoma
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Medulloblastoma
Tumor Growth in the High Frequency Medulloblastoma Mouse Model Ptch1+/-/Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611.
Megalencephaly
Identification and Characterization of a Novel Constitutional PIK3CA Mutation in a Child Lacking the Typical Segmental Overgrowth of "PIK3CA-Related Overgrowth Spectrum".
Melanoma
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Melanoma
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.
Melanoma
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms.
Melanoma
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Melanoma
Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells.
Melanoma
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Melanoma
Active ?-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A.
Melanoma
Analysis of Caveolin-1 and Phosphoinositol-3 Kinase expression in primary uveal melanomas.
Melanoma
Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.
Melanoma
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Melanoma
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Melanoma
Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RAR?/RAR? in melanoma cells.
Melanoma
Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma.
Melanoma
BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation.
Melanoma
C6-ceramide nanoliposome suppresses tumor metastasis by eliciting PI3K and PKC? tumor-suppressive activities and regulating integrin affinity modulation.
Melanoma
Chondroitin Sulfate Proteoglycan-4 Does Not Protect Melanoma Cells During Inhibition of PI3K and mTOR Pathways.
Melanoma
Circular RNA has circ 0001591 promoted cell proliferation and metastasis of human melanoma via ROCK1/PI3K/AKT by targeting miR-431-5p.
Melanoma
Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.
Melanoma
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
Melanoma
Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages.
Melanoma
Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner.
Melanoma
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Melanoma
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Melanoma
Concomitant Inhibition of PI3K? and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K?-Selective Inhibitor.
Melanoma
Constitutive Rac Activation Is Not Sufficient to Initiate Melanocyte Neoplasia but Accelerates Malignant Progression.
Melanoma
Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells.
Melanoma
Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Melanoma
Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.
Melanoma
Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten(LoxP/LoxP);Braf(CA/+) Mice.
Melanoma
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Melanoma
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Melanoma
Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.
Melanoma
Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Melanoma
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Melanoma
Dual MAPK / PI3K pathway inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild type melanoma.
Melanoma
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Melanoma
Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma.
Melanoma
Endothelin signaling axis activates osteopontin expression through PI3 kinase pathway in A375 melanoma cells.
Melanoma
Enhanced chemosensitization of anoikis-resistant melanoma cells through syndecan-2 upregulation upon anchorage independency.
Melanoma
ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis.
Melanoma
Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.
Melanoma
Evidence of the involvement of phosphatidylinositol 3-kinase in the migration, actin stress fiber formation, and alpha v beta 3-integrin-mediated adherence of human melanoma cells.
Melanoma
Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition.
Melanoma
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Melanoma
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Melanoma
FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome.
Melanoma
FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
Melanoma
G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells.
Melanoma
Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.
Melanoma
GM3 suppresses anchorage-independent growth via Rho GDP dissociation inhibitor beta in melanoma B16 cells.
Melanoma
GM3 Upregulation of matrix metalloproteinase-9 possibly through PI3K, AKT, RICTOR, RHOGDI-2, and TNF-A pathways in mouse melanoma B16 cells.
Melanoma
H3K27 Demethylase JMJD3 Employs the NF-?B and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.
Melanoma
Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
Melanoma
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
Melanoma
Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
Melanoma
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.
Melanoma
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Melanoma
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Melanoma
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitises melanoma cells to Bortezomib by blocking Akt pathway.
Melanoma
Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation.
Melanoma
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
Melanoma
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.
Melanoma
Inosine Strongly Enhances Proliferation of Human C32 Melanoma Cells through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways.
Melanoma
Interplay between PREX2 mutations and the PI3K pathway and its effect on epigenetic regulation of gene expression in NRAS-mutant melanoma.
Melanoma
Involvement of phospholipase C signaling in melanoma cell-induced endothelial junction disassembly.
Melanoma
Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells.
Melanoma
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Melanoma
Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23.
Melanoma
Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2.
Melanoma
Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors.
Melanoma
Low Mutational Burden of Eight Genes Involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 Pathways in Female Genital Tract Primary Melanomas.
Melanoma
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Melanoma
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Melanoma
Mechanism of miR-137 regulating migration and invasion of melanoma cells by targeting PIK3R3 gene.
Melanoma
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Melanoma
Melanoma cell-derived factors stimulate hyaluronan synthesis in dermal fibroblasts by upregulating HAS2 through PDGFR-PI3K-AKT and p38 signaling.
Melanoma
Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways.
Melanoma
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.
Melanoma
Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Melanoma
Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
Melanoma
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.
Melanoma
Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary.
Melanoma
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis.
Melanoma
Neural cell adhesion molecule potentiates invasion and metastasis of melanoma cells through CAMP-dependent protein kinase and phosphatidylinositol 3-kinase pathways.
Melanoma
NPS - 2143 (hydrochloride) inhibits melanoma cancer cell proliferation and induces autophagy and apoptosis.
Melanoma
NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.
Melanoma
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Melanoma
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.
Melanoma
Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.
Melanoma
P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils.
Melanoma
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Melanoma
Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.
Melanoma
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells.
Melanoma
PI3'-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma.
Melanoma
PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
Melanoma
PI3K signalling is required for a TGF?-induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells.
Melanoma
PIK3CA-Mutated Melanoma Cells Rely on Cooperative Signaling through mTORC1/2 for Sustained Proliferation.
Melanoma
PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
Melanoma
Positive Feedback Loop Between PI3K-Akt-mTORC1 Signaling and the Lipogenic Pathway Boosts Akt Signaling: Induction of the Lipogenic Pathway by a Melanoma Antigen.
Melanoma
Protein kinase C-betaII represses hepatocyte growth factor-induced invasion by preventing the association of adapter protein Gab1 and phosphatidylinositol 3-kinase in melanoma cells.
Melanoma
Regulation of melanogenesis through phosphatidylinositol 3-kinase-Akt pathway in human G361 melanoma cells.
Melanoma
RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.
Melanoma
RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma.
Melanoma
Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
Melanoma
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.
Melanoma
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Melanoma
Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment.
Melanoma
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.
Melanoma
Subcutaneous adipocytes promote melanoma cell growth by activating the Akt signaling pathway: role of palmitic acid.
Melanoma
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Melanoma
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Melanoma
Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression.
Melanoma
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Melanoma
Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma.
Melanoma
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
Melanoma
TBX3 Promotes Melanoma Migration by Transcriptional Activation of ID1, which Prevents Activation of E-Cadherin by MITF.
Melanoma
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Melanoma
The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb.
Melanoma
The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K.
Melanoma
The dual PI3K/mTOR inhibitor (PI-103) promotes immunosupression, in vivo tumor growth and increases survival of sorafenib treated melanoma cells.
Melanoma
The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.
Melanoma
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.
Melanoma
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
Melanoma
The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
Melanoma
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
Melanoma
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Melanoma
Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma.
Melanoma
Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.
Melanoma
Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.
Melanoma
Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors.
Melanoma
Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF.
Melanoma
VEGF Induce Vasculogenic Mimicry of Choroidal Melanoma through the PI3k Signal Pathway.
Melanoma
Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo.
Melanoma
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
Melanoma
VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
Melanoma
Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.
Memory Disorders
Aluminum-Induced Cognitive Impairment and PI3K/Akt/mTOR Signaling Pathway Involvement in Occupational Aluminum Workers.
Memory Disorders
Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase.
Memory Disorders
PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila.
Memory Disorders
Remifentanil postconditioning improves global cerebral ischemia-induced spatial learning and memory deficit in rats via inhibition of neuronal apoptosis through the PI3K signaling pathway.
Memory Disorders
Wortmannin Attenuates Seizure-Induced Hyperactive PI3K/Akt/mTOR Signaling, Impaired Memory, and Spine Dysmorphology in Rats.
Meningioma
Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.
Meningioma
Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas.
Meningioma
Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
Meningioma
Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells.
Meningioma
Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Meningioma
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.
Meningioma
The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges.
Meningitis
Escherichia coli K-1 interaction with human brain micro-vascular endothelial cells triggers phospholipase C-gamma1 activation downstream of phosphatidylinositol 3-kinase.
Meningitis
Restoration of Akt activity by the bisperoxovanadium compound bpV(pic) attenuates hippocampal apoptosis in experimental neonatal pneumococcal meningitis.
Meningitis, Bacterial
Inhibition of meningitis-associated neutrophil apoptosis by TNF-? depends on functional PI3-kinase in monocytes.
Mesothelioma
Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.
Mesothelioma
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Mesothelioma
Mitochondrial ROS Induce Partial Dedifferentiation of Human Mesothelioma via Upregulation of NANOG.
Mesothelioma
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Mesothelioma
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Mesothelioma
PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Mesothelioma
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
Mesothelioma, Malignant
A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells.
Mesothelioma, Malignant
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Mesothelioma, Malignant
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Mesothelioma, Malignant
PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Mesothelioma, Malignant
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
Metabolic Diseases
Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
Metabolic Diseases
The PI3K pathway preserves metabolic health through MARCO-dependent lipid uptake by adipose tissue macrophages.
Metabolic Syndrome
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Metabolic Syndrome
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Metabolic Syndrome
Metabolic effects of RUBCN/Rubicon deficiency in kidney proximal tubular epithelial cells.
Metabolic Syndrome
Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.
Metabolic Syndrome
Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
Metabolic Syndrome
Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.
Metabolic Syndrome
The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome.
Microcephaly
Deletion of PDK1 in oligodendrocyte lineage cells causes white matter abnormality and myelination defect in the central nervous system.
Mouth Neoplasms
Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer.
Mouth Neoplasms
Evaluating the role of microRNAs alterations in oral squamous cell carcinoma.
Mouth Neoplasms
Kalopanaxsaponin a inhibits the invasion of human oral squamous cell carcinoma by reducing metalloproteinase-9 mRNA stability and protein trafficking.
Mouth Neoplasms
Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3? signalling pathway in oral cancer.
Mouth Neoplasms
Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3? in a hamster model of oral oncogenesis.
Mouth Neoplasms
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Mouth Neoplasms
The novel pterostilbene derivative ANK-199 induces autophagic cell death through regulating PI3 kinase class III/beclin 1/Atg?related proteins in cisplatin?resistant CAR human oral cancer cells.
Multiple Endocrine Neoplasia
Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.
Multiple Endocrine Neoplasia Type 2a
Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
Multiple Endocrine Neoplasia Type 2a
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
Multiple Endocrine Neoplasia Type 2b
Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
Multiple Myeloma
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.
Multiple Myeloma
A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Multiple Myeloma
A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.
Multiple Myeloma
A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.
Multiple Myeloma
Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Multiple Myeloma
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Multiple Myeloma
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Multiple Myeloma
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.
Multiple Myeloma
Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Multiple Myeloma
Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.
Multiple Myeloma
Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line.
Multiple Myeloma
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Multiple Myeloma
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Multiple Myeloma
Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
Multiple Myeloma
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Multiple Myeloma
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Multiple Myeloma
PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.
Multiple Myeloma
PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.
Multiple Myeloma
PI3K? and PI3K? isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
Multiple Myeloma
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
Multiple Myeloma
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Multiple Myeloma
Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Multiple Myeloma
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Multiple Myeloma
Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.
Multiple Myeloma
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Multiple Myeloma
Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.
Multiple Myeloma
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Multiple Myeloma
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Multiple Myeloma
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Multiple Myeloma
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.
Multiple Sclerosis
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Multiple Sclerosis
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.
Multiple Sclerosis
Transendothelial migratory pathways of V delta 1+TCR gamma delta+ and V delta 2+TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II.
Multiple Sclerosis
ZSTK474, a novel PI3K inhibitor, modulates human CD14(+) monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.
Muscle Spasticity
ZFYVE26/SPASTIZIN and SPG11/SPATACSIN mutations in hereditary spastic paraplegia types AR-SPG15 and AR-SPG11 have different effects on autophagy and endocytosis.
Muscular Atrophy
Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice.
Muscular Atrophy
Icaritin requires Phosphatidylinositol 3 kinase (PI3K)/Akt signaling to counteract skeletal muscle atrophy following mechanical unloading.
Muscular Atrophy
Microgravity-Induced Transcriptome Adaptation in Mouse Paraspinal longissimus dorsi Muscle Highlights Insulin Resistance-Linked Genes.
Muscular Atrophy
Myostatin Activates the Ubiquitin-Proteasome and Autophagy-Lysosome Systems Contributing to Muscle Wasting in Chronic Kidney Disease.
Muscular Dystrophies
PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle.
Mycosis Fungoides
In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features.
Myelodysplastic Syndromes
ON 01910.Na is selectively cytotoxic for Chronic Lymphocytic Leukemia cells through a dual mechanism involving PI3K/AKT inhibition and induction of oxidative stress.
Myelodysplastic Syndromes
Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.
Myelodysplastic Syndromes
The role of autophagy in targeted therapy for acute myeloid leukemia.
Myeloproliferative Disorders
Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten+/-SHIP-/- mice: a novel model of myelodysplasia.
Myocardial Infarction
Apelin shorten QT interval by inhibiting Kir2.1/IK1 via a PI3K way in acute myocardial infarction.
Myocardial Infarction
Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signaling.
Myocardial Infarction
Crucial lncRNAs associated with adipocyte differentiation from human adipose-derived stem cells based on co-expression and ceRNA network analyses.
Myocardial Infarction
Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart.
Myocardial Infarction
Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart.
Myocardial Infarction
Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.
Myocardial Infarction
Effect of lithium on ventricular remodelling in infarcted rats via the Akt/mTOR signalling pathways.
Myocardial Infarction
Endocrine Protection of Ischemic Myocardium by FGF21 from the Liver and Adipose Tissue.
Myocardial Infarction
Fibrauretine reduces ischemia/reperfusion injury via RISK/eNOS activation.
Myocardial Infarction
Impact of age and sex on response to ischemic preconditioning in the rat heart: differential role of the PI3K-AKT pathway.
Myocardial Infarction
Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.
Myocardial Infarction
Ischemic postconditioning protects both adult and aged Sprague Dawley rat hearts from ischemia/reperfusion injury through the PI3-K/Akt and GSK-3beta pathway.
Myocardial Infarction
Isoflurane-induced myocardial preconditioning is dependent on phosphatidylinositol-3-kinase/Akt signalling.
Myocardial Infarction
Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
Myocardial Infarction
Long-term aerobic exercise protects the heart against ischemia/reperfusion injury via PI3 kinase-dependent and Akt-mediated mechanism.
Myocardial Infarction
LY294002 prevents lipopolysaccharide?induced hepatitis in a murine model by suppressing I?B phosphorylation.
Myocardial Infarction
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
Myocardial Infarction
MicroRNA-146b induces the PI3K/Akt/NF-?B signaling pathway to reduce vascular inflammation and apoptosis in myocardial infarction by targeting PTEN.
Myocardial Infarction
Pharmacological Inhibition of Phosphoinositide 3-Kinase Gamma (PI3K?) Promotes Infarct Resorption and Prevents Adverse Cardiac Remodeling after Myocardial Infarction in Mice.
Myocardial Infarction
Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.
Myocardial Infarction
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
Myocardial Infarction
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Myocardial Infarction
Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway.
Myocardial Infarction
Research on protective mechanism of ibuprofen in myocardial ischemia-reperfusion injury in rats through the PI3K/Akt/mTOR signaling pathway.
Myocardial Infarction
Targeting phosphatidylinositol 3-kinase-Akt through hepatocyte growth factor for cardioprotection.
Myocardial Infarction
The novel adipocytokine visfatin exerts direct cardioprotective effects.
Myocardial Infarction
The PI3K/Akt pathway mediates the protection of SO2 preconditioning against myocardial ischemia/reperfusion injury in rats.
Myocardial Ischemia
(?)?Epicatechin protects against myocardial ischemia?induced cardiac injury via activation of the PTEN/PI3K/AKT pathway.
Myocardial Ischemia
(S)-1-(alpha-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (CKD712) reduces rat myocardial apoptosis against ischemia and reperfusion injury by activation of phosphatidylinositol 3-kinase/Akt signaling and anti-inflammatory action in vivo.
Myocardial Ischemia
Ginsenoside Rb1 preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction.
Myocardial Ischemia
Investigating the Signal Transduction Pathways Underlying Remote Ischemic Conditioning in the Porcine Heart.
Myocardial Ischemia
Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3? in Rats.
Myocardial Ischemia
SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.
Myocardial Ischemia
U50,488H postconditioning reduces apoptosis after myocardial ischemia and reperfusion.
Myocardial Ischemia
Vagal stimulation suppresses ischemia-induced myocardial interstitial myoglobin release.
Myocardial Ischemia
Volatile anesthetic preconditioning attenuates myocardial apoptosis in rabbits after regional ischemia and reperfusion via Akt signaling and modulation of Bcl-2 family proteins.
Myocarditis
Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice.
Myopathies, Structural, Congenital
Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway.
Myxoma
Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain.
Myxoma
Myxoma virus induces type I IFN production in murine plasmacytoid dendritic cells via a TLR9/MyD88, IRF5/IRF7, and IFNAR-dependent pathway.
Nasal Polyps
Expression of galectin-9 by IFN-? stimulated human nasal polyp fibroblasts through MAPK, PI3K, and JAK/STAT signaling pathways.
Nasopharyngeal Carcinoma
Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase.
Nasopharyngeal Carcinoma
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
Human nasopharyngeal carcinoma can be radiosensitized by trichosanthin via inhibition of the PI3K pathway.
Nasopharyngeal Carcinoma
Increased Expression of Phosphatidylinositol 3-Kinase p110? and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo.
Nasopharyngeal Carcinoma
Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).
Nasopharyngeal Carcinoma
Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis.
Nasopharyngeal Carcinoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Nasopharyngeal Neoplasms
Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK.
Neoplasm Metastasis
(-)-4-O-(4-O-?-D-glucopyranosylcaffeoyl) quinic acid exerts anti-tumour effects against uveal melanoma through PI3K/AKT pathway.
Neoplasm Metastasis
(-)-Kusunokinin inhibits breast cancer in N-nitrosomethylurea-induced mammary tumor rats.
Neoplasm Metastasis
17?-Oestradiol activates proteolysis and increases invasion through phosphatidylinositol 3-kinase pathway in human cervical cancer cells.
Neoplasm Metastasis
5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells.
Neoplasm Metastasis
?-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
Neoplasm Metastasis
?ig-h3 Promotes Human Osteosarcoma Cells Metastasis by Interacting with Integrin ?2?1 and Activating PI3K Signaling Pathway.
Neoplasm Metastasis
?Np63? is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
Neoplasm Metastasis
A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1? and HIF2? stability and tumor growth, angiogenesis, and metastasis.
Neoplasm Metastasis
A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8.
Neoplasm Metastasis
Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN?28 cells via the PI3K signaling pathway.
Neoplasm Metastasis
Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma.
Neoplasm Metastasis
Acquisition of paclitaxel resistance via PI3K?dependent epithelial?mesenchymal transition in A2780 human ovarian cancer cells.
Neoplasm Metastasis
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Neoplasm Metastasis
Activation of the RalGEF/Ral Pathway Promotes Prostate Cancer Metastasis to Bone.
Neoplasm Metastasis
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.
Neoplasm Metastasis
Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme.
Neoplasm Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Neoplasm Metastasis
Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer.
Neoplasm Metastasis
Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer.
Neoplasm Metastasis
Anti-metastasis effects of gallic acid on gastric cancer cells involves inhibition of NF-kappaB activity and downregulation of PI3K/AKT/small GTPase signals.
Neoplasm Metastasis
Anti-metastatic Effects of Cationic KT2 Peptide (a Lysine/Tryptophan-rich Peptide) on Human Melanoma A375.S2 Cells.
Neoplasm Metastasis
AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin.
Neoplasm Metastasis
Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.
Neoplasm Metastasis
Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
Neoplasm Metastasis
Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
Neoplasm Metastasis
Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study.
Neoplasm Metastasis
Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and in-silico expression analysis of CXCL12-CXCR4 associated biological regulatory network.
Neoplasm Metastasis
Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF??1?mediated PI3K and MAPK pathways.
Neoplasm Metastasis
Autophagy-related protein PIK3C3/VPS34 controls T cell metabolism and function.
Neoplasm Metastasis
BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating ?-catenin/ZEB1 regulatory loop.
Neoplasm Metastasis
C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Neoplasm Metastasis
C6-ceramide nanoliposome suppresses tumor metastasis by eliciting PI3K and PKC? tumor-suppressive activities and regulating integrin affinity modulation.
Neoplasm Metastasis
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2.
Neoplasm Metastasis
CDX2 enhances HTR-8/SVneo trophoblast cell invasion by altering the expression of matrix metalloproteinases.
Neoplasm Metastasis
Chemokine (C-X-C motif) receptor 4 RNA interference inhibits bone metastasis in breast cancer.
Neoplasm Metastasis
Clinical implications of Girdin and PI3K protein expression in breast cancer.
Neoplasm Metastasis
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Neoplasm Metastasis
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Neoplasm Metastasis
Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles.
Neoplasm Metastasis
Connective tissue growth factor stimulates osteosarcoma cell migration and induces osteosarcoma metastasis by upregulating VCAM-1 expression.
Neoplasm Metastasis
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
Neoplasm Metastasis
CXCL8 induces epithelial-mesenchymal transition in colon cancer cells via the PI3K/Akt/NF-?B signaling pathway.
Neoplasm Metastasis
Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis.
Neoplasm Metastasis
Cytochrome P450 ?-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer.
Neoplasm Metastasis
Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice.
Neoplasm Metastasis
Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K?.
Neoplasm Metastasis
DOC-2/DAB2 interactive protein regulates proliferation and mobility of nasopharyngeal carcinoma cells by targeting PI3K/Akt pathway.
Neoplasm Metastasis
Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Neoplasm Metastasis
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Neoplasm Metastasis
EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration.
Neoplasm Metastasis
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Neoplasm Metastasis
EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3.
Neoplasm Metastasis
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Neoplasm Metastasis
Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signaling pathways.
Neoplasm Metastasis
Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.
Neoplasm Metastasis
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.
Neoplasm Metastasis
Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.
Neoplasm Metastasis
Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
Neoplasm Metastasis
Formal model of the interplay between TGF?1 and MMP-9 and their dynamics in hepatocellular carcinoma.
Neoplasm Metastasis
Functional vinorelbine plus schisandrin B liposomes destroying tumor metastasis in treatment of gastric cancer.
Neoplasm Metastasis
Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
Neoplasm Metastasis
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
Neoplasm Metastasis
Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Neoplasm Metastasis
Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.
Neoplasm Metastasis
Genetics of breast cancer bone metastasis: a sequential multistep pattern.
Neoplasm Metastasis
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.
Neoplasm Metastasis
Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
Neoplasm Metastasis
Giant obscurins regulate the PI3K cascade in breast epithelial cells via direct binding to the PI3K/p85 regulatory subunit.
Neoplasm Metastasis
Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
Neoplasm Metastasis
GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT-Mediated EMT.
Neoplasm Metastasis
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
Neoplasm Metastasis
Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.
Neoplasm Metastasis
HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer.
Neoplasm Metastasis
Human ?-defensin 5 suppressed colon cancer growth by targeting PI3K pathway.
Neoplasm Metastasis
Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway.
Neoplasm Metastasis
Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells.
Neoplasm Metastasis
IL13 Receptor ?2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis.
Neoplasm Metastasis
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Neoplasm Metastasis
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Neoplasm Metastasis
Influence and mechanism of 5-aminolevulinic acid-photodynamic therapy on the metastasis of esophageal carcinoma.
Neoplasm Metastasis
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.
Neoplasm Metastasis
Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity.
Neoplasm Metastasis
Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1? expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.
Neoplasm Metastasis
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.
Neoplasm Metastasis
Inhibitory effect of penta-acetyl geniposide on C6 glioma cells metastasis by inhibiting matrix metalloproteinase-2 expression involved in both the PI3K and ERK signaling pathways.
Neoplasm Metastasis
Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice.
Neoplasm Metastasis
Integrated bioinformatic analysis and experiment confirmation of the antagonistic effect and molecular mechanism of ginsenoside Rh2 in metastatic osteosarcoma.
Neoplasm Metastasis
IRS-1 regulates proliferation, invasion and metastasis of pancreatic cancer cells through MAPK and PI3K signaling pathways.
Neoplasm Metastasis
ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways.
Neoplasm Metastasis
JTC-801 inhibits the proliferation and metastasis of ovarian cancer cell SKOV3 through inhibition of the PI3K - AKT signaling pathway.
Neoplasm Metastasis
Knockdown of ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.
Neoplasm Metastasis
Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23.
Neoplasm Metastasis
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin.
Neoplasm Metastasis
Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways.
Neoplasm Metastasis
Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model.
Neoplasm Metastasis
LY404039 Inhibits Proliferation and Metastasis of Osteosarcoma Cells via PI3K Signaling Pathway.
Neoplasm Metastasis
Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
Neoplasm Metastasis
Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model.
Neoplasm Metastasis
Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways.
Neoplasm Metastasis
MARCH8 is associated with poor prognosis in non-small cell lung cancers patients.
Neoplasm Metastasis
Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling.
Neoplasm Metastasis
MicroRNA-153-5p promotes the proliferation and metastasis of renal cell carcinoma via direct targeting of AGO1.
Neoplasm Metastasis
MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.
Neoplasm Metastasis
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
Neoplasm Metastasis
MicroRNA-552 Accelerates the Progression of Gastric Cancer by Targeting FOXO1 and Regulating PI3K/AKT Pathway.
Neoplasm Metastasis
MiR-328-3p inhibits cell proliferation and metastasis in colorectal cancer by targeting Girdin and inhibiting the PI3K/Akt signaling pathway.
Neoplasm Metastasis
MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway.
Neoplasm Metastasis
miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.
Neoplasm Metastasis
miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma.
Neoplasm Metastasis
miRNA?148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways.
Neoplasm Metastasis
Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
Neoplasm Metastasis
Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Neoplasm Metastasis
Molecular mechanisms of action of Trehalose in cancer: A comprehensive review.
Neoplasm Metastasis
Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
Neoplasm Metastasis
Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth and Metastasis.
Neoplasm Metastasis
Multiorgan metastasis of human HER-2? breast cancer in Rag2?/?;Il2rg?/? mice and treatment with PI3K inhibitor.
Neoplasm Metastasis
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.
Neoplasm Metastasis
Neural cell adhesion molecule potentiates invasion and metastasis of melanoma cells through CAMP-dependent protein kinase and phosphatidylinositol 3-kinase pathways.
Neoplasm Metastasis
Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation.
Neoplasm Metastasis
Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.
Neoplasm Metastasis
Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription.
Neoplasm Metastasis
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
Neoplasm Metastasis
Obesity and Obese-related Chronic Low-grade Inflammation in Promotion of Colorectal Cancer Development.
Neoplasm Metastasis
Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination.
Neoplasm Metastasis
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Neoplasm Metastasis
Overview of Protein Kinase B Enzyme:a Potential Target for breast and Prostate Cancer.
Neoplasm Metastasis
P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils.
Neoplasm Metastasis
P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.
Neoplasm Metastasis
P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway.
Neoplasm Metastasis
Phosphatidylinositol 3-kinase ? and ? isoforms play key roles in metastasis of prostate cancer DU145 cells.
Neoplasm Metastasis
Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.
Neoplasm Metastasis
Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes.
Neoplasm Metastasis
Phosphatidylinositol 3-kinase mediates the ability of retinol to decrease colorectal cancer cell invasion.
Neoplasm Metastasis
Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
Neoplasm Metastasis
Phosphoinositide 3-kinase in disease: timing, location, and scaffolding.
Neoplasm Metastasis
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Neoplasm Metastasis
PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma.
Neoplasm Metastasis
PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
Neoplasm Metastasis
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
Neoplasm Metastasis
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Neoplasm Metastasis
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.
Neoplasm Metastasis
PI3K-PKB-mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis.
Neoplasm Metastasis
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Neoplasm Metastasis
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
Neoplasm Metastasis
PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer.
Neoplasm Metastasis
PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition.
Neoplasm Metastasis
PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance.
Neoplasm Metastasis
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Neoplasm Metastasis
PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.
Neoplasm Metastasis
Pre-clinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts.
Neoplasm Metastasis
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Neoplasm Metastasis
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma.
Neoplasm Metastasis
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Neoplasm Metastasis
Promotion of invasion by mutant RAS is dependent on activation of the WASF3 metastasis promoter gene.
Neoplasm Metastasis
Protein Phosphorylation in Cancer: Role of Nitric Oxide Signaling Pathway.
Neoplasm Metastasis
PTEN/MAPK pathways play a key role in platelet-activating factor-induced experimental pulmonary tumor metastasis.
Neoplasm Metastasis
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.
Neoplasm Metastasis
Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.
Neoplasm Metastasis
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.
Neoplasm Metastasis
Role of phosphoinositide 3-kinase in cardiac function and heart failure.
Neoplasm Metastasis
Rosmarinic Acid Induces Proliferation Suppression of Hepatoma Cells Associated with NF-?B Signaling Pathway.
Neoplasm Metastasis
SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer.
Neoplasm Metastasis
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Neoplasm Metastasis
Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin ?1 expression and the ERK1/2 signaling pathway.
Neoplasm Metastasis
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Neoplasm Metastasis
Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.
Neoplasm Metastasis
Sinomenine inhibits hypoxia induced breast cancer side population cells metastasis by PI3K/Akt/mTOR pathway.
Neoplasm Metastasis
SLC39A6 Promotes Aggressiveness of Esophageal Carcinoma Cells by Increasing Intracellular Levels of Zinc, Activating Phosphatidylinositol 3-kinase Signaling, and Upregulating Genes That Regulate Metastasis.
Neoplasm Metastasis
Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers.
Neoplasm Metastasis
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Neoplasm Metastasis
Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K.
Neoplasm Metastasis
Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model.
Neoplasm Metastasis
Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling.
Neoplasm Metastasis
Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.
Neoplasm Metastasis
Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook.
Neoplasm Metastasis
Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Neoplasm Metastasis
TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer.
Neoplasm Metastasis
The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
Neoplasm Metastasis
The Cytoplasmic Expression Of CLDN12 Predicts An Unfavorable Prognosis And Promotes Proliferation And Migration Of Osteosarcoma.
Neoplasm Metastasis
The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.
Neoplasm Metastasis
The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis.
Neoplasm Metastasis
The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways.
Neoplasm Metastasis
The mechanisms of renin-angiotensin system in hepatocellular carcinoma: From the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures.
Neoplasm Metastasis
The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K /Akt pathway.
Neoplasm Metastasis
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Neoplasm Metastasis
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
Neoplasm Metastasis
The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings.
Neoplasm Metastasis
The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2.
Neoplasm Metastasis
The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.
Neoplasm Metastasis
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
Neoplasm Metastasis
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
Neoplasm Metastasis
Thioredoxin-Like Protein 2 Is Overexpressed in Colon Cancer and Promotes Cancer Cell Metastasis by Interaction with Ran.
Neoplasm Metastasis
Transcriptome Analysis Reveals Key Genes and Pathways Associated with Metastasis in Breast Cancer.
Neoplasm Metastasis
Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Neoplasm Metastasis
Tumor-derived exosomal microRNA-7-5p enhanced by verbascoside inhibits biological behaviors of glioblastoma in vitro and in vivo.
Neoplasm Metastasis
UNBS5162 inhibits the proliferation of human A549 non-small-cell lung cancer cells by promoting apoptosis.
Neoplasm Metastasis
uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.
Neoplasm Metastasis
Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma.
Neoplasm Metastasis
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear ?-Catenin depend on active PI3K signaling.
Neoplasm Metastasis
Wortmannin Reduces Metastasis and Angiogenesis of Human Breast Cancer Cells via Nuclear Factor- B-dependent Matrix Metalloproteinase-9 and Interleukin-8 Pathways.
Neoplasm Metastasis
Xmrks the Spot: Fish Models for Investigating Epidermal Growth Factor Receptor Signaling in Cancer Research.
Neoplasm Metastasis
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
Neoplasm Metastasis
[Clinicopathological Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-small Cell Lung Cancer.]
Neoplasm Metastasis
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]
Neoplasm Metastasis
[Expression and significance of Ki-67, PI3K and Beclin1 in oral squamous cell carcinoma].
Neoplasm Metastasis
[Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer]
Neoplasm Metastasis
[Integrin ?5 silencing inhibits proliferation, invasion and metastasis of human liver cancer Bel-7404 cells in vitro].
Neoplasm, Residual
SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.
Neoplasms
'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells.
Neoplasms
(-)-Kusunokinin inhibits breast cancer in N-nitrosomethylurea-induced mammary tumor rats.
Neoplasms
10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models.
Neoplasms
16-Hydroxycleroda-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis.
Neoplasms
17 ?-Estradiol Reverses Leptin-Inducing Ovarian Cancer Cell Migration by the PI3K/Akt Signaling Pathway.
Neoplasms
17ß-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling.
Neoplasms
18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
Neoplasms
2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer.
Neoplasms
20(S)-ginsenoside Rh2 induces caspase-dependent promyelocytic leukemia-retinoic acid receptor A degradation in NB4 cells via Akt/Bax/caspase9 and TNF-?/caspase8 signaling cascades.
Neoplasms
3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer.
Neoplasms
3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth.
Neoplasms
3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms.
Neoplasms
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Neoplasms
3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway.
Neoplasms
3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Neoplasms
3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
Neoplasms
5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells.
Neoplasms
5-fluorouracil enhances the anti-tumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers.
Neoplasms
?-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.
Neoplasms
?2-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism.
Neoplasms
?4-integrin/PI3K Signaling Promotes Tumor Progression through Galectin-3-N-glycan Complex.
Neoplasms
?5?1-integrinpromotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site.
Neoplasms
?Np63? is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
Neoplasms
A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway.
Neoplasms
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
Neoplasms
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.
Neoplasms
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Neoplasms
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Neoplasms
A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers.
Neoplasms
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Neoplasms
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
Neoplasms
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
Neoplasms
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.
Neoplasms
A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-?B Activation.
Neoplasms
A drug targeting only p110? can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
Neoplasms
A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines.
Neoplasms
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Neoplasms
A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.
Neoplasms
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Neoplasms
A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies.
Neoplasms
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Neoplasms
A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.
Neoplasms
A humanized yeast-based toolkit for monitoring phosphatidylinositol 3-kinase activity at both single cell and population levels.
Neoplasms
A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma.
Neoplasms
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.
Neoplasms
A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1? and HIF2? stability and tumor growth, angiogenesis, and metastasis.
Neoplasms
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Neoplasms
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.
Neoplasms
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Neoplasms
A new layer of phosphoinositide-mediated allosteric regulation uncovered for SHIP2.
Neoplasms
A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Neoplasms
A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma.
Neoplasms
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
Neoplasms
A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway.
Neoplasms
A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer.
Neoplasms
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.
Neoplasms
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death.
Neoplasms
A novel pathway for tumor necrosis factor-alpha and ceramide signaling involving sequential activation of tyrosine kinase, p21(ras), and phosphatidylinositol 3-kinase.
Neoplasms
A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.
Neoplasms
A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Neoplasms
A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.
Neoplasms
A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer.
Neoplasms
A p110?-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-?B.
Neoplasms
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Neoplasms
A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy.
Neoplasms
A Personalized Medicine Approach to Treat Malignant Proliferating Trichilemmal Tumors.
Neoplasms
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Neoplasms
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
Neoplasms
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Neoplasms
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Neoplasms
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
Neoplasms
A Phase I study of safety, pharmacokinetics, and pharmacodynamics of concurrent everolimus and buparlisib treatment in advanced solid tumors.
Neoplasms
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Neoplasms
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
Neoplasms
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Neoplasms
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Neoplasms
A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Neoplasms
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Neoplasms
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Neoplasms
A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.
Neoplasms
A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Neoplasms
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
Neoplasms
A PI3K inhibitor-induced growth inhibition of cancer cells is linked to MEK-ERK pathway.
Neoplasms
A PI3K p110?-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.
Neoplasms
A PI3K p110?-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.
Neoplasms
A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis.
Neoplasms
A positive feedback loop between GRP78 and VPS34 is critical for GRP78-mediated autophagy in cancer cells.
Neoplasms
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
Neoplasms
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Neoplasms
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
Neoplasms
A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.
Neoplasms
A primary splenic angiosarcoma hepatic metastasis after splenectomy and its genomic alteration profile.
Neoplasms
A Probabilistic Boolean Network Approach for the Analysis of Cancer-Specific Signalling: A Case Study of Deregulated PDGF Signalling in GIST.
Neoplasms
A Prospective Pilot Study of Target-guided Personalized Chemotherapy with Intensity-modulated Radiotherapy in Patients With Early Rectal Cancer.
Neoplasms
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Neoplasms
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Neoplasms
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Neoplasms
A SNP-mediated lncRNA (LOC146880) and microRNA (miR-539-5p) interaction and its potential impact on the NSCLC risk.
Neoplasms
A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
Neoplasms
A Structurally Optimized Celecoxib Derivative Inhibits Human Pancreatic Cancer Cell Growth.
Neoplasms
A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway.
Neoplasms
A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells.
Neoplasms
A Tumor initiating cell-enriched prognostic signature for HER2+:ER?- breast cancer; rationale, new features, controversies and future directions.
Neoplasms
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms.
Neoplasms
A Tumor-Associated Mutation of FYVE-CENT Prevents Its Interaction with Beclin 1 and Interferes with Cytokinesis.
Neoplasms
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Neoplasms
Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion.
Neoplasms
Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
Neoplasms
Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation.
Neoplasms
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Neoplasms
Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Neoplasms
Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.
Neoplasms
Acetylsalicylic acid suppression of the PI3K pathway as a novel medical therapy for head and neck lymphatic malformations.
Neoplasms
Acid Ceramidase Promotes Nuclear Export of PTEN through Sphingosine 1-Phosphate Mediated Akt Signaling.
Neoplasms
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Neoplasms
Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110?.
Neoplasms
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Neoplasms
Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias.
Neoplasms
Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor ?2 in cancer cells.
Neoplasms
Activation of human neutrophils by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor alpha: role of phosphatidylinositol 3-kinase.
Neoplasms
Activation of IGF1R/p110?/AKT/mTOR confers resistance to ?-specific PI3K inhibition.
Neoplasms
Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein.
Neoplasms
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Neoplasms
Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
Neoplasms
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
Neoplasms
Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: its direct inhibition by quercetin.
Neoplasms
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
Neoplasms
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Neoplasms
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Neoplasms
Activation of PI3K-AKT pathway in oral epithelial dysplasia and early cancer of tongue.
Neoplasms
Activation of PI3K/Akt/HIF-1? Signaling is Involved in Lung Protection of Dexmedetomidine in Patients Undergoing Video-Assisted Thoracoscopic Surgery: A Pilot Study.
Neoplasms
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.
Neoplasms
Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.
Neoplasms
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.
Neoplasms
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.
Neoplasms
Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.
Neoplasms
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.
Neoplasms
Active TGF-? signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Neoplasms
Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
Neoplasms
Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1.
Neoplasms
Addition of the p110? inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Neoplasms
Adenocarcinoma in Crohn's disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease.
Neoplasms
Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice.
Neoplasms
Adenovirus E4-ORF1 Dysregulates Epidermal Growth Factor and Insulin/Insulin-Like Growth Factor Receptors To Mediate Constitutive Myc Expression.
Neoplasms
Adenovirus mediated knockdown of bone morphogenetic protein 2 inhibits human lung cancer growth and invasion in vitro and in vivo.
Neoplasms
Adenovirus-mediated PTEN treatment combined with caffeine produces a synergistic therapeutic effect in colorectal cancer cells.
Neoplasms
Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo.
Neoplasms
Adhesion-independent alpha6beta4 integrin clustering is mediated by phosphatidylinositol 3-kinase.
Neoplasms
ADORA1 promotes nasopharyngeal carcinoma cell progression through regulation of PI3K/AKT/GSK-3?/?-catenin signaling.
Neoplasms
Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas.
Neoplasms
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.
Neoplasms
Airway Microbiota Is Associated with Up-Regulation of the PI3K Pathway in Lung Cancer.
Neoplasms
Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2.
Neoplasms
Akt determines cell fate through inhibition of the PERK-eIF2? phosphorylation pathway.
Neoplasms
AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.
Neoplasms
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
Neoplasms
Akt protects mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis through NK-kappa B activation.
Neoplasms
Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.
Neoplasms
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
Neoplasms
Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation.
Neoplasms
AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.
Neoplasms
Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor.
Neoplasms
Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.
Neoplasms
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Neoplasms
Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
Neoplasms
All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies.
Neoplasms
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Neoplasms
Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei.
Neoplasms
Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing.
Neoplasms
Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer.
Neoplasms
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Neoplasms
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer.
Neoplasms
Alphavbeta3 integrin blocking inhibits apoptosis and induces autophagy in murine breast tumor cells.
Neoplasms
Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme.
Neoplasms
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.
Neoplasms
AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer.
Neoplasms
An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.
Neoplasms
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Neoplasms
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Neoplasms
An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells.
Neoplasms
An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer.
Neoplasms
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Neoplasms
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Neoplasms
An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells.
Neoplasms
An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Neoplasms
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Neoplasms
An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Neoplasms
Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Neoplasms
Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy.
Neoplasms
Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions.
Neoplasms
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Neoplasms
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Neoplasms
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Neoplasms
Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Neoplasms
Analysis of the Internal Hypoxic Environment in Solid Tumor Tissue Using a Folding Paper System.
Neoplasms
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.
Neoplasms
Analysis of the ways and methods of signaling pathways in regulating cell cycle of NIH3T3 at transcriptional level.
Neoplasms
Androgen blockade based clinical trials landscape in triple negative breast cancer.
Neoplasms
Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.
Neoplasms
Androgen receptor-induced integrin ?6?1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
Neoplasms
Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer.
Neoplasms
Annexin A2 is involved in activation of extracellular signal-regulated kinase upon endothelin-1 stimulation.
Neoplasms
Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy.
Neoplasms
Antagonistic effect of selenium on lead-induced neutrophil apoptosis in chickens via miR-16-5p targeting of PiK3R1 and IGF1R.
Neoplasms
Anti-breast-Cancer Activity Exerted by ?-Sitosterol-d-glucoside from Sweet Potato via Upregulation of MicroRNA-10a and via the PI3K-Akt Signaling Pathway.
Neoplasms
Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation.
Neoplasms
Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
Neoplasms
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Neoplasms
Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
Neoplasms
Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy.
Neoplasms
Anticancer potential of novel ?,?-unsaturated ?-lactam derivatives targeting the PI3K/AKT signaling pathway.
Neoplasms
Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.
Neoplasms
Antinociceptive and anti-inflammatory effects of cryptotanshinone through PI3K/Akt signaling pathway in a rat model of neuropathic pain.
Neoplasms
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Neoplasms
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Neoplasms
Antitumor and Anti-Invasive Effect of Apigenin on Human Breast Carcinoma through Suppression of IL-6 Expression.
Neoplasms
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model.
Neoplasms
Antitumor effects of ?-elemene via targeting the phosphorylation of insulin receptor.
Neoplasms
Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation.
Neoplasms
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Neoplasms
AP-2? Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.
Neoplasms
APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer.
Neoplasms
Apoptosis initiation of ?-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway.
Neoplasms
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
Neoplasms
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Neoplasms
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Neoplasms
Architecture and dynamics of the autophagic phosphatidylinositol 3-kinase complex.
Neoplasms
ARID1A is a tumour suppressor and inhibits glioma cell proliferation via the PI3K pathwa.
Neoplasms
Artesunate Attenuates Pro-Inflammatory Cytokine Release from Macrophages by Inhibiting TLR4-Mediated Autophagic Activation via the TRAF6-Beclin1-PI3KC3 Pathway.
Neoplasms
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.
Neoplasms
Asparagus Polysaccharide inhibits the Hypoxia-induced migration, invasion and angiogenesis of Hepatocellular Carcinoma Cells partly through regulating HIF1?/VEGF expression via MAPK and PI3K signaling pathway.
Neoplasms
Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Neoplasms
Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.
Neoplasms
Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast.
Neoplasms
Assessment of tris (1, 3-dichloro-2-propyl) phosphate toxicology in PC12 cells by using digital gene expression profiling.
Neoplasms
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Neoplasms
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.
Neoplasms
Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas.
Neoplasms
Association of PIK3CA gene mutations with head and neck squamous cell carcinomas.
Neoplasms
Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports.
Neoplasms
Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF-??/STAT3 signalling axis in oral squamous cell carcinoma models.
Neoplasms
Astilbin-induced inhibition of the PI3K/AKT signaling pathway decelerates the progression of osteoarthritis.
Neoplasms
Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF??1?mediated PI3K and MAPK pathways.
Neoplasms
Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis.
Neoplasms
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Neoplasms
Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma.
Neoplasms
Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.
Neoplasms
Author Correction: Tumours with PI3K activation are resistant to dietary restriction.
Neoplasms
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Neoplasms
Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway.
Neoplasms
Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome (APDS): Case Report and Review.
Neoplasms
Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Neoplasms
Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells.
Neoplasms
Autophagy modulation as a potential targeted cancer therapy: From drug repurposing to new drug development.
Neoplasms
Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin in?ammation.
Neoplasms
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Neoplasms
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Neoplasms
B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer.
Neoplasms
Baicalein induces autophagic cell death through AMPK/ULK1 activation and downregulation of mTORC1 complex components in human cancer cells.
Neoplasms
Baicalin attenuates myocardial ischemia-reperfusion injury through Akt/NF-?B pathway.
Neoplasms
BAP1 antagonizes WWP1-mediated transcription factor KLF5 ubiquitination and inhibits autophagy to promote melanoma progression.
Neoplasms
Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
Neoplasms
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110? and p110? activities in tumor cell lines and xenograft models.
Neoplasms
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of Mek Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models.
Neoplasms
BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.
Neoplasms
Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
Neoplasms
BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating ?-catenin/ZEB1 regulatory loop.
Neoplasms
Berberine-induced autophagic cell death by elevating GRP78 levels in cancer cells.
Neoplasms
beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease.
Neoplasms
Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.
Neoplasms
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Neoplasms
Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting.
Neoplasms
Bi2 S3 -Tween 20 Nanodots Loading PI3K Inhibitor, LY294002, for Mild Photothermal Therapy of LoVo Cells In Vitro and In Vivo.
Neoplasms
BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors.
Neoplasms
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Neoplasms
Biochemical and biological characterization of tumor-associated mutations of p110alpha.
Neoplasms
Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.
Neoplasms
Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Neoplasms
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Neoplasms
Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression Is Lost in Ovarian and Breast Cancers.
Neoplasms
Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4).
Neoplasms
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.
Neoplasms
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3K?, in comparison to established pan PI3K inhibitors.
Neoplasms
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Neoplasms
Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Neoplasms
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
Neoplasms
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Neoplasms
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
Neoplasms
Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers.
Neoplasms
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Neoplasms
Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway.
Neoplasms
BMP4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.
Neoplasms
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Neoplasms
Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation.
Neoplasms
Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.
Neoplasms
Both p110? and p110? isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Neoplasms
Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Neoplasms
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Neoplasms
Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-alpha, releasing matrix metalloproteinase-9 and migrating in vitro.
Neoplasms
Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells.
Neoplasms
Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Neoplasms
Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells.
Neoplasms
Brassinin Represses Invasive Potential of Lung Carcinoma Cells through Deactivation of PI3K/Akt/mTOR Signaling Cascade.
Neoplasms
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Neoplasms
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
Neoplasms
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.
Neoplasms
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Neoplasms
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Neoplasms
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Neoplasms
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.
Neoplasms
C-terminal domain of p42 Ebp1 is essential for down regulation of p85 subunit of PI3K, inhibiting tumor growth.
Neoplasms
C6-ceramide nanoliposome suppresses tumor metastasis by eliciting PI3K and PKC? tumor-suppressive activities and regulating integrin affinity modulation.
Neoplasms
Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.
Neoplasms
CAL-101, a p110{delta} selective phosphatidylinositol-3-kinase inhibitor (PI3K) for the treatment of B cell malignancies inhibits PI3K signaling and cellular viability.
Neoplasms
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Neoplasms
Calcium-sensing receptor induces proliferation through p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase but not extracellularly regulated kinase in a model of humoral hypercalcemia of malignancy.
Neoplasms
Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
Neoplasms
Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/?-catenin/CBP pathway.
Neoplasms
Cancer cells dysregulate PI3K/AKT/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses.
Neoplasms
Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion.
Neoplasms
Cancer cells regulate biomechanical properties of human microvascular endothelial cells.
Neoplasms
Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production.
Neoplasms
Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways.
Neoplasms
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Neoplasms
Cancer invasion and resistance: interconnected processes of disease progression and therapy failure.
Neoplasms
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Neoplasms
Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer.
Neoplasms
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Neoplasms
Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds.
Neoplasms
Capitalizing on Tumor genotyping: Towards the design of mutation specific inhibitors of Phosphoinsitide-3-Kinase.
Neoplasms
Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.
Neoplasms
Cardamonin inhibits the progression of oesophageal cancer by inhibiting the PI3K/AKT signalling pathway.
Neoplasms
Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
Neoplasms
CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead.
Neoplasms
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.
Neoplasms
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Neoplasms
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Neoplasms
Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion.
Neoplasms
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Neoplasms
Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade.
Neoplasms
Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38.
Neoplasms
Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.
Neoplasms
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Neoplasms
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Neoplasms
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
Neoplasms
Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells.
Neoplasms
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors.
Neoplasms
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Neoplasms
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Neoplasms
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Neoplasms
Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases.
Neoplasms
Characterization of molecular recognition of Phosphoinositide-3-kinase ? inhibitor through molecular dynamics simulation.
Neoplasms
Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
Neoplasms
Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor.
Neoplasms
Characterization of selective and potent PI3K? inhibitor (PI3KDIN- 015) for B-Cell malignances.
Neoplasms
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Impacting the PI3K Pathway.
Neoplasms
Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.
Neoplasms
Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition.
Neoplasms
Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors.
Neoplasms
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.
Neoplasms
Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells.
Neoplasms
Chloroform fraction of Serratulae chinensis S. Moore suppresses proliferation and induces apoptosis via the phosphatidylinositide 3-kinase/Akt pathway in human gastric cancer cells.
Neoplasms
Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote ?-irradiation-induced cell death in primary stem-like glioma cells.
Neoplasms
Chromosome localization analysis of genes strongly expressed in human visceral adipose tissue.
Neoplasms
Circadian Clock Protein PERIOD2 Suppresses the PI3K/Akt Pathway and Promotes Cisplatin Sensitivity in Ovarian Cancer.
Neoplasms
Circular RNA hsa_circ_0005046 and hsa_circ_0001791 May Become Diagnostic Biomarkers for Breast Cancer Early Detection.
Neoplasms
Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors.
Neoplasms
CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways.
Neoplasms
Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.
Neoplasms
Class I Phosphoinositide 3-Kinase PIK3CA/p110? and PIK3CB/p110? Isoforms in Endometrial Cancer.
Neoplasms
Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Neoplasms
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.
Neoplasms
Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery.
Neoplasms
Class II phosphoinositide 3-kinase C2? regulates a novel signaling pathway involved in breast cancer progression.
Neoplasms
Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Neoplasms
Cleavage of Syndecan-1 Promotes the Proliferation of the Basal-Like Breast Cancer Cell Line BT-549 Via Akt SUMOylation.
Neoplasms
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
Neoplasms
Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma.
Neoplasms
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Neoplasms
Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.
Neoplasms
Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Neoplasms
Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.
Neoplasms
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Neoplasms
Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer.
Neoplasms
Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets.
Neoplasms
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Neoplasms
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Neoplasms
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Neoplasms
Clionosterol and Ethyl Cholestan-22-enol Isolated from the Rhizome of Polygala tenuifolia Inhibit Phosphatidylinositol 3-Kinase/Akt Pathway.
Neoplasms
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
Neoplasms
Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors.
Neoplasms
Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages.
Neoplasms
Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Neoplasms
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Neoplasms
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Neoplasms
Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs.
Neoplasms
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Neoplasms
Codelivery of HIF-1? siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Neoplasms
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Neoplasms
CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network.
Neoplasms
Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3K? in myeloid cells.
Neoplasms
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Neoplasms
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
Neoplasms
Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo.
Neoplasms
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Neoplasms
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Neoplasms
Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
Neoplasms
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Neoplasms
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110? Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers.
Neoplasms
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Neoplasms
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Neoplasms
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Neoplasms
Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
Neoplasms
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Neoplasms
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Neoplasms
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
Neoplasms
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Neoplasms
Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
Neoplasms
Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Neoplasms
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice.
Neoplasms
Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer.
Neoplasms
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Neoplasms
Combined Inhibition of Both p110? and p110? Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER(+) Breast Cancer.
Neoplasms
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Neoplasms
Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Neoplasms
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Neoplasms
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Neoplasms
Combined MEK and PI3K/p110? Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Neoplasms
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Neoplasms
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Neoplasms
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Neoplasms
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Neoplasms
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Neoplasms
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Neoplasms
Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non?small cell lung cancer cells in vitro and in vivo.
Neoplasms
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Neoplasms
Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.
Neoplasms
Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features.
Neoplasms
Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation.
Neoplasms
Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
Neoplasms
Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Neoplasms
Comparative transcriptome analysis of transcultured human skin-derived precursors (tSKPs) from adherent monolayer culture system and tSKPs-derived fibroblasts (tFBs) by RNA-Seq.
Neoplasms
Comparing the Roles of the p110? and p110? Isoforms of PI3K in Signaling and Cancer.
Neoplasms
Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor.
Neoplasms
Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production.
Neoplasms
Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology.
Neoplasms
Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure.
Neoplasms
Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
Neoplasms
Compartmentalization and Insulin-Induced Translocations of Insulin Receptor Substrates, Phosphatidylinositol 3-Kinase, and Protein Kinase B in Rat Liver* * This work was supported by grants from the Medical Research Council and from the National Cancer Institute of Canada, and by the Cleghorn Fund at McGill University and the M. Pollack Foundation of Montreal.
Neoplasms
Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation.
Neoplasms
Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes.
Neoplasms
Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues.
Neoplasms
Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
Neoplasms
Concomitant Inhibition of PI3K? and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K?-Selective Inhibitor.
Neoplasms
Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
Neoplasms
Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.
Neoplasms
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Neoplasms
Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production.
Neoplasms
Constitutive activation of phosphatidylinositol 3-kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-alpha release in alveolar macrophages from asymptomatic HIV-positive persons in vitro.
Neoplasms
Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription.
Neoplasms
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Neoplasms
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
Neoplasms
Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis.
Neoplasms
Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.
Neoplasms
Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression.
Neoplasms
Cooperation Between Pten and Smad4 in Murine Salivary Gland Tumor Formation and Progression.
Neoplasms
Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta.
Neoplasms
Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain.
Neoplasms
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Neoplasms
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Neoplasms
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Neoplasms
Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Neoplasms
Correction: PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Neoplasms
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Neoplasms
Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer.
Neoplasms
Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Neoplasms
Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Neoplasms
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
Neoplasms
Correspondence re: M. Tresini et al. A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts. Cancer Res., 58: 1-4, 1998.
Neoplasms
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Neoplasms
Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma.
Neoplasms
Cross-regulation between protein L-isoaspartyl O-methyltransferase and ERK in epithelial mesenchymal transition of MDA-MB-231 cells.
Neoplasms
Cross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by PI3K inhibitors.
Neoplasms
Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions.
Neoplasms
Crosslink among phosphatidylinositol-3 kinase/Akt, PTEN and STAT-5A signaling pathways post liposomal galactomannan hepatocellular carcinoma therapy.
Neoplasms
Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Neoplasms
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Neoplasms
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
Neoplasms
CRYAB inhibits migration and invasion of bladder cancer cells through the PI3K/AKT and ERK pathways.
Neoplasms
Crystal Structures of PI3K? Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design.
Neoplasms
CTRP3 improves the insulin sensitivity of 3T3-L1 adipocytes by inhibiting inflammation and ameliorating insulin signalling transduction.
Neoplasms
CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression.
Neoplasms
Curcumin attenuates high glucose-induced inflammatory injury through the reactive oxygen species-phosphoinositide 3-kinase/protein kinase B-nuclear factor-?B signaling pathway in rat thoracic aorta endothelial cells.
Neoplasms
Current and future management strategies for relapsed or progressive hepatoblastoma.
Neoplasms
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3K?/? and HDAC.
Neoplasms
Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin.
Neoplasms
Cytochrome P450 ?-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer.
Neoplasms
Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.
Neoplasms
Dally Proteoglycan Mediates the Autonomous and Nonautonomous Effects on Tissue Growth Caused by Activation of the PI3K and TOR Pathways.
Neoplasms
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Neoplasms
Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis.
Neoplasms
Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of PI3K, ERK and NF-kappaB activation.
Neoplasms
Defects in cytochrome c oxidase expression induce a metabolic shift to glycolysis and carcinogenesis.
Neoplasms
Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Neoplasms
Definition of the binding mode of phosphoinositide 3-kinase ?-selective inhibitor A-66S through molecular dynamics simulation.
Neoplasms
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Neoplasms
Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K.
Neoplasms
Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells.
Neoplasms
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation.
Neoplasms
Deoxyshikonin isolated from Arnebia euchroma inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway.
Neoplasms
Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis.
Neoplasms
Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice.
Neoplasms
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
Neoplasms
Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Neoplasms
Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
Neoplasms
Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets.
Neoplasms
Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K?.
Neoplasms
Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3K? inhibitors.
Neoplasms
Design, synthesis and biological evaluation of novel urea and thiourea bearing thieno[3,2-d]-pyrimidines as PI3 kinase inhibitors.
Neoplasms
Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Neoplasms
Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.
Neoplasms
Design, Synthesis and Preliminary Biological Evaluation of Benzylsulfone Coumarin Derivatives as Anti-Cancer Agents.
Neoplasms
Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-d]Pyrimidine Series as Novel PI3K/mTOR Inhibitors.
Neoplasms
Design, Synthesis, and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment.
Neoplasms
Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3K? inhibitors.
Neoplasms
Design, Synthesis, and Structure-Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylinositol 3-Kinase Signaling Pathway.
Neoplasms
Detection of functional PTEN lipid phosphatase protein and enzyme activity in squamous cell carcinomas of the head and neck, despite loss of heterozygosity at this locus.
Neoplasms
Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
Neoplasms
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Neoplasms
Developing a Novel Embryo-Larval Zebrafish Xenograft Assay to Prioritize Human Glioblastoma Therapeutics.
Neoplasms
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Neoplasms
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Neoplasms
Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors.
Neoplasms
Development of New Molecular Markers for Cancer: A Highly Sensitive Assay for Detecting Mutations of Phosphatidylinositol 3-kinase and p53.
Neoplasms
Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3K?.
Neoplasms
Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing piperazine as inhibitors of PI3K?.
Neoplasms
Development of novel PET probes targeting phosphatidylinositol 3-kinase (PI3K) in tumors.
Neoplasms
Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB.
Neoplasms
Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway.
Neoplasms
DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
Neoplasms
Differences in autophagy-associated mRNAs in peritoneal fluid of patients with endometriosis and gynecologic cancers.
Neoplasms
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.
Neoplasms
Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
Neoplasms
Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
Neoplasms
Different correlations between tumor size and cancer-related gene profiles according to histologic type of salivary gland tumor.
Neoplasms
Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
Neoplasms
Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration.
Neoplasms
Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors.
Neoplasms
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Neoplasms
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Neoplasms
Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
Neoplasms
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Neoplasms
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
Neoplasms
Differential radio-adaptive responses in BALB/c and C57BL/6 mice: pivotal role of calcium and nitric oxide signalling.
Neoplasms
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Neoplasms
Differential response of neuroblastoma cells to TRAIL is independent of PI3K/AKT.
Neoplasms
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.
Neoplasms
Difuran-substituted quinoxalines as a novel class of PI3K? H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship.
Neoplasms
Dimethylsulfoxide induces upregulation of tumor suppressor protein PTEN through nuclear factor-kappaB activation in HL-60 cells.
Neoplasms
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Neoplasms
Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway.
Neoplasms
Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.
Neoplasms
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Neoplasms
Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.
Neoplasms
Discovering and developing PI3 kinase inhibitors for cancer: rapid progress through academic-biotech-pharma interactions.
Neoplasms
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
Neoplasms
Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.
Neoplasms
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3K? inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Neoplasms
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Neoplasms
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
Neoplasms
Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.
Neoplasms
Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.
Neoplasms
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
Neoplasms
Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
Neoplasms
Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3K?) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Neoplasms
Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors.
Neoplasms
Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer.
Neoplasms
Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy.
Neoplasms
Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Neoplasms
Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) library.
Neoplasms
Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Neoplasms
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
Neoplasms
Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo.
Neoplasms
Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT Oncogenes.
Neoplasms
Disease-related mutations in PI3K? disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors.
Neoplasms
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Neoplasms
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.
Neoplasms
Dissecting the different biological effects of oncogenic Ras isoforms in cancer cell lines: Could stimulation of oxidative stress be the one more weapon of H-Ras?: Regulation of oxidative stress and Ras biological effects.
Neoplasms
Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.
Neoplasms
Dissecting the roles of Ephrin-A3 in malignant peripheral nerve sheath tumor by TALENs.
Neoplasms
Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.
Neoplasms
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Neoplasms
Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex.
Neoplasms
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Neoplasms
Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.
Neoplasms
Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
Neoplasms
DJ-1 promotes survival of human colon cancer cells under hypoxia by modulating HIF-1? expression through the PI3K-AKT pathway.
Neoplasms
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Neoplasms
Do Wortmannin and Thalidomide induce apoptosis by autophagy inhibition in 4T1 breast cancer cells in vitro and in vivo?
Neoplasms
Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.
Neoplasms
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K? inhibitors.
Neoplasms
Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Neoplasms
Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
Neoplasms
Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.
Neoplasms
Down-regulation of Inositol Polyphosphate 4-Phosphatase Type II Expression in Colorectal Carcinoma.
Neoplasms
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Neoplasms
Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop.
Neoplasms
Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.
Neoplasms
Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer.
Neoplasms
Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells.
Neoplasms
Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike.
Neoplasms
Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections.
Neoplasms
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Neoplasms
Dual effects of the PI3K inhibitor ZSTK474 on multidrug efflux pumps in resistant cancer cells.
Neoplasms
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Neoplasms
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.
Neoplasms
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Neoplasms
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Neoplasms
Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.
Neoplasms
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Neoplasms
Dual Inhibiton of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110? as a Therapeutic Approach to Treat non-Hodgkin's B cell Malignancies.
Neoplasms
Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
Neoplasms
Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy.
Neoplasms
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.
Neoplasms
Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
Neoplasms
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Neoplasms
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma.
Neoplasms
Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.
Neoplasms
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Neoplasms
Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Neoplasms
Duvelisib: a phosphoinositide-3 kinase ?/? inhibitor for chronic lymphocytic leukemia.
Neoplasms
Dynamic palmitoylation controls the microdomain localization of the DKK1 receptors CKAP4 and LRP6.
Neoplasms
Dynamics of GFP-Fusion p110? and p110? Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells.
Neoplasms
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
Neoplasms
Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis.
Neoplasms
E1A inhibition of radiation-induced NF-kappaB activity through suppression of IKK activity and IkappaB degradation, independent of Akt activation.
Neoplasms
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Neoplasms
Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1?.
Neoplasms
Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts.
Neoplasms
Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
Neoplasms
Effect of bevacizumab on expression level of GLI1 and ING4 in colon cancer animal model.
Neoplasms
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Neoplasms
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
Neoplasms
Effect of dexmedetomidine on the cognitive function of patients undergoing gastric cancer surgery by regulating the PI3K/AKT signaling pathway.
Neoplasms
Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells.
Neoplasms
Effect of nutrient intake on intramuscular glucose metabolism during the early growth stage in cross-bred steers (Japanese Black male?×?Holstein female).
Neoplasms
Effect of PI3K gene silencing on growth, migration and related proteins expression of CD40 signal-mediated gastric cancer cells.
Neoplasms
Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.
Neoplasms
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Neoplasms
Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy (Review).
Neoplasms
Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease.
Neoplasms
Effective treatment of HER2-amplified breast cancer by targeting HER3 and ?1 integrin.
Neoplasms
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Neoplasms
Effects of an inhibitor of the gamma-secretase complex on proliferation and apoptotic parameters in a FOXL2-mutated granulosa tumor cell line (KGN).
Neoplasms
Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy.
Neoplasms
Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Neoplasms
Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.
Neoplasms
Effects of Macrothele raven venom on intrarenal invasion and metastasis of H22 liver cancer cells in mice.
Neoplasms
Effects of mutations in Wnt/?-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.
Neoplasms
Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).
Neoplasms
Effects of PI3K Inhibition on Afucosylated Antibody-Driven Fc?RIIIa Events and Phospho-S6 Activity in NK Cells.
Neoplasms
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Neoplasms
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.
Neoplasms
Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells.
Neoplasms
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
Neoplasms
Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Neoplasms
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Neoplasms
Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.
Neoplasms
Efficacy of Providing the PI3K p110? Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet.
Neoplasms
Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Neoplasms
EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway.
Neoplasms
EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin.
Neoplasms
EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3.
Neoplasms
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.
Neoplasms
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Neoplasms
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
Neoplasms
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.
Neoplasms
EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumour-Initiating Cell Frequency.
Neoplasms
Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines.
Neoplasms
Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.
Neoplasms
Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma.
Neoplasms
Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.
Neoplasms
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity.
Neoplasms
Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2.
Neoplasms
Endothelial Barrier Protection by Local Anesthetics: Ropivacaine and Lidocaine Block Tumor Necrosis Factor-?-Induced Endothelial Cell Src Activation.
Neoplasms
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.
Neoplasms
Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy.
Neoplasms
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.
Neoplasms
Enhanced Phosphoinositide 3-Kinase {delta} Activity Is a Frequent Event in Systemic Lupus Erythematosus That Confers Resistance to Activation-Induced T Cell Death.
Neoplasms
Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
Neoplasms
Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.
Neoplasms
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Neoplasms
ENTPD5, an Endoplasmic Reticulum UDPase, Alleviates ER Stress Induced by Protein Overloading in ATK-Activated Cancer Cells.
Neoplasms
Enzymatic and non-enzymatic activities of SHIP-1 in signal transduction and cancer.
Neoplasms
EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Neoplasms
Epidermal growth factor protects fibroblasts from apoptosis via PI3 kinase and Rac signaling pathways.
Neoplasms
Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model.
Neoplasms
Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.
Neoplasms
Epigallocatechin-3-gallate inhibits proliferation and triggers apoptosis in colon cancer via the hedgehog/phosphoinositide 3-kinase pathways.
Neoplasms
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Neoplasms
Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling.
Neoplasms
Epstein-Barr virus latent membrane protein 1 represses DNA repair through the PI3K/Akt/FOXO3a pathway in human epithelial cells.
Neoplasms
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
Neoplasms
ER?-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Neoplasms
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
Neoplasms
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Neoplasms
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas.
Neoplasms
ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.
Neoplasms
Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3? Signaling Pathway in Human Hepatocellular Carcinoma.
Neoplasms
ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1.
Neoplasms
ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Neoplasms
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Neoplasms
Erratum for the Research Article: "Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy".
Neoplasms
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Neoplasms
Establishment and Characterization of Cell Lines from a Novel Mouse Model of Poorly Differentiated Thyroid Carcinoma: Powerful Tools for Basic and Preclinical Research.
Neoplasms
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Neoplasms
Establishment of a Choriocarcinoma Model from Immortalized Normal Extravillous Trophoblast Cells Transduced with HRASV12.
Neoplasms
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.
Neoplasms
Establishment of PI3K inhibitor-resistant cancer cell lines and the therapeutic strategies for overcoming the resistance.
Neoplasms
Estrogen receptor ? induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells.
Neoplasms
Estrogen sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.
Neoplasms
Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway.
Neoplasms
Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway.
Neoplasms
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Neoplasms
ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia.
Neoplasms
Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signaling pathways.
Neoplasms
Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.
Neoplasms
Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines.
Neoplasms
Evaluation of type 2 diabetic mellitus animal models via interactions between insulin and mitogen?activated protein kinase signaling pathways induced by a high fat and sugar diet and streptozotocin.
Neoplasms
Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen.
Neoplasms
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.
Neoplasms
Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.
Neoplasms
Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis.
Neoplasms
Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway.
Neoplasms
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Neoplasms
Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight.
Neoplasms
Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
Neoplasms
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Neoplasms
Exploring the Pharmacological Mechanisms of Tripterygium wilfordii Hook F against Cardiovascular Disease Using Network Pharmacology and Molecular Docking.
Neoplasms
Exposure of breast cancer cells to a subcytotoxic dose of apigenin causes growth inhibition, oxidative stress, and hypophosphorylation of Akt.
Neoplasms
Expression Analysis of GRHL3 and PHLDA3 in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.
Neoplasms
Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1.
Neoplasms
Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay.
Neoplasms
Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma.
Neoplasms
Expression of biomarkers in the AKT pathway correlates with malignancy and recurrence in phyllodes tumours of the breast.
Neoplasms
Expression of factors and key components associated with the PI3K signaling pathway in colon cancer.
Neoplasms
Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
Neoplasms
Expression of interleukin (IL)-11 and IL-11 receptor in human colorectal adenocarcinoma: IL-11 up-regulation of the invasive and proliferative activity of human colorectal carcinoma cells.
Neoplasms
Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma.
Neoplasms
Expression of PI3K and ERK in Uygur and Han patients with cervical squamous cancer.
Neoplasms
Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.
Neoplasms
Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.
Neoplasms
Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV).
Neoplasms
Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation.
Neoplasms
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.
Neoplasms
Expression status and mutational analysis of the PTEN and P13K subunit genes in ovarian granulosa cell tumors.
Neoplasms
Extracellular and subcellular regulation of the PI3K/Akt cassette: new mechanisms for controlling insulin and growth factor signalling.
Neoplasms
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
Neoplasms
Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review.
Neoplasms
Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.
Neoplasms
EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer.
Neoplasms
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers.
Neoplasms
Familial Intracranial Hypertension in 2 Brothers With PTEN Mutation: Expansion of the Phenotypic Spectrum.
Neoplasms
Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells.
Neoplasms
Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Neoplasms
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Neoplasms
Feedback autophagy activation as a key resistance factor of Ku-0060648 in colorectal cancer cells.
Neoplasms
Feedback suppression of PI3K? signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K?.
Neoplasms
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Neoplasms
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
Neoplasms
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Neoplasms
First-In-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer.
Neoplasms
First-in-human trial of the PI3K?-selective inhibitor SAR260301 in patients with advanced solid tumors.
Neoplasms
Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Neoplasms
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Neoplasms
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Neoplasms
Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter-1 and hypoxia-inducible-factor-1? and the phosphoinositide 3-kinase/protein kinase B pathway.
Neoplasms
Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.
Neoplasms
Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling.
Neoplasms
Formal Modeling of mTOR Associated Biological Regulatory Network Reveals Novel Therapeutic Strategy for the Treatment of Cancer.
Neoplasms
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.
Neoplasms
Four major factors regulate phosphatidylinositol 3-kinase signaling pathway in cancers induced by infection of human papillomaviruses.
Neoplasms
FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
Neoplasms
FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesis.
Neoplasms
FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma.
Neoplasms
Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.
Neoplasms
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.
Neoplasms
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Neoplasms
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Neoplasms
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Neoplasms
Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Neoplasms
Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway.
Neoplasms
Functional characterization of an isoform-selective inhibitor of PI3K-p110? as a potential anticancer agent.
Neoplasms
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.
Neoplasms
Functional interaction of phosphatase and tensin homologue (PTEN) with the E3 ligase NEDD4-1 during neuronal response to zinc.
Neoplasms
Functional role of phosphatidylinositol 3-kinase in direct tumor lysis by human natural killer cells.
Neoplasms
Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
Neoplasms
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Neoplasms
Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking.
Neoplasms
Functional vinorelbine plus schisandrin B liposomes destroying tumor metastasis in treatment of gastric cancer.
Neoplasms
Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
Neoplasms
G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling.
Neoplasms
Gab2 Is Involved in Differential Phosphoinositide 3-Kinase Signaling by Two Splice Forms of c-Kit.
Neoplasms
Gain of interaction with IRS1 by p110?-helical domain mutants is crucial for their oncogenic functions.
Neoplasms
Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells.
Neoplasms
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Neoplasms
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Neoplasms
Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells.
Neoplasms
Gene amplifications associated with the development of hormone-resistant prostate cancer.
Neoplasms
Gene expression profiling demonstrates WNT/?-catenin pathway genes alteration in Mexican patients with colorectal cancer and diabetes mellitus.
Neoplasms
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Neoplasms
Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Neoplasms
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
Neoplasms
Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States.
Neoplasms
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Neoplasms
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Neoplasms
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.
Neoplasms
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
Neoplasms
Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.
Neoplasms
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Neoplasms
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Neoplasms
Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.
Neoplasms
Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels.
Neoplasms
Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway.
Neoplasms
Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery.
Neoplasms
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Neoplasms
Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients.
Neoplasms
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Neoplasms
Genome-wide association study in esophageal cancer using GeneChip mapping 10K array.
Neoplasms
Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer.
Neoplasms
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.
Neoplasms
Genome-wide screen for serum microRNA expression profile in mfat-1 transgenic mice.
Neoplasms
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.
Neoplasms
Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.
Neoplasms
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Neoplasms
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.
Neoplasms
Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition.
Neoplasms
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Neoplasms
Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer.
Neoplasms
Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma.
Neoplasms
Genomic profiling of high-grade large-cell neuroendocrine carcinoma of the colon.
Neoplasms
Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.
Neoplasms
Germline disruption of Pten localization causes enhanced sex-dependent social motivation and increased glial production.
Neoplasms
Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis.
Neoplasms
GIV/Girdin Creates a Positive Feedback Loop that Potentiates Outside-in Integrin Signaling in Cancer Cells.
Neoplasms
GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
Neoplasms
Glucocorticoid adrenal steroids and glucocorticoid-inducible kinase isoforms in the regulation of GluR6 expression.
Neoplasms
Glucocorticoid Receptor Counteracts Tumorigenic Activity of Akt in Skin through Interference with the Phosphatidylinositol 3-Kinase Signaling Pathway.
Neoplasms
Glucose Metabolism Measured by [F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells.
Neoplasms
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Neoplasms
Glycine-extended gastrin activates two independent tyrosine-kinases in upstream of p85/p110 phosphatidylinositol 3-kinase in human colonic tumour cells.
Neoplasms
Glycyrrhizic Acid and 18?-Glycyrrhetinic Acid Modulate Lipopolysaccharide-Induced Inflammatory Response by Suppression of NF-?B through PI3K p110? and p110? Inhibitions.
Neoplasms
Grape Proanthocyanidin Inhibit Pancreatic Cancer Cell Growth In Vitro and In Vivo through Induction of Apoptosis and by Targeting the PI3K/Akt Pathway.
Neoplasms
Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor.
Neoplasms
GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
Neoplasms
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.
Neoplasms
H3K27 Demethylase JMJD3 Employs the NF-?B and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.
Neoplasms
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
Neoplasms
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.
Neoplasms
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
Neoplasms
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Neoplasms
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Neoplasms
Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells.
Neoplasms
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
Neoplasms
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110?.
Neoplasms
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer.
Neoplasms
Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways.
Neoplasms
Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.
Neoplasms
Hepatoprotective effect of forsythiaside a against acetaminophen-induced liver injury in zebrafish: Coupling network pharmacology with biochemical pharmacology.
Neoplasms
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
Neoplasms
HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment.
Neoplasms
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Neoplasms
Herbal cake-partitioned moxibustion inhibits colonic autophagy in Crohn's disease via signaling involving distinct classes of phosphatidylinositol 3-kinases.
Neoplasms
Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
Neoplasms
Heterogeneous kinetics of AKT signaling in individual cells are accounted for by variable protein concentration.
Neoplasms
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
Neoplasms
Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects.
Neoplasms
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Neoplasms
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability.
Neoplasms
High level of p37?-mRNA relative to p110?-mRNA in neuroblastoma tumors correlates with poor patient survival.
Neoplasms
High levels of p110? PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110? inhibitors through PTEN activation.
Neoplasms
High throughput chemical library screening identifies a novel p110-? inhibitor that potentiates the anti-myeloma effect of bortezomib.
Neoplasms
High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.
Neoplasms
High-fat diet feeding promotes stemness and precancerous changes in murine gastric mucosa mediated by leptin receptor signaling pathway.
Neoplasms
High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1?) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells.
Neoplasms
High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing.
Neoplasms
High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
Neoplasms
High-throughput screening campaigns against a PI3K? isoform bearing the H1047R mutation identified potential inhibitors with novel scaffolds.
Neoplasms
Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype.
Neoplasms
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.
Neoplasms
Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Neoplasms
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
Neoplasms
hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Neoplasms
Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation.
Neoplasms
Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Neoplasms
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Neoplasms
HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Neoplasms
HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy.
Neoplasms
HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
Neoplasms
Hsa_circ_CSPP1/MiR-361-5p/ITGB1 Regulates Proliferation and Migration of Cervical Cancer (CC) by Modulating the PI3K-Akt Signaling Pathway.
Neoplasms
Hsp90 inhibitor gedunin causes apoptosis in A549 lung cancer cells by disrupting Hsp90:Beclin-1:Bcl-2 interaction and downregulating autophagy.
Neoplasms
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.
Neoplasms
Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Neoplasms
Human papillomavirus 16 infection predicts poor outcome in patients with esophageal squamous cell carcinoma.
Neoplasms
Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
Neoplasms
Hyperhomocysteinemia inhibits tibial fracture healing in rats through PI3K/AKT signaling pathway.
Neoplasms
Hypoxia-induced PIM kinase and laminin-activated integrin ?6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.
Neoplasms
Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer.
Neoplasms
Icariside II ameliorates myocardial ischemia and reperfusion injury by attenuating inflammation and apoptosis through the regulation of the PI3K/AKT signaling pathway.
Neoplasms
Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway.
Neoplasms
Idelalisib impacts cell growth through inhibiting translation regulatory mechanisms in mantle cell lymphoma.
Neoplasms
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas.
Neoplasms
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Neoplasms
Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase.
Neoplasms
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
Neoplasms
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
Neoplasms
Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Neoplasms
Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt.
Neoplasms
Identification of a potent and selective phosphatidylinositol 3-kinase ? inhibitor for the treatment of non-Hodgkin's lymphoma.
Neoplasms
Identification of a subset of human non-small cell lung cancer patients with high PI3K? and low PTEN expression, more prevalent in squamous cell carcinoma.
Neoplasms
Identification of allosteric binding sites for PI3K? oncogenic mutant specific inhibitor design.
Neoplasms
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
Neoplasms
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Neoplasms
Identification of dysregulated pathways associated with pancreatic cancer by survival analysis.
Neoplasms
Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Neoplasms
Identification of ETP-46321, a potent and orally bioavailable PI3K ?, ? inhibitor.
Neoplasms
Identification of key pathways and hub genes in the myogenic differentiation of pluripotent stem cell: a bioinformatics and experimental study.
Neoplasms
Identification of MALT1 Feedback Mechanisms Enables Rational Design of Potent Anti-Lymphoma Regimens for ABC-DLBCL.
Neoplasms
Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.
Neoplasms
Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway.
Neoplasms
Identification of novel PI3K? inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Neoplasms
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.
Neoplasms
Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreenTM high-throughput screen.
Neoplasms
Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
Neoplasms
Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.
Neoplasms
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
Neoplasms
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer.
Neoplasms
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
Neoplasms
IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K/Akt1/NF-?B-p65.
Neoplasms
IL-33 suppresses GSK-3? activation through an ST2-independent MyD88/TRAF6/RIP/PI3K/Akt pathway.
Neoplasms
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.
Neoplasms
ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression.
Neoplasms
Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number Variation.
Neoplasms
Immune signaling-based Cascade Propagation approach re-stratifies HNSCC patients.
Neoplasms
Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors.
Neoplasms
Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
Neoplasms
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Neoplasms
Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
Neoplasms
Immunohistochemical study of correlation between histologic subtype and expression of epithelial-mesenchymal transition-related proteins in synovial sarcomas.
Neoplasms
Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-?+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Neoplasms
Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
Neoplasms
Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.
Neoplasms
Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.
Neoplasms
Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Neoplasms
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.
Neoplasms
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Neoplasms
Impaired caudal fin-fold regeneration in zebrafish deficient for the tumor suppressor Pten.
Neoplasms
In silico docking of phytocompounds to identify potent inhibitors of signaling pathways involved in prostate cancer.
Neoplasms
In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features.
Neoplasms
In vitro and in vivo anti-malignant melanoma activity of Alocasia cucullata via modulation of the phosphatase and tensin homolog/phosphoinositide 3-kinase/AKT pathway.
Neoplasms
In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells.
Neoplasms
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Neoplasms
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Neoplasms
In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer.
Neoplasms
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Neoplasms
In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.
Neoplasms
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.
Neoplasms
In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.
Neoplasms
Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase.
Neoplasms
Inactivation of Pten in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth.
Neoplasms
Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
Neoplasms
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Neoplasms
Increased apoptosis is associated with robust immune cell infiltration and cytolytic activity in breast cancer.
Neoplasms
Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas.
Neoplasms
Increased Expression of Phosphatidylinositol 3-Kinase p110? and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Neoplasms
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Neoplasms
Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer.
Neoplasms
Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation.
Neoplasms
Individual and combined soy isoflavones exert differential effects on metastatic cancer progression.
Neoplasms
Indole-3-carbinol inhibits cell proliferation and induces apoptosis in Hep-2 laryngeal cancer cells.
Neoplasms
Induction of apoptosis and suppression of angiogenesis of hepatocellular carcinoma by HS-159, a novel phosphatidylinositol 3-kinase inhibitor.
Neoplasms
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Neoplasms
Induction of H2AX phosphorylation in tumor cells by gossypol acetic acid is mediated by phosphatidylinositol 3-kinase (PI3K) family.
Neoplasms
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3K? inhibition through PIK3IP1.
Neoplasms
Infection with genotoxin-producing Salmonella enterica synergises with loss of the tumour suppressor APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells.
Neoplasms
Inflammation-induced GluA1 trafficking and membrane insertion of Ca(2+) permeable AMPA receptors in dorsal horn neurons is dependent on spinal tumor necrosis factor, PI3 kinase and protein kinase A.
Neoplasms
Influence and mechanism of 5-aminolevulinic acid-photodynamic therapy on the metastasis of esophageal carcinoma.
Neoplasms
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.
Neoplasms
Inhibiting effect of Endostar combined with ginsenoside Rg3 on breast cancer tumor growth in tumor-bearing mice.
Neoplasms
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Neoplasms
Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity.
Neoplasms
Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Neoplasms
Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Neoplasms
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma.
Neoplasms
Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K? inhibition through the transcriptional regulation of ER?.
Neoplasms
Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations.
Neoplasms
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Neoplasms
Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Neoplasms
Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.
Neoplasms
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Neoplasms
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Neoplasms
Inhibition of p110? PI3K prevents inflammatory response and restenosis after artery injury.
Neoplasms
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Neoplasms
Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.
Neoplasms
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Neoplasms
Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma.
Neoplasms
Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
Neoplasms
Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Neoplasms
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
Neoplasms
Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
Neoplasms
Inhibition of phosphoinositide 3-kinase is associated with reduced angiogenesis and an altered expression of angiogenic markers in endothelioma cells.
Neoplasms
Inhibition of phosphoinositide 3-kinase/Akt pathway decreases hypoxia inducible factor-1? expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells.
Neoplasms
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Neoplasms
Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors.
Neoplasms
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Neoplasms
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Neoplasms
Inhibition of PI3K Isoform p110? Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
Neoplasms
Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
Neoplasms
Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells.
Neoplasms
Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.
Neoplasms
Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma.
Neoplasms
Inhibition of PI3K? signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Neoplasms
Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer.
Neoplasms
Inhibition of the p110? isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.
Neoplasms
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Neoplasms
Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation.
Neoplasms
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.
Neoplasms
Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
Neoplasms
Inhibition of the PI 3-kinase pathway disrupts the unfolded protein response and reduces sensitivity to ER stress-dependent apoptosis.
Neoplasms
Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner.
Neoplasms
Inhibition of the PI3K/AKT Pathway Reduces Tumor Necrosis Factor-Alpha Production in the Cellular Response to Wear Particles In Vitro.
Neoplasms
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3.
Neoplasms
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
Neoplasms
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Neoplasms
Inhibitors of phosphatidylinositol 3'-kinases promote mitotic cell death in HeLa cells.
Neoplasms
Inhibitors of PI3K/ERK 1/2/p38 MAPK Show Preferential Activity Against Endocrine Resistant Breast Cancer Cells.
Neoplasms
Inhibitors of STAT3, ?-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Neoplasms
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.
Neoplasms
Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Neoplasms
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Neoplasms
Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice.
Neoplasms
Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
Neoplasms
Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549.
Neoplasms
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Neoplasms
Inosine Strongly Enhances Proliferation of Human C32 Melanoma Cells through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways.
Neoplasms
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Neoplasms
INPP4B promotes PI3K?-dependent late endosome formation and Wnt/?-catenin signaling in breast cancer.
Neoplasms
Inpp5f Is a Polyphosphoinositide Phosphatase That Regulates Cardiac Hypertrophic Responsiveness.
Neoplasms
Insight into the PTEN - p85? interaction and lipid binding properties of the p85? BH domain.
Neoplasms
Insights into the pathological mechanisms of p85? mutations using a yeast-based phosphatidylinositol 3-kinase model.
Neoplasms
Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer.
Neoplasms
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
Neoplasms
Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3? to regulate aerobic glycolysis.
Neoplasms
Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.
Neoplasms
Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3K? and PI3K? Activities and Is Promoted by RAS.
Neoplasms
Insulin-like Growth Factor Binding Protein 2 (IGFBP-2) Promotes Growth and Survival of Breast Epithelial Cells: Novel Regulation of the Estrogen Receptor.
Neoplasms
Intake of high-fat diet stimulates the risk of ultraviolet radiation-induced skin tumors and malignant progression of papillomas to carcinoma in SKH-1 hairless mice.
Neoplasms
Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability.
Neoplasms
Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development.
Neoplasms
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Neoplasms
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Neoplasms
Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.
Neoplasms
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Neoplasms
Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer.
Neoplasms
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Neoplasms
Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN.
Neoplasms
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Neoplasms
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
Neoplasms
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Neoplasms
Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival.
Neoplasms
Interactions between Ras1, dMyc, and dPI3K signaling in the developing Drosophila wing.
Neoplasms
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Neoplasms
Interleukin-10-induced gene expression and suppressive function are selectively modulated by the PI3K-Akt-GSK3 pathway.
Neoplasms
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Neoplasms
Intracellular paired agent imaging enables improved evaluation of tyrosine kinase inhibitor target engagement.
Neoplasms
Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
Neoplasms
Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor.
Neoplasms
Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer.
Neoplasms
Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: Therapeutic implications.
Neoplasms
Involvement of phosphatidylinositol 3-kinase/Akt pathway in gemcitabine-induced apoptosis-like cell death in insulinoma cell line INS-1.
Neoplasms
Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells.
Neoplasms
Iodine catalyzed three component synthesis of 1-((2-hydroxy naphthalen-1-yl)(phenyl)(methyl))pyrrolidin-2-one derivatives: Rationale as potent PI3K inhibitors and anticancer agents.
Neoplasms
IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Neoplasms
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Neoplasms
Isoliquiritigenin inhibits the proliferation, apoptosis and migration of osteosarcoma cells.
Neoplasms
Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways.
Neoplasms
Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
Neoplasms
Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets.
Neoplasms
Jiedu Sangen decoction inhibits chemoresistance to 5-fluorouracil of colorectal cancer cells by suppressing glycolysis via PI3K/AKT/HIF-1? signaling pathway.
Neoplasms
JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Neoplasms
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo.
Neoplasms
Kaposi¿s sarcoma-associated herpesvirus G-protein coupled receptor activates the canonical Wnt/ß-catenin signaling pathway.
Neoplasms
Kathon Induces Fibrotic Inflammation in Lungs: The First Animal Study Revealing a Causal Relationship between Humidifier Disinfectant Exposure and Eosinophil and Th2-Mediated Fibrosis Induction.
Neoplasms
Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Neoplasms
Key factors mediated by PI3K signaling pathway and related genes in endometrial carcinoma.
Neoplasms
Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts.
Neoplasms
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
Neoplasms
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.
Neoplasms
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.
Neoplasms
Kirenol inhibited the cell survival and induced apoptosis in human thyroid cancer cells by altering PI3K/AKT and MAP kinase signaling pathways.
Neoplasms
KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity.
Neoplasms
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.
Neoplasms
Knockdown of hTERT by siRNA inhibits cervical cancer cell growth in vitro and in vivo.
Neoplasms
Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo.
Neoplasms
KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer.
Neoplasms
Krebs medal review. How a lipid mediates tumour suppression: Delivered on 29 June 2010 at the 35th FEBS Congress in Gothenburg, Sweden.
Neoplasms
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
Neoplasms
Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation.
Neoplasms
Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation.
Neoplasms
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
Neoplasms
LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling.
Neoplasms
Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling.
Neoplasms
Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways.
Neoplasms
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Neoplasms
Linarin inhibits radiation-induced cancer invasion by downregulating MMP-9 expression via the suppression of NF-?B activation in human non-small-cell lung cancer A549.
Neoplasms
Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model.
Neoplasms
Live or let die: E2F1 and PI3K pathways intersect to make life or death decisions.
Neoplasms
lncRNA LOC102724169 plus cisplatin exhibit the synergistic anti-tumor effect in ovarian cancer with chronic stress.
Neoplasms
Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway.
Neoplasms
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Neoplasms
Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179.
Neoplasms
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.
Neoplasms
Loss of endogenous interleukin-12 activates survival signals in ultraviolet-exposed mouse skin and skin tumors.
Neoplasms
Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.
Neoplasms
Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Neoplasms
Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Neoplasms
Loss of phosphatase activity in PTEN (phosphatase and tensin homolog deleted on chromosome ten) results in endometrial carcinoma in humans: An in-silico study.
Neoplasms
Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.
Neoplasms
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib.
Neoplasms
Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Neoplasms
Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin.
Neoplasms
Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1.
Neoplasms
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Neoplasms
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Neoplasms
Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
Neoplasms
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Neoplasms
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Neoplasms
Low-dose testosterone alleviates vascular damage caused by castration in male rats in puberty via modulation of the PI3K/AKT signaling pathway.
Neoplasms
Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Neoplasms
Lowered Expression of Tumor Suppressor Candidate MYO1C Stimulates Cell Proliferation, Suppresses Cell Adhesion and Activates AKT.
Neoplasms
LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.
Neoplasms
LRP1B mutation is associated with tumor HPV status and promotes poor disease outcomes with a higher mutation count in HPV-related cervical carcinoma and head & neck squamous cell carcinoma.
Neoplasms
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
Neoplasms
LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
Neoplasms
LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity.
Neoplasms
LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Neoplasms
LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway.
Neoplasms
Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
Neoplasms
Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
Neoplasms
Macrophage migration inhibitory factor induces phosphorylation of Mdm2 mediated by phosphatidylinositol 3-kinase/Akt kinase: Role of this pathway in decidual cell survival.
Neoplasms
Macrophage PTEN regulates expression and secretion of arginase I modulating innate and adaptive immune responses.
Neoplasms
Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-?B signaling.
Neoplasms
Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition.
Neoplasms
Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells.
Neoplasms
Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Neoplasms
Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model.
Neoplasms
Management of adverse events associated with idelalisib treatment - expert panel opinion.
Neoplasms
Mapping the Germline and Somatic Mutation Interaction Landscape in Indolent and Aggressive Prostate Cancers.
Neoplasms
Markers CD40, VEGF, AKT, PI3K, and S100 Correlate with Tumor Stage in Gastric Cancer.
Neoplasms
Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.
Neoplasms
Mast cells are directly activated by contact with cancer cells by a mechanism involving autocrine formation of adenosine and autocrine/paracrine signaling of the adenosine A3 receptor.
Neoplasms
Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways.
Neoplasms
MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells.
Neoplasms
mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
Neoplasms
MDM2 regulates hypoxic hypoxia-inducible factor 1? stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
Neoplasms
Measurement of PIP3 levels reveals an unexpected role for p110? in early adaptive responses to p110?-specific inhibitors in luminal breast cancer.
Neoplasms
Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.
Neoplasms
Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks.
Neoplasms
Mechanisms behind resistance to PI3K Inhibitor treatment induced by the PIM kinase.
Neoplasms
Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling.
Neoplasms
Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets.
Neoplasms
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity.
Neoplasms
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
Neoplasms
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
Neoplasms
MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance.
Neoplasms
Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting Survivin and XIAP.
Neoplasms
Membrane androgen receptor sensitive Na(+)/H(+) exchanger activity in prostate cancer cells.
Neoplasms
MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.
Neoplasms
Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1.
Neoplasms
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
Neoplasms
Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFN? receptor signaling.
Neoplasms
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
Neoplasms
Methionine-stress: A pleiotropic approach in enhancing the efficacy of chemotherapy.
Neoplasms
Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.
Neoplasms
Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy.
Neoplasms
Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.
Neoplasms
Microarray-based identification of differentially expressed genes associated with andrographolide derivatives-induced resistance in colon and prostate cancer cell lines.
Neoplasms
Microcystin-leucine arginine exhibits immunomodulatory roles in testicular cells resulting in orchitis.
Neoplasms
MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells.
Neoplasms
MicroRNA-124-3p inhibited progression of nasopharyngeal carcinoma by interaction with PCDH8 and the inactivation of PI3K/AKT/mTOR pathway.
Neoplasms
MicroRNA-126 acts as a tumor suppressor in glioma cells by targeting insulin receptor substrate 1 (IRS-1).
Neoplasms
microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.
Neoplasms
MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/Akt signaling pathway.
Neoplasms
MicroRNA-17?92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.
Neoplasms
MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.
Neoplasms
MicroRNA-2053 overexpression inhibits the development and progression of hepatocellular carcinoma.
Neoplasms
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
Neoplasms
MicroRNA-492 expression promotes the progression of hepatic cancer by targeting PTEN.
Neoplasms
Mild chronic hypoxia-induced HIF-2? interacts with c-MYC through competition with HIF-1? to induce hepatocellular carcinoma cell proliferation.
Neoplasms
Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse.
Neoplasms
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy.
Neoplasms
MiR-126-3p-Enriched Extracellular Vesicles from Hypoxia-Preconditioned VSC 4.1 Neurons Attenuate Ischaemia-Reperfusion-Induced Pain Hypersensitivity by Regulating the PIK3R2-Mediated Pathway.
Neoplasms
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells.
Neoplasms
Mir-190b negatively contributes to the Trypanosoma cruzi- infected cell survival by repressing PTEN protein expression.
Neoplasms
miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study.
Neoplasms
miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin.
Neoplasms
MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway.
Neoplasms
MiR-374b Promotes Proliferation and Inhibits Apoptosis of Human GIST Cells by Inhibiting PTEN through Activation of the PI3K/Akt Pathway.
Neoplasms
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling.
Neoplasms
Mislocalization of the cell polarity protein Scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
Neoplasms
MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Neoplasms
Model free approach to kinetic analysis of real-time hyperpolarized (13)c magnetic resonance spectroscopy data.
Neoplasms
Modeling human disease in yeast: recreating the PI3K-PTEN-Akt signaling pathway in Saccharomyces cerevisiae.
Neoplasms
Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability.
Neoplasms
Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma.
Neoplasms
Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Neoplasms
Modulation of cell signaling pathways by Phyllanthus amarus and its major constituents: potential role in the prevention and treatment of inflammation and cancer.
Neoplasms
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
Neoplasms
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
Neoplasms
Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth.
Neoplasms
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Neoplasms
Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXR?.
Neoplasms
Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and rapamycin in thyroid cells.
Neoplasms
Modulation of the activity of certain genes involved in tumor cell metabolism in the presence of the cytotoxic peptides defensin and cathelicidin LL37.
Neoplasms
Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
Neoplasms
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Neoplasms
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation.
Neoplasms
Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer.
Neoplasms
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Neoplasms
Molecular determinants of PI3K?-mediated activation downstream of G-protein-coupled receptors (GPCRs).
Neoplasms
Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations.
Neoplasms
Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Neoplasms
Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents.
Neoplasms
Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Neoplasms
Molecular Mechanism Exploration of Potent Fluorinated PI3K Inhibitors with a Triazine Scaffold: Unveiling the Unusual Synergistic Effect of Pyridine-to-Pyrimidine Ring Interconversion and CF3 Defluorination.
Neoplasms
Molecular mechanisms of anticancer activity of deoxyelephantopin in cancer cells.
Neoplasms
Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells.
Neoplasms
Molecular Modeling, Synthesis and Biological Evaluation of N-Phenyl-4-Hydroxy-6-Methyl-2-Quinolone-3-CarboxAmides as Anticancer Agents.
Neoplasms
Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.
Neoplasms
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Neoplasms
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.
Neoplasms
Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue.
Neoplasms
Molecular Profiling Establishes Genetic Features Predictive of the Efficacy of the p110? Inhibitor KIN-193.
Neoplasms
Molecular Profiling Reveals Common and Specific Development Processes in Different Types of Gynecologic Cancers.
Neoplasms
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Neoplasms
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Neoplasms
Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy.
Neoplasms
Molybdenum disulfide-based hyaluronic acid-guided multifunctional theranostic nanoplatform for magnetic resonance imaging and synergetic chemo-photothermal therapy.
Neoplasms
Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth and Metastasis.
Neoplasms
Morphine inhibits the promotion of inflammatory microenvironment on chronic tibial cancer pain through the PI3K-Akt-NF-?B pathway.
Neoplasms
Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer.
Neoplasms
Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents.
Neoplasms
Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations.
Neoplasms
Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
Neoplasms
mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Neoplasms
mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells.
Neoplasms
mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations.
Neoplasms
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
Neoplasms
mTORC1 inhibition is required for sensitivity to PI3K p110? inhibitors in PIK3CA-mutant breast cancer.
Neoplasms
mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Neoplasms
Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy.
Neoplasms
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.
Neoplasms
Multiple defects of cell cycle checkpoints in U937-ASPI3K, an U937 cell mutant stably expressing anti-sense ATM gene cDNA.
Neoplasms
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Neoplasms
Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source.
Neoplasms
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.
Neoplasms
Murine Polyomavirus Cell Surface Receptors Activate Distinct Signaling Pathways Required for Infection.
Neoplasms
Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway.
Neoplasms
Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
Neoplasms
Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways.
Neoplasms
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
Neoplasms
Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway.
Neoplasms
Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.
Neoplasms
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
Neoplasms
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Neoplasms
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.
Neoplasms
Mutational and immunohistochemical analysis of ezrin-, radixin-, moesin (ERM) molecules in epilepsy-associated glioneuronal lesions.
Neoplasms
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Neoplasms
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Neoplasms
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
Neoplasms
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Neoplasms
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers.
Neoplasms
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Neoplasms
MYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation.
Neoplasms
MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.
Neoplasms
Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition.
Neoplasms
Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma.
Neoplasms
Myristoylated p110? Causes Embryonic Death Due to Developmental and Vascular Defects.
Neoplasms
Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance.
Neoplasms
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis.
Neoplasms
Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.
Neoplasms
Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.
Neoplasms
Natural forms of vitamin E and metabolites-regulation of cancer cell death and underlying mechanisms.
Neoplasms
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Neoplasms
Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia.
Neoplasms
Nedd4-dependent lysine-11-linked polyubiquitination of the tumour suppressor Beclin 1.
Neoplasms
NEDD4L Protein Catalyzes Ubiquitination of PIK3CA Protein and Regulates PI3K-AKT Signaling.
Neoplasms
Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells).
Neoplasms
Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
Neoplasms
Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation.
Neoplasms
Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice.
Neoplasms
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Neoplasms
Nerve growth factor protects oligodendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms.
Neoplasms
Network Pharmacology Analysis of Traditional Chinese Medicine Formula Xiao Ke Yin Shui Treating Type 2 Diabetes Mellitus.
Neoplasms
Network Pharmacology-Based Study on the Mechanism of Bushen-Jianpi Decoction in Liver Cancer Treatment.
Neoplasms
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.
Neoplasms
Neurofibromatosis-like phenotype in Drosophila caused by lack of glucosylceramide extension.
Neoplasms
New Insights into PI3K Inhibitor Design using X-ray Structures of PI3K? Complexed with a Potent Lead Compound.
Neoplasms
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Neoplasms
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi.
Neoplasms
Next generation sequencing of progressive colorectal liver metastases after portal vein embolization.
Neoplasms
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Neoplasms
Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Neoplasms
Nicotine Stimulated Dendritic Cells Could Achieve Anti-Tumor Effects in Mouse Lung and Liver Cancer.
Neoplasms
Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation.
Neoplasms
NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation.
Neoplasms
Nobiletin Inhibits Helicobacterium pylori Infection-Induced Gastric Carcinogenic Signaling by Blocking Inflammation, Apoptosis, and Mitogen-Activated Protein Kinase Events in Gastric Epithelial-1 Cells.
Neoplasms
Non-coding RNAs in Wilms' tumor: biological function, mechanism, and clinical implications.
Neoplasms
Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Neoplasms
Non-invasive (89)Zr-Transferrin PET Shows Improved Tumor Targeting Compared to (18)F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer.
Neoplasms
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Neoplasms
Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.
Neoplasms
Nongenomic effects of thyroid hormones on the immune system cells: New targets, old players.
Neoplasms
Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-Cadherin Expression.
Neoplasms
Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3K? inhibition.
Neoplasms
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Neoplasms
Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.
Neoplasms
Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.
Neoplasms
Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors.
Neoplasms
Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.
Neoplasms
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
Neoplasms
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.
Neoplasms
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Neoplasms
Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy.
Neoplasms
Novel strategy in breast cancer therapy: Revealing the bright side of ginsenosides.
Neoplasms
Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Neoplasms
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo.
Neoplasms
Nuclear accumulation of ?-catenin and forkhead box O3a in colon cancer: Dangerous liaison.
Neoplasms
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Neoplasms
Nuclear PTEN interferes with binding of Ku70 at double-strand breaks through post-translational poly(ADP-ribosyl)ation.
Neoplasms
Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
Neoplasms
Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival.
Neoplasms
Nutrient restriction enhances the proliferative potential of cells lacking the tumor suppressor PTEN in mitotic tissues.
Neoplasms
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
Neoplasms
NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells.
Neoplasms
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Neoplasms
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Neoplasms
Obesity and Obese-related Chronic Low-grade Inflammation in Promotion of Colorectal Cancer Development.
Neoplasms
Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors.
Neoplasms
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Neoplasms
Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.
Neoplasms
Oncogenic activation of the PI3-kinase p110? isoform via the tumor-derived PIK3C?(D1067V) kinase domain mutation.
Neoplasms
Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking.
Neoplasms
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Neoplasms
Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor.
Neoplasms
Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.
Neoplasms
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
Neoplasms
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.
Neoplasms
Oncogenic met receptor induces cell-cycle progression in Xenopus oocytes independent of direct Grb2 and Shc binding or mos synthesis, but requires phosphatidylinositol 3-kinase and raf signaling.
Neoplasms
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.
Neoplasms
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
Neoplasms
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
Neoplasms
Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Neoplasms
Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway.
Neoplasms
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Neoplasms
Only a subset of Met-activated pathways are required to sustain oncogene addiction.
Neoplasms
Only a subset of met-activated pathways are required to sustain oncogene addiction.
Neoplasms
Opposing roles of the two isoforms of ErbB3 binding protein 1 in human cancer cells.
Neoplasms
Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Neoplasms
Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Neoplasms
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
Neoplasms
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Neoplasms
Ovatodiolide Suppresses Oral Cancer Malignancy by Down-Regulating Exosomal Mir-21/STAT3/?-Catenin Cargo and Preventing Oncogenic Transformation of Normal Gingival Fibroblasts.
Neoplasms
Overexpression of 14-3-3? in cancer cells activates PI3K via binding the p85 regulatory subunit.
Neoplasms
Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
Neoplasms
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Neoplasms
Overexpression of DJ-1 and HSP90?, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers.
Neoplasms
Overexpression of Long Noncoding RNA H19 Downregulates miR-140-5p and Activates PI3K/AKT Signaling Pathway to Promote Invasion, Migration and Epithelial-Mesenchymal Transition of Ovarian Cancer Cells.
Neoplasms
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Neoplasms
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Neoplasms
Overexpression of Suppressor of Cytokine Signaling 3 in Adipose Tissue Causes Local but Not Systemic Insulin Resistance.
Neoplasms
Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells.
Neoplasms
Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition.
Neoplasms
Oxytocin effects on the inhibition of the NF-?B/miR195 pathway in mice breast cancer.
Neoplasms
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
Neoplasms
P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.
Neoplasms
p110? and p110? isoforms of PI3K are involved in protection against H2O2 induced oxidative stress in cancer cells.
Neoplasms
p110? deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.
Neoplasms
p120-Catenin Downregulation and PIK3CA Mutations Cooperate to Induce Invasion through MMP1 in HNSCC.
Neoplasms
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K? inhibitor idelalisib.
Neoplasms
p37? is a new isoform of PI3K p110? that increases cell proliferation and is overexpressed in tumors.
Neoplasms
P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP.
Neoplasms
P450-mediated O-demethylated metabolite is responsible for rat hepatobiliary toxicity of pyridyltriazine-containing PI3K inhibitors.
Neoplasms
p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression.
Neoplasms
p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-?B pathway.
Neoplasms
p85alpha acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation.
Neoplasms
Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.
Neoplasms
Pan-Cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many Cancers.
Neoplasms
Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Neoplasms
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
Neoplasms
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Neoplasms
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase ? Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
Neoplasms
Parsaclisib, a potent and highly selective PI3K? inhibitor, in patients with relapsed or refractory B-cell malignancies.
Neoplasms
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Neoplasms
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Neoplasms
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Neoplasms
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway.
Neoplasms
Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.
Neoplasms
Peroxiredoxin 1 silencing inhibited the growth and promoted apoptosis of pancreatic cancer cells via targeting FOXO3 gene.
Neoplasms
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Neoplasms
Perspective: Potential Impact and Therapeutic Implications of Oncogenic PI3K Activation on Chromosomal Instability.
Neoplasms
PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells.
Neoplasms
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Neoplasms
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Neoplasms
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Neoplasms
Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.
Neoplasms
Pharmacological inactivation of the PI3K p110? prevents breast tumour progression by targeting cancer cells and macrophages.
Neoplasms
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Neoplasms
Phase 1 clinical trial of the PI3K? inhibitor YY-20394 in patients with B-cell hematological malignancies.
Neoplasms
Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Neoplasms
Phase 1 study of the PI3K? inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Neoplasms
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Neoplasms
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Neoplasms
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Neoplasms
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Neoplasms
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Neoplasms
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Neoplasms
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Neoplasms
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Neoplasms
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors.
Neoplasms
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Neoplasms
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Neoplasms
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Neoplasms
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Neoplasms
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors.
Neoplasms
Phase I study of alpelisib (BYL719), an ?-specific PI3K inhibitor, in Japanese patients with advanced solid tumors.
Neoplasms
Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers.
Neoplasms
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Neoplasms
Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.
Neoplasms
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies.
Neoplasms
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Neoplasms
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Neoplasms
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Neoplasms
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Neoplasms
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Neoplasms
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Neoplasms
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Neoplasms
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Neoplasms
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.
Neoplasms
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Neoplasms
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Neoplasms
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Neoplasms
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.
Neoplasms
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Neoplasms
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Neoplasms
PHLDA2 regulates EMT and autophagy in colorectal cancer via the PI3K/AKT signaling pathway.
Neoplasms
Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration.
Neoplasms
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Neoplasms
Phosphatidylinositol 3-kinase (PI3K) signaling does not activate the Wnt cascade.
Neoplasms
Phosphatidylinositol 3-kinase ? and ? isoforms play key roles in metastasis of prostate cancer DU145 cells.
Neoplasms
Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Neoplasms
Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.
Neoplasms
Phosphatidylinositol 3-kinase affects mitochondrial function in part through inducing peroxisome proliferator-activated receptor ? coactivator-1? expression.
Neoplasms
Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter.
Neoplasms
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
Neoplasms
Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.
Neoplasms
Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes.
Neoplasms
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Neoplasms
Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.
Neoplasms
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.
Neoplasms
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
Neoplasms
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
Neoplasms
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Neoplasms
Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Neoplasms
Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells.
Neoplasms
Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer.
Neoplasms
Phosphatidylinositol 3-kinase signaling and immune regulation: insights into disease pathogenesis and clinical implications.
Neoplasms
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.
Neoplasms
Phosphatidylinositol 3-kinase translocates to the nucleus of osteoblast-like MC3T3-E1 cells in response to insulin-like growth factor I and platelet-derived growth factor but not to the proapoptotic cytokine tumor necrosis factor alpha.
Neoplasms
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis.
Neoplasms
Phosphatidylinositol 3-kinase/Akt activation by integrin-tumor matrix interaction suppresses Fas-mediated apoptosis in T cells.
Neoplasms
Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation.
Neoplasms
Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations.
Neoplasms
Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
Neoplasms
Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.
Neoplasms
Phosphatidylinositol Phosphate 5-Kinase I? and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth.
Neoplasms
Phosphatidylinositol-3 kinase p85 enhances expression from the myelin basic protein promoter in oligodendrocytes.
Neoplasms
Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes.
Neoplasms
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Neoplasms
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Neoplasms
Phosphatidylinositol-3-Kinase-AKT Pathway, Phospho-JUN and Phospho-JNK Expression in Spontaneously Arising Bovine Urinary Bladder Tumours.
Neoplasms
Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer.
Neoplasms
Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy.
Neoplasms
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Neoplasms
Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia..
Neoplasms
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Neoplasms
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Neoplasms
Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy.
Neoplasms
Phosphoinositide 3-kinase controls early and late events in mammalian cell division.
Neoplasms
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth.
Neoplasms
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Neoplasms
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Neoplasms
Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
Neoplasms
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Neoplasms
Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry.
Neoplasms
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Neoplasms
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
Neoplasms
Phosphoinositide 3-kinase signaling pathway mediated by p110? regulates invadopodia formation.
Neoplasms
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Neoplasms
Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.
Neoplasms
Phosphoinositide 3-kinase-related overgrowth: cellular phenotype and future therapeutic options.
Neoplasms
Phosphoinositide 3?kinase/protein kinase B regulates inflammation severity via signaling of Toll?like receptor 4 in severe acute pancreatitis.
Neoplasms
Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer.
Neoplasms
Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Neoplasms
Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells.
Neoplasms
Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition.
Neoplasms
Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate.
Neoplasms
Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44.
Neoplasms
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Neoplasms
Phosphorylated T567 ezrin is associated with merlin expression in KIT-mutant gastrointestinal stromal tumors.
Neoplasms
Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion.
Neoplasms
Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.
Neoplasms
Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
Neoplasms
PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS.
Neoplasms
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
Neoplasms
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells.
Neoplasms
PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Neoplasms
PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
Neoplasms
PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
Neoplasms
PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis.
Neoplasms
PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL.
Neoplasms
PI3K abrogation using pan PI3K inhibitor BKM120 give rise to a weighty anti-cancer effect on AML-derived KG-1 cells by inducing apoptosis and G2/M arrest
Neoplasms
PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.
Neoplasms
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
Neoplasms
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
Neoplasms
PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
Neoplasms
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.
Neoplasms
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
Neoplasms
PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment.
Neoplasms
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Neoplasms
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Neoplasms
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.
Neoplasms
PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
Neoplasms
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Neoplasms
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Neoplasms
PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy.
Neoplasms
PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Neoplasms
PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/?-catenin signaling pathway.
Neoplasms
PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
Neoplasms
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Neoplasms
PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine.
Neoplasms
PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235.
Neoplasms
PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation.
Neoplasms
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Neoplasms
PI3K mediates tumor necrosis factor induced-necroptosis through initiating RIP1-RIP3-MLKL signaling pathway activation.
Neoplasms
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Neoplasms
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
Neoplasms
PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.
Neoplasms
PI3K p110? isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
Neoplasms
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
Neoplasms
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers.
Neoplasms
PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia.
Neoplasms
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer.
Neoplasms
PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells.
Neoplasms
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.
Neoplasms
PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation.
Neoplasms
PI3K regulates intraepithelial cell positioning through Rho GTP-ases in the developing neural tube.
Neoplasms
PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells.
Neoplasms
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
Neoplasms
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
Neoplasms
PI3K target based novel cyano derivative of betulinic acid induces its signalling inhibition by down-regulation of pGSK3? and cyclin D1 and potentially checks cancer cell proliferation.
Neoplasms
PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer.
Neoplasms
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Neoplasms
PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics.
Neoplasms
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
Neoplasms
PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.
Neoplasms
PI3K-p110? mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85?.
Neoplasms
PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells.
Neoplasms
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.
Neoplasms
PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines.
Neoplasms
PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Neoplasms
PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells.
Neoplasms
PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
Neoplasms
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches.
Neoplasms
PI3K/AKT signaling is essential for communication between tissue infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
Neoplasms
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Neoplasms
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Neoplasms
PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic colorectal cancer.
Neoplasms
PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Neoplasms
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases.
Neoplasms
PI3K? inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Neoplasms
PI3K? inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism.
Neoplasms
PI3K? is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart.
Neoplasms
PI3K?/? inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.
Neoplasms
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Neoplasms
Pieces of the complex puzzle of cancer cell energy metabolism: an overview of energy metabolism and alternatives for targeted cancer therapy.
Neoplasms
PIK3C3 Acts as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and Was Regulated by MiR-340-5p.
Neoplasms
PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells.
Neoplasms
PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor.
Neoplasms
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Neoplasms
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Neoplasms
PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System.
Neoplasms
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Neoplasms
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.
Neoplasms
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Neoplasms
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
Neoplasms
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
Neoplasms
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Neoplasms
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Neoplasms
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
Neoplasms
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Neoplasms
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Neoplasms
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Neoplasms
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
Neoplasms
PIK3CA is critical for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells.
Neoplasms
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Neoplasms
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Neoplasms
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Neoplasms
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
Neoplasms
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
Neoplasms
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Neoplasms
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Neoplasms
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Neoplasms
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
Neoplasms
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
Neoplasms
PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
Neoplasms
PIK3CA, a hotspot for postzygotic mutations in nonhereditary overgrowth syndromes.
Neoplasms
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
Neoplasms
PIK3R1 (p85-alpha/p85{alpha}) is Somatically Mutated at High Frequency in Primary Endometrial Cancer.
Neoplasms
PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer.
Neoplasms
PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.
Neoplasms
PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition.
Neoplasms
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.
Neoplasms
Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers.
Neoplasms
Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer.
Neoplasms
Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent.
Neoplasms
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Neoplasms
Pivotal role of Pten in the balance between proliferation and differentiation of hematopoietic stem cells in zebrafish.
Neoplasms
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
Neoplasms
PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase.
Neoplasms
Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation.
Neoplasms
Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling.
Neoplasms
Plk1 phosphorylates PTEN and regulates its mitotic activity during the cell cycle.
Neoplasms
Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
Neoplasms
Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.
Neoplasms
Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer.
Neoplasms
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Neoplasms
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
Neoplasms
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Neoplasms
Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells.
Neoplasms
pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation.
Neoplasms
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
Neoplasms
Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human.
Neoplasms
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Neoplasms
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
Neoplasms
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.
Neoplasms
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.
Neoplasms
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
Neoplasms
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Neoplasms
Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer.
Neoplasms
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Neoplasms
Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019.
Neoplasms
Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
Neoplasms
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.
Neoplasms
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors.
Neoplasms
Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study.
Neoplasms
Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations.
Neoplasms
Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.
Neoplasms
Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
Neoplasms
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Neoplasms
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Neoplasms
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Neoplasms
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Neoplasms
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
Neoplasms
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.
Neoplasms
Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.
Neoplasms
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Neoplasms
Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity.
Neoplasms
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
Neoplasms
Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3?/?-catenin signalling.
Neoplasms
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.
Neoplasms
Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation.
Neoplasms
Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling.
Neoplasms
Pronounced induction of endoplasmic reticulum stress and tumor suppression by surfactant-free poly(lactic-co-glycolic acid) nanoparticles via modulation of the PI3K signaling pathway.
Neoplasms
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Neoplasms
Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
Neoplasms
Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.
Neoplasms
Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.
Neoplasms
Protein kinase B phosphorylation correlates with vascular endothelial growth factor a and microvessel density in gastric adenocarcinoma.
Neoplasms
Protein kinase C ? regulates survivin expression and inhibits apoptosis in colon cancer.
Neoplasms
Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.
Neoplasms
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Neoplasms
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.
Neoplasms
Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells.
Neoplasms
PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the ?-catenin signaling pathway.
Neoplasms
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition.
Neoplasms
PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
Neoplasms
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.
Neoplasms
PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Neoplasms
PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Neoplasms
PTEN deletion potentiates invasion of colorectal cancer spheroidal cells through 3D Matrigel.
Neoplasms
PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.
Neoplasms
PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.
Neoplasms
PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
Neoplasms
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Neoplasms
PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model.
Neoplasms
PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.
Neoplasms
PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway.
Neoplasms
Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma.
Neoplasms
PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.
Neoplasms
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Neoplasms
PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects.
Neoplasms
PTEN on Chromosome 10 Is Phosphorylated in Primary Effusion Lymphoma and Kaposi's Sarcoma.
Neoplasms
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
Neoplasms
PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells: PTEN regulates angiogenesis in HepG2.
Neoplasms
PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3? signaling pathway in DMH induced early colon carcinogenesis in rat.
Neoplasms
PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a).
Neoplasms
PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex.
Neoplasms
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.
Neoplasms
PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Neoplasms
PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
Neoplasms
Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells.
Neoplasms
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation.
Neoplasms
PWT-458, A Novel Pegylated-17-Hydroxywortmannin, Inhibits Phosphatidylinositol 3-Kinase Signaling and Suppresses Growth of Solid Tumors.
Neoplasms
Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode.
Neoplasms
Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors.
Neoplasms
Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer.
Neoplasms
Quantitative phosphoproteomics reveals Wee1 kinase as a therapeutic target in a model of proneural glioblastoma.
Neoplasms
Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.
Neoplasms
Quantitative redox imaging biomarkers for studying tissue metabolic state and its heterogeneity.
Neoplasms
Quercetin Regresses Dalton's Lymphoma Growth via Suppression of PI3K/AKT Signaling Leading to Upregulation of p53 and Decrease in Energy Metabolism.
Neoplasms
Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
Neoplasms
Rac is activated by tumor necrosis factor alpha and is involved in activation of Erk.
Neoplasms
Rac1-mediated membrane raft localization of PI3K/p110? is required for its activation by GPCRs or PTEN loss.
Neoplasms
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
Neoplasms
Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition.
Neoplasms
RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation.
Neoplasms
RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK.
Neoplasms
Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
Neoplasms
Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Neoplasms
Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Neoplasms
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Neoplasms
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling.
Neoplasms
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.
Neoplasms
Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.
Neoplasms
RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms.
Neoplasms
Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins.
Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Neoplasms
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Neoplasms
Ras-related C3 Botulinum Toxin Substrate (Rac) and Src Family Kinases (SFK) Are Proximal and Essential for Phosphatidylinositol 3-Kinase (PI3K) Activation in Natural Killer (NK) Cell-mediated Direct Cytotoxicity against Cryptococcus neoformans.
Neoplasms
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.
Neoplasms
Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.
Neoplasms
Rational Design of Novel Phosphoinositide 3-Kinase Gamma (PI3K?) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.
Neoplasms
Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.
Neoplasms
RB independent G1-phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor and histone deacetylase inhibitor.
Neoplasms
RCE?4, a potential anti?cervical cancer drug isolated from Reineckia carnea, induces autophagy via the dual blockade of PI3K and ERK pathways in cervical cancer CaSki cells.
Neoplasms
Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects.
Neoplasms
Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth.
Neoplasms
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.
Neoplasms
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Neoplasms
Recent Development in Targeting PI3K-Akt-Mtor Signaling for Anticancer Therapeutic Strategies.
Neoplasms
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Neoplasms
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Neoplasms
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Neoplasms
Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.
Neoplasms
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Neoplasms
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
Neoplasms
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Neoplasms
Recurrent prognostic factors and expression of GLUT-1, PI3K and p-Akt in adenoid cystic carcinomas of the head and neck: Clinicopathological features and biomarkers of adenoid cystic carcinoma.
Neoplasms
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
Neoplasms
Regulation and signaling of human bombesin receptors and their biological effects.
Neoplasms
Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
Neoplasms
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Neoplasms
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment.
Neoplasms
Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains.
Neoplasms
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway.
Neoplasms
Regulation of nuclear factor kappa B transactivation. Implication of phosphatidylinositol 3-kinase and protein kinase C zeta in c-Rel activation by tumor necrosis factor alpha.
Neoplasms
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.
Neoplasms
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Neoplasms
Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD.
Neoplasms
Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition.
Neoplasms
Regulation of SHP2 by PTEN/AKT/GSK-3? signaling facilitates IFN-? resistance in hyperproliferating gastric cancer.
Neoplasms
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
Neoplasms
Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy.
Neoplasms
Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery.
Neoplasms
Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.
Neoplasms
Requirement for Ras and phosphatidylinositol 3-kinase signaling uncouples the glucocorticoid-induced junctional organization and transepithelial electrical resistance in mammary tumor cells.
Neoplasms
Research on protective mechanism of ibuprofen in myocardial ischemia-reperfusion injury in rats through the PI3K/Akt/mTOR signaling pathway.
Neoplasms
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Neoplasms
Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy.
Neoplasms
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Neoplasms
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Neoplasms
Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice.
Neoplasms
Resveratrol mediated cell death in cigarette smoke transformed breast epithelial cells is through induction of p21Waf1/Cip1 and inhibition of long patch base excision repair pathway.
Neoplasms
Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.
Neoplasms
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.
Neoplasms
Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach.
Neoplasms
Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059.
Neoplasms
Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers.
Neoplasms
Review: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.
Neoplasms
RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling.
Neoplasms
RhoC Mediates Epidermal Growth Factor-Stimulated Migration and Invasion in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-?B signaling pathways.
Neoplasms
RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF-{kappa}B-Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN.
Neoplasms
RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells.
Neoplasms
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
Neoplasms
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Neoplasms
Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression.
Neoplasms
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Neoplasms
Role of estrogen in lung cancer based on the estrogen receptor-epithelial mesenchymal transduction signaling pathways.
Neoplasms
Role of phosphatidylinositol signaling pathway in the development of cross-resistance of tumor cells to hormonal cytostatics and hypoxia.
Neoplasms
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.
Neoplasms
Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion.
Neoplasms
Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation.
Neoplasms
Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle.
Neoplasms
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Neoplasms
Role of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in the secretion of tumor necrosis factor-alpha and interleukin-10 by the PPD antigen of Mycobacterium tuberculosis.
Neoplasms
Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Neoplasms
Roles of ERK, PI3 kinase, and PLC-gamma pathways induced by overexpression of translationally controlled tumor protein in HeLa cells.
Neoplasms
Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Neoplasms
Roles of phosphatidylinositol 3-kinase and Rac in the nuclear signaling by tumor necrosis factor-alpha in rat-2 fibroblasts.
Neoplasms
Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression.
Neoplasms
Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.
Neoplasms
Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.
Neoplasms
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
Neoplasms
Romidepsin (FK228) and its analogs directly inhibit PI3K activity and potently induce apoptosis as HDAC/PI3K dual inhibitors.
Neoplasms
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.
Neoplasms
S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Neoplasms
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Neoplasms
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Neoplasms
Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110?, Following Single Ascending Dose Administration to Healthy Volunteers.
Neoplasms
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.
Neoplasms
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Neoplasms
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Neoplasms
Salidroside Mitigates Sepsis-Induced Myocarditis in Rats by Regulating IGF-1/PI3K/Akt/GSK-3? Signaling.
Neoplasms
SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis.
Neoplasms
SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells.
Neoplasms
Science Signaling Podcast for 21 February 2017: Pentraxin-3 in basal-like breast cancer.
Neoplasms
Sclerosing Polycystic "Adenosis" of Salivary Glands: A Neoplasm Characterized by PI3K Pathway Alterations More Correctly Named Sclerosing Polycystic Adenoma.
Neoplasms
Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity.
Neoplasms
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.
Neoplasms
Scutellarin Inhibits the Growth and EMT of Gastric Cancer Cells through Regulating PTEN/PI3K Pathway.
Neoplasms
Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro.
Neoplasms
Secretin Receptor Promotes the Proliferation of Endocrine Tumor Cells Via the PI3K/AKT Pathway.
Neoplasms
SECTM1 Produced by Tumor Cells Attracts Human Monocytes via CD7-Mediated Activation of the PI3K Pathway.
Neoplasms
Seeking out the sweet spot in cancer therapeutics: an interview with Lewis Cantley.
Neoplasms
Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511.
Neoplasms
Selective Inhibition of Phosphoinositide 3-Kinase p110? Preserves Lymphocyte Function.
Neoplasms
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Neoplasms
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.
Neoplasms
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Neoplasms
Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein.
Neoplasms
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Neoplasms
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils.
Neoplasms
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Neoplasms
SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance.
Neoplasms
SGK2 is overexpressed in colon cancer and promotes epithelial-mesenchymal transition in colon cancer cells.
Neoplasms
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report.
Neoplasms
Shen-Yuan-Dan Capsule Inhibiting Inflammatory Reaction by Regulating Insulin Receptor Substrate 1/PI3K/Akt/NF-?B Signaling Pathway in Apoliprotein E Knockout Mice Fed with a High-Fat Diet.
Neoplasms
Shiga toxin 1-induced proinflammatory cytokine production is regulated by the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway.
Neoplasms
Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin ?1 expression and the ERK1/2 signaling pathway.
Neoplasms
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.
Neoplasms
Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-?B Pathway Activity: A Novel Approach to a Long-Standing Enigma.
Neoplasms
Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase.
Neoplasms
Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
Neoplasms
Signaling pathways responsible for cancer cell invasion as targets for cancer therapy.
Neoplasms
Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.
Neoplasms
Signals Controlling Un-Differentiated States in Embryonic Stem and Cancer Cells: Role of the Phosphatidylinositol 3' Kinase Pathway.
Neoplasms
Significance of p85 expression as a prognostic factor for patients with breast cancer.
Neoplasms
Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.
Neoplasms
Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Neoplasms
Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways.
Neoplasms
Simultaneous Inhibition of EGFR and PI3K Enhances Radiosensitivity In Human Breast Cancer.
Neoplasms
Simultaneous inhibition of Vps34 kinase would enhance PI3K? inhibitor cytotoxicity in the B-cell malignancies.
Neoplasms
Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Neoplasms
Single-cell resolved imaging reveals intra-tumor heterogeneity in glycolysis, transitions between metabolic states, and their regulatory mechanisms.
Neoplasms
siRNA Knockdown of REDD1 Facilitates Aspirin-Mediated Dephosphorylation of mTORC1 Target 4E-BP1 in MDA-MB-468 Human Breast Cancer Cell Line.
Neoplasms
Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin.
Neoplasms
SIRT4 suppresses the PI3K/Akt/NF??B signaling pathway and attenuates HUVEC injury induced by oxLDL.
Neoplasms
SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.
Neoplasms
Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers.
Neoplasms
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Neoplasms
Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
Neoplasms
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Neoplasms
Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.
Neoplasms
Soluble klotho binds monosialoganglioside to regulate membrane microdomains and growth factor signaling.
Neoplasms
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Neoplasms
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Neoplasms
Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Further Options for an Orphan Cancer.
Neoplasms
Sorafenib/Regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Neoplasms
SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2.
Neoplasms
Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
Neoplasms
Specific inhibition of PI3K p110? inhibits CSF-1-induced macrophage spreading and invasive capacity.
Neoplasms
Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target.
Neoplasms
Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
Neoplasms
SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis.
Neoplasms
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
Neoplasms
Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment.
Neoplasms
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
Neoplasms
Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.
Neoplasms
Statistical method on nonrandom clustering with application to somatic mutations in cancer.
Neoplasms
Stem cell factor (SCF)-kit mediated phosphatidylinositol 3 (PI3) kinase signaling during mammalian oocyte growth and early follicular development.
Neoplasms
Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Neoplasms
Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.
Neoplasms
Structural analysis of a glucoglucuronan derived from laminarin and the mechanisms of its anti-lung cancer activity.
Neoplasms
Structural Insights into the Interactions of Digoxin and Na+/K+-ATPase and Other Targets for the Inhibition of Cancer Cell Proliferation.
Neoplasms
Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.
Neoplasms
Structure, function and inhibition of the phosphoinositide 3-kinase p110? enzyme.
Neoplasms
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.
Neoplasms
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Neoplasms
Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
Neoplasms
Study on the anti-hepatocarcinoma effect and molecular mechanism of Prunella vulgaris total flavonoids.
Neoplasms
STYK1 promotes autophagy through enhancing the assembly of autophagy-specific class III phosphatidylinositol 3-kinase complex I.
Neoplasms
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Neoplasms
Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN.
Neoplasms
Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model.
Neoplasms
Suppression of cell migration by phospholipase C-related catalytically inactive protein-dependent modulation of PI3K signalling.
Neoplasms
Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras.
Neoplasms
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Neoplasms
Suppression of phospho-p85?-GTP-Rac1 lipid raft interaction by bichalcone analog attenuates cancer cell invasion.
Neoplasms
Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002.
Neoplasms
Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling.
Neoplasms
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.
Neoplasms
Survival pathways regulating the apoptosis induced by tumour necrosis factor-alpha in primary cultured bovine endothelial cells.
Neoplasms
Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines.
Neoplasms
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Neoplasms
Synergism between altered cortical polarity and the PI3K/TOR pathway in the suppression of tumour growth.
Neoplasms
Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Neoplasms
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
Neoplasms
Synergistic induction of cancer cell migration regulated by G?? and phosphatidylinositol 3-kinase.
Neoplasms
Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.
Neoplasms
Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002.
Neoplasms
Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.
Neoplasms
Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3K? inhibitors.
Neoplasms
Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K? inhibitors.
Neoplasms
Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K?-specific inhibitors for the treatment of hematologic malignancies.
Neoplasms
Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors.
Neoplasms
Synthesis and Characterization of a Novel Prostate Cancer-Targeted Phosphatidylinositol-3-kinase Inhibitor Prodrug.
Neoplasms
Synthesis and evaluation of pyrrolotriazine based molecules as PI3 kinase inhibitors.
Neoplasms
Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors.
Neoplasms
Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
Neoplasms
Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3K? H1047R mutant inhibitors.
Neoplasms
Synthetic Lethality in PTEN-mutant Prostate Cancer is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.
Neoplasms
Synthetic peptides containing ITIM-like domains block expression of inflammatory mediators and migration/invasion of cancer cells through activation of SHP-1 and PI3K.
Neoplasms
Systematic functional characterization of resistance to PI3K inhibition in breast cancer.
Neoplasms
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
Neoplasms
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K? inhibition in head and neck squamous cell carcinoma.
Neoplasms
Tankyrase Inhibition Blocks Wnt/?-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Neoplasms
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
Neoplasms
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Neoplasms
Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Neoplasms
Targeted inhibition of phosphatidyl inositol-3-kinase p110?, but not p110?, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Neoplasms
Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression.
Neoplasms
Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
Neoplasms
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Neoplasms
Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells.
Neoplasms
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Neoplasms
Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Neoplasms
Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells.
Neoplasms
Targeting B cell receptor signalling in cancer: preclinical and clinical advances.
Neoplasms
Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K?/? Inhibitor RP6530.
Neoplasms
Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.
Neoplasms
Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma.
Neoplasms
Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Neoplasms
Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Neoplasms
Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
Neoplasms
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Neoplasms
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Neoplasms
Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment.
Neoplasms
Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110? inhibition.
Neoplasms
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
Neoplasms
Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
Neoplasms
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.
Neoplasms
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Neoplasms
Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth.
Neoplasms
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Neoplasms
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.
Neoplasms
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Neoplasms
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Neoplasms
Targeting the Autophagy Specific Lipid Kinase VPS34 for Cancer Treatment: An Integrative Repurposing Strategy.
Neoplasms
Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.
Neoplasms
Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
Neoplasms
Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition.
Neoplasms
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
Neoplasms
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Neoplasms
Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promise.
Neoplasms
Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
Neoplasms
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Neoplasms
Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
Neoplasms
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Neoplasms
Targeting the PI3K-AKT-mTOR Pathway in Castration Resistant Prostate Cancer: A Review Article.
Neoplasms
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Neoplasms
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
Neoplasms
Targeting the protein-protein interaction between IRS1 and mutant p110? for cancer therapy.
Neoplasms
Targetome Analysis Revealed Involvement of MiR-126 in Neurotrophin Signaling Pathway: A Possible Role in Prevention of Glioma Development.
Neoplasms
TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells.
Neoplasms
Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells.
Neoplasms
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Neoplasms
TGF-? promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85?.
Neoplasms
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
Neoplasms
The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.
Neoplasms
The Adherens Junction Protein Afadin Is an AKT Substrate that Regulates Breast Cancer Cell Migration.
Neoplasms
The adhesion of anti-CD3-activated mouse T cells to syngeneic colon adenocarcinoma cells is differentially regulated by protein tyrosine kinase-, protein kinase C-, and cAMP-dependent pathways in the effector cell.
Neoplasms
The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.
Neoplasms
The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor.
Neoplasms
The Androgen Receptor Induces Integrin {alpha}6{beta}1 to Promote Prostate Tumor Cell Survival via NF-{kappa}B and Bcl-xL Independently of PI3K Signaling.
Neoplasms
The anti-tumor effect of taxifolin on lung cancer via suppressing stemness and epithelial-mesenchymal transition in vitro and oncogenesis in nude mice.
Neoplasms
The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
Neoplasms
The Antitumor Effect of Xihuang Pill on Treg Cells Decreased in Tumor Microenvironment of 4T1 Breast Tumor-Bearing Mice by PI3K/AKT~AP-1 Signaling Pathway.
Neoplasms
The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2?×?2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
Neoplasms
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.
Neoplasms
The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population.
Neoplasms
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Neoplasms
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Neoplasms
The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
Neoplasms
The Class I PI3K inhibitor S14161 induces autophagy in malignant blood cells by modulating the Beclin 1/Vps34 complex.
Neoplasms
The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention.
Neoplasms
The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in Drosophila.
Neoplasms
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Neoplasms
The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
Neoplasms
The Comparison of RhoC and PI3K Gene Expression on the Breast Cancer Tissue and Benign Tumour Tissue.
Neoplasms
The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase ?
Neoplasms
The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Neoplasms
The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
Neoplasms
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Neoplasms
The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2(+/-) mice through suppression of cell proliferation and induction of apoptosis.
Neoplasms
The dual PI3K?/CK1? inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
Neoplasms
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Neoplasms
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Neoplasms
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Neoplasms
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Neoplasms
The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways.
Neoplasms
The Essential Role of Phosphoinositide 3-Kinases (PI3Ks) in Regulating Pro-Inflammatory Responses and the Progression of Cancer.
Neoplasms
The Evolutionarily Conserved Domain of Beclin 1 is Required for Vps34 Binding, Autophagy and Tumor Suppressor Function.
Neoplasms
The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism.
Neoplasms
The functions of Atg8-family proteins in autophagy and cancer: linked or unrelated?
Neoplasms
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
Neoplasms
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Neoplasms
The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma.
Neoplasms
The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis.
Neoplasms
The genomic architecture of EBV and infected gastric tissue from precursor lesions to carcinoma.
Neoplasms
The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells.
Neoplasms
The hexosamine biosynthesis pathway and O-GlcNAcylation maintain insulin-stimulated PI3K-PKB phosphorylation and tumour cell growth after short-term glucose deprivation.
Neoplasms
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
Neoplasms
The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
Neoplasms
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Neoplasms
The impact of heterogeneity in Phosphoinositide 3-Kinase pathway in human cancer and possible therapeutic treatments.
Neoplasms
The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.
Neoplasms
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Neoplasms
The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells.
Neoplasms
The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis.
Neoplasms
The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells.
Neoplasms
The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets.
Neoplasms
The K1 Protein of Kaposi's Sarcoma-Associated Herpesvirus Augments Viral Lytic Replication.
Neoplasms
The lipid phosphatase activity of PTEN is critical for its tumor supressor function.
Neoplasms
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
Neoplasms
The Mechanism of Trivalent Inorganic Arsenic on HIF-1?: a Systematic Review and Meta-analysis.
Neoplasms
The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities.
Neoplasms
The metastasis suppressor protein NM23-H1 modulates the PI3K-AKT axis through interaction with the p110? catalytic subunit.
Neoplasms
The Mitotic Kinase Aurora-A Induces Mammary Cell Migration and Breast Cancer Metastasis by Activating the Cofilin-F-actin Pathway.
Neoplasms
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to the Cytotoxic Effect of Carboplatin in Breast Cancer In Vitro.
Neoplasms
The N-terminal Phosphodegron Targets TAZ/WWTR1 Protein for SCF?-TrCP-dependent Degradation in Response to Phosphatidylinositol 3-Kinase Inhibition.
Neoplasms
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.
Neoplasms
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
Neoplasms
The novel non-immunological role and underlying mechanisms of B7-H3 in tumorigenesis.
Neoplasms
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Neoplasms
The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Neoplasms
The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Neoplasms
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Neoplasms
The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Neoplasms
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.
Neoplasms
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes quiescent but not proliferating MG-63 human osteosarcoma cells to radiation.
Neoplasms
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.
Neoplasms
The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
Neoplasms
The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors.
Neoplasms
The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Neoplasms
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.
Neoplasms
The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors.
Neoplasms
The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.
Neoplasms
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
Neoplasms
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Neoplasms
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Neoplasms
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Neoplasms
The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis.
Neoplasms
The PI3K pathway at the crossroads of cancer and the immune system: strategies for next generation immunotherapy combinations.
Neoplasms
The PI3K pathway impacts stem gene expression in a set of glioblastoma cell lines.
Neoplasms
The PI3K subunits, P110? and P110? are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Neoplasms
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism.
Neoplasms
The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.
Neoplasms
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Neoplasms
The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor.
Neoplasms
The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1? Phosphorylation.
Neoplasms
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
Neoplasms
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
Neoplasms
The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
Neoplasms
The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Neoplasms
The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Neoplasms
The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Neoplasms
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Neoplasms
The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the ?-catenin/SIRT3 signaling pathway in cervical cancer.
Neoplasms
The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype.
Neoplasms
The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.
Neoplasms
The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling.
Neoplasms
The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.
Neoplasms
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.
Neoplasms
The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star.
Neoplasms
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
Neoplasms
The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma.
Neoplasms
The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation.
Neoplasms
The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophia myotonica protein kinase (DMPK)1 as a novel angiogenesis target.
Neoplasms
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.
Neoplasms
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Neoplasms
The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
Neoplasms
The Rho guanine nucleotide exchange factor ARHGEF5 promotes tumor malignancy via epithelial-mesenchymal transition.
Neoplasms
The Role of Breast Cancer Stem Cells and Some Related Molecular Biomarkers in Metastatic and Nonmetastatic Breast Cancer.
Neoplasms
The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.
Neoplasms
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
Neoplasms
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.
Neoplasms
The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Neoplasms
The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses.
Neoplasms
The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer.
Neoplasms
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.
Neoplasms
The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.
Neoplasms
The role of PI3K/Akt/mTOR signaling in dose-dependent biphasic effects of glycine on vascular development.
Neoplasms
The roles of microbial products in the development of colorectal cancer: a review.
Neoplasms
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
Neoplasms
The Selective Phosphoinoside-3-Kinase p110? Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.
Neoplasms
The selective PI3K inhibitor XL147 (SAR245408) inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
Neoplasms
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.
Neoplasms
The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
Neoplasms
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
Neoplasms
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Neoplasms
The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy.
Neoplasms
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
Neoplasms
The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL.
Neoplasms
The TLR3, PI3K, survivin, FasL, and Fas genes as major risk factors of occurrence and development of cervical cancer disease.
Neoplasms
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
Neoplasms
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.
Neoplasms
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.
Neoplasms
The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF.
Neoplasms
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.
Neoplasms
The Tumor Suppressor p53 Fine-Tunes Reactive Oxygen Species Levels and Neurogenesis via PI3 Kinase Signaling.
Neoplasms
The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.
Neoplasms
The type of KRAS mutation drives PI3K?/? signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients.
Neoplasms
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Neoplasms
The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
Neoplasms
The unfolded protein response is a major mechanism by which LRP1 regulates Schwann cell survival after injury.
Neoplasms
The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo.
Neoplasms
The uremic toxin p-cresol promotes the invasion and migration on carcinoma cells via Ras and mTOR signaling.
Neoplasms
The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3K?/? inhibitor.
Neoplasms
The Zinc Finger Protein Zbtb18 Represses Expression of Class I Phosphatidylinositol 3-Kinase Subunits and Inhibits Plasma Cell Differentiation.
Neoplasms
Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Neoplasms
Therapeutic benefit of selective inhibition of p110? PI3-kinase in pancreatic neuroendocrine tumors.
Neoplasms
Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways.
Neoplasms
Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress.
Neoplasms
Therapeutic Potential of SH2 Domain-Containing Inositol-5'-Phosphatase 1 (SHIP1) and SHIP2 Inhibition in Cancer.
Neoplasms
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.
Neoplasms
Thioredoxin-Like Protein 2 Is Overexpressed in Colon Cancer and Promotes Cancer Cell Metastasis by Interaction with Ran.
Neoplasms
Tie2-FGFR1 interaction induces adaptive PI3K inhibitor resistance by upregulating Aurora A/PLK1/CDK1 signaling in glioblastoma.
Neoplasms
Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling.
Neoplasms
Timosaponin AIII, a steroidal saponin, exhibits anti-tumor effect on taxol-resistant cells in vitro and in vivo.
Neoplasms
Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.
Neoplasms
Tissue-specific signaling networks rewired by major somatic mutations in human cancer revealed by proteome-wide discovery.
Neoplasms
TNF-induced necroptosis initiates early autophagy events via RIPK3-dependent AMPK activation, but inhibits late autophagy.
Neoplasms
Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
Neoplasms
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Neoplasms
Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.
Neoplasms
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
Neoplasms
TP53INP2 contributes to autophagosome formation by promoting LC3-ATG7 interaction.
Neoplasms
TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
Neoplasms
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Neoplasms
Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy.
Neoplasms
Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway.
Neoplasms
Transcriptome Analysis Reveals Key Genes and Pathways Associated with Metastasis in Breast Cancer.
Neoplasms
Transcriptome sequencing identifies genes associated with invasion of ovarian cancer.
Neoplasms
Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting.
Neoplasms
Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer.
Neoplasms
Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis.
Neoplasms
Transforming growth factor-beta (TGF-beta)-inducible gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast cancer.
Neoplasms
Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101).
Neoplasms
Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis.
Neoplasms
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
Neoplasms
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Neoplasms
Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance.
Neoplasms
Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.
Neoplasms
Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
Neoplasms
TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Neoplasms
Triggering PIK3CA mutations in PI3K/AKT/mTOR axis: Exploration of newer inhibitors and rational preventive strategies.
Neoplasms
TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism.
Neoplasms
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Neoplasms
Triptolide, a diterpenoid triepoxide, induces antitumor proliferation via activation of c-Jun NH2-terminal kinase 1 by decreasing phosphatidylinositol 3-kinase activity in human tumor cells.
Neoplasms
TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Neoplasms
Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice.
Neoplasms
Tumor educated platelets, a promising source for early detection of hepatocellular carcinoma: Liquid biopsy an alternative approach to tissue biopsy.
Neoplasms
Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors.
Neoplasms
Tumor Growth in the High Frequency Medulloblastoma Mouse Model Ptch1+/-/Tis21KO Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611.
Neoplasms
Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
Neoplasms
Tumor induction by a transformation-defective polyoma virus mutant blocked in signaling through Shc.
Neoplasms
Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.
Neoplasms
Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner.
Neoplasms
Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes.
Neoplasms
Tumor necrosis factor-alpha, sphingomyelinase and ceramides activate tyrosine kinase, p21Ras and phosphatidylinositol 3-kinase: implications for glucose transport and insulin resistance.
Neoplasms
Tumor necrosis factor-related apoptosis-inducing ligand promotes microvascular endothelial cell hyperpermeability through phosphatidylinositol 3-kinase pathway.
Neoplasms
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies.
Neoplasms
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Neoplasms
Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway.
Neoplasms
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN.
Neoplasms
Tumor suppressor Hippo/MST1 kinase mediates chemotaxis by regulating spreading and adhesion.
Neoplasms
Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.
Neoplasms
Tumor-derived CSF-1 induces the NKG2D ligand RAE-1? on tumor-infiltrating macrophages.
Neoplasms
Tumor-derived exosomal microRNA-7-5p enhanced by verbascoside inhibits biological behaviors of glioblastoma in vitro and in vivo.
Neoplasms
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Neoplasms
Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.
Neoplasms
Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.
Neoplasms
Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation.
Neoplasms
Ubiquitination and phosphorylation of Beclin 1 and its binding partners: Tuning class III phosphatidylinositol 3-kinase activity and tumor suppression.
Neoplasms
Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.
Neoplasms
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Neoplasms
Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.
Neoplasms
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Neoplasms
Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Neoplasms
Uncovering the PI3Ksome: phosphoinositide 3-kinases and counteracting PTEN form a signaling complex with intrinsic regulatory properties.
Neoplasms
Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer.
Neoplasms
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling.
Neoplasms
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype.
Neoplasms
Up-regulation of interleukin-17 expression by human papillomavirus type 16 E6 in nonsmall cell lung cancer.
Neoplasms
Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation.
Neoplasms
uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.
Neoplasms
Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
Neoplasms
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.
Neoplasms
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.
Neoplasms
Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo.
Neoplasms
Upregulation of polymeric immunoglobulin receptor expression in flounder (Paralichthys olivaceus) gill cells by cytokine tumor necrosis factor-? via activating PI3K and NF-?B signaling pathways.
Neoplasms
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.
Neoplasms
Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.
Neoplasms
Using Molecular Docking Analysis to Discovery Dregea sinensis Hemsl. Potential Mechanism of Anticancer, Antidepression, and Immunoregulation.
Neoplasms
Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
Neoplasms
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.
Neoplasms
V-ATPase controls tumor growth and autophagy in a Drosophila model of gliomagenesis.
Neoplasms
Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Neoplasms
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Neoplasms
Vanillin suppresses metastatic potential of human cancer cells through PI3K inhibition and decreases angiogenesis in vivo.
Neoplasms
Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
Neoplasms
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
Neoplasms
Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells.
Neoplasms
VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-?/ERK/RSK2 signaling.
Neoplasms
Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma.
Neoplasms
Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers.
Neoplasms
Volatile Inhibitors of Phosphatidylinositol-3-Kinase (PI3K) Pathway: Anticancer Potential of Aroma Compounds of Plant Essential Oils.
Neoplasms
VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation.
Neoplasms
Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
Neoplasms
W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors.
Neoplasms
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.
Neoplasms
When less is more: the PI3K pathway as a determinant of tumor response to dietary restriction.
Neoplasms
Whole Genome Resequencing of Arkansas Progressor and Regressor Line Chickens to Identify SNPs Associated with Tumor Regression.
Neoplasms
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
Neoplasms
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Neoplasms
Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Neoplasms
Withholding of M-CSF Supplement Reprograms Macrophages to M2-Like via Endogenous CSF-1 Activation.
Neoplasms
WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Neoplasms
WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism.
Neoplasms
Wnt3a regulates tumor necrosis factor-?-stimulated interleukin-6 release in osteoblasts.
Neoplasms
Wogonin induced calreticulin/annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK/AKT dependent manner.
Neoplasms
Wogonoside Shows Antifibrotic Effects in an Experimental Regression Model of Hepatic Fibrosis.
Neoplasms
Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo.
Neoplasms
Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.
Neoplasms
Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, enhances LPS-induced NO production from murine peritoneal macrophages.
Neoplasms
WWP2 is a physiological ubiquitin ligase for phosphatase and tensin homolog (PTEN) in mice.
Neoplasms
XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Neoplasms
YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo.
Neoplasms
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.
Neoplasms
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.
Neoplasms
ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.
Neoplasms
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
Neoplasms
[18F]-FLT Positron Emission Tomography can be used to image the response of sensitive tumors to PI3-Kinase inhibition with the novel agent GDC-0941.
Neoplasms
[Anti-tumor effect and its related mechanisms of cinobufotalin combined with cisplatin on H22 liver cancer mice].
Neoplasms
[Clinical Significance and Mechanism of PI3K p110? Overexpression? in Non-small Cell Lung Cancer].
Neoplasms
[Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells].
Neoplasms
[Dynamic analysis of modification of peripheral neutrophils functional activity and its regulation during tumor growth in vivo]
Neoplasms
[Effect of Buzhong Yiqi decoction on PI3K and AKT in spleen, stomach and lung of nude mice with lung adenocarcinoma transplantation tumor].
Neoplasms
[Effects of combined therapy of LY294002 and SN50 on nude mice model with gastric cancer].
Neoplasms
[Expression and clinical significance of phosphatidylinositol 3-kinase and protein kinase B in cervical carcinoma]
Neoplasms
[Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer]
Neoplasms
[Integrin ?5 silencing inhibits proliferation, invasion and metastasis of human liver cancer Bel-7404 cells in vitro].
Neoplasms
[PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Neoplasms
[Relationship between the inhibitory effect of fraxetin on breast cancer and estrogen signaling pathway].
Neoplasms
[Research of reversal effect of PESV to multi-drug resistance of leukemia stem cell].
Neoplasms
[Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma]
Neoplasms
[Studies of betuionic acid on cell cycle and related protein expressions on mice of bearing H22 tumor cells]
Neoplasms
[Targeted molecular strategies for cancer therapy based on the blockage of oncogenic pathways in human tumor cells]
Neoplasms
[The molecular mechanism responsible for the adaptation of malignant tumors to hormonal drugs: a role of phophatidylinositol-3-kinase and phosphoinositide-dependent proteins]
Neoplasms
[Therapeutic effect of IGF-1R-targeting inhibitor (TAE226) on malignant pleural effusion in nude mice].
Neoplasms, Germ Cell and Embryonal
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Neoplasms, Squamous Cell
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Neoplasms, Squamous Cell
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Neoplasms, Squamous Cell
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Neoplasms, Squamous Cell
Motility-related proteins as markers for head and neck squamous cell cancer.
Neoplastic Cells, Circulating
Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
Neoplastic Cells, Circulating
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Neoplastic Processes
Serum- and glucocorticoid-inducible kinase 3 is a potential oncogene in nasopharyngeal carcinoma.
Nervous System Diseases
A PI3-kinase-mediated negative feedback regulates neuronal excitability.
Nervous System Diseases
PI3K? deficiency enhances seizures severity and associated outcomes in a mouse model of convulsions induced by intrahippocampal injection of pilocarpine.
Nervous System Diseases
Target identification, screening and in vivo evaluation of pyrrolone-fused benzosuberene compounds against human epilepsy using Zebrafish model of pentylenetetrazol-induced seizures.
Neuralgia
Activation of phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root ganglia and spinal cord contributes to the neuropathic pain induced by spinal nerve ligation in rats.
Neuralgia
Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib.
Neuralgia
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury.
Neuralgia
Microglial BDNF, PI3K, and p-ERK in the Spinal Cord Are Suppressed by Pulsed Radiofrequency on Dorsal Root Ganglion to Ease SNI-Induced Neuropathic Pain in Rats.
Neuralgia
MiR-1906 Attenuates Neuropathic Pain in Rats by Regulating the TLR4/mTOR/ Akt Signaling Pathway.
Neuralgia
PI3K/Akt Pathway is Required for Spinal Central Sensitization in Neuropathic Pain.
Neurilemmoma
Changes in the mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling associated with the induction of apoptosis.
Neurilemmoma
Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Neurilemmoma
Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling.
Neurilemmoma
The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Neurilemmoma
The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Neuroacanthocytosis
Chorein-sensitive polymerization of cortical actin and suicidal cell death in chorea-acanthocytosis.
Neuroaxonal Dystrophies
Risk of false positive genetic associations in complex traits with underlying population structure: a case study.
Neuroblastoma
15-Deoxy-?(12,14)-prostaglandin J2 induced neurotoxicity via suppressing phosphoinositide 3-kinase.
Neuroblastoma
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.
Neuroblastoma
A novel function of Goalpha: mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells.
Neuroblastoma
Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.
Neuroblastoma
ALK positively regulates MYCN activity through repression of HBP1 expression.
Neuroblastoma
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Neuroblastoma
Association of high microvessel ?v?3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.
Neuroblastoma
Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1{alpha} in Neuroblastoma Cells.
Neuroblastoma
Carbachol inhibits insulin-stimulated phosphatidylinositol 3-kinase activity in SH-SY5Y neuroblastoma cells.
Neuroblastoma
Clioquinol inhibits peroxide-mediated toxicity through up-regulation of phosphoinositol-3-kinase and inhibition of p53 activity.
Neuroblastoma
Cross down-regulation of leptin and insulin receptor expression and signalling in a human neuronal cell line.
Neuroblastoma
Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11kappa7) neurons.
Neuroblastoma
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Neuroblastoma
Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
Neuroblastoma
Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.
Neuroblastoma
Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y.
Neuroblastoma
Gli1 Transcriptional Activity is Negatively Regulated by AKT2 in Neuroblastoma.
Neuroblastoma
High level of p37?-mRNA relative to p110?-mRNA in neuroblastoma tumors correlates with poor patient survival.
Neuroblastoma
HspB8 mediates neuroprotection against OGD/R in N2A cells through the phosphoinositide 3-kinase/Akt pathway.
Neuroblastoma
IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Neuroblastoma
Inactivation of glycogen synthase kinase-3 by protein kinase C delta: implications for regulation of tau phosphorylation.
Neuroblastoma
Inhibition of neuroblastoma cell phosphatidylinositol 3-kinase by CDP-diacylglycerol and phosphatidate.
Neuroblastoma
Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma.
Neuroblastoma
Inhibition of PI3k class III-dependent autophagy prevents apoptosis and necrosis by oxidative stress in dopaminergic neuroblastoma cells.
Neuroblastoma
Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells.
Neuroblastoma
L-Dopa decarboxylase interaction with the major signaling regulator ??3? in tissues and cells of neural and peripheral origin.
Neuroblastoma
Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
Neuroblastoma
Mechanisms of platelet-derived growth factor-mediated neuroprotection--implications in HIV dementia.
Neuroblastoma
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Neuroblastoma
Neuroprotective properties of ciliary neurotrophic factor on retinoic acid (RA)-predifferentiated SH-SY5Y neuroblastoma cells.
Neuroblastoma
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Neuroblastoma
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo.
Neuroblastoma
Nuclear estrogen receptor activation by insulin-like growth factor-1 in Neuro-2A neuroblastoma cells requires endogenous estrogen synthesis and is mediated by mutually repressive MAPK and PI3K cascades.
Neuroblastoma
Orexin-A Protects Human Neuroblastoma SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Neurotoxicity: Involvement of PKC and PI3K Signaling Pathways.
Neuroblastoma
Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagy.
Neuroblastoma
Ouabain-Induced Signaling and Cell Survival in SK-N-SH Neuroblastoma Cells Differentiated by Retinoic Acid.
Neuroblastoma
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
Neuroblastoma
Phosphatidylinositol 3-kinase and glycogen synthase kinase 3 regulate estrogen receptor-mediated transcription in neuronal cells.
Neuroblastoma
Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.
Neuroblastoma
Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells.
Neuroblastoma
Phosphatidylinositol 3-kinase, Cdc42, and Rac1 act downstream of Ras in integrin-dependent neurite outgrowth in N1E-115 neuroblastoma cells.
Neuroblastoma
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis.
Neuroblastoma
Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells.
Neuroblastoma
PI3K activation prevents A?42-induced synapse loss and favors insoluble amyloid deposit formation.
Neuroblastoma
PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma.
Neuroblastoma
PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Neuroblastoma
PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Neuroblastoma
PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells.
Neuroblastoma
PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.
Neuroblastoma
Possible involvement of rapamycin-sensitive pathway in Bcl-2 expression in human neuroblastoma SH-SY5Y cells.
Neuroblastoma
Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.
Neuroblastoma
Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR.
Neuroblastoma
Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Neuroblastoma
The inhibition of phosphatidylinositol-3-kinase induces neurite retraction and activates GSK3.
Neuroblastoma
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Neuroblastoma
Type I interferons impair BDNF-induced cell signaling and neurotrophic activity in differentiated human SH-SY5Y neuroblastoma cells and mouse primary cortical neurons.
Neuroblastoma
Tyrosine 251 at the C-terminus of neuronal glycoprotein M6a is critical for neurite outgrowth.
Neuroblastoma
[Exogenous HSP70 and Signaling Pathways Involved in the Inhibition of LPS-Induced Neurotoxicity of Neuroblastoma Cells].
Neurodegenerative Diseases
Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway.
Neurodegenerative Diseases
Biochemical re-programming of human dermal stem cells to neurons by increasing mitochondrial membrane potential.
Neurodegenerative Diseases
Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death.
Neurodegenerative Diseases
Derivatives of caffeic acid, a natural antioxidant, as the basis for the discovery of novel nonpeptidic neurotrophic agents.
Neurodegenerative Diseases
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease.
Neuroectodermal Tumors, Primitive
PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Neuroendocrine Tumors
Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors.
Neuroendocrine Tumors
Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Neuroendocrine Tumors
Identification and chromosome assignment of a human gene encoding a novel phosphatidylinositol-3 kinase.
Neuroendocrine Tumors
Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Neuroendocrine Tumors
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Neuroendocrine Tumors
PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Neuroendocrine Tumors
Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch.
Neuroendocrine Tumors
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Neurofibromatoses
A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.
Neurofibromatoses
Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.
Neurofibromatosis 2
A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2.
Neurofibromatosis 2
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.
Neurofibrosarcoma
Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor.
Neurofibrosarcoma
Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Neuroinflammatory Diseases
Berberine enhances survival and axonal regeneration of motoneurons following spinal root avulsion and re-implantation in rats.
Neuroinflammatory Diseases
CircRNA 001372 Reduces Inflammation in Propofol-Induced Neuroinflammation and Neural Apoptosis through PIK3CA/Akt/NF-?B by miRNA-148b-3p.
Neuroinflammatory Diseases
Lipopolysaccharide induces neuroinflammation in microglia by activating the MTOR pathway and downregulating Vps34 to inhibit autophagosome formation.
Neuroinflammatory Diseases
Mechanism underlying ?2-AR agonist-mediated phenotypic conversion of LPS-activated microglial cells.
Neuroinflammatory Diseases
Phosphoinositide 3-Kinase Gamma Contributes to Neuroinflammation in a Rat Model of Surgical Brain Injury.
Neuroinflammatory Diseases
Role of hydrogen sulfide in cognitive deficits: Evidences and mechanisms.
Neuroinflammatory Diseases
Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer's disease through modulation of brain insulin resistance induced tau pathology.
Neuroinflammatory Diseases
The expression pattern of Nischarin after lipopolysaccharides (LPS)-induced neuroinflammation in rats brain cortex.
Neuroinflammatory Diseases
The phosphoinositide-3 kinase signaling is involved in neuroinflammation in hypertensive rats.
Neurologic Manifestations
?-Caryophyllene Pretreatment Alleviates Focal Cerebral Ischemia-Reperfusion Injury by Activating PI3K/Akt Signaling Pathway.
Neurologic Manifestations
Isorhapontigenin alleviates cerebral ischemia/reperfusion injuries in rats and modulated the PI3K/Akt signaling pathway.
Neurologic Manifestations
The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction.
Neurologic Manifestations
Two Monogenetic Disorders, Activated PI3-Kinase-? Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Neutropenia
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Nevus
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Nevus
Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Nevus, Pigmented
Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Niemann-Pick Disease, Type C
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Niemann-Pick Diseases
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Non-alcoholic Fatty Liver Disease
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Non-alcoholic Fatty Liver Disease
Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).
Non-alcoholic Fatty Liver Disease
Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Folic Acid Reduced Triglycerides Deposition in Primary Chicken Hepatocytes.
Non-alcoholic Fatty Liver Disease
Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization.
Non-alcoholic Fatty Liver Disease
Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
Non-alcoholic Fatty Liver Disease
High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation.
Non-alcoholic Fatty Liver Disease
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD.
Non-alcoholic Fatty Liver Disease
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes.
Non-alcoholic Fatty Liver Disease
PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells.
Non-alcoholic Fatty Liver Disease
PIK3R3 regulates PPAR? expression to stimulate fatty acid ?-oxidation and decrease hepatosteatosis.
Non-alcoholic Fatty Liver Disease
PPAR ? inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell.
Non-alcoholic Fatty Liver Disease
Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Roles and mechanisms of NRG1 in modulating the pathogenesis of NAFLD through ErbB3 signaling in hepatocytes (NRG1 modulates NAFLD through ErbB3 signaling).
Non-alcoholic Fatty Liver Disease
Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
The ménage à trois of autophagy, lipid droplets and liver disease.
non-specific protein-tyrosine kinase deficiency
Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.
Obesity
Adipose tissue insulin resistance due to loss of PI3K p110? leads to decreased energy expenditure and obesity.
Obesity
Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2(-/-) mice.
Obesity
Central leptin action improves skeletal muscle AKT, AMPK, and PGC1alpha activation by hypothalamic PI3K-dependent mechanism.
Obesity
Creatine Inhibits Adipogenesis by Downregulating Insulin-Induced Activation of the Phosphatidylinositol 3-Kinase Signaling Pathway.
Obesity
Differential effects of insulin on sympathetic nerve activity in agouti obese mice.
Obesity
Differential PI3K signal transduction in obesity-associated cardiac hypertrophy and response to ischemia.
Obesity
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Obesity
Enhanced ?-adrenergic signalling underlies an age-dependent beneficial metabolic effect of PI3K p110? inactivation in adipose tissue.
Obesity
High fat diet induced obesity alters ovarian phosphatidylinositol-3 kinase signaling gene expression.
Obesity
High-Fat Diet Obesity Associated with Insulin Resistance Increases Cell Proliferation, Estrogen Receptor, and PI3K Proteins in Rat Ventral Prostate.
Obesity
High-fat feeding promotes obesity via insulin receptor/PI3K-dependent inhibition of SF-1 VMH neurons.
Obesity
High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats.
Obesity
Hirsutenone Directly Targets PI3K and ERK to Inhibit Adipogenesis in 3T3-L1 Preadipocytes.
Obesity
Hypothalamic phosphatidylinositol 3-kinase pathway of leptin signaling is impaired during the development of diet-induced obesity in FVB/N mice.
Obesity
Impact of Obesity on Ovotoxicity Induced by 7,12-dimethylbenz[a]anthracene in Mice.
Obesity
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity.
Obesity
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD.
Obesity
Impairment of central leptin-mediated PI3K signaling manifested as hepatic steatosis independent of hyperphagia and obesity.
Obesity
Inhibition of 11?-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance.
Obesity
Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGF?, and IDO1.
Obesity
Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities.
Obesity
Insulin-Dependent Activation of MCH Neurons Impairs Locomotor Activity and Insulin Sensitivity in Obesity.
Obesity
Intracellular Leptin-Signaling Pathways in Hypothalamic Neurons: The Emerging Role of Phosphatidylinositol-3 Kinase-Phosphodiesterase-3B-cAMP Pathway.
Obesity
Leptin and the Regulation of Renal Sodium Handling and Renal Na-Transporting ATPases: Role in the Pathogenesis of Arterial Hypertension.
Obesity
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Obesity
Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes.
Obesity
Neuronal suppressor of cytokine signaling-3 (Socs3) deficiency enhances hypothalamic leptin-dependent phosphatidylinositol 3-kinase (PI3K) signaling.
Obesity
Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.
Obesity
Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
Obesity
PI3K signaling in the ventromedial hypothalamic nucleus is required for normal energy homeostasis.
Obesity
PI3K/Akt pathway expression in children with different obesity degrees and its relationship with glucolipid metabolism and insulin resistance.
Obesity
PI3K: An Attractive Candidate for the Central Integration of Metabolism and Reproduction.
Obesity
Progressive obesity alters ovarian insulin, phosphatidylinositol-3 kinase, and chemical metabolism signaling pathways and potentiates ovotoxicity induced by phosphoramide mustard in mice.
Obesity
Progressive obesity alters ovarian insulin, phosphatidylinositol-3 kinase, and chemical metabolism signaling pathways and potentiates ovotoxicity induced by phosphoramide mustard in mice.
Obesity
Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.
Obesity
Retraction notice to: Impairment of central leptin-mediated PI3K signaling manifested as hepatic steatosis independent of hyperphagia and obesity.
Obesity
Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.
Obesity
Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle.
Obesity
The PI3K pathway preserves metabolic health through MARCO-dependent lipid uptake by adipose tissue macrophages.
Obesity
[Development of insulin resistance in muscle and adipose tissue during obesity in the mouse. Role of phosphatidylinositol 3-kinase]
Obesity, Maternal
Maternal obesity and increased neonatal adiposity correspond with altered infant mesenchymal stem cell metabolism.
Obesity, Maternal
Maternal obesity is associated with ovarian inflammation and upregulation of early growth response factor 1.
Obstetric Labor, Premature
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Oculocerebrorenal Syndrome
Finding patients using similarity measures in a rare diseases-oriented clinical data warehouse: Dr. Warehouse and the needle in the needle stack.
Odontogenic Tumors
FAK, paxillin, and PI3K in ameloblastoma and adenomatoid odontogenic tumor.
Odontogenic Tumors
Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
Oligodendroglioma
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
Oligodendroglioma
Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways.
Oncogene Addiction
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Oncogene Addiction
The Oncogene Addiction Switch from NOTCH to PI3K Requires Simultaneous Targeting of NOTCH and PI3K Pathway Inhibition in Glioblastoma.
Opportunistic Infections
Phosphatidylinositol 3-Kinase ? Inhibitor-Induced Immunomodulation and Secondary Opportunistic Infection in the Cynomolgus Monkey (Macaca fascicularis).
Opsoclonus-Myoclonus Syndrome
IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.
Optic Nerve Injuries
The upregulation of GLAST-1 is an indirect antiapoptotic mechanism of GDNF and neurturin in the adult CNS.
Oropharyngeal Neoplasms
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
Oropharyngeal Neoplasms
Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure.
Oropharyngeal Neoplasms
Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma.
Osteoarthritis
Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts.
Osteoarthritis
Discoidin domain receptor 2 mediates the collagen II-dependent release of interleukin-6 in primary human chondrocytes.
Osteoarthritis
Downregulation of miR-34a Promotes Proliferation and Inhibits Apoptosis of Rat Osteoarthritic Cartilage Cells by Activating PI3K/Akt Pathway.
Osteoarthritis
MicroRNA-130a regulates chondrocyte proliferation and alleviates osteoarthritis through PTEN/PI3K/Akt signaling pathway.
Osteoarthritis
MiRNA-132 regulates the development of osteoarthritis in correlation with the modulation of PTEN/PI3K/AKT signaling.
Osteoarthritis
The effects of amphiregulin induced MMP-13 production in human osteoarthritis synovial fibroblast.
Osteoarthritis
The Inhibitory Effects of Slow-Releasing Hydrogen Sulfide Donors in the Mechanical Allodynia, Grip Strength Deficits, and Depressive-Like Behaviors Associated with Chronic Osteoarthritis Pain.
Osteoarthritis
TNF-? increases the expression of inflammatory factors in synovial fibroblasts by inhibiting the PI3K/AKT pathway in a rat model of monosodium iodoacetate-induced osteoarthritis.
Osteoarthritis
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Osteoarthritis, Knee
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Osteochondritis Dissecans
Autophagy in farm animals: current knowledge and future challenges.
Osteolysis
PI3K? deletion reduces variability in the in vivo osteolytic response induced by orthopaedic wear particles.
Osteolysis
Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway.
Osteolysis
RNA Interference Targeting p110? Reduces Tumor Necrosis Factor-Alpha Production in Cellular Response to Wear Particles In vitro and Osteolysis In vivo.
Osteopetrosis
Proteomic Profiling of the First Human Dental Pulp Mesenchymal Stem/Stromal Cells from Carbonic Anhydrase II Deficiency Osteopetrosis Patients.
Osteoporosis
PSMC6 promotes osteoblast apoptosis through inhibiting PI3K/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model.
Osteoporosis
TAZ accelerates osteogenesis differentiation of mesenchymal stem cells via targeting PI3K/Akt.
Osteoporosis
The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis.
Osteoporosis, Postmenopausal
Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene.
Osteosarcoma
?ig-h3 Promotes Human Osteosarcoma Cells Metastasis by Interacting with Integrin ?2?1 and Activating PI3K Signaling Pathway.
Osteosarcoma
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Osteosarcoma
BTG2 inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/AKT pathway.
Osteosarcoma
BYL719, a new ?-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.
Osteosarcoma
Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Osteosarcoma
Connective tissue growth factor stimulates osteosarcoma cell migration and induces osteosarcoma metastasis by upregulating VCAM-1 expression.
Osteosarcoma
Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis.
Osteosarcoma
Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells.
Osteosarcoma
Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.
Osteosarcoma
Downregulation of lncRNA H19 inhibits migration and invasion of human osteosarcoma through the NF-?B pathway.
Osteosarcoma
Examination of the signal transduction pathways leading to activation of gelatinolytic activity by interleukin-1alpha and Porphyromonas gingivalis in human osteosarcoma cells.
Osteosarcoma
Fangchinoline suppresses the proliferation, invasion and tumorigenesis of human osteosarcoma cells through the inhibition of PI3K and downstream signaling pathways.
Osteosarcoma
Galangin suppresses human osteosarcoma cells: An exploration of its underlying mechanism.
Osteosarcoma
High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
Osteosarcoma
Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway.
Osteosarcoma
Inhibition of miRNA-21 attenuates the proliferation and metastasis of human osteosarcoma by upregulating PTEN.
Osteosarcoma
Long non-coding RNA phosphatase and tensin homolog pseudogene 1 suppresses osteosarcoma cell growth via the phosphoinositide 3-kinase/protein kinase B signaling pathway.
Osteosarcoma
LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity.
Osteosarcoma
LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3?kinase/Akt/fatty acid synthase signaling pathway in vitro.
Osteosarcoma
LY404039 Inhibits Proliferation and Metastasis of Osteosarcoma Cells via PI3K Signaling Pathway.
Osteosarcoma
Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
Osteosarcoma
P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway.
Osteosarcoma
Phosphatidylinositol 3-kinase translocation to the nucleus is an early event in the interleukin-1 signalling mechanism in human osteosarcoma Saos-2 cells.
Osteosarcoma
Phosphatidylinositol 3-kinase translocation to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 receptor in human osteosarcoma Saos-2 cells.
Osteosarcoma
PI3K? isoform-dependent activation of RhoA regulates Wnt5a-induced osteosarcoma cell migration.
Osteosarcoma
Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway.
Osteosarcoma
Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Osteosarcoma
Possible involvement of PI3K-dependent pathways in the increased VEGF120 release from osteoblastic cells preloaded with palmitate in vitro.
Osteosarcoma
Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line.
Osteosarcoma
ROR2 receptor promotes the migration of osteosarcoma cells in response to Wnt5a.
Osteosarcoma
Signal transduction pathways involved in the stimulation of tissue type plasminogen activator by interleukin-1alpha and Porphyromonas gingivalis in human osteosarcoma cells.
Osteosarcoma
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.
Osteosarcoma
The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes quiescent but not proliferating MG-63 human osteosarcoma cells to radiation.
Osteosarcoma
Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway.
Osteosarcoma
Up-regulation of LINC00619 promotes apoptosis and inhibits proliferation, migration and invasion while promoting apoptosis of osteosarcoma cells through inactivation of the HGF-mediated PI3K-Akt signalling pathway.
Osteosarcoma
VPS34 regulates dynamin to determine the endocytosis of mitochondria-targeted zinc oxide nanoparticles in human osteosarcoma cells.
Ototoxicity
Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling.
Ovarian Diseases
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Ovarian Neoplasms
17 ?-Estradiol Reverses Leptin-Inducing Ovarian Cancer Cell Migration by the PI3K/Akt Signaling Pathway.
Ovarian Neoplasms
5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells.
Ovarian Neoplasms
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Ovarian Neoplasms
A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition.
Ovarian Neoplasms
Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis.
Ovarian Neoplasms
Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX.
Ovarian Neoplasms
AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance.
Ovarian Neoplasms
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Ovarian Neoplasms
Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.
Ovarian Neoplasms
ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.
Ovarian Neoplasms
Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Ovarian Neoplasms
c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.
Ovarian Neoplasms
Ceramide limits phosphatidylinositol-3-kinase C2?-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.
Ovarian Neoplasms
Chrysin Attenuates Progression of Ovarian Cancer Cells by Regulating Signaling Cascades and Mitochondrial Dysfunction.
Ovarian Neoplasms
Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
Ovarian Neoplasms
CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway.
Ovarian Neoplasms
Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.
Ovarian Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Ovarian Neoplasms
Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment.
Ovarian Neoplasms
Correction: Enhanced GAB2 Expression Is Associated with Improved Survival in High-grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Ovarian Neoplasms
Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Ovarian Neoplasms
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Ovarian Neoplasms
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma.
Ovarian Neoplasms
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
Ovarian Neoplasms
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Ovarian Neoplasms
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Ovarian Neoplasms
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
Ovarian Neoplasms
Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells.
Ovarian Neoplasms
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Ovarian Neoplasms
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Ovarian Neoplasms
Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c.
Ovarian Neoplasms
Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.
Ovarian Neoplasms
Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.
Ovarian Neoplasms
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Ovarian Neoplasms
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Ovarian Neoplasms
Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells.
Ovarian Neoplasms
Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
Ovarian Neoplasms
Highly efficient Gab2 siRNA delivery to ovarian cancer cells mediated by chitosan-polyethyleneimine nanoparticles.
Ovarian Neoplasms
HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Ovarian Neoplasms
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Ovarian Neoplasms
IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer.
Ovarian Neoplasms
IL-13 regulates cancer invasion and metastasis through IL-13R?2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.
Ovarian Neoplasms
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.
Ovarian Neoplasms
Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Ovarian Neoplasms
Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
Ovarian Neoplasms
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Ovarian Neoplasms
Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.
Ovarian Neoplasms
Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Ovarian Neoplasms
Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel.
Ovarian Neoplasms
Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.
Ovarian Neoplasms
Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells.
Ovarian Neoplasms
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
Ovarian Neoplasms
Integrin alpha x stimulates cancer angiogenesis through PI3K/Akt signaling-mediated VEGFR2/VEGF-A overexpression in blood vessel endothelial cells.
Ovarian Neoplasms
JTC-801 inhibits the proliferation and metastasis of ovarian cancer cell SKOV3 through inhibition of the PI3K - AKT signaling pathway.
Ovarian Neoplasms
Knockdown of Hypoxia-Inducible Factor 1? (HIF-1?) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
Ovarian Neoplasms
KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Ovarian Neoplasms
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Ovarian Neoplasms
Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1alpha and the PI3K pathway.
Ovarian Neoplasms
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Ovarian Neoplasms
Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.
Ovarian Neoplasms
Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation.
Ovarian Neoplasms
MicroRNA-301a Promotes Cell Proliferation and Resistance to Apoptosis through PTEN/PI3K/Akt Signaling Pathway in Human Ovarian Cancer.
Ovarian Neoplasms
MiR-200b-5p inhibits proliferation of ovarian cancer cells by targeting ATAD2 and regulating PI3K/AKT signaling pathway.
Ovarian Neoplasms
miR?338?3p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2.
Ovarian Neoplasms
MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.
Ovarian Neoplasms
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.
Ovarian Neoplasms
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Ovarian Neoplasms
Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1.
Ovarian Neoplasms
Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
Ovarian Neoplasms
Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.
Ovarian Neoplasms
Overexpression of glycosyltransferase 8 domain containing 2 confers ovarian cancer to CDDP resistance by activating FGFR/PI3K signalling axis.
Ovarian Neoplasms
p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells.
Ovarian Neoplasms
p85? alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
Ovarian Neoplasms
PAK5 Induces EMT and Promotes Cell Migration and Invasion by Activating the PI3K/AKT Pathway in Ovarian Cancer.
Ovarian Neoplasms
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Ovarian Neoplasms
Phosphatidylinositol 3-kinase Inhibitor (PIK75) Containing Surface Functionalized Nanoemulsion for Enhanced Drug Delivery, Cytotoxicity and Pro-apoptotic Activity in Ovarian Cancer Cells.
Ovarian Neoplasms
Phosphatidylinositol 3-kinase inhibitors are a triple threat to ovarian cancer.
Ovarian Neoplasms
PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
Ovarian Neoplasms
PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.
Ovarian Neoplasms
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Ovarian Neoplasms
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Ovarian Neoplasms
Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.
Ovarian Neoplasms
Progesterone protects ovarian cancer cells from cisplatin-induced inhibitory effects through progesterone receptor membrane component 1/2 as well as AKT signaling.
Ovarian Neoplasms
Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Ovarian Neoplasms
Progranulin expression induced by follicle-stimulating hormone in ovarian cancer cell lines depends on the histological subtype.
Ovarian Neoplasms
Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines.
Ovarian Neoplasms
Prucalopride Inhibits Proliferation of Ovarian Cancer Cells via Phosphatidylinositol 3-Kinase (PI3K) Signaling Pathway.
Ovarian Neoplasms
RNA Interference-Mediated Silencing of the Phosphatidylinositol 3-Kinase Catalytic Subunit Attenuates Growth of Human Ovarian Cancer Cells in vitroand in vivo.
Ovarian Neoplasms
RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.
Ovarian Neoplasms
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Ovarian Neoplasms
Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.
Ovarian Neoplasms
Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.
Ovarian Neoplasms
Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.
Ovarian Neoplasms
Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation.
Ovarian Neoplasms
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
Ovarian Neoplasms
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Ovarian Neoplasms
Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model.
Ovarian Neoplasms
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
Ovarian Neoplasms
Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells.
Ovarian Neoplasms
Tanshinone IIA induces apoptosis of ovarian cancer cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways.
Ovarian Neoplasms
Targeted inhibition of phosphatidyl inositol-3-kinase p110?, but not p110?, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Ovarian Neoplasms
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.
Ovarian Neoplasms
TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
Ovarian Neoplasms
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.
Ovarian Neoplasms
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Ovarian Neoplasms
The circadian rhythm and core gene Period2 regulate the chemotherapy effect and multidrug resistance of ovarian cancer through the PI3K signaling pathway.
Ovarian Neoplasms
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Ovarian Neoplasms
The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Ovarian Neoplasms
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
Ovarian Neoplasms
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
Ovarian Neoplasms
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.
Ovarian Neoplasms
TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Ovarian Neoplasms
TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer.
Ovarian Neoplasms
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Ovarian Neoplasms
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
Ovarian Neoplasms
TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.
Ovarian Neoplasms
Upregulated microRNA-15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3.
Ovarian Neoplasms
Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling.
Ovarian Neoplasms
Wogonin Increases Cisplatin Sensitivity in Ovarian Cancer Cells Through Inhibition of the Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway.
Ovarian Neoplasms
[Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Ovarian Neoplasms
[Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma]
Ovarian Neoplasms
[Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells]
Paget Disease, Extramammary
PI3K, Rac1 and pPAK1 are overexpressed in extramammary Paget's disease.
Pancreatic Neoplasms
A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer.
Pancreatic Neoplasms
A Structurally Optimized Celecoxib Derivative Inhibits Human Pancreatic Cancer Cell Growth.
Pancreatic Neoplasms
A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
Pancreatic Neoplasms
Activation of PPARgamma increases PTEN expression in pancreatic cancer cells.
Pancreatic Neoplasms
Activation of the PI3K/Akt Pathway Mediates Bone Morphogenetic Protein 2-Induced Invasion of Pancreatic Cancer Cells Panc-1.
Pancreatic Neoplasms
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Pancreatic Neoplasms
Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells.
Pancreatic Neoplasms
Associations of novel variants in PIK3C3, INSR and MAP3K4 of the ATM pathway genes with pancreatic cancer risk.
Pancreatic Neoplasms
Attenuating PI3K isoforms in pancreatic cancer: Focus on immune PI3K?.
Pancreatic Neoplasms
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.
Pancreatic Neoplasms
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
Pancreatic Neoplasms
BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition.
Pancreatic Neoplasms
Co-Targeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer.
Pancreatic Neoplasms
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
Pancreatic Neoplasms
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Pancreatic Neoplasms
Complement component 1, q subcomponent binding protein (C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by regulating IGF-1/IGF-1R signaling.
Pancreatic Neoplasms
Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models.
Pancreatic Neoplasms
Correction: Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models.
Pancreatic Neoplasms
Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
Pancreatic Neoplasms
Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.
Pancreatic Neoplasms
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
Pancreatic Neoplasms
Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Pancreatic Neoplasms
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation.
Pancreatic Neoplasms
Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides.
Pancreatic Neoplasms
Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF-? pathway.
Pancreatic Neoplasms
Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.
Pancreatic Neoplasms
Grape Proanthocyanidin Inhibit Pancreatic Cancer Cell Growth In Vitro and In Vivo through Induction of Apoptosis and by Targeting the PI3K/Akt Pathway.
Pancreatic Neoplasms
Growth-inhibitory effect of phosphatidylinositol 3-kinase inhibitor on human pancreatic cancer cells and expression of Bcl-2 family.
Pancreatic Neoplasms
HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
Pancreatic Neoplasms
HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer.
Pancreatic Neoplasms
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Pancreatic Neoplasms
Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients.
Pancreatic Neoplasms
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
Pancreatic Neoplasms
Increase in PI3K signalling mimics mutated-Kras induction of pancreatic cancer.
Pancreatic Neoplasms
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Pancreatic Neoplasms
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Pancreatic Neoplasms
Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells.
Pancreatic Neoplasms
Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells.
Pancreatic Neoplasms
Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.
Pancreatic Neoplasms
Integrin ?1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110? signaling.
Pancreatic Neoplasms
Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.
Pancreatic Neoplasms
IRS-1 regulates proliferation, invasion and metastasis of pancreatic cancer cells through MAPK and PI3K signaling pathways.
Pancreatic Neoplasms
Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway.
Pancreatic Neoplasms
ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways.
Pancreatic Neoplasms
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo.
Pancreatic Neoplasms
lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity.
Pancreatic Neoplasms
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
Pancreatic Neoplasms
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells.
Pancreatic Neoplasms
miRNAs in insulin resistance and diabetes-associated pancreatic cancer: the 'minute and miracle' molecule moving as a monitor in the 'genomic galaxy'.
Pancreatic Neoplasms
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Pancreatic Neoplasms
Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
Pancreatic Neoplasms
Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
Pancreatic Neoplasms
Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway.
Pancreatic Neoplasms
Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Pancreatic Neoplasms
PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration.
Pancreatic Neoplasms
Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent.
Pancreatic Neoplasms
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway.
Pancreatic Neoplasms
Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Pancreatic Neoplasms
Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1.
Pancreatic Neoplasms
Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.
Pancreatic Neoplasms
Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo.
Pancreatic Neoplasms
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.
Pancreatic Neoplasms
Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas.
Pancreatic Neoplasms
Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression.
Pancreatic Neoplasms
PI-3' kinase and NF-kappaB cross-signaling in human pancreatic cancer cells.
Pancreatic Neoplasms
PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
Pancreatic Neoplasms
PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells.
Pancreatic Neoplasms
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
Pancreatic Neoplasms
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Pancreatic Neoplasms
PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.
Pancreatic Neoplasms
Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer.
Pancreatic Neoplasms
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Pancreatic Neoplasms
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Pancreatic Neoplasms
Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Pancreatic Neoplasms
Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
Pancreatic Neoplasms
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
Pancreatic Neoplasms
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress.
Pancreatic Neoplasms
The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo.
Pancreatic Neoplasms
The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer.
Pancreatic Neoplasms
Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy.
Pancreatic Neoplasms
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
Pancreatitis
Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis.
Pancreatitis
Akt1 signalling supports acinar proliferation and limits acinar-to-ductal metaplasia formation upon induction of acute pancreatitis.
Pancreatitis
Expression of phosphatidylinositol-3 kinase and effects of inhibitor Wortmannin on expression of tumor necrosis factor-? in severe acute pancreatitis associated with acute lung injury.
Pancreatitis
LAP-like non-canonical autophagy and evolution of endocytic vacuoles in pancreatic acinar cells.
Pancreatitis
Phosphatidylinositide 3-kinase gamma regulates key pathologic responses to cholecystokinin in pancreatic acinar cells.
Pancreatitis
Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis.
Pancreatitis, Chronic
Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation.
Pancreatitis, Chronic
LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
Pancreatitis, Chronic
Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.
Papilloma
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Papilloma
Loss of miR-143 and miR-145 in condyloma acuminatum promotes cellular proliferation and inhibits apoptosis by targeting NRAS.
Papilloma
Phosphatidylinositol 3-kinase regulates early differentiation in human laryngeal keratinocytes.
Papilloma
PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells.
Paralysis
Absence of metabotropic glutamate receptor homolog(s) accelerates acetylcholine neurotransmission in Caenorhabditis elegans.
Paramyxoviridae Infections
Emerging views of mitophagy in immunity and autoimmune diseases.
Paresthesia
PI3K mediated activation of GSK-3? reduces at-level primary afferent growth responses associated with excitotoxic spinal cord injury dysesthesias.
Parkinson Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Parkinson Disease
Autophagy and innate immunity: Insights from invertebrate model organisms.
Parkinson Disease
Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.
Parkinson Disease
Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson's model: a promising candidate for the treatment of Parkinson's disease.
Parkinson Disease
Neuroprotective effect of Annona muricata-derived polysaccharides in neuronal HT22 cell damage induced by hydrogen peroxide.
Parkinson Disease
Neurotrophic Effect of Asiatic acid, a Triterpene of Centella asiatica Against Chronic 1-Methyl 4-Phenyl 1, 2, 3, 6-Tetrahydropyridine Hydrochloride/Probenecid Mouse Model of Parkinson's disease: The Role of MAPK, PI3K-Akt-GSK3? and mTOR Signalling Pathways.
Parkinson Disease
Upstream regulators of phosphoinositide 3-kinase and their role in diseases.
Parkinsonian Disorders
Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease.
Parkinsonian Disorders
Sex differences in autophagy-mediated diseases: toward precision medicine.
Parkinsonian Disorders
Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.
Periodontitis
Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation.
Peripheral Nervous System Diseases
Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy.
Peripheral Nervous System Diseases
Mechanical allodynia and enhanced responses to capsaicin are mediated by PI3K in a paclitaxel model of peripheral neuropathy.
Persistent Infection
Genetic Defects in Phosphoinositide 3-Kinase ? Influence CD8+ T Cell Survival, Differentiation, and Function.
Persistent Infection
ICOS-deficient and ICOS YF mutant mice fail to control Toxoplasma gondii infection of the brain.
Peste-des-Petits-Ruminants
Autophagy in farm animals: current knowledge and future challenges.
Pheochromocytoma
Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells.
Pheochromocytoma
Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells.
Pheochromocytoma
MiR-199a-5p regulates sirtuin1 and PI3K in the rat hippocampus with intrauterine growth restriction.
Pheochromocytoma
Mitogenic signaling by cyclic adenosine monophosphate in chromaffin cells involves phosphatidylinositol 3-kinase activation.
Pheochromocytoma
Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase.
Pheochromocytoma
Nuclear translocation of phosphatidylinositol 3-kinase in rat pheochromocytoma PC 12 cells after treatment with nerve growth factor.
Pheochromocytoma
Phosphatidylinositol 3-kinase is activated by nerve growth factor and epidermal growth factor in PC12 cells.
Pheochromocytoma
Secretin Receptor Promotes the Proliferation of Endocrine Tumor Cells Via the PI3K/AKT Pathway.
phosphatidylinositol 3-kinase deficiency
A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth.
phosphatidylinositol 3-kinase deficiency
Active vacuolar H+ ATPase and functional cycle of Rab5 are required for the vacuolation defect triggered by PtdIns(3,5)P2 loss under PIKfyve or Vps34 deficiency.
phosphatidylinositol 3-kinase deficiency
Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase.
phosphatidylinositol 3-kinase deficiency
Deficiency in class III PI3-kinase confers postnatal lethality with IBD-like features in zebrafish.
phosphatidylinositol 3-kinase deficiency
Distinct roles of phosphoinositide-3 kinase and phospholipase Cgamma2 in B-cell receptor-mediated signal transduction.
phosphatidylinositol 3-kinase deficiency
Lens differentiation is controlled by the balance between PDGF and FGF signaling.
phosphatidylinositol 3-kinase deficiency
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1? production.
phosphatidylinositol 3-kinase deficiency
Precision Therapy for the Treatment of Primary Immunodysregulatory Diseases.
phosphatidylinositol 3-kinase deficiency
Role of phosphatidylinositol-3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc gamma receptor ligation in murine macrophages.
phosphatidylinositol 3-kinase deficiency
Vps34 Deficiency Reveals the Importance of Endocytosis for Podocyte Homeostasis.
phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase deficiency
SHIP-1 Regulates Phagocytosis and M2 Polarization Through the PI3K/Akt-STAT5-Trib1 Circuit in Pseudomonas aeruginosa Infection.
phosphatidylinositol-3,4-bisphosphate 4-phosphatase deficiency
The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.
phosphoinositide phospholipase c deficiency
Distinct roles of phosphoinositide-3 kinase and phospholipase Cgamma2 in B-cell receptor-mediated signal transduction.
phospholipase d deficiency
Differential Roles of Phospholipase D Proteins in Fc?RI-Mediated Signaling and Mast Cell Function.
phospholipase d deficiency
Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid.
Pituitary ACTH Hypersecretion
Dual HDAC and PI3K Inhibitor: A Novel Potential Therapeutic Option in Cushing Disease.
Pituitary Neoplasms
Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors.
Pituitary Neoplasms
Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors.
Pituitary Neoplasms
Differential effects of PI3K and dual PI3K/mTOR inhibition in rat prolactin-secreting pituitary tumors.
Pituitary Neoplasms
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Pituitary Neoplasms
MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
Pituitary Neoplasms
Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase.
Pituitary Neoplasms
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
Pituitary Neoplasms
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression.
Pituitary Neoplasms
Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
Pleural Effusion
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Pleural Effusion
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Pleural Effusion, Malignant
Activation of calpain by renin-angiotensin system in pleural mesothelial cells mediates tuberculous pleural fibrosis.
Pleurisy
Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation.
Pneumococcal Infections
Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection.
Pneumococcal Infections
Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase.
Pneumonia
Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases.
Pneumonia
Effects of phosphoinositide 3-kinase in protease-induced acute and chronic lung inflammation, remodeling and emphysema in rats.
Pneumonia
Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation.
Pneumonia
Highly pathogenic PRRSV induces IL-17 production via the activation of IRAK1-PI3K-p38MAPK-C/EBP?/CREB pathways.
Pneumonia
Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis.
Pneumonia
Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia.
Pneumonia
Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway.
Pneumonia
Platelet PI3K Modulates Innate Leukocyte Extravasation during Acid-Induced Acute Lung Inflammation.
Pneumonia
Roles of PI3K pan-inhibitors and PI3K-? inhibitors in allergic lung inflammation: a systematic review and meta-analysis.
Pneumonia
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.
Pneumonia
SIGNALING PATHWAYS AND MEDIATORS IN LPS-INDUCED LUNG INFLAMMATION IN DIABETIC RATS: ROLE OF INSULIN.
Pneumonia
Slit2 Regulates Attractive Eosinophil and Repulsive Neutrophil Chemotaxis through Differential srGAP1 Expression during Lung Inflammation.
Pneumonia, Pneumococcal
Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia.
Pneumonia, Pneumocystis
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Pneumoperitoneum
TIMP-3 and Phosphatidylinositol 3-kinase genes were found to be related to the progression of colon cancer in a comparison of pneumoperitoneum and laparotomy in a murine model.
Polycystic Kidney Diseases
Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys.
Polycystic Kidney Diseases
PKD2/polycystin-2 induces autophagy by forming a complex with BECN1.
Polycystic Kidney, Autosomal Dominant
PKD2/polycystin-2 induces autophagy by forming a complex with BECN1.
Polycystic Ovary Syndrome
Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway.
Polycystic Ovary Syndrome
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Polycystic Ovary Syndrome
Defective Activation of Protein Kinase C-z in Muscle by Insulin and Phosphatidylinositol-3,4,5,-(PO(4))(3) in Obesity and Polycystic Ovary Syndrome.
Polycystic Ovary Syndrome
Phosphatidylinositide 3-kinase inhibition: A new potential target for the treatment of polycystic ovarian syndrome.
Polycystic Ovary Syndrome
Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Role of the PI3K-Akt Signaling Pathway in the Pathogenesis of Polycystic Ovary Syndrome.
Polycystic Ovary Syndrome
[Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients].
Polycystic Ovary Syndrome
[Detection and significance of phosphatidylinositol 3-kinase in adipose tissue of polycystic ovary syndrome patients with insulin resistance]
Polymicrogyria
Characterisation of mutations of the phosphoinositide-3-kinase regulatory subunit, PIK3R2, in perisylvian polymicrogyria: a next-generation sequencing study.
Polymyalgia Rheumatica
Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.
Porcine Reproductive and Respiratory Syndrome
Autophagy and innate immunity: Insights from invertebrate model organisms.
Porcine Reproductive and Respiratory Syndrome
Role of phosphatidylinositol 3-kinase (PI3K) and Akt1 kinase in porcine reproductive and respiratory syndrome virus (PRRSV) replication.
Port-Wine Stain
Activation of PKC? and PI3K Kinases in Hypertrophic and Nodular Port Wine Stain Lesions.
Port-Wine Stain
The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation.
Pre-Eclampsia
Down-Regulation of Laminin (LN)- ?5 is Associated with Preeclampsia and Impairs Trophoblast Cell Viability and Invasiveness Through PI3K Signaling Pathway.
Pre-Eclampsia
Inhibition of the PI3K-Akt pathway suppresses sFlt1 expression in human placental hypoxia models in vitro.
Pre-Eclampsia
LncRNA MALAT1 regulates trophoblast cells migration and invasion via miR-206/IGF-1 axis.
Pre-Eclampsia
miR-483 is downregulated in pre-eclampsia via targeting insulin-like growth factor 1 (IGF1) and regulates the PI3K/Akt/mTOR pathway of endothelial progenitor cells.
Pre-Eclampsia
Nicotine Alleviates Cortical Neuronal Injury by Suppressing Neuroinflammation and Upregulating Neuronal PI3K-AKT Signaling in an Eclampsia-Like Seizure Model.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PI3K-? inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting PI3K Signaling in Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR/PI3K/Akt expression.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
NOTCH1 downregulation contributes to PI3K inhibitor resistance in T-ALL.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Preclinical testing of the AKT inhibitor triciribine in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Targeting Wnt/?-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
[Reaserch Advances on the Role of PI3K/AKT Signaling Pathway and MiRNA in Acute T-Cell Lymphocytic Leukemia--Review].
Prediabetic State
Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Premature Birth
Hepatic Insulin Resistance and Altered Gluconeogenic Pathway in Premature Baboons.
Premature Birth
IL-27 induces a pro-inflammatory response in human fetal membranes mediating preterm birth.
Primary Immunodeficiency Diseases
A human immunodeficiency caused by mutations in the PIK3R1 gene.
Primary Immunodeficiency Diseases
Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys.
Primary Immunodeficiency Diseases
Conformational disruption of PI3K? regulation by immunodeficiency mutations in PIK3CD and PIK3R1.
Primary Immunodeficiency Diseases
Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase ? syndrome-like immunodeficiency.
Primary Immunodeficiency Diseases
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Primary Myelofibrosis
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
Primary Myelofibrosis
VEGF Regulation of Angiogenic Factors via Inflammatory Signaling in Myeloproliferative Neoplasms.
Primary Ovarian Insufficiency
Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary.
Primary Ovarian Insufficiency
Hippo signaling in the ovary and polycystic ovarian syndrome.
Primary Ovarian Insufficiency
New strategy for in vitro activation of primordial follicles with mTOR and PI3K stimulators.
Prolactinoma
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
prostaglandin-e synthase deficiency
Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway.
prostaglandin-endoperoxide synthase deficiency
Cyclooxygenase-2 deficiency in macrophages leads to defective p110? PI3K signaling and impairs cell adhesion and migration.
Prostatic Hyperplasia
miR-27b expression in diagnosis and evaluation prognosis of prostate cancer.
Prostatic Hyperplasia
Over expression of PI3K-AkT reduces apoptosis and increases prostate size in benign prostatic hyperplasia.
Prostatic Intraepithelial Neoplasia
Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease.
Prostatic Intraepithelial Neoplasia
Expression of phosphorylated-mTOR during the development of prostate cancer.
Prostatic Neoplasms
1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Prostatic Neoplasms
A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
Prostatic Neoplasms
A novel inhibitor of hypoxia-inducible factor-1alpha P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.
Prostatic Neoplasms
A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Prostatic Neoplasms
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Prostatic Neoplasms
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.
Prostatic Neoplasms
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
Prostatic Neoplasms
A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer.
Prostatic Neoplasms
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms.
Prostatic Neoplasms
Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.
Prostatic Neoplasms
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Prostatic Neoplasms
Activation of the RalGEF/Ral Pathway Promotes Prostate Cancer Metastasis to Bone.
Prostatic Neoplasms
Active ?-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A.
Prostatic Neoplasms
AKT and cytosolic phospholipase A2? form a positive loop in prostate cancer cells.
Prostatic Neoplasms
Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.
Prostatic Neoplasms
An enzyme-responsive conjugate improves the delivery of a PI3K inhibitor to prostate cancer.
Prostatic Neoplasms
An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells.
Prostatic Neoplasms
Androgen receptor-induced integrin ?6?1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
Prostatic Neoplasms
Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Prostatic Neoplasms
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Prostatic Neoplasms
Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Prostatic Neoplasms
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
Prostatic Neoplasms
Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer.
Prostatic Neoplasms
Arctigenin Triggers Apoptosis and Autophagy via PI3K/Akt/mTOR Inhibition in PC-3M Cells.
Prostatic Neoplasms
Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.
Prostatic Neoplasms
Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.
Prostatic Neoplasms
Association between the Met326Ile polymorphism of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study.
Prostatic Neoplasms
Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.
Prostatic Neoplasms
AURKA suppression induces DU145 apoptosis and sensitizes DU145 to docetaxel treatment.
Prostatic Neoplasms
Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.
Prostatic Neoplasms
B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer.
Prostatic Neoplasms
BAD Dephosphorylation and Decreased Expression of MCL-1 Induce Rapid Apoptosis in Prostate Cancer Cells.
Prostatic Neoplasms
Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
Prostatic Neoplasms
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Prostatic Neoplasms
Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.
Prostatic Neoplasms
Clinical implications of genomic alterations in metastatic prostate cancer.
Prostatic Neoplasms
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Prostatic Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Prostatic Neoplasms
Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439.
Prostatic Neoplasms
CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Prostatic Neoplasms
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism.
Prostatic Neoplasms
DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.
Prostatic Neoplasms
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.
Prostatic Neoplasms
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Prostatic Neoplasms
Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer.
Prostatic Neoplasms
Diarylpentanoid (1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one) (MS13) Exhibits Anti-proliferative, Apoptosis Induction and Anti-migration Properties on Androgen-independent Human Prostate Cancer by Targeting Cell Cycle-Apoptosis and PI3K Signalling Pathways.
Prostatic Neoplasms
Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD.
Prostatic Neoplasms
Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.
Prostatic Neoplasms
Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth.
Prostatic Neoplasms
Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.
Prostatic Neoplasms
Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer.
Prostatic Neoplasms
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
Prostatic Neoplasms
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Prostatic Neoplasms
Effects of adipocytes on the proliferation and differentiation of prostate cancer cells in a 3-D culture model.
Prostatic Neoplasms
Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types.
Prostatic Neoplasms
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
Prostatic Neoplasms
Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3-kinase-mediated Akt signaling.
Prostatic Neoplasms
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Prostatic Neoplasms
Expression of phosphorylated-mTOR during the development of prostate cancer.
Prostatic Neoplasms
Feed Forward Cycle of Hypotonic Stress-induced ATP Release, Purinergic Receptor Activation, and Growth Stimulation of Prostate Cancer Cells.
Prostatic Neoplasms
Feedback suppression of PI3K? signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K?.
Prostatic Neoplasms
FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.
Prostatic Neoplasms
G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells.
Prostatic Neoplasms
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Prostatic Neoplasms
Gut Microbiota-Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling.
Prostatic Neoplasms
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Prostatic Neoplasms
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.
Prostatic Neoplasms
Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth.
Prostatic Neoplasms
Impact of E6-associated protein on the proliferation and invasion of prostate cancer cells in bone metastasis.
Prostatic Neoplasms
In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells.
Prostatic Neoplasms
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
Prostatic Neoplasms
Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism.
Prostatic Neoplasms
Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism.
Prostatic Neoplasms
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Prostatic Neoplasms
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
Prostatic Neoplasms
Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Prostatic Neoplasms
Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor.
Prostatic Neoplasms
Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers.
Prostatic Neoplasms
Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets.
Prostatic Neoplasms
Leptin induces cell migration and the expression of growth factors in human prostate cancer cells.
Prostatic Neoplasms
Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A?? via AKT in prostate cancer cells.
Prostatic Neoplasms
Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.
Prostatic Neoplasms
Mapping the Germline and Somatic Mutation Interaction Landscape in Indolent and Aggressive Prostate Cancers.
Prostatic Neoplasms
Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.
Prostatic Neoplasms
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.
Prostatic Neoplasms
Microarray-based identification of differentially expressed genes associated with andrographolide derivatives-induced resistance in colon and prostate cancer cell lines.
Prostatic Neoplasms
MIIP inhibits the growth of prostate cancer via interaction with PP1? and negative modulation of AKT signaling.
Prostatic Neoplasms
miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study.
Prostatic Neoplasms
miR-27b expression in diagnosis and evaluation prognosis of prostate cancer.
Prostatic Neoplasms
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Prostatic Neoplasms
Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.
Prostatic Neoplasms
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Prostatic Neoplasms
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.
Prostatic Neoplasms
MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Prostatic Neoplasms
Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.
Prostatic Neoplasms
Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
Prostatic Neoplasms
No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.
Prostatic Neoplasms
Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Prostatic Neoplasms
NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
Prostatic Neoplasms
NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3.
Prostatic Neoplasms
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.
Prostatic Neoplasms
Over expression of PI3K-AkT reduces apoptosis and increases prostate size in benign prostatic hyperplasia.
Prostatic Neoplasms
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Prostatic Neoplasms
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Prostatic Neoplasms
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Prostatic Neoplasms
Phosphatidylinositol 3-kinase ? and ? isoforms play key roles in metastasis of prostate cancer DU145 cells.
Prostatic Neoplasms
Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Prostatic Neoplasms
Phosphoinositide-3-kinase pathway activation in PTEN deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110{beta} and p110{delta} catalytic subunits.
Prostatic Neoplasms
Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients.
Prostatic Neoplasms
PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells.
Prostatic Neoplasms
PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Prostatic Neoplasms
PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation.
Prostatic Neoplasms
PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer.
Prostatic Neoplasms
PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures.
Prostatic Neoplasms
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Prostatic Neoplasms
PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.
Prostatic Neoplasms
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
Prostatic Neoplasms
Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
Prostatic Neoplasms
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Prostatic Neoplasms
Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
Prostatic Neoplasms
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.
Prostatic Neoplasms
Protein expression of PTEN, insulin-like growth factor I receptor (IGF1R), and lethal prostate cancer: a prospective study.
Prostatic Neoplasms
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Prostatic Neoplasms
PSMA brings new flavors to PI3K signaling: A role for glutamate in prostate cancer.
Prostatic Neoplasms
PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.
Prostatic Neoplasms
Rac1-dependent lamellipodial motility in prostate cancer PC-3 cells revealed by optogenetic control of Rac1 activity.
Prostatic Neoplasms
Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Prostatic Neoplasms
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Prostatic Neoplasms
Regulation of cell survival by resveratrol involves inhibition of NFkappaB-regulated gene expression in prostate cancer cells.
Prostatic Neoplasms
Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
Prostatic Neoplasms
Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA.
Prostatic Neoplasms
Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.
Prostatic Neoplasms
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.
Prostatic Neoplasms
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Prostatic Neoplasms
Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells.
Prostatic Neoplasms
Sanggenol L Induces Apoptosis and Cell Cycle Arrest via Activation of p53 and Suppression of PI3K/Akt/mTOR Signaling in Human Prostate Cancer Cells.
Prostatic Neoplasms
Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
Prostatic Neoplasms
SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP?2.
Prostatic Neoplasms
Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells.
Prostatic Neoplasms
SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.
Prostatic Neoplasms
Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors.
Prostatic Neoplasms
Structure-based assessment and network analysis of targeting 14-3-3 proteins in prostate cancer.
Prostatic Neoplasms
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Prostatic Neoplasms
Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002.
Prostatic Neoplasms
Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Prostatic Neoplasms
Synthesis and Characterization of a Novel Prostate Cancer-Targeted Phosphatidylinositol-3-kinase Inhibitor Prodrug.
Prostatic Neoplasms
Synthesis and PI3 Kinase Inhibition Activity of a Wortmannin-Leucine Derivative.
Prostatic Neoplasms
Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Prostatic Neoplasms
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Prostatic Neoplasms
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
Prostatic Neoplasms
The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.
Prostatic Neoplasms
The Androgen Receptor Induces Integrin {alpha}6{beta}1 to Promote Prostate Tumor Cell Survival via NF-{kappa}B and Bcl-xL Independently of PI3K Signaling.
Prostatic Neoplasms
The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.
Prostatic Neoplasms
The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Prostatic Neoplasms
The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells.
Prostatic Neoplasms
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.
Prostatic Neoplasms
The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways.
Prostatic Neoplasms
TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway.
Prostatic Neoplasms
Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells.
Prostatic Neoplasms
Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Prostatic Neoplasms
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
Prostatic Neoplasms
[Molecular subtypes and perspectives of targeted therapies in prostate cancer].
Prostatic Neoplasms
[PI3K/p110?-specific inhibitors in castration-resistant prostate cancer].
Protein Deficiency
Wiskott-Aldrich Syndrome Interacting Protein Deficiency Uncovers the Role of the Co-receptor CD19 as a Generic Hub for PI3 Kinase Signaling in B Cells.
Proteinuria
1,25-Dihydroxyvitamin D(3) Prevents Puromycin Aminonucleoside-Induced Apoptosis of Glomerular Podocytes by Activating the Phosphatidylinositol 3-Kinase/Akt-Signaling Pathway.
Proteinuria
Vps34 Deficiency Reveals the Importance of Endocytosis for Podocyte Homeostasis.
Psoriasis
Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin in?ammation.
Psoriasis
Expression of PI3K Signaling Associated with T Cells in Psoriasis Is Inhibited by Seletalisib, a PI3K? Inhibitor, and Is Required for Functional Activity.
Psoriasis
[Expressions of survivin, PI3K and AKT in keratinocytes in skin lesions and their pathogenic role in psoriasis vulgaris].
Psychomotor Agitation
Learning Deficits and Agenesis of Synapses and Myelinated Axons in Phosphoinositide-3 Kinase-Deficient Mice.
Puberty, Delayed
Loss of PI3K p110? in the Adipose Tissue Results in Infertility and Delayed Puberty Onset in Male Mice.
Pulmonary Adenomatosis, Ovine
A phosphatidylinositol 3-kinase docking site in the cytoplasmic tail of the Jaagsiekte sheep retrovirus transmembrane protein is essential for envelope-induced transformation of NIH 3T3 cells.
Pulmonary Adenomatosis, Ovine
Transformation of mouse fibroblasts by Jaagsiekte sheep retrovirus envelope does not require phosphatidylinositol 3-kinase.
Pulmonary Arterial Hypertension
Reversal of the Warburg effect with DCA in PDGF?treated human PASMC is potentiated by pyruvate dehydrogenase kinase?1 inhibition mediated through blocking Akt/GSK?3? signalling.
Pulmonary Arterial Hypertension
SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Suppression of Phosphatidylinositol 3-Kinase/Akt Signaling Attenuates Hypoxia-Induced Pulmonary Hypertension Through the Downregulation of Lysyl Oxidase.
Pulmonary Disease, Chronic Obstructive
Aberrant neutrophil functions in stable Chronic Obstructive Pulmonary Disease: The neutrophil as an immunotherapeutic target.
Pulmonary Disease, Chronic Obstructive
Bu-Shen-Fang-Chuan formula attenuates cigarette smoke-induced inflammation by modulating the PI3K/Akt-Nrf2 and NF-?B signalling pathways.
Pulmonary Disease, Chronic Obstructive
Combined Inhibition of PDE4 and PI3K? Modulates the Inflammatory Component Involved in the Progression of Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD.
Pulmonary Disease, Chronic Obstructive
Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.
Pulmonary Disease, Chronic Obstructive
Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling.
Pulmonary Disease, Chronic Obstructive
Endoplasmic reticulum stress and unfolded protein response in diaphragm muscle dysfunction of patients with stable chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Extracellular matrix promotes proliferation, migration and adhesion of airway smooth muscle cells in a rat model of chronic obstructive pulmonary disease via upregulation of the PI3K/AKT signaling pathway.
Pulmonary Disease, Chronic Obstructive
Functional redundancy of class I phosphoinositide 3-kinase (PI3K) isoforms in signaling growth factor-mediated human neutrophil survival.
Pulmonary Disease, Chronic Obstructive
Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing neutrophil migration.
Pulmonary Disease, Chronic Obstructive
Inactivation of MTOR promotes autophagy-mediated epithelial injury in particulate matter-induced airway inflammation.
Pulmonary Disease, Chronic Obstructive
Oxidative stress dependent microRNA-34a activation via PI3K? reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells.
Pulmonary Disease, Chronic Obstructive
PI3K signaling in chronic obstructive pulmonary disease: mechanisms, targets, and therapy.
Pulmonary Disease, Chronic Obstructive
PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy.
Pulmonary Disease, Chronic Obstructive
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Pulmonary Disease, Chronic Obstructive
The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.
Pulmonary Disease, Chronic Obstructive
The phosphoinositide 3'-kinase p110? modulates contractile protein production and IL-6 release in human airway smooth muscle.
Pulmonary Disease, Chronic Obstructive
The PI3K/AKT/mTOR pathway regulates autophagy to induce apoptosis of alveolar epithelial cells in chronic obstructive pulmonary disease caused by PM2.5 particulate matter.
Pulmonary Disease, Chronic Obstructive
Upregulation of IL-17A/F from human lung tissue explants with cigarette smoke exposure: implications for COPD.
Pulmonary Disease, Chronic Obstructive
[Expression of mitogen-actived protein kinase, phosphatidylinositol 3-kinase and hypoxia-inducible factor-1alpha in pulmonary arteries of patients with chronic obstructive pulmonary disease]
Pulmonary Edema
17ß-estradiol suppresses lipopolysaccharide-induced acute lung injury through PI3K/Akt/SGK1 mediated up-regulation of epithelial sodium channel (ENaC) in vivo and in vitro.
Pulmonary Fibrosis
Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis.
Pulmonary Fibrosis
Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis.
Pulmonary Fibrosis
Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis.
Pulmonary Fibrosis
Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.
Pulmonary Fibrosis
MiR-503 modulates epithelial-mesenchymal transition in silica-induced pulmonary fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1.
Pulmonary Fibrosis
Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways.
Pulmonary Fibrosis
[Preliminary study of exon sequence in pneumoconiosis using high-throughput and intervention of EGFR-TKIs on silicosis rats].
receptor protein-tyrosine kinase deficiency
p75NTR-dependent modulation of cellular handling of reactive oxygen species.
Rectal Neoplasms
A systematic approach introduced novel targets in rectal cancer by considering miRNA/mRNA interactions in response to radiotherapy.
Rectal Neoplasms
CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer.
Rectal Neoplasms
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Rectal Neoplasms
The Frequencies and Clinical Implications of Mutations in 33 Kinase-Related Genes in Locally Advanced Rectal Cancer: A Pilot Study.
Rectal Neoplasms
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies.
Relative Energy Deficiency in Sport
PI3K/AKT Pathway Involvement in the Osteogenic Effects of Osteoclast Culture Supernatants on Preosteoblast Cells.
Renal Insufficiency, Chronic
Investigation of the effects of indoxyl sulfate, a uremic toxin, on the intracellular oxidation level and phagocytic activity using an HL-60-differentiated human macrophage cell model.
Reperfusion Injury
Activation of cGMP/Protein Kinase G Pathway in Postconditioned Myocardium Depends on Reduced Oxidative Stress and Preserved Endothelial Nitric Oxide Synthase Coupling.
Reperfusion Injury
Apelin protects against ischemia-reperfusion injury in diabetic myocardium via inhibiting apoptosis and oxidative stress through PI3K and p38-MAPK signaling pathways.
Reperfusion Injury
Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts.
Reperfusion Injury
Cardioprotection of ischemic postconditioning and pharmacological post-treatment with adenosine or acetylcholine.
Reperfusion Injury
CTGF/CCN2 Postconditioning Increases Tolerance of Murine Hearts towards Ischemia-Reperfusion Injury.
Reperfusion Injury
Dexmedetomidine protects against lung ischemia-reperfusion injury by the PI3K/Akt/HIF-1? signaling pathway.
Reperfusion Injury
Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.
Reperfusion Injury
Enhanced recovery from ischemia-reperfusion injury in PI3K? dominant negative hearts: investigating the role of alternate PI3K isoforms, increased glucose oxidation and MAPK signaling.
Reperfusion Injury
Ginsenoside Rb1 preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction.
Reperfusion Injury
Intestinal Epithelial Cell-Derived ?-Opioid Signaling Protects against Ischemia Reperfusion Injury through PI3K Signaling.
Reperfusion Injury
Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency.
Reperfusion Injury
Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling.
Reperfusion Injury
MG53 constitutes a primary determinant of cardiac ischemic preconditioning.
Reperfusion Injury
Milrinone-induced postconditioning reduces hepatic ischemia-reperfusion injury in rats: the roles of phosphatidylinositol 3-kinase and nitric oxide.
Reperfusion Injury
Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition.
Reperfusion Injury
p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation.
Reperfusion Injury
Pharmacological postconditioning with Neuregulin-1 mimics the cardioprotective effects of ischaemic postconditioning via ErbB4-dependent activation of reperfusion injury salvage kinase pathway.
Reperfusion Injury
Pharmacological postconditioning with tanshinone IIA attenuates myocardial ischemia-reperfusion injury in rats by activating the phosphatidylinositol 3-kinase pathway.
Reperfusion Injury
PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats.
Reperfusion Injury
Protective effect of urantide against ischemia-reperfusion injury via protein kinase C and phosphtidylinositol 3'-kinase - Akt pathway.
Reperfusion Injury
Relaxin Protects Rat Lungs from Ischemia-Reperfusion Injury via Inducible NO Synthase: Role of ERK-1/2, PI3K, and Forkhead Transcription Factor FKHRL1.
Reperfusion Injury
Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3? in Rats.
Reperfusion Injury
Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium.
Reperfusion Injury
Role of Erk1/2, p70s6K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo: [Le role des Erk1/2, p70s6K et eNOS dans la cardioprotection induite par l'isoflurane pendant la reperfusion in vivo precoce].
Reperfusion Injury
The role of microRNA in modulating myocardial ischemia-reperfusion injury.
Reperfusion Injury
Therapeutic modulation of the phosphatidylinositol 3-kinases (PI3K) pathway in cerebral ischemic injury.
Respiratory Tract Infections
PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Retinal Diseases
Activation of type 5 metabotropic glutamate receptor promotes the proliferation of rat retinal progenitor cell via activation of the PI-3-K and MAPK signaling pathways.
Retinal Neovascularization
Down-regulation of microRNA-155 attenuates retinal neovascularization via the PI3K/Akt pathway.
Retinal Neovascularization
Effects of the phosphatidylinositol 3-kinase inhibitor in a mouse model of retinal neovascularization.
Retinal Neovascularization
Inhibition of LY294002 in retinal neovascularization via down-regulation the PI3K/AKT-VEGF pathway in vivo and in vitro.
Retinitis Pigmentosa
Activation of type 5 metabotropic glutamate receptor promotes the proliferation of rat retinal progenitor cell via activation of the PI-3-K and MAPK signaling pathways.
Retinoblastoma
A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy.
Retinoblastoma
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Retinoblastoma
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Retinoblastoma
Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.
Retinoblastoma
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Retinoblastoma
Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes.
Retinoblastoma
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
Retinoblastoma
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Retinoblastoma
Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.
Retinoblastoma
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Retinoblastoma
The botanical component p-hydroxycinnamic acid suppresses the growth and bone metastatic activity of human prostate cancer PC-3 cells in vitro.
Retinoblastoma
The phytochemical p-hydroxycinnamic acid suppresses the growth and stimulates the death in human liver cancer HepG2 cells.
Retinoblastoma
Transcriptional regulation of cellular ageing by the CCAAT box-binding factor CBF/NF-Y.
Rett Syndrome
Finding patients using similarity measures in a rare diseases-oriented clinical data warehouse: Dr. Warehouse and the needle in the needle stack.
Rhabdomyosarcoma
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Rhabdomyosarcoma
Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors.
Rhabdomyosarcoma
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Rhabdomyosarcoma
Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
Rhabdomyosarcoma
DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110? (H1047R).
Rhabdomyosarcoma
Effect of paraquat-induced oxidative stress on insulin regulation of insulin-like growth factor-binding protein-1 gene expression.
Rhabdomyosarcoma
Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
Rhabdomyosarcoma
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Rhabdomyosarcoma
It takes two to tango: dual inhibition of PI3K & MAPK in rhabdomyosarcoma.
Rhabdomyosarcoma
Regulation of hepatic insulin-like growth factor-binding protein-1 gene expression by insulin: central role for mammalian target of rapamycin independent of forkhead box O proteins.
Rhabdomyosarcoma, Alveolar
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rheumatic Diseases
The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.
Rhinitis, Allergic
Enhancement of allergic responses in vivo and in vitro by butylated hydroxytoluene.
Rhinitis, Allergic
PI3-Kinase Regulates Eosinophil and Neutrophil Degranulation in Patients with Allergic Rhinitis and Allergic Asthma Irrespective of Allergen Challenge Model.
Rhinitis, Allergic
Randomized phase 1 study of the phosphatidylinositol 3-kinase ? inhibitor idelalisib in patients with allergic rhinitis.
Rotavirus Infections
Activation of PI3K, Akt, and ERK during early rotavirus infection leads to V-ATPase-dependent endosomal acidification required for uncoating.
Rotavirus Infections
Death mechanisms in epithelial cells following rotavirus infection, exposure to inactivated rotavirus or genome transfection.
Rotavirus Infections
Molecular mechanism behind rotavirus NSP1-mediated PI3 kinase activation: interaction between NSP1 and the p85 subunit of PI3 kinase.
Rubella
Well begun is half done: Rubella virus perturbs autophagy signaling, thereby facilitating the construction of viral replication compartments.
Salivary Gland Neoplasms
The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Salmonella Infections
Modulation of chloride secretory responses and barrier function of intestinal epithelial cells by the Salmonella effector protein SigD.
Sarcoidosis, Pulmonary
Phosphoinositide 3-kinase/protein kinase B inhibition restores regulatory T cell's function in pulmonary sarcoidosis.
Sarcoma
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics.
Sarcoma
Biochemical and biological characterization of tumor-associated mutations of p110alpha.
Sarcoma
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
Sarcoma
Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Sarcoma
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Sarcoma
Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review.
Sarcoma
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Sarcoma
Diosgenin and 5-Methoxypsoralen Ameliorate Insulin Resistance through ER-?/PI3K/Akt-Signaling Pathways in HepG2 Cells.
Sarcoma
Effects of PTEN Loss and Activated KRAS Overexpression on Mechanical Properties of Breast Epithelial Cells.
Sarcoma
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Sarcoma
Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.
Sarcoma
ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Sarcoma
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Sarcoma
Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Sarcoma
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Sarcoma
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.
Sarcoma
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
Sarcoma
Identification of dysregulated pathways associated with pancreatic cancer by survival analysis.
Sarcoma
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma.
Sarcoma
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Sarcoma
PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance.
Sarcoma
Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.
Sarcoma
Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Sarcoma
Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling.
Sarcoma
Recurrent papillary thyroid carcinoma with pleural metastasis diagnosed by effusion cytology: a report of cases with clinicopathologic correlation.
Sarcoma
Reelin induces the detachment of postnatal subventricular zone cells and the expression of the Egr-1 through Erk1/2 activation.
Sarcoma
Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Sarcoma
Targeted genome-wide methylation and gene expression analyses reveal signaling pathways involved in ovarian dysfunction after developmental EDC exposure in rats.
Sarcoma
The Inhibition of PI3K-Akt Pathway Enhances Gamma-2 Herpesvirus Lytic Replication and Facilitates Reactivation from Latency.
Sarcoma
The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.
Sarcoma
Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
Sarcoma, Avian
Initiation factor eIF2B not p70 S6 kinase is involved in the activation of the PI-3K signalling pathway induced by the v-src oncogene.
Sarcoma, Avian
Stimulation of gene expression in neonatal rat ventricular myocytes by Ras is mediated by Ral guanine nucleotide dissociation stimulator (Ral.GDS) and phosphatidylinositol 3-kinase in addition to Raf.
Sarcoma, Avian
The PPAR? agonist efatutazone impairs TGF-?2-induced motility of EGFR tyrosine kinase inhibitor-resistant lung cancer cells.
Sarcoma, Avian
The SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytes.
Sarcoma, Ewing
Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma.
Sarcoma, Ewing
Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
Sarcoma, Synovial
Phosphatidylinositol-3'-kinase/AKT signalling is essential in synovial sarcoma.
Scleroderma, Diffuse
Analysis of PI3K Pathway Associated Molecules Reveals Dysregulated Innate and Adaptive Functions of B Cells in Early Diffuse Cutaneous Systemic Sclerosis.
Scleroderma, Systemic
Analysis of PI3K Pathway Associated Molecules Reveals Dysregulated Innate and Adaptive Functions of B Cells in Early Diffuse Cutaneous Systemic Sclerosis.
Seizures
Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death.
Seizures
CB2R induces a protective response for epileptic seizure via the PI3K 110?-AKT signaling pathway.
Seizures
Nicotine Alleviates Cortical Neuronal Injury by Suppressing Neuroinflammation and Upregulating Neuronal PI3K-AKT Signaling in an Eclampsia-Like Seizure Model.
Seizures
NMDA preconditioning protects against quinolinic acid-induced seizures via PKA, PI3K and MAPK/ERK signaling pathways.
Seizures
Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.
Seizures
Role of Phosphatidylinositol-3 Kinase Pathway in NMDA Preconditioning: Different Mechanisms for Seizures and Hippocampal Neuronal Degeneration Induced by Quinolinic Acid.
Seizures
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
Seizures
[Roles and mechanisms of traditional Chinese medicine and its active ingredients in treating epilepsy].
Seminoma
Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.
Seminoma
TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway.
Sepsis
A tetrahydroisoquinoline alkaloid THI-28 reduces LPS-induced HMGB1 and diminishes organ injury in septic mice through p38 and PI3K/Nrf2/HO-1 signals.
Sepsis
Activation of myocardial phosphoinositide-3-kinase p110? ameliorates cardiac dysfunction and improves survival in polymicrobial sepsis.
Sepsis
Artesunate ameliorates sepsis-induced acute lung injury by activating the mTOR/AKT/PI3K axis.
Sepsis
Deficiency of Phosphatidylinositol 3-Kinase ? Signaling Leads to Diminished Numbers of Regulatory T Cells and Increased Neutrophil Activity Resulting in Mortality Due to Endotoxic Shock.
Sepsis
Diacerhein attenuates the inflammatory response and improves survival in a model of severe sepsis.
Sepsis
Inhibition of the phosphoinositide 3-kinase pathway decreases innate resistance to lipopolysaccharide toxicity in TLR4 deficient mice.
Sepsis
Insulin hypersensitivity induced by hepatic PTEN gene ablation protects from murine endotoxemia.
Sepsis
Insulin modulates the inflammatory granulocyte response to streptococci via phosphatidylinositol 3-kinase.
Sepsis
Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism.
Sepsis
Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis.
Sepsis
Myeloid cell-specific inositol polyphosphate-4-phosphatase type I knockout mice impair bacteria clearance in a murine peritonitis model.
Sepsis
PKC and AKT Modulate cGMP/PKG Signaling Pathway on Platelet Aggregation in Experimental Sepsis.
Sepsis
Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis.
Sepsis
The phosphatidylinositol 3-kinase signaling pathway exerts protective effects during sepsis by controlling C5a-mediated activation of innate immune functions.
Severe Acute Respiratory Syndrome
Coronavirus interactions with the cellular autophagy machinery.
Severe Acute Respiratory Syndrome
Targeting autophagy in disease: established and new strategies.
Severe Combined Immunodeficiency
DNA-PKcs mutations in dogs and horses: allele frequency and association with neoplasia.
Shock, Septic
Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis.
Skin Neoplasms
5-deoxykaempferol plays a potential therapeutic role by targeting multiple signaling pathways in skin cancer.
Skin Neoplasms
Negative feedback regulation of phosphatidylinositol 3-kinase/Akt pathway by over-expressed cyclooxygenase-2 in human epidermal cancer cells.
Small Cell Lung Carcinoma
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
Small Cell Lung Carcinoma
Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.
Small Cell Lung Carcinoma
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
Small Cell Lung Carcinoma
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Small Cell Lung Carcinoma
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Small Cell Lung Carcinoma
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
Small Cell Lung Carcinoma
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Small Cell Lung Carcinoma
Targeting the phosphoinositide 3-kinase p110-? isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
Smith-Magenis Syndrome
Two Monogenetic Disorders, Activated PI3-Kinase-? Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Spasm
Regulatory role of hippocampal PI3K and mTOR signaling pathway in NMDA-induced infant spasm rats.
Spastic Paraplegia, Hereditary
ZFYVE26/SPASTIZIN and SPG11/SPATACSIN mutations in hereditary spastic paraplegia types AR-SPG15 and AR-SPG11 have different effects on autophagy and endocytosis.
sphingosine kinase deficiency
Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2.
Spinal Cord Injuries
A retinoic acid receptor beta agonist (CD2019) overcomes inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.
Spinal Cord Injuries
PI3 Kinase regulation of neural regeneration and muscle hypertrophy after spinal cord injury.
Spinal Cord Injuries
PI3K mediated activation of GSK-3? reduces at-level primary afferent growth responses associated with excitotoxic spinal cord injury dysesthesias.
Spinal Cord Injuries
Spinal cord injury causes insulin resistance associated with PI3K signaling pathway in hypothalamus.
Spinal Cord Injuries
Triggering of Autophagy by Baicalein in Response to Apoptosis after Spinal Cord Injury: Possible Involvement of the PI3K Activation.
Spinal Dysraphism
Disruption of PDGFRalpha-initiated PI3K activation and migration of somite derivatives leads to spina bifida.
Squamous Cell Carcinoma of Head and Neck
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K? inhibition in controlling tumor growth.
Squamous Cell Carcinoma of Head and Neck
A highway to carcinogenesis: the role of IQGAP1, a signaling scaffolding protein, in head and neck cancer development.
Squamous Cell Carcinoma of Head and Neck
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
Squamous Cell Carcinoma of Head and Neck
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Abnormal expression of PI3K isoforms in patients with tobacco-related oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
Squamous Cell Carcinoma of Head and Neck
Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy.
Squamous Cell Carcinoma of Head and Neck
AKT3 is a key regulator of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.
Squamous Cell Carcinoma of Head and Neck
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.
Squamous Cell Carcinoma of Head and Neck
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
Squamous Cell Carcinoma of Head and Neck
Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.
Squamous Cell Carcinoma of Head and Neck
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Squamous Cell Carcinoma of Head and Neck
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Squamous Cell Carcinoma of Head and Neck
EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers.
Squamous Cell Carcinoma of Head and Neck
Emerging Role of miR-372 and miR-101a in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors.
Squamous Cell Carcinoma of Head and Neck
Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors.
Squamous Cell Carcinoma of Head and Neck
Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor.
Squamous Cell Carcinoma of Head and Neck
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Squamous Cell Carcinoma of Head and Neck
Erratum to: Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Squamous Cell Carcinoma of Head and Neck
Exploring the importance of cancer pathways by meta-analysis of differential protein expression networks in three different cancers.
Squamous Cell Carcinoma of Head and Neck
Expression Analysis of GRHL3 and PHLDA3 in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Squamous Cell Carcinoma of Head and Neck
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Squamous Cell Carcinoma of Head and Neck
Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Squamous Cell Carcinoma of Head and Neck
Genomic landscape of human papillomavirus-associated cancers.
Squamous Cell Carcinoma of Head and Neck
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Inhibition of PI3K Isoform p110? Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
Squamous Cell Carcinoma of Head and Neck
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/?-catenin signaling pathway.
Squamous Cell Carcinoma of Head and Neck
Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab.
Squamous Cell Carcinoma of Head and Neck
Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
Squamous Cell Carcinoma of Head and Neck
Molecular landscape of head and neck cancer and implications for therapy.
Squamous Cell Carcinoma of Head and Neck
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
Squamous Cell Carcinoma of Head and Neck
Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Squamous Cell Carcinoma of Head and Neck
Omega-3 polyunsaturated fatty acids selectively inhibit growth in neoplastic oral keratinocytes by differentially activating ERK1/2.
Squamous Cell Carcinoma of Head and Neck
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Squamous Cell Carcinoma of Head and Neck
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Oral squamous cell carcinoma (OSCC)-derived exosomal MiR-221 targets and regulates phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) to promote human umbilical vein endothelial cells migration and tube formation.
Squamous Cell Carcinoma of Head and Neck
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
Squamous Cell Carcinoma of Head and Neck
Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF? signaling.
Squamous Cell Carcinoma of Head and Neck
p120-catenin suppresses proliferation and tumor growth of oral squamous cell carcinoma via inhibiting nuclear phospholipase C-?1 signaling.
Squamous Cell Carcinoma of Head and Neck
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
Squamous Cell Carcinoma of Head and Neck
PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice.
Squamous Cell Carcinoma of Head and Neck
PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Squamous Cell Carcinoma of Head and Neck
RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Squamous Cell Carcinoma of Head and Neck
Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Squamous Cell Carcinoma of Head and Neck
Role of IQGAP1 in Papillomavirus-Associated Head and Neck Tumorigenesis.
Squamous Cell Carcinoma of Head and Neck
Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target.
Squamous Cell Carcinoma of Head and Neck
Selective inhibition of PI3K110? as a novel therapeutic strategy for cetuximab?resistant oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
STAT3/HOTAIR signaling axis regulates HNSCC growth in an EZH2-dependent manner.
Squamous Cell Carcinoma of Head and Neck
TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K? inhibition in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Squamous Cell Carcinoma of Head and Neck
Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC).
Squamous Cell Carcinoma of Head and Neck
Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Taselisib (GDC-0032), a Potent ?-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Squamous Cell Carcinoma of Head and Neck
The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck.
Squamous Cell Carcinoma of Head and Neck
The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas.
Squamous Cell Carcinoma of Head and Neck
The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
Squamous Cell Carcinoma of Head and Neck
The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers.
Squamous Cell Carcinoma of Head and Neck
The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells.
Squamous Cell Carcinoma of Head and Neck
The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells.
Squamous Cell Carcinoma of Head and Neck
The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, crosstalk, and therapies.
Squamous Cell Carcinoma of Head and Neck
The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Squamous Cell Carcinoma of Head and Neck
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.
Squamous Cell Carcinoma of Head and Neck
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
[Expression and significance of Ki-67, PI3K and Beclin1 in oral squamous cell carcinoma].
Starvation
A fine-tuning mechanism underlying self-control for autophagy: deSUMOylation of BECN1 by SENP3.
Starvation
Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
Starvation
Biogenesis of autophagosomal precursors for LC3 lipidation from the ER-Golgi intermediate compartment.
Starvation
Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.
Starvation
Branched-Chain Amino Acid Negatively Regulates KLF15 Expression via PI3K-AKT Pathway.
Starvation
Class III phosphoinositide 3-kinase--Beclin1 complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes.
Starvation
Cul3-KLHL20 Ubiquitin Ligase Governs the Turnover of ULK1 and VPS34 Complexes to Control Autophagy Termination.
Starvation
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
Starvation
Cytokine-mediated FOXO3a phosphorylation suppresses FasL expression in hemopoietic cell lines: investigations of the role of Fas in apoptosis due to cytokine starvation.
Starvation
DAPK3 inhibits gastric cancer progression via activation of ULK1-dependent autophagy.
Starvation
Defect in skeletal muscle phosphatidylinositol-3-kinase in obese insulin-resistant mice.
Starvation
Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy.
Starvation
Endonuclease G promotes autophagy by suppressing mTOR signaling and activating the DNA damage response.
Starvation
Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication.
Starvation
Foot-and-mouth disease virus induces autophagosomes during cell entry via a class III phosphatidylinositol 3-kinase-independent pathway.
Starvation
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Starvation
hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase.
Starvation
IL-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway.
Starvation
Integrated and comparative miRNA analysis of starvation-induced autophagy in mouse embryonic fibroblasts.
Starvation
MAP1B-LC1 prevents autophagosome formation by linking syntaxin 17 to microtubules.
Starvation
Negative feedback loops: nutrient starvation employs a new tr(IKK) to inhibit PI3K.
Starvation
Negative regulation of miR-145 by C/EBP-? through the Akt pathway in cancer cells.
Starvation
Nutritional control of gene expression in Drosophila larvae via TOR, Myc and a novel cis-regulatory element.
Starvation
p85? SH2 Domain Phosphorylation by IKK Promotes Feedback Inhibition of PI3K and Akt in Response to Cellular Starvation.
Starvation
PAQR3 controls autophagy by integrating AMPK signaling to enhance ATG14L-associated PI3K activity.
Starvation
Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34.
Starvation
Phosphatidylinositol 3-kinase and COPII generate LC3 lipidation vesicles from the ER-Golgi intermediate compartment.
Starvation
Phosphatidylinositol 3-kinase, Cdc42, and Rac1 act downstream of Ras in integrin-dependent neurite outgrowth in N1E-115 neuroblastoma cells.
Starvation
Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria.
Starvation
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans.
Starvation
Post-transcriptional regulation of autophagy in C2C12 myotubes following starvation and nutrient restoration.
Starvation
PRKAA/AMPK? phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.
Starvation
Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy.
Starvation
Regulation of V-ATPase Assembly in Nutrient Sensing and Function of V-ATPases in Breast Cancer Metastasis.
Starvation
Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy.
Starvation
The Ancient Phosphatidylinositol 3-Kinase Signaling System Is a Master Regulator of Energy and Carbon Metabolism in Algae.
Starvation
ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase.
Starvation
ULK1 phosphorylates Ser30 of BECN1 in association with ATG14 to stimulate autophagy induction.
Status Epilepticus
Peroxisome Proliferator-Activated Receptor ? Coactivator 1? Activates Vascular Endothelial Growth Factor That Protects Against Neuronal Cell Death Following Status Epilepticus through PI3K/AKT and MEK/ERK Signaling.
Stomach Neoplasms
2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer.
Stomach Neoplasms
A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
Stomach Neoplasms
Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN?28 cells via the PI3K signaling pathway.
Stomach Neoplasms
Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer.
Stomach Neoplasms
Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions.
Stomach Neoplasms
Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
Stomach Neoplasms
Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway.
Stomach Neoplasms
Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1.
Stomach Neoplasms
BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.
Stomach Neoplasms
Celastrol Induces Apoptosis of Gastric Cancer Cells by miR-21 Inhibiting PI3K/Akt-NF-?B Signaling Pathway.
Stomach Neoplasms
Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates autophagy and induces apoptosis through p53 pathway in gastric cancer cell line SGC7901.
Stomach Neoplasms
Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.
Stomach Neoplasms
Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer.
Stomach Neoplasms
Combination of cecropinXJ and LY294002 induces synergistic cytotoxicity, and apoptosis in human gastric cancer cells via inhibition of the PI3K/Akt signaling pathway.
Stomach Neoplasms
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Stomach Neoplasms
Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer.
Stomach Neoplasms
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Stomach Neoplasms
Curcumin regulates proliferation, autophagy and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling.
Stomach Neoplasms
Curcumol improves cisplatin sensitivity of human gastric cancer cells through inhibiting PI3K/AKT pathway.
Stomach Neoplasms
Downregulation of HIF-1? inhibits the proliferation, migration and invasion of gastric cancer by inhibiting PI3K/AKT pathway and VEGF expression.
Stomach Neoplasms
Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy.
Stomach Neoplasms
Effect of PI3K gene silencing on growth, migration and related proteins expression of CD40 signal-mediated gastric cancer cells.
Stomach Neoplasms
Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells.
Stomach Neoplasms
Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.
Stomach Neoplasms
Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library.
Stomach Neoplasms
GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT-Mediated EMT.
Stomach Neoplasms
Helicobacter pylori regulates cellular migration and apoptosis by activation of phosphatidylinositol 3-kinase signaling.
Stomach Neoplasms
HER-2-induced PI3K signaling pathway was involved in the pathogenesis of gastric cancer.
Stomach Neoplasms
IL-1? promotes the nuclear translocaiton of S100A4 protein in gastric cancer cells MGC803 and the cell's stem-like properties through PI3K pathway.
Stomach Neoplasms
Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Stomach Neoplasms
Intestinal trefoil factor confers colonic epithelial resistance to apoptosis.
Stomach Neoplasms
Isorhamnetin Promotes MKN-45 Gastric Cancer Cell Apoptosis by Inhibiting PI3K-Mediated Adaptive Autophagy in a Hypoxic Environment.
Stomach Neoplasms
Kaempferol suppresses human gastric cancer SNU-216 cell proliferation, promotes cell autophagy, but has no influence on cell apoptosis.
Stomach Neoplasms
Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Stomach Neoplasms
Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer.
Stomach Neoplasms
LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells.
Stomach Neoplasms
LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Stomach Neoplasms
Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells.
Stomach Neoplasms
Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway.
Stomach Neoplasms
Markers CD40, VEGF, AKT, PI3K, and S100 Correlate with Tumor Stage in Gastric Cancer.
Stomach Neoplasms
Metformin inhibits gastric cancer via the inhibition of HIF1?/PKM2 signaling.
Stomach Neoplasms
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
Stomach Neoplasms
MicroRNA?495 regulates human gastric cancer cell apoptosis and migration through Akt and mTOR signaling.
Stomach Neoplasms
miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.
Stomach Neoplasms
Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer.
Stomach Neoplasms
Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway.
Stomach Neoplasms
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Stomach Neoplasms
Osteopontin promotes the progression of gastric cancer through the NF-?B pathway regulated by the MAPK and PI3K.
Stomach Neoplasms
Overexpression of PI3K p110? contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Stomach Neoplasms
Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells.
Stomach Neoplasms
Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric cancer cells.
Stomach Neoplasms
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation.
Stomach Neoplasms
Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.
Stomach Neoplasms
Piperine Inhibits Cell Proliferation and Induces Apoptosis of Human Gastric Cancer Cells by Downregulating Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway.
Stomach Neoplasms
PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.
Stomach Neoplasms
PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo.
Stomach Neoplasms
Rafoxanide promotes apoptosis and autophagy of gastric cancer cells by suppressing PI3K /Akt/mTOR pathway.
Stomach Neoplasms
Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.
Stomach Neoplasms
Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Stomach Neoplasms
Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma.
Stomach Neoplasms
Silencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell proliferation, migration, and invasion while promoting apoptosis through the PI3k-Akt signaling pathway.
Stomach Neoplasms
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Stomach Neoplasms
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Stomach Neoplasms
The Effect of hsa-miR-451b Knockdown on Biological Functions of Gastric Cancer Stem-Like Cells.
Stomach Neoplasms
Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Stomach Neoplasms
VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-?/ERK/RSK2 signaling.
Stomach Neoplasms
ZIC1 modulates cell-cycle distributions and cell migration through regulation of sonic hedgehog, PI3K and MAPK signaling pathways in gastric cancer.
Stomach Neoplasms
[Effects of combined therapy of LY294002 and SN50 on nude mice model with gastric cancer].
Stomach Neoplasms
[Impact of PI3K /Akt /mdm2 signaling pathway on the sensitivity of gastric cancer cell line SGC7901 to doxorubicin]
Stomach Neoplasms
[Recombinant methioninase regulates PI3K/Akt/Glut-1 pathway and inhibits aerobic glycolysis to promote apoptosis of gastric cancer cells].
Stomach Neoplasms
[The relationship of mTOR signaling pathway and histone acetylation in human gastric cancer cell lines]
Stomach Ulcer
Novel roles of local insulin-like growth factor-1 activation in gastric ulcer healing: promotes actin polymerization, cell proliferation, re-epithelialization, and induces cyclooxygenase-2 in a phosphatidylinositol 3-kinase-dependent manner.
Stomatitis
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Stroke
Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway.
Stroke
Ferulic acid-loaded nanostructured lipid carriers: A promising nanoformulation against the ischemic neural injuries.
Stroke
Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor.
Stroke
Regulation of PI3K and Hand2 gene on physiological hypertrophy of heart following high-intensity interval, and endurance training.
Stroke
The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction.
Stroke
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Sturge-Weber Syndrome
The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation.
Subarachnoid Hemorrhage
Phosphatidylinositol 3-kinase inhibitor failed to reduce cerebral vasospasm in dog model of experimental subarachnoid hemorrhage.
Subarachnoid Hemorrhage
The anti-apoptotic effect of PI3K-Akt signaling pathway after subarachnoid hemorrhage in rats.
Synovitis
PI3K/Akt inhibitor partly decreases TNF-?-induced activation of fibroblast-like synoviocytes in osteoarthritis.
Syphilis
Recombinant Treponema pallidum protein Tp0136 promotes fibroblast migration by modulating MCP-1/CCR2 through TLR4.
Tachycardia
Receptor-independent activation of GABAergic neurotransmission and receptor-dependent nontranscriptional activation of phosphatidylinositol 3-kinase/protein kinase Akt pathway in short-term cardiovascular actions of dexamethasone at the nucleus tractus solitarii of the rat.
Telangiectasia, Hereditary Hemorrhagic
ALK1 (Activin-Receptor Like Kinase 1) Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K (Phosphatidylinositol 3-Kinase) Activation.
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
ALK1 (Activin-Receptor Like Kinase 1) Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K (Phosphatidylinositol 3-Kinase) Activation.
Telangiectasis
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia.
Telangiectasis
PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1.
Telangiectasis
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Testicular Neoplasms
Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility.
Tetanus
Estrogen enhances depolarization-induced glutamate release through activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase in cultured hippocampal neurons.
Tetanus
Morphine Prevents Lipopolysaccharide-Induced TNF Secretion in Mast Cells Blocking I?B Kinase Activation and SNAP-23 Phosphorylation: Correlation with the Formation of a ?-Arrestin/TRAF6 Complex.
Tetanus
Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat.
Tetanus
Soluble ?Klotho downregulates Orai1-mediated store-operated Ca2+ entry via PI3K-dependent signaling.
Tetanus
The C-terminal domain of the heavy chain of tetanus toxin rescues cerebellar granule neurones from apoptotic death: involvement of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways.
Thrombocythemia, Essential
IL6 inhibition of inflammatory S100A8/9 proteins is NF-?B mediated in essential thrombocythemia.
Thrombocytopenia
Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.
Thromboembolism
PI3K pathway activation and thromboembolism in ovarian clear cell carcinomas.
Thrombosis
A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth.
Thrombosis
Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
Thrombosis
Anti-thrombotic effects of ?-linolenic acid isolated from Zanthoxylum bungeanum Maxim seeds.
Thrombosis
Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Thrombosis
Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase.
Thrombosis
Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization.
Thrombosis
Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release.
Thrombosis
Letter by Sonkar et al Regarding Article, "Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase".
Thrombosis
Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161.
Thrombosis
Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation.
Thrombosis
Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces.
Thrombosis
Platelet CD40L Modulates Thrombus Growth Via Phosphatidylinositol 3-Kinase ?, and Not Via CD40 and I?B Kinase ?.
Thrombosis
Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Thrombosis
Repetitive progressive thermal preconditioning hinders thrombosis by reinforcing phosphatidylinositol 3-kinase/Akt-dependent heat-shock protein/endothelial nitric oxide synthase signaling.
Thrombosis
Response by Liu and Hu to Letter Regarding Article, "Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase".
Thrombosis
Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of PI3K.
Thrombosis
Stimulation of mTORC2 by integrin ?IIb?3 is required for PI3K?-dependent activation of Akt but is dispensable for platelet spreading on fibrinogen.
Thrombosis
The lipid products of phosphoinositide 3-kinase isoforms in cancer and thrombosis.
Thrombosis
The PI3K? Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
Thrombosis
The role of class I, II and III PI 3-kinases in platelet production and activation and their implication in thrombosis.
Thrombosis
Tripeptide SQL Inhibits Platelet Aggregation and Thrombus Formation by Affecting PI3K/Akt Signaling.
Thymoma
A common variation of the PTEN gene is associated with peripheral insulin resistance.
Thymoma
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.
Thymoma
A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice.
Thymoma
Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt.
Thymoma
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics.
Thymoma
Cell quality control mechanisms maintain stemness and differentiation potential of P19 embryonic carcinoma cells.
Thymoma
Deficient tyrosine phosphorylation of c-Cbl and associated proteins in phorbol ester-resistant EL4 mouse thymoma cells.
Thymoma
Effects of low-level laser irradiation on mesenchymal stem cell proliferation: a microarray analysis.
Thymoma
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Thymoma
Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Thymoma
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Thymoma
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
Thymoma
Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
Thymoma
Green tea polyphenols improve cardiac muscle mRNA and protein levels of signal pathways related to insulin and lipid metabolism and inflammation in insulin-resistant rats.
Thymoma
Hypoglycaemia induced by Trichinella infection is due to the increase of glucose uptake in infected muscle cells.
Thymoma
Interleukin-1 beta induced synthesis of protein kinase C-delta and protein kinase C-epsilon in EL4 thymoma cells: possible involvement of phosphatidylinositol 3-kinase.
Thymoma
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Thymoma
Phosphoinositide 3-Kinase p110? Mediates Estrogen- and FSH-Stimulated Ovarian Follicle Growth.
Thymoma
PI3K/AKT, JNK, and ERK pathways are not crucial for the induction of cholesterol biosynthesis gene transcription in intestinal epithelial cells following treatment with the potato glycoalkaloid alpha-chaconine.
Thymoma
Regulation of cumulus expansion and hyaluronan synthesis in porcine oocyte-cumulus complexes during in vitro maturation.
Thymoma
Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal.
Thymoma
Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth.
Thymoma
The PPAR? agonist efatutazone impairs TGF-?2-induced motility of EGFR tyrosine kinase inhibitor-resistant lung cancer cells.
Thymoma
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Thymoma
TP53 Tumor-suppressor Gene Plays a Key Role in IGF1 Signaling Pathway Related to the Aging of Human Melanocytes.
Thymoma
Transcriptomic differences of genes in the avian target of rapamycin (avTOR) pathway in a divergent line of meat-type chickens selected for feed efficiency.
Thyroid Cancer, Papillary
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Thyroid Cancer, Papillary
Downregulation of BANCR Promotes Aggressiveness in Papillary Thyroid Cancer via the MAPK and PI3K Pathways.
Thyroid Cancer, Papillary
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Thyroid Cancer, Papillary
Mammaliam target of rapamycin (mTOR) down-regulates iodide uptake in thyrocytes.
Thyroid Cancer, Papillary
miRNA?148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways.
Thyroid Cancer, Papillary
Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
Thyroid Cancer, Papillary
Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
Thyroid Cancer, Papillary
Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma.
Thyroid Cancer, Papillary
The role of PI3K signaling pathway and its associated genes in papillary thyroid cancer.
Thyroid Carcinoma, Anaplastic
Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice.
Thyroid Carcinoma, Anaplastic
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Thyroid Carcinoma, Anaplastic
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.
Thyroid Carcinoma, Anaplastic
Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem Cells
Thyroid Carcinoma, Anaplastic
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
Thyroid Carcinoma, Anaplastic
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.
Thyroid Diseases
Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
Thyroid Neoplasms
A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
Thyroid Neoplasms
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
Thyroid Neoplasms
Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.
Thyroid Neoplasms
Calcium-mediated activation of PI3K and p53 leads to apoptosis in thyroid carcinoma cells.
Thyroid Neoplasms
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Thyroid Neoplasms
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.
Thyroid Neoplasms
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Thyroid Neoplasms
Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.
Thyroid Neoplasms
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Thyroid Neoplasms
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Thyroid Neoplasms
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Thyroid Neoplasms
HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway.
Thyroid Neoplasms
Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway.
Thyroid Neoplasms
Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity.
Thyroid Neoplasms
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Thyroid Neoplasms
Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway.
Thyroid Neoplasms
LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110?.
Thyroid Neoplasms
MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Thyroid Neoplasms
Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin.
Thyroid Neoplasms
O-GlcNAcylation enhances the invasion of thyroid anaplastic cancer cells partially by PI3K/Akt1 pathway.
Thyroid Neoplasms
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.
Thyroid Neoplasms
Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas.
Thyroid Neoplasms
Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
Thyroid Neoplasms
PI3K inhibitors IC87114 inhibits the migration and invasion of thyroid cancer cell in vitro and in vivo.
Thyroid Neoplasms
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
Thyroid Neoplasms
RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation.
Thyroid Neoplasms
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.
Thyroid Neoplasms
SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway.
Thyroid Neoplasms
Signaling pathways in follicular cell-derived thyroid carcinomas (review).
Thyroid Neoplasms
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.
Thyroid Neoplasms
Synergistic action of a RAF inhibitor and a dual PI-3 Kinase / mTOR inhibitor in thyroid cancer.
Thyroid Neoplasms
Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Thyroid Neoplasms
The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.
Thyroid Neoplasms
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.
Thyroid Neoplasms
Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.
Thyroid Neoplasms
Treatment Directed To Signalling Molecules In Patients With Advanced Differentiated Thyroid Cancer.
Thyroid Neoplasms
ß-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation.
Thyroid Nodule
HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Thyroid Nodule
The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization.
Thyroiditis
Edaravone ameliorates experimental autoimmune thyroiditis in rats through HO-1-dependent STAT3/PI3K/Akt pathway.
Thyroiditis
The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization.
Tics
Cancer Stem Cell-Like Phenotype and Survival Are Coordinately Regulated by Akt/FoxO/Bim Pathway.
Tongue Neoplasms
In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines.
Tongue Neoplasms
LncRNA MALAT1 expression inhibition suppresses tongue squamous cell carcinoma proliferation, migration and invasion by inactivating PI3K/Akt pathway and downregulating MMP-9 expression.
Tongue Neoplasms
Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations.
Tonsillar Neoplasms
Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Toxic Optic Neuropathy
Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors.
Triple Negative Breast Neoplasms
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.
Triple Negative Breast Neoplasms
BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells.
Triple Negative Breast Neoplasms
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Triple Negative Breast Neoplasms
Closing escape routes: inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors.
Triple Negative Breast Neoplasms
Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Triple Negative Breast Neoplasms
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Triple Negative Breast Neoplasms
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Triple Negative Breast Neoplasms
Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Triple Negative Breast Neoplasms
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer.
Triple Negative Breast Neoplasms
Expression of Bioinformatically Candidate miRNAs including, miR-576-5p, miR-501-3p and miR-3143, Targeting PI3K Pathway in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.
Triple Negative Breast Neoplasms
MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
Triple Negative Breast Neoplasms
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Triple Negative Breast Neoplasms
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Triple Negative Breast Neoplasms
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Triple Negative Breast Neoplasms
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Triple Negative Breast Neoplasms
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Triple Negative Breast Neoplasms
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Triple Negative Breast Neoplasms
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Triple Negative Breast Neoplasms
PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K?
Triple Negative Breast Neoplasms
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.
Triple Negative Breast Neoplasms
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Triple Negative Breast Neoplasms
Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.
Triple Negative Breast Neoplasms
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.
Triple Negative Breast Neoplasms
Targeting PI3K and AMPK? Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer.
Triple Negative Breast Neoplasms
TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer.
Triple Negative Breast Neoplasms
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
Triple Negative Breast Neoplasms
[Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Trophoblastic Neoplasms
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
Tuberculosis
B Cells and Programmed Death-Ligand 2 Signaling Are Required for Maximal Interferon-? Recall Response by Splenic CD4? Memory T Cells of Mice Vaccinated with Mycobacterium tuberculosis Ag85B.
Tuberculosis
Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection.
Tuberculosis
Hydrogen sulfide-induced GAPDH sulfhydration disrupts the CCAR2-SIRT1 interaction to initiate autophagy.
Tuberculosis
Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages.
Tuberculosis
M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival.
Tuberculosis
Role of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in the secretion of tumor necrosis factor-alpha and interleukin-10 by the PPD antigen of Mycobacterium tuberculosis.
Tuberculosis
Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase.
Tuberculosis
Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade.
Tuberous Sclerosis
A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.
Tuberous Sclerosis
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
Tuberous Sclerosis
Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.
Tuberous Sclerosis
Dally Proteoglycan Mediates the Autonomous and Nonautonomous Effects on Tissue Growth Caused by Activation of the PI3K and TOR Pathways.
Tuberous Sclerosis
Dexamethasone may inhibit placental growth by blocking glucocorticoid receptors via phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin and reactive oxygen species/AMP-activated protein kinase signalling pathways in human placental JEG-3 cells.
Tuberous Sclerosis
Effect of Sishen Pill on Memory T Cells From Experimental Colitis Induced by Dextran Sulfate Sodium.
Tuberous Sclerosis
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.
Tuberous Sclerosis
Neuropsychological Attention Skills and Related Behaviours in Adults with Tuberous Sclerosis Complex.
Tuberous Sclerosis
New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
Tuberous Sclerosis
p38? senses environmental stress to control innate immune responses via mechanistic target of rapamycin.
Tuberous Sclerosis
Significance of dynamic changes in gastric smooth muscle cell apoptosis, PI3K-AKT-mTOR and AMPK-mTOR signaling in a rat model of diabetic gastroparesis.
Tuberous Sclerosis
Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promise.
Tuberous Sclerosis
The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1? and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
Tuberous Sclerosis
The mitochondrial uncoupler DNP triggers brain cell mTOR signaling network reprogramming and CREB pathway up-regulation.
Tuberous Sclerosis
The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
Tuberous Sclerosis
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.
Tuberous Sclerosis
Transforming Growth Factor-? Signaling Participates in the Maintenance of the Primordial Follicle Pool in the Mouse Ovary.
Tuberous Sclerosis
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling.
Ureteral Obstruction
Increased Phosphorylation of PI3K/Akt/mTOR in the Obstructed Kidney of Rats with Unilateral Ureteral Obstruction.
Urinary Bladder Neoplasms
Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.
Urinary Bladder Neoplasms
Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer.
Urinary Bladder Neoplasms
Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
Urinary Bladder Neoplasms
Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance.
Urinary Bladder Neoplasms
Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin ?1 Signaling Pathways in Bladder Carcinoma.
Urinary Bladder Neoplasms
Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Urinary Bladder Neoplasms
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Urinary Bladder Neoplasms
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
Matrine inhibits bladder cancer cell growth and invasion in vitro through PI3K/AKT signaling pathway: An experimental study.
Urinary Bladder Neoplasms
Molecular pathways of urothelial development and bladder tumorigenesis.
Urinary Bladder Neoplasms
Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.
Urinary Bladder Neoplasms
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Urinary Bladder Neoplasms
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
Urinary Bladder Neoplasms
Phosphatidylinositol 3-Kinase Inhibitor LY294002 Suppresses Proliferation and Sensitizes Doxorubicin Chemotherapy in Bladder Cancer Cells.
Urinary Bladder Neoplasms
Prediction of recurrence and progression in patients with T1G3 bladder cancer by gene expression of circulating tumor cells.
Urinary Bladder Neoplasms
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
Urinary Bladder Neoplasms
Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling.
Urinary Bladder Neoplasms
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
Urinary Bladder Neoplasms
Suppressive effect of platycodin D on bladder cancer through microRNA-129-5p-mediated PABPC1/PI3K/AKT axis inactivation.
Urinary Bladder Neoplasms
Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells.
Urinary Bladder Neoplasms
The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo.
Urinary Bladder Neoplasms
The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
Urinary Bladder Neoplasms
Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways.
Uterine Cervical Neoplasms
17?-Oestradiol activates proteolysis and increases invasion through phosphatidylinositol 3-kinase pathway in human cervical cancer cells.
Uterine Cervical Neoplasms
?-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling.
Uterine Cervical Neoplasms
A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth.
Uterine Cervical Neoplasms
Astragaloside IV inhibits the invasion and metastasis of SiHa cervical cancer cells via the TGF??1?mediated PI3K and MAPK pathways.
Uterine Cervical Neoplasms
Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3-kinase Inhibition in the Human Cervical Cancer Cell-line.
Uterine Cervical Neoplasms
Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway.
Uterine Cervical Neoplasms
CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer.
Uterine Cervical Neoplasms
Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells.
Uterine Cervical Neoplasms
CLIC1 promotes the progression of cervical cancer through the PTEN / PI3K / AKT pathway.
Uterine Cervical Neoplasms
Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.
Uterine Cervical Neoplasms
Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.
Uterine Cervical Neoplasms
Expression of PI3K and ERK in Uygur and Han patients with cervical squamous cancer.
Uterine Cervical Neoplasms
Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-?B Signaling Pathway.
Uterine Cervical Neoplasms
Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway.
Uterine Cervical Neoplasms
Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States.
Uterine Cervical Neoplasms
Genetic and methylation-induced loss of miR-181a2/181b2 within chr9q33.3 facilitate tumor growth of cervical cancer through PIK3R3/Akt/FoxO signaling pathway.
Uterine Cervical Neoplasms
Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Uterine Cervical Neoplasms
Hypoxia stimulates invasion and migration of human cervical cancer cell lines HeLa/SiHa through the Rab11 trafficking of integrin ?v?3/FAK/PI3K pathway-mediated Rac1 activation.
Uterine Cervical Neoplasms
Identification and characterization of HPV-independent cervical cancers.
Uterine Cervical Neoplasms
Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.
Uterine Cervical Neoplasms
INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
Uterine Cervical Neoplasms
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19?784 Diverse Solid Tumors.
Uterine Cervical Neoplasms
Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells.
Uterine Cervical Neoplasms
MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Uterine Cervical Neoplasms
MicroRNA?433 inhibits cell growth and induces apoptosis in human cervical cancer through PI3K/AKT signaling by targeting FAK.
Uterine Cervical Neoplasms
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Uterine Cervical Neoplasms
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
Uterine Cervical Neoplasms
Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer.
Uterine Cervical Neoplasms
Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Uterine Cervical Neoplasms
PI3K p110? inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673.
Uterine Cervical Neoplasms
PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis.
Uterine Cervical Neoplasms
PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Uterine Cervical Neoplasms
RCE?4, a potential anti?cervical cancer drug isolated from Reineckia carnea, induces autophagy via the dual blockade of PI3K and ERK pathways in cervical cancer CaSki cells.
Uterine Cervical Neoplasms
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Uterine Cervical Neoplasms
S100A6 promotes the proliferation and migration of cervical cancer cells via the PI3K/Akt signaling pathway.
Uterine Cervical Neoplasms
Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway.
Uterine Cervical Neoplasms
STC1 promotes cell apoptosis via NF-?B phospho-P65 Ser536 in cervical cancer cells.
Uterine Cervical Neoplasms
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Uterine Cervical Neoplasms
Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
Uterine Cervical Neoplasms
The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer.
Uterine Cervical Neoplasms
The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Uterine Cervical Neoplasms
The TLR3, PI3K, survivin, FasL, and Fas genes as major risk factors of occurrence and development of cervical cancer disease.
Uterine Cervical Neoplasms
Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
Uterine Cervical Neoplasms
[Influce of lysophosphatidic acid on proliferation, adhesion, migration and apoptosis of cervical cancer HeLa cells.]
Uterine Hemorrhage
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
Uterine Neoplasms
Activated Mutant p110? Causes Endometrial Carcinoma in the Setting of Biallelic Pten Deletion.
Uterine Neoplasms
The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer.
Vaccinia
A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
Vaccinia
Integrin ?1 mediates vaccinia virus entry through activation of PI3K/Akt signaling.
Vaccinia
PI3K signaling regulates rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells.
Varicocele
Human sperm anatomy: different expression and localization of phosphatidylinositol 3-kinase in normal and varicocele human spermatozoa.
Vascular Malformations
mTORc1 activity is necessary and sufficient for phosphorylation of eNOSS1177.
Vascular Malformations
PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia.
Vascular Malformations
Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
Vascular Malformations
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.
Vascular System Injuries
Differential Phosphoinositide 3-Kinase Signaling: Implications for PTCA?
Vascular System Injuries
Naringenin-induced HO-1 ameliorates high glucose or free fatty acids-associated apoptosis via PI3K and JNK/Nrf2 pathways in human umbilical vein endothelial cells.
Vascular System Injuries
Neutralizing interferon-? blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus.
Vasculitis
A phosphatidylinositol 3-kinase inhibitor strongly suppressed pulmonary vascular remodeling of allergic vasculitis in a murine model.
Vasospasm, Intracranial
Phosphatidylinositol 3-kinase inhibitor failed to reduce cerebral vasospasm in dog model of experimental subarachnoid hemorrhage.
Vasospasm, Intracranial
Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase.
Ventilator-Induced Lung Injury
Pulmonary-derived phosphoinositide 3-kinase gamma (PI3K?) contributes to ventilator-induced lung injury and edema.
Vesicular Stomatitis
Autophagy and innate immunity: Insights from invertebrate model organisms.
Vesicular Stomatitis
HIV-1 Nef counteracts autophagy restriction by enhancing the association between BECN1 and its inhibitor BCL2 in a PRKN-dependent manner.
Vesicular Stomatitis
Influenza M2 protein regulates MAVS-mediated signaling pathway through interacting with MAVS and increasing ROS production.
Vesicular Stomatitis
TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages.
Viremia
A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
Viremia
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Viremia
Early diagnosis of PI3K? syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Viremia
Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility.
Virus Diseases
Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway during porcine circovirus type 2 infection facilitates cell survival and viral replication.
Virus Diseases
Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence.
Virus Diseases
CATION CURRENTS IN HUMAN AIRWAY EPITHELIAL CELLS INDUCED BY INFECTION WITH INFLUENZA A VIRUS.
Virus Diseases
Crimean-Congo hemorrhagic fever virus entry into host cells occurs through the multivesicular body and requires ESCRT regulators.
Virus Diseases
Early events in the generation of autophagosomes are required for the formation of membrane structures involved in hepatitis C virus genome replication.
Virus Diseases
Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation.
Virus Diseases
Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection.
Virus Diseases
Impaired B cell function during viral infections due to PTEN-mediated inhibition of the PI3K pathway.
Virus Diseases
Infectious bursal disease virus activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway by interaction of VP5 protein with the p85? subunit of PI3K.
Virus Diseases
Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K.
Virus Diseases
Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses.
Virus Diseases
Integrin ?1 mediates vaccinia virus entry through activation of PI3K/Akt signaling.
Virus Diseases
IRF-3 activation by sendai virus infection is required for cellular apoptosis and avoidance of persistence.
Virus Diseases
Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity.
Virus Diseases
Phosphatidylinositol 3-kinase regulates macrophage responses to double-stranded RNA and encephalomyocarditis virus.
Virus Diseases
Phosphatidylinositol-3-kinase and Akt are required for RIG-I-mediated anti-viral signalling through cross-talk with IPS-1.
Virus Diseases
PI3K signaling delays Sendai virus-induced apoptosis by preventing XIAP degradation.
Virus Diseases
PI3K? Is Critical for Dendritic Cell-Mediated CD8+ T Cell Priming and Viral Clearance during Influenza Virus Infection.
Virus Diseases
Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent.
Virus Diseases
SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation.
Virus Diseases
Suppression of Virulent Porcine Epidemic Diarrhea Virus Proliferation by the PI3K/Akt/GSK-3?/? Pathway.
Virus Diseases
Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.
Virus Diseases
TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages.
Virus Diseases
Transient activation of the PI3K/Akt pathway promotes Newcastle disease virus replication and enhances anti-apoptotic signaling responses.
Vitiligo
Reduced Nrf2 activation in PI3K phosphorylation-impaired vitiliginous keratinocytes increases susceptibility to ROS-generating chemical-induced apoptosis.
Vitreoretinopathy, Proliferative
All-trans retinoic acid suppresses the adhering ability of ARPE-19 cells via mitogen-activated protein kinase and focal adhesion kinase.
Waldenstrom Macroglobulinemia
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Waldenstrom Macroglobulinemia
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Wasting Syndrome
Impaired autophagy, defective T cell homeostasis, and a wasting syndrome in mice with a T cell-specific deletion of Vps34.
Werner Syndrome
Association of impaired phosphatidylinositol 3-kinase activity in GLUT1-containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome.
Whooping Cough
1?,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-? phagocytosis and inflammation in Alzheimer's disease patients.
Whooping Cough
5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons.
Whooping Cough
A dual role of protein kinase C in insulin signal transduction via adenylyl cyclase signaling system in muscle tissues of vertebrates and invertebrates.
Whooping Cough
A novel function of Goalpha: mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells.
Whooping Cough
A novel signaling pathway for beta-adrenergic receptor-mediated activation of phosphoinositide 3-kinase in H9c2 cardiomyocytes.
Whooping Cough
Activation of delta-, kappa-, and mu-opioid receptors induces phosphorylation of tuberin in transfected HEK 293 cells and native cells.
Whooping Cough
Activation of MAPK by TRH requires clathrin-dependent endocytosis and PKC but not receptor interaction with beta-arrestin or receptor endocytosis.
Whooping Cough
Activation of phosphatidylinositol 3-kinase by concanavalin A through dual signaling pathways, G-protein-coupled and phosphotyrosine-related, and an essential role of the G-protein-coupled signals for the lectin-induced respiratory burst in human monocytic THP-1 cells.
Whooping Cough
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway and endogenous nitric oxide are needed for the antiarrhythmic effect of centrally administered rilmenidine.
Whooping Cough
Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG.
Whooping Cough
Adenosine A3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1/2 via phosphatidylinositol-3'-kinase.
Whooping Cough
Agonist stimulation of the serotonin1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells.
Whooping Cough
Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells.
Whooping Cough
Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
Whooping Cough
Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells.
Whooping Cough
Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcgamma receptor ligation.
Whooping Cough
Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
Whooping Cough
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Whooping Cough
Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is required in beta3-adrenergic receptor-induced primary smooth muscle cell proliferation.
Whooping Cough
Bombyx adipokinetic hormone receptor activates extracellular signal-regulated kinase 1 and 2 via G protein-dependent PKA and PKC but ?-arrestin-independent pathways.
Whooping Cough
Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons.
Whooping Cough
Carbachol-induced actin reorganization involves Gi activation of Rho in human airway smooth muscle cells.
Whooping Cough
Characterization of a G protein-activated phosphoinositide 3-kinase in vascular smooth muscle cell nuclei.
Whooping Cough
Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases.
Whooping Cough
Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.
Whooping Cough
Coupling of serotonin 5-HT1B receptors to activation of mitogen-activated protein kinase (ERK-2) and p70 S6 kinase signaling systems.
Whooping Cough
CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells.
Whooping Cough
CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity.
Whooping Cough
CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation.
Whooping Cough
Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells.
Whooping Cough
Differential calcium regulation of proinflammatory activities in human neutrophils exposed to the neuropeptide pituitary adenylate cyclase-activating protein.
Whooping Cough
Differential fMet-Leu-Phe- and platelet-activating factor-induced signaling toward Ral activation in primary human neutrophils.
Whooping Cough
Dose-dependent activation of antiapoptotic and proapoptotic pathways by ethanol treatment in human vascular endothelial cells: differential involvement of adenosine.
Whooping Cough
Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts.
Whooping Cough
Eotaxin/CCL11 suppresses IL-8/CXCL8 secretion from human dermal microvascular endothelial cells.
Whooping Cough
Epidermal growth factor differentially augments G(i)-mediated stimulation of c-Jun N-terminal kinase activity.
Whooping Cough
fMLP-induced in vitro nitric oxide production and its regulation in murine peritoneal macrophages.
Whooping Cough
Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists.
Whooping Cough
G protein-coupled APJ receptor signaling induces focal adhesion formation and cell motility.
Whooping Cough
Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors.
Whooping Cough
Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells.
Whooping Cough
HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.
Whooping Cough
Inhibition of chemokine (C-X-C motif) ligand 12/chemokine (C-X-C motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
Whooping Cough
Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase.
Whooping Cough
Insulin-like growth factor-I induces alpha(1B)-adrenergic receptor phosphorylation through G beta gamma and epidermal growth factor receptor transactivation.
Whooping Cough
Involvement of G(i) proteins and Src tyrosine kinase in TNFalpha production induced by lipopolysaccharide, group B Streptococci and Staphylococcus aureus.
Whooping Cough
Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells.
Whooping Cough
KATP channels in the nodose ganglia mediate the orexigenic actions of ghrelin.
Whooping Cough
Leptin Elicits LTC4 Synthesis by Eosinophils Mediated by Sequential Two-Step Autocrine Activation of CCR3 and PGD2 Receptors.
Whooping Cough
Leukotriene B4 mediates vascular smooth muscle cell migration through ?v?3 integrin transactivation.
Whooping Cough
Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells.
Whooping Cough
Lysophosphatidic acid modulates alpha(1b)-adrenoceptor phosphorylation and function: roles of Gi and phosphoinositide 3-kinase.
Whooping Cough
Lysophosphatidic acid sensitizes mechanical stress-induced Ca2+ response via activation of phospholipase C and tyrosine kinase in cultured smooth muscle cells.
Whooping Cough
Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21.
Whooping Cough
Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis.
Whooping Cough
Mechanism of phytoestrogen puerarin-mediated cytoprotection following oxidative injury: estrogen receptor-dependent up-regulation of PI3K/Akt and HO-1.
Whooping Cough
Mechanisms and modulation of pituitary adenylate cyclase-activating protein-induced calcium mobilization in human neutrophils.
Whooping Cough
Mechanisms of endothelin 1-stimulated proliferation in colorectal cancer cell lines.
Whooping Cough
Membrane electrical activity elicits inositol 1,4,5-trisphosphate-dependent slow Ca2+ signals through a Gbetagamma/phosphatidylinositol 3-kinase gamma pathway in skeletal myotubes.
Whooping Cough
Molecular pathways mediating activation by kainate of mitogen-activated protein kinase in oligodendrocyte progenitors.
Whooping Cough
Monocyte chemoattractant protein-1-induced activation of p42/44 MAPK and c-Jun in murine peritoneal macrophages: a potential pathway for macrophage activation.
Whooping Cough
Multiple Signaling Pathways Contribute to the Thrombin-induced Secretory Phenotype in Vascular Smooth Muscle Cells.
Whooping Cough
N-methyl D-aspartate receptor-mediated bidirectional control of extracellular signal-regulated kinase activity in cortical neuronal cultures.
Whooping Cough
Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways.
Whooping Cough
Noradrenaline and alpha-adrenergic signaling induce the hsp70 gene promoter in mollusc immune cells.
Whooping Cough
Norepinephrine activates extracellular-regulated kinase in cortical neurons.
Whooping Cough
Orexin-A protects against oxygen-glucose deprivation/reoxygenation-induced cell damage by inhibiting endoplasmic reticulum stress-mediated apoptosis via the Gi and PI3K signaling pathways.
Whooping Cough
P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B.
Whooping Cough
Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP.
Whooping Cough
Pertussis Toxin, an Inhibitor of G(?i) PCR, Inhibits Bile Acid- and Cytokine-Induced Apoptosis in Primary Rat Hepatocytes.
Whooping Cough
Pertussis toxin-sensitive and insensitive intracellular signalling pathways in undifferentiated 3T3-L1 cells stimulated by insulin converge with phosphatidylinositol 3-kinase upstream of the Ras mitogen-activated protein kinase cascade.
Whooping Cough
Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation.
Whooping Cough
Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8.
Whooping Cough
Platelet-conditioned medium increases endothelial electrical resistance independently of cAMP/PKA and cGMP/PKG.
Whooping Cough
Possible involvement of C-C chemokines in functional augmentation of adhesion molecules in asthmatic patients.
Whooping Cough
Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation.
Whooping Cough
Protective effects of morphine in peroxynitrite-induced apoptosis of primary rat neonatal astrocytes: potential involvement of G protein and phosphatidylinositol 3-kinase (PI3 kinase).
Whooping Cough
Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases.
Whooping Cough
Rat white adipocytes activate p85/p110 PI3K and induce PM GLUT4 in response to adrenoceptor agonists or aluminum fluoride.
Whooping Cough
Regulation of expression of early growth response transcription factors in rat primary cortical neurons by extracellular ATP.
Whooping Cough
Regulation of STAT3 by mu-opioid receptors in human neuroblastoma SH-SY5Y cells.
Whooping Cough
Regulator of G-protein signalling 3 redirects prototypical Gi-coupled receptors from Rac1 to RhoA activation.
Whooping Cough
Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide.
Whooping Cough
Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells.
Whooping Cough
Role of phosphatidylinositol 3-kinase in the binding of Bordetella pertussis to human monocytes.
Whooping Cough
Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning.
Whooping Cough
Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
Whooping Cough
Secretory IgA-mediated basophil activation. II. Roles of GTP-binding regulatory proteins and phosphatidylinositol 3-kinase.
Whooping Cough
Selective ?1B- and ?1D-adrenoceptor antagonists suppress noradrenaline-induced activation, proliferation and ECM secretion of rat hepatic stellate cells in vitro.
Whooping Cough
Signal transduction pathways for activation of extracellular signal-regulated kinase by arachidonic acid in rat neutrophils.
Whooping Cough
Signaling pathways leading to phosphorylation of Akt and GSK-3{beta} by activation of cloned human and cerebral rat D2 and D3 receptors.
Whooping Cough
Signalling pathways involved in the chemotactic activity of CXCL12 in cultured rat cerebellar neurons and CHP100 neuroepithelioma cells.
Whooping Cough
Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).
Whooping Cough
Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts.
Whooping Cough
Sphingosine-1-phosphate activates the AKT pathway to inhibit chemotherapy induced human granulosa cell apoptosis.
Whooping Cough
Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta.
Whooping Cough
Stimulation of human neutrophils by chemotactic factors is associated with the activation of phosphatidylinositol 3-kinase gamma.
Whooping Cough
Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: new pharmacological profile and mechanism of activation.
Whooping Cough
Store-operated Ca2+ influx and stimulation of exocytosis in HL-60 granulocytes.
Whooping Cough
Study of the functional organization of a novel adenylate cyclase signaling mechanism of insulin action.
Whooping Cough
Synthesis of phosphatidylinositol 3,4,5-trisphosphate in permeabilized neutrophils regulated by receptors and G-proteins.
Whooping Cough
TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis.
Whooping Cough
The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase.
Whooping Cough
The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.
Whooping Cough
The chemokine CX3CL1 reduces migration and increases adhesion of neurons with mechanisms dependent on the beta1 integrin subunit.
Whooping Cough
The isoflavone Equol mediates rapid vascular relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells.
Whooping Cough
The K+-ATP channel-independent pathway of regulation of insulin secretion by glucose: in search of the underlying mechanism.
Whooping Cough
TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src.
Whooping Cough
Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion.
Whooping Cough
[Influence of pertussis toxin on GPER-mediated activation of phosphatidylinositol 3-kinase/protein kinase B signaling induced by 17?-estradiol in endometrial carcinoma cells].
Wilms Tumor
Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells.
Wilms Tumor
MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
Wiskott-Aldrich Syndrome
The mechanism of CSF-1-induced Wiskott-Aldrich syndrome protein activation in vivo: a role for phosphatidylinositol 3-kinase and Cdc42.
Wiskott-Aldrich Syndrome
Wiskott-Aldrich Syndrome Interacting Protein Deficiency Uncovers the Role of the Co-receptor CD19 as a Generic Hub for PI3 Kinase Signaling in B Cells.
Yellow Fever
Identification and characterization of the catalytic subunit of phosphatidylinositol 3-kinase in the yellow fever mosquito Aedes aegypti.
Zika Virus Infection
Mechanistic Target of Rapamycin (mTOR) Signaling Activation Antagonizes Autophagy to Facilitate Zika Virus Replication.
Zika Virus Infection
Zika virus infection differentially affects genome-wide transcription in neuronal cells and myeloid dendritic cells.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Chantry, D.; Vojtek, A.; Kashishian, A.; Holtzman, D.A.; Wood, C.; Gray, P.W.; Cooper, J.A.; Hoekstra, M.F.
p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes
J. Biol. Chem.
272
19236-19241
1997
Homo sapiens, Homo sapiens (O00329), Mus musculus, Mus musculus (O35940)
brenda
EXTERNAL LINKS (specific for EC-Number 2.7.1.137)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
